Epidemiology of Parkinson's disease

Lancet Neurology, The

5, 525-535

DOI: 10.1016/s1474-4422(06)70471-9

Citation Report

#	Article	IF	Citations
1	Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nature Reviews Neuroscience, 2006, 7, 697-709.	4.9	1,472
2	Cost of Caring for Medicare Beneficiaries with Parkinson's Disease: Impact of the CMS-HCC Risk-Adjustment Model. Disease Management: DM, 2006, 9, 339-348.	1.0	7
3	Cell-replacement and gene-therapy strategies for Parkinsonâ€™s and Alzheimerâ€™s disease. Regenerative Medicine, 2007, 2, 425-446.	0.8	55
4	Role of tolcapone in the treatment of Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2007, 7, 1649-1657.	1.4	18
5	Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13804-13809.	3.3	170
6	Analysis of surface EMG signal morphology in Parkinson's disease. Physiological Measurement, 2007, 28, 1507-1521.	1.2	52
7	A Randomized Trial Comparing Unilateral Pallidotomy with Bilateral Subthalamic Nucleus Stimulation in PD: Perspectives for Future Implication in Clinical Practice. Progress in Neurotherapeutics and Neuropsychopharmacology, 2007, 2, 13-26.	0.0	0
8	Role of the Pharmacist in the Effective Management of Wearing-Off in Parkinson's Disease. Annals of Pharmacotherapy, 2007, 41, 1842-1849.	0.9	12
9	The economic impact of Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S8-S12.	1.1	166
10	Orthostatic Hypotension-Related Hospitalizations in the United States. American Journal of Medicine, 2007, 120, 975-980.	0.6	183
11	Coenzyme Q treatment of neurodegenerative diseases of aging. Mitochondrion, 2007, 7, S146-S153.	1.6	65
12	Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson???s Disease. CNS Drugs, 2007, 21, 677-692.	2.7	172
13	Enviromimetics: exploring gene environment interactions to identify therapeutic targets for brain disorders. Expert Opinion on Therapeutic Targets, 2007, 11, 899-913.	1.5	58
14	Differential Effects of Black versus Green Tea on Risk of Parkinson's Disease in the Singapore Chinese Health Study. American Journal of Epidemiology, 2007, 167, 553-560.	1.6	153
15	Quality of life scale in parkinson's disease PDQ-39 - (Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation. Arquivos De Neuro-Psiquiatria, 2007, 65, 787-791.	0.3	65
16	Clinical Overview and Phenomenology of Movement Disorders. , 2007, , 1-42.		6
17	Parkinson's Disease (PD). , 2007, , 178-179.		0
18	Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Annals of Neurology, 2007, 62, 468-474.	2.8	121

#	Article	IF	Citations
19	Restless legs syndrome in Parkinson's disease and other neurodegenerative diseases of the central nervous system. Movement Disorders, 2007, 22, S424-S430.	2.2	71
20	Behavioural and neural deficits induced by rotenone in the pond snailLymnaea stagnalis. A possible model for Parkinson's disease in an invertebrate. European Journal of Neuroscience, 2007, 25, 2123-2130.	1.2	27
21	p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. Journal of Neurochemistry, 2007, 100, 070209222715077-???.	2.1	177
22	Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochemical Pharmacology, 2007, 73, 550-560.	2.0	186
23	Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochemical Pharmacology, 2007, 74, 177-190.	2.0	225
24	LRRK2 Low-penetrance Mutations (Gly2019Ser) and Risk Alleles (Gly2385Arg)â€”Linking Familial and Sporadic Parkinsonâ€™s Disease. Neurochemical Research, 2007, 32, 1700-1708.	1.6	69
25	Cross-sectional study discloses a positive family history for Parkinsonâ€™s disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity. Journal of Neural Transmission, 2007, 114, 1167-1171.	1.4	39
26	Mitochondrial Dysfunction and Oxidative Stress in Parkinsonâ€™s Disease. Neurochemical Research, 2008, 33, 589-597.	1.6	83
27	Generation of Reactive Oxygen Species by Mitochondrial Complex I: Implications in Neurodegeneration. Neurochemical Research, 2008, 33, 2487-2501.	1.6	75
28	Surface EMG and acceleration signals in Parkinsonâ€™s disease: feature extraction and cluster analysis. Medical and Biological Engineering and Computing, 2008, 46, 849-858.	1.6	78
29	Triptolide protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats: Implication for immunosuppressive therapy in Parkinsonâ€™s disease. Neuroscience Bulletin, 2008, 24, 133-142.	1.5	36
30	Familial aggregation of Parkinson's disease: A metaâ€analysis. Movement Disorders, 2008, 23, 1174-1183.	2.2	58
31	Gout and the risk of parkinson's disease: A cohort study. Arthritis and Rheumatism, 2008, 59, 1549-1554.	6.7	91
33	Variation in the miRNA-433 Binding Site of FGF20 Confers Risk for Parkinson Disease by Overexpression of Î±-Synuclein. American Journal of Human Genetics, 2008, 82, 283-289.	2.6	437
34	Prospective study of coffee consumption and risk of Parkinson's disease. European Journal of Clinical Nutrition, 2008, 62, 908-915.	1.3	158
35	A Genomeâ€wide Scan in an Amish Pedigree with Parkinsonism. Annals of Human Genetics, 2008, 72, 621-629.	0.3	12
36	Progress in neuroprotection in Parkinsonâ€™s disease. European Journal of Neurology, 2008, 15, 5-13.	1.7	82
37	Characterization of PINK1 processing, stability, and subcellular localization. Journal of Neurochemistry, 2008, 106, 464-474.	2.1	216

#	Article	IF	Citations
38	Visual signs and symptoms of Parkinson's disease. Australasian journal of optometry, The, 2008, 91, 129-138.	0.6	61
39	Trace elements in serum from patients with Parkinson's disease â€" a prospective case-control study. Brain Research, 2008, 1219, 111-115.	1.1	36
40	Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurology, The, 2008, 7, 97-109.	4.9	757
41	LRRK2 Gly2019Ser penetrance in Arabâ€"Berber patients from Tunisia: a case-control genetic study. Lancet Neurology, The, 2008, 7, 591-594.	4.9	172
43	Genetics of iron regulation and the possible role of iron in Parkinson's disease. Neurobiology of Disease, 2008, 32, 183-195.	2.1	92
44	Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: Novel cytoprotective mechanism against oxidative damage. Pharmacological Research, 2008, 57, 325-331.	3.1	121
45	Induction of Human Mesenchymal Stem Cells into Dopamine-Producing Cells with Different Differentiation Protocols. Stem Cells and Development, 2008, 17, 547-554.	1.1	90
46	Neuroanatomy and Pathology of Sporadic Parkinson's Disease. Advances in Anatomy, Embryology and Cell Biology, 2008, , .	1.0	85
47	Cannabinoids and the Brain. , 2008, , .		8
48	Erythropoietin and Parkinsonâ€™s disease: Suggested mechanisms and therapeutic implications. Medical Hypotheses, 2008, 70, 211-212.	0.8	3
49	Potassium channels: Possible new therapeutic targets in Parkinsonâ€™s disease. Medical Hypotheses, 2008, 71, 546-550.	0.8	28
50	The coenzyme Q10 status of the brain regions of Parkinsonâ€™s disease patients. Neuroscience Letters, 2008, 447, 17-19.	1.0	56
51	Complete ascertainment of Parkinson disease in the Swedish Twin Registry. Neurobiology of Aging, 2008, 29, 1765-1773.	1.5	27
52	Frailty in Parkinson's disease and its clinical implications. Parkinsonism and Related Disorders, 2008, 14, 334-337.	1.1	53
53	Prevalence of Parkinson's disease and other types of parkinsonism in the Aeolian Archipelago, Sicily. Parkinsonism and Related Disorders, 2008, 14, 572-575.	1.1	13
54	Parkinson's disease and functional decline in older Mexican Americans. Parkinsonism and Related Disorders, 2008, 14, 397-406.	1.1	4
55	Progress in Parkinson's diseaseâ€"Where do we stand?. Progress in Neurobiology, 2008, 85, 376-392.	2.8	164
56	Visualization of monoaminergic neurons and neurotoxicity of MPTP in live transgenic zebrafish. Developmental Biology, 2008, 314, 84-92.	0.9	160

#	Article	IF	Citations
57	Dopaminergic neurons are preferentially sensitive to long-term rotenone toxicity in primary cell culture. Toxicology in Vitro, 2008, 22, 68-74.	1.1	25
58	Diagnostic Value of ¹²³I-Ioflupane and ¹²³I-Iodobenzamide SPECT Scans in 248 Patients with Parkinsonian Syndromes. European Neurology, 2008, 59, 258-266.	0.6	114
59	Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology, 2008, 70, 1916-1925.	1.5	471
60	Antidopaminergic therapy for managing comorbidities in patients with Parkinsonâ€™s disease. American Journal of Health-System Pharmacy, 2008, 65, 414-419.	0.5	27
61	Neuroprotective Effects of Resveratrol on MPTP-Induced Neuron Loss Mediated by Free Radical Scavenging. Journal of Agricultural and Food Chemistry, 2008, 56, 6910-6913.	2.4	153
62	The Spectrum of Parkinsonian Manifestations Associated With Glucocerebrosidase Mutations. Archives of Neurology, 2008, 65, 1353-7.	4.9	170
63	Parkin deletion causes cerebral and systemic amyloidosis in human mutated tau over-expressing mice. Human Molecular Genetics, 2008, 17, 3128-3143.	1.4	34
64	How many people would benefit from a smart wheelchair?. Journal of Rehabilitation Research and Development, 2008, 45, 53-72.	1.6	181
65	Parkinson's disease: emerging pharmacotherapy. Expert Opinion on Emerging Drugs, 2008, 13, 573-591.	1.0	18
66	Efficacy and Safety of Acupuncture for Idiopathic Parkinson's Disease: A Systematic Review. Journal of Alternative and Complementary Medicine, 2008, 14, 663-671.	2.1	62
67	AnÃ¡lise de compostos bioativos, grupos Ã¡cidos e da atividade antioxidante do cafÃ© arÃ¡bica (Coffea) Tj ETQq0 0 0 rgBT /Overlock 10 and Technology, 2008, 28, 198-207.	0.8	9
68	Treating neuroinflammation: Exploring its potential in Parkinson's disease. British Journal of Neuroscience Nursing, 2009, 5, 511-517.	0.1	0
69	Parkinsonian Syndromes. , 2009, , 453-459.		0
70	Muscle strength in Parkinsonâ€™s disease. Commentary on Pang and Mak (2008). Journal of Rehabilitation Medicine, 2009, 41, 291-292.	0.8	1
71	Validation of the brazilian version of the berg balance scale for patients with parkinson's disease. Arquivos De Neuro-Psiquiatria, 2009, 67, 831-835.	0.3	49
72	Coenzyme Q10 and its effects in the treatment of neurodegenerative diseases. Brazilian Journal of Pharmaceutical Sciences, 2009, 45, 607-618.	1.2	18
73	Depressive symptoms and perception of quality of life in Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2009, 67, 203-208.	0.3	33
75	Involvment of Cytosolic and Mitochondrial GSK-3Î² in Mitochondrial Dysfunction and Neuronal Cell Death of MPTP/MPP+-Treated Neurons. PLoS ONE, 2009, 4, e5491.	1.1	99

#	Article	IF	Citations
76	Role of Two Efflux Proteins, ABCB1 and ABCG2 in Blood-Brain Barrier Transport of Bromocriptine in a Murine Model of MPTP-Induced Dopaminergic Degeneration. Journal of Pharmacy and Pharmaceutical Sciences, 2009, 12, 199.	0.9	10
77	Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects. Genetics in Medicine, 2009, 11, 139-146.	1.1	186
78	Unmet Needs of Patients with Parkinson's Disease: Interview Survey of Patients and Caregivers. Journal of International Medical Research, 2009, 37, 717-726.	0.4	41
79	The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology, 2009, 72, S1-136.	1.5	685
80	Therapeutic History of Parkinson's Disease in Chinese Medical Treatises. Journal of Alternative and Complementary Medicine, 2009, 15, 1223-1230.	2.1	28
81	Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Human Molecular Genetics, 2009, 18, 3832-3850.	1.4	162
82	Lentiviral Delivery of LMX1a Enhances Dopaminergic Phenotype in Differentiated Human Bone Marrow Mesenchymal Stem Cells. Stem Cells and Development, 2009, 18, 591-602.	1.1	59
83	The retina in Parkinson's disease. Brain, 2009, 132, 1128-1145.	3.7	327
84	Complementary Acupuncture Treatment Increases Cerebral Metabolism in Patients with Parkinson's Disease. International Journal of Neuroscience, 2009, 119, 1190-1197.	0.8	31
85	Mutations for Gaucher Disease Confer High Susceptibility to Parkinson Disease. Archives of Neurology, 2009, 66, 571-6.	4.9	183
86	Changes in Prevalence and Incidence of Parkinsonâ€™s Disease in Japan during a Quarter of a Century. Neuroepidemiology, 2009, 32, 263-269.	1.1	83
87	Aging and Parkinson's Disease: Personal Identification, Embodiment, and Experience with a Degenerative Disease. Gerontologist, The, 2009, 49, 720-723.	2.3	0
88	Association Between the Ubiquitin Carboxyl-Terminal Esterase L1 Gene (UCHL1) S18Y Variant and Parkinson's Disease: A HuGE Review and Meta-Analysis. American Journal of Epidemiology, 2009, 170, 1344-1357.	1.6	67
89	Bone and mineral metabolism in older adults with Parkinson's disease. Age and Ageing, 2009, 38, 675-680.	0.7	90
90	Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease. Brain, 2009, 132, 3298-3307.	3.7	238
91	Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radical Biology and Medicine, 2009, 46, 1574-1580.	1.3	127
92	Neurological risks associated with manganese exposure from welding operations â€“ A literature review. International Journal of Hygiene and Environmental Health, 2009, 212, 459-469.	2.1	98
93	Movement disorders: a call for papers. Lancet Neurology, The, 2009, 8, 601.	4.9	0

#	Article	IF	Citations
94	StratÃ©gie thÃ©rapeutique, avant tout amÃ©liorer le vÃ©cu de la maladie. Actualites Pharmaceutiques, 2009, 48, 21-25.	0.0	0
95	Consejo genÃ©tico en las enfermedades neurolÃ³gicas. FMC Formacion Medica Continuada En Atencion Primaria, 2009, 16, 92-102.	0.0	2
96	Drug selection and timing of initiation of treatment in early Parkinson's disease. Annals of Neurology, 2008, 64, S47-S55.	2.8	29
97	Molecular pathology of the fibroblast growth factor family. Human Mutation, 2009, 30, 1245-1255.	1.1	86
98	Geographical difference in Parkinson's disease prevalence within West Scotland. Movement Disorders, 2009, 24, 401-406.	2.2	29
99	No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Movement Disorders, 2009, 24, 1519-1523.	2.2	72
100	Parkinsonism in Gaucher's disease type 1: Ten new cases and a review of the literature. Movement Disorders, 2009, 24, 1524-1530.	2.2	28
101	Bell's palsy preceding Parkinson's disease: A caseâ€control study. Movement Disorders, 2009, 24, 1530-1533.	2.2	1
102	Vertical optokinetic nystagmus in Parkinson's disease. Movement Disorders, 2009, 24, 1533-1538.	2.2	4
103	Deep brain stimulation in dystonia: Sonographic monitoring of electrode placement into the globus pallidus internus. Movement Disorders, 2009, 24, 1538-1541.	2.2	22
104	Tremor on smiling. Movement Disorders, 2009, 24, 1542-1545.	2.2	9
105	Brain mitochondrial dysfunction and oxidative damage in Parkinsonâ€™s disease. Journal of Bioenergetics and Biomembranes, 2009, 41, 517-521.	1.0	112
106	Parkinson's Disease and Cancer. Annals of the New York Academy of Sciences, 2009, 1155, 324-334.	1.8	35
107	Dopamine transporter relation to levodopaâ€derived synaptic dopamine in a rat model of Parkinsonâ€™s: an in vivo imaging study. Journal of Neurochemistry, 2009, 109, 85-92.	2.1	50
108	Pathogenesis of familial Parkinsonâ€™s disease: new insights based on monogenic forms of Parkinsonâ€™s disease. Journal of Neurochemistry, 2009, 111, 1075-1093.	2.1	93
109	Trends in Parkinsonâ€™s disease related mortality in England and Wales, 1993â€“2006. European Journal of Neurology, 2009, 16, 1010-1016.	1.7	27
110	Current strategies in the treatment of Parkinsonâ€™s disease and a personalized approach to management. Expert Review of Neurotherapeutics, 2009, 9, 1781-1789.	1.4	48
111	Chapter 3 Small-Molecule Proteinâ€“Protein Interaction Inhibitors as Therapeutic Agents for Neurodegenerative Diseases: Recent Progress and Future Directions. Annual Reports in Medicinal Chemistry, 2009, , 51-69.	0.5	8

#	Article	IF	Citations
112	Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors. Cell, 2009, 136, 964-977.	13.5	1,437
113	Prevalence of Parkinson's disease in Northern Jordan. Clinical Neurology and Neurosurgery, 2009, 111, 812-815.	0.6	16
114	Imaging the impact of genes on Parkinson's disease. Neuroscience, 2009, 164, 191-204.	1.1	27
115	A nationwide population study of severe head injury and Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 12-14.	1.1	21
116	Minority enrollment in Parkinson's disease clinical trials. Parkinsonism and Related Disorders, 2009, 15, 258-262.	1.1	67
117	The influence of microglia on the pathogenesis of Parkinson's disease. Progress in Neurobiology, 2009, 89, 277-287.	2.8	247
118	Novel parameters of surface EMG in patients with Parkinsonâ€™s disease and healthy young and old controls. Journal of Electromyography and Kinesiology, 2009, 19, e206-e213.	0.7	103
119	Why do Alzheimerâ€™s disease and Parkinsonâ€™s disease target the same neurons?. Medical Hypotheses, 2009, 72, 698-700.	0.8	7
120	Quantitative plasma DNA analysis in Parkinson's disease. Neuroscience Letters, 2009, 452, 5-7.	1.0	6
121	Cell Death Pathways in Parkinson's Disease: Role of Mitochondria. Antioxidants and Redox Signaling, 2009, 11, 2135-2149.	2.5	70
123	Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole. Current Medical Research and Opinion, 2009, 25, 2977-2987.	0.9	27
124	Statins and the risk of Parkinson disease: an update on the controversy. Expert Opinion on Drug Safety, 2009, 8, 261-271.	1.0	17
125	Relation between ability to track force during dual tasking and function in individuals with Parkinson's disease. , 2009, , .		1
126	Zonisamide. CNS Drugs, 2009, 23, 703-711.	2.7	18
127	How People with Parkinson's Disease Get Out of Bed. Physical and Occupational Therapy in Geriatrics, 2009, 27, 333-359.	0.2	10
128	Predicting Parkinson's disease â€“ why, when, and how?. Parkinsonism and Related Disorders, 2009, 15, S105-S109.	1.1	52
129	Is there a pathogenic role for mitochondria in Parkinson's disease?. Parkinsonism and Related Disorders, 2009, 15, S241-S244.	1.1	6
130	Dietary intake of folate, vitamin B₆, vitamin B₁₂ and riboflavin and risk of Parkinson's disease: a caseâ€“control study in Japan. British Journal of Nutrition, 2010, 104, 757-764.	1.2	81

#	Article	IF	Citations
131	A Survey on the Impact of the Menstrual Cycle on Movement Disorders Severity. Canadian Journal of Neurological Sciences, 2010, 37, 478-481.	0.3	6
132	Perceptions of healthcare and familial communications in the context of Parkinson's Disease and Multiple Sclerosis. Journal of Communication in Healthcare, 2010, 3, 124-137.	0.8	3
133	Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 2364-2370.	3.3	34
135	The FRAGAMP study: environmental and genetic factors in Parkinsonâ€™s disease, methods and clinical features. Neurological Sciences, 2010, 31, 47-52.	0.9	15
136	Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients. Neurotoxicity Research, 2010, 18, 229-243.	1.3	11
137	Dual effects of Î±-synuclein on neurotoxicity induced by low dosage of rotenone are dependent on exposure time in dopaminergic neuroblastoma cells. Science China Life Sciences, 2010, 53, 590-597.	2.3	11
138	Neuroprotective and Anti-inflammatory Activities of Ketogenic Diet on MPTP-induced Neurotoxicity. Journal of Molecular Neuroscience, 2010, 42, 145-153.	1.1	129
139	D-Î²-Hydroxybutyrate Prevents MPP+-Induced Neurotoxicity in PC12 Cells. Neurochemical Research, 2010, 35, 444-451.	1.6	17
140	Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurology, The, 2010, 9, 1200-1213.	4.9	753
141	Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiology of Disease, 2010, 39, 423-438.	2.1	275
142	Dietary glycemic index is inversely associated with the risk of Parkinson's disease: A caseâ€“control study in Japan. Nutrition, 2010, 26, 515-521.	1.1	53
143	From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and Î±2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. , 2010, 128, 229-273.		68
144	Dopaminergic cells repolarization induced by calcium and Na+/K+ ATPase pumps. BMC Neuroscience, 2010, 11, .	0.8	0
145	SNPs in CAST are associated with Parkinson disease: A confirmation study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 973-979.	1.1	6
146	A case-control study of Parkinson's disease and tobacco use: Gene-tobacco interactions. Movement Disorders, 2010, 25, 912-919.	2.2	28
147	Timed motor tests can detect subtle motor dysfunction in early Parkinson's disease. Movement Disorders, 2010, 25, 1150-1156.	2.2	48
148	Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Movement Disorders, 2010, 25, 2156-2163.	2.2	108
149	Falls in Parkinson's disease: Kinematic evidence for impaired head and trunk control. Movement Disorders, 2010, 25, 2369-2378.	2.2	99

#	Article	IF	Citations
150	Voluptuary habits and clinical subtypes of Parkinson's disease: The FRAGAMP caseâ€“control study. Movement Disorders, 2010, 25, 2387-2394.	2.2	35
151	Magnetic resonance imaging findings of shoulders in Parkinson's disease. Movement Disorders, 2010, 25, 2524-2530.	2.2	16
152	Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Movement Disorders, 2010, 25, 2717-2723.	2.2	103
153	CHANGES IN THE SERUM BONE METABOLISM MARKERS OF ELDERLY ALCOHOLICS DURING ABSTINENCE. Journal of the American Geriatrics Society, 2010, 58, 984-986.	1.3	2
154	PARKINSON'S DISEASE IN OLDER ADULTS: A NEW SCENARIO FOR THIS OLD ACTOR?. Journal of the American Geriatrics Society, 2010, 58, 982-984.	1.3	4
155	Melatonin or silymarin reduces manebâ€•and paraquatâ€induced Parkinsonâ€™s disease phenotype in the mouse. Journal of Pineal Research, 2011, 50, 97-109.	3.4	137
156	How should we treat a patient with early Parkinsonâ€™s disease?. International Journal of Clinical Practice, 2010, 64, 1210-1219.	0.8	16
157	Neuroimaging of Parkinson's disease. , 2010, , 361-370.		0
158	Brief practical clinical diagnostic criteria for the neurodegenerative diseases in the elderly. Drugs and Therapy Studies, 2010, 1, 6.	0.6	2
159	Cross-talk between mitochondria and proteasome in Parkinsonâ€™s disease pathogenesis. Frontiers in Aging Neuroscience, 2010, 2, 17.	1.7	39
160	Vulnerability of mesostriatal dopaminergic neurons in Parkinsonâ€™s disease. Frontiers in Neuroanatomy, 2010, 4, 140.	0.9	55
161	CpG Demethylation Enhances Alpha-Synuclein Expression and Affects the Pathogenesis of Parkinson's Disease. PLoS ONE, 2010, 5, e15522.	1.1	268
162	Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®). Neuropsychiatric Disease and Treatment, 2010, 6, 483.	1.0	16
163	The Impact of COMT-inhibition on Gastrointestinal Levodopa Absorption in Patients with Parkinson's Disease. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S1169.	0.4	11
164	The role of rasagiline in the treatment of Parkinson’s disease. Clinical Interventions in Aging, 2010, 5, 149.	1.3	21
165	Costs of Parkinsonâ€™s Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study. Neurodegenerative Diseases, 2010, 7, 365-372.	0.8	30
166	Pathology of Parkinson's Disease. Blue Books of Neurology, 2010, 34, 132-154.	0.1	6
167	Clinical prediction of Parkinson's disease: planning for the age of neuroprotection. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1008-1013.	0.9	92

#	Article	IF	Citations
168	Clinical Criteria for the Diagnosis of Parkinsonâ€™s Disease. Neurodegenerative Diseases, 2010, 7, 284-290.	0.8	104
169	Caffeine Exposure and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis of Observational Studiess. Journal of Alzheimer's Disease, 2010, 20, S221-S238.	1.2	196
170	The Toll-Like Receptor-3 Agonist Polyinosinic:Polycytidylic Acid Triggers Nigrostriatal Dopaminergic Degeneration. Journal of Neuroscience, 2010, 30, 16091-16101.	1.7	89
171	Scales for Assessing Nonmotor Symptom Severity Changes in Parkinson's Disease Patients With Symptom Fluctuations. International Journal of Neuroscience, 2010, 120, 523-530.	0.8	11
172	LRRK2 and Parkinson Disease. Archives of Neurology, 2010, 67, 542-7.	4.9	137
173	Study of the prevalence of Parkinson's disease using dopamine transporter imaging. Neurological Research, 2010, 32, 845-851.	0.6	6
174	Induced Pluripotent Stem Cells as a Model for Accelerated Patient- and Disease-specific Drug Discovery. Current Medicinal Chemistry, 2010, 17, 759-766.	1.2	88
175	Extending palliative care to patients with Parkinson's disease. British Journal of Hospital Medicine (London, England: 2005), 2010, 71, 26-30.	0.2	11
177	Decaffeinated Coffee and Nicotine-Free Tobacco Provide Neuroprotection in Drosophila Models of Parkinson's Disease through an NRF2-Dependent Mechanism. Journal of Neuroscience, 2010, 30, 5525-5532.	1.7	94
178	Trends in resource utilization for Parkinson's disease in Germany. Journal of the Neurological Sciences, 2010, 294, 18-22.	0.3	23
179	Entacapone. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 983-993.	1.5	21
180	No evidence for pathogenic role of GIGYF2 mutation in Parkinson disease in Japanese patients. Neuroscience Letters, 2010, 479, 245-248.	1.0	7
181	Trials of neuroprotective therapies for Parkinsonâ€™s disease: Problems and limitations. Parkinsonism and Related Disorders, 2010, 16, 365-369.	1.1	44
182	Parkinson's disease: Insights from non-traditional model organisms. Progress in Neurobiology, 2010, 92, 558-571.	2.8	60
183	What causes the death of dopaminergic neurons in Parkinsonâ€™s disease?. Progress in Brain Research, 2010, 183, 59-77.	0.9	102
184	Polyphenols and Human Health: Prevention of Disease and Mechanisms of Action. Nutrients, 2010, 2, 1106-1131.	1.7	619
186	Levodopa in Parkinson's disease: from the past to the future. Expert Opinion on Pharmacotherapy, 2010, 11, 627-635.	0.9	54
187	Zonisamide in ParkinsonÊ¼s Diseaseâ€. Drugs and Aging, 2010, 27, 73-75.	1.3	0

#	Article	IF	Citations
188	Pramipexole Extended Release. CNS Drugs, 2010, 24, 327-336.	2.7	13
189	Perceptions of persons with Parkinson's disease, family and professionals on quality of life: an international focus group study. Disability and Rehabilitation, 2011, 33, 2490-2508.	0.9	34
190	Functional neuroimaging in Parkinson's disease. Expert Opinion on Medical Diagnostics, 2011, 5, 109-120.	1.6	7
191	Clinical evidence linking coffee and tea intake with Parkinsonâ€™s disease. Basal Ganglia, 2011, 1, 127-130.	0.3	8
192	Prevalence of parkinsonism and Parkinson's disease in the Arosa Island (Spain): A community-based door-to-door survey. Journal of the Neurological Sciences, 2011, 304, 49-54.	0.3	18
193	Highly Potent Activity of (1R,2R,6S)-3-Methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in Animal Models of Parkinsonâ€™s Disease. Journal of Medicinal Chemistry, 2011, 54, 3866-3874.	2.9	61
194	Parkinson's Disease: Genetics and Pathogenesis. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 193-222.	9.6	654
195	The Origins of Oxidant Stress in Parkinson's Disease and Therapeutic Strategies. Antioxidants and Redox Signaling, 2011, 14, 1289-1301.	2.5	132
196	Automatic Trajectory Planning of DBS Neurosurgery from Multi-modal MRI Datasets. Lecture Notes in Computer Science, 2011, 14, 259-266.	1.0	27
197	Medical Image Computing and Computer-Assisted Intervention â€“ MICCAI 2011. Lecture Notes in Computer Science, 2011, , .	1.0	13
198	Parkinson disease: Insights in clinical, genetic and pathological features of monogenic disease subtypes. Journal of Chemical Neuroanatomy, 2011, 42, 131-141.	1.0	65
199	Genetic mutations and functions of PINK1. Trends in Pharmacological Sciences, 2011, 32, 573-580.	4.0	79
200	Lack of association of dairy food, calcium, and vitamin D intake with the risk of Parkinsonâ€™s disease: A case-control study in Japan. Parkinsonism and Related Disorders, 2011, 17, 112-116.	1.1	41
201	Health-related quality of life and its determinants in Parkinsonâ€™s disease: Results of an Italian cohort study. Parkinsonism and Related Disorders, 2011, 17, 265-269.	1.1	65
202	Intake of Japanese and Chinese teas reduces risk of Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2011, 17, 446-450.	1.1	61
203	Ongoing challenges to finding people with Parkinsonâ€™s disease for epidemiological studies: A comparison of population-level case ascertainment methods. Parkinsonism and Related Disorders, 2011, 17, 464-469.	1.1	6
204	Occupational exposure in Parkinsonian disorders: A 43-year prospective cohort study in men. Parkinsonism and Related Disorders, 2011, 17, 677-682.	1.1	32
205	Epigenetics in neurodegeneration: A new layer of complexity. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 348-355.	2.5	84

#	Article	IF	Citations
206	NEW evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease. Neurobiology of Aging, 2011, 32, 443-458.	1.5	73
207	GSK3Î² polymorphisms, MAPT H1 haplotype and Parkinson's disease in a Greek cohort. Neurobiology of Aging, 2011, 32, 546.e1-546.e5.	1.5	23
208	Physiological and Biomechanical Analyses of Rigidity in Parkinson's Disease. , 2011, , .		8
209	Effects of a Multimodal Exercise Program on Clinical, Functional Mobility and Cognitive Parameters of Idiopathic Parkinson's Disease Patients. , 0, , .		3
210	Brain Mitochondrial Dysfunction and Complex I Syndrome in Parkinson Ìs Disease. , 0, , .		0
211	The Potential of Neurotrophic Factors for the Treatment of Parkinsonâ€™s Disease. , 2011, , .		1
212	Cognitive and Psychiatric Aspects of Parkinsonâ€™s Disease. , 2011, , .		0
213	Mitochondrial Dysfunction in Parkinson's Disease: Pathogenesis and Neuroprotection. Parkinson's Disease, 2011, 2011, 1-18.	0.6	47
214	Use of a Refined Drug Tracer Algorithm to Estimate Prevalence and Incidence of Parkinson's Disease in a Large Israeli Population. Journal of Parkinson's Disease, 2011, 1, 35-47.	1.5	37
215	Molecular Chaperones in Parkinson's Disease â€“ Present and Future. Journal of Parkinson's Disease, 2011, 1, 299-320.	1.5	63
216	Pedunculopontine nucleus deep brain stimulation in Parkinsonâ€™s disease. Archives of Medical Science, 2011, 4, 555-564.	0.4	29
217	Protective Effect of Tetrahydroxystilbene Glucoside on 6-OHDA-Induced Apoptosis in PC12 Cells through the ROS-NO Pathway. PLoS ONE, 2011, 6, e26055.	1.1	55
218	Parkinsonâ€™s disease: diagnostic relevance of elevated levels of soluble Î±-synuclein oligomers in cerebrospinal fluid. Future Neurology, 2011, 6, 159-163.	0.9	4
219	Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction. Experimental and Therapeutic Medicine, 2011, 2, 771-775.	0.8	28
220	Changes in Executive Function After Acute Bouts of Passive Cycling in Parkinsonâ€™s Disease. Journal of Aging and Physical Activity, 2011, 19, 87-98.	0.5	72
221	Examination of the UPDRS Bradykinesia Subscale: Equivalence, Reliability and Validity. Journal of Parkinson's Disease, 2011, 1, 253-258.	1.5	13
222	DJ-1â€“Mediated Protective Effect of Protocatechuic Aldehyde Against Oxidative Stress in SH-SY5Y Cells. Journal of Pharmacological Sciences, 2011, 115, 36-44.	1.1	25
223	DNA methylation in neurodegenerative disorders: a missing link between genome and environment?. Clinical Genetics, 2011, 80, 1-14.	1.0	53

#	Article	IF	Citations
224	A Genomeâ€Wide Linkage Screen in the Amish with Parkinson Disease Points to Chromosome 6. Annals of Human Genetics, 2011, 75, 351-358.	0.3	9
225	Pharmacological treatment and the prospect of pharmacogenetics in Parkinsonâ€™s disease. International Journal of Clinical Practice, 2011, 65, 1289-1294.	0.8	50
226	Prevalence of malnutrition in Parkinson's disease: a systematic review. Nutrition Reviews, 2011, 69, 520-532.	2.6	100
227	Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. Journal of Cellular and Molecular Medicine, 2011, 15, 701-717.	1.6	50
228	Deprenyl prevents MPP+-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk. Toxicology, 2011, 290, 286-294.	2.0	58
229	A process-model based approach to prospective memory impairment in Parkinson's disease. Neuropsychologia, 2011, 49, 2166-2177.	0.7	128
230	The most cited works in major depression: The â€˜Citation classicsâ€™. Journal of Affective Disorders, 2011, 134, 39-44.	2.0	33
231	Comparative Bioavailability of 2 Tablet Formulations of Levodopa/Benserazide in Healthy, Fasting Volunteers: A Single-Dose, Randomized-Sequence, Open-Label Crossover Study. Clinical Therapeutics, 2011, 33, 500-510.	1.1	13
232	Salidroside protects against MPP+-induced apoptosis in PC12 cells by inhibiting the NO pathway. Brain Research, 2011, 1382, 9-18.	1.1	58
233	Degeneration of mesencephalic dopaminergic neurons in klotho mouse related to vitamin D exposure. Brain Research, 2011, 1382, 109-117.	1.1	44
234	Nondopaminergic treatments for Parkinsonâ€™s disease. Neurodegenerative Disease Management, 2011, 1, 491-512.	1.2	8
235	What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease. Physiological Reviews, 2011, 91, 1161-1218.	13.1	515
236	Recent Advances in the Genetics of Parkinson's Disease. Annual Review of Genomics and Human Genetics, 2011, 12, 301-325.	2.5	355
237	Translation Initiator EIF4G1 Mutations in Familial Parkinson Disease. American Journal of Human Genetics, 2011, 89, 398-406.	2.6	250
238	Quinoprotein Adducts Accumulate in the Substantia Nigra of Aged Rats and Correlate with Dopamine-Induced Toxicity in SH-SY5Y Cells. Neurochemical Research, 2011, 36, 2169-2175.	1.6	23
239	Risk of sleep-disordered breathing in Parkinson's disease. Sleep and Breathing, 2011, 15, 471-478.	0.9	41
240	Preserved serotonin transporter binding in de novo Parkinsonâ€™s disease: negative correlation with the dopamine transporter. Journal of Neurology, 2011, 258, 19-26.	1.8	65
241	The value of Arabidopsis research in understanding human disease states. Current Opinion in Biotechnology, 2011, 22, 300-307.	3.3	25

#	Article	IF	Citations
242	Activated Immune Cells in Parkinson's Disease. Journal of NeuroImmune Pharmacology, 2011, 6, 323-329.	2.1	53
243	Use of sensitive devices to assess the effect of medication on attentional demands of precision and power grips in individuals with Parkinson disease. Medical and Biological Engineering and Computing, 2011, 49, 1195-1199.	1.6	7
244	Occupational risk factors for Parkinson's disease: a case-control study in Japan. BMC Neurology, 2011, 11, 83.	0.8	9
245	Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson's disease in a Japanese population. BMC Neurology, 2011, 11, 89.	0.8	39
246	Psychometric validation of the revised SCOPA-Diary Card: expanding the measurement of non-motor symptoms in parkinson's disease. Health and Quality of Life Outcomes, 2011, 9, 69.	1.0	3
247	Oxidation of the cysteine-rich regions of parkin perturbs its E3 ligase activity and contributes to protein aggregation. Molecular Neurodegeneration, 2011, 6, 34.	4.4	134
248	Calidad de vida de los enfermos de Parkinson tras tratamiento quirÃºrgico. Complejo Hospitalario Universitario de Albacete. Revista CientÃfica De La Sociedad EspaÃ±ola De EnfermerÃa NeurolÃ³gica, 2011, 33, 10-15.	0.1	0
249	Revisiting the relationship between essential tremor and Parkinson's disease. Movement Disorders, 2011, 26, 391-398.	2.2	99
250	Wine drinking and essential tremor: A possible protective role. Movement Disorders, 2011, 26, 1310-1315.	2.2	8
251	Genetic variants of Î±â€synuclein are not associated with essential tremor. Movement Disorders, 2011, 26, 2552-2556.	2.2	14
252	Temporal stability of the Unified Dyskinesia Rating Scale. Movement Disorders, 2011, 26, 2556-2559.	2.2	20
253	Patients with idiopathic rapidâ€eyeâ€movement sleep behavior disorder show normal gastric motility assessed by the ¹³Câ€octanoate breath test. Movement Disorders, 2011, 26, 2559-2563.	2.2	26
254	Reproductive factors and Parkinson's disease: A multicenter caseâ€“control study. Movement Disorders, 2011, 26, 2563-2566.	2.2	31
255	Camptocormia in Japanese patients with Parkinson's disease: A multicenter study. Movement Disorders, 2011, 26, 2567-2571.	2.2	40
256	DJâ€1 modulates the expression of Cu/Znâ€superoxide dismutaseâ€1 through the Erk1/2â€“Elk1 pathway in neuroprotection. Annals of Neurology, 2011, 70, 591-599.	2.8	92
257	Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinsonâ€™s disease-associated protein. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2953-2957.	1.0	25
258	ASK1 Overexpression Accelerates Paraquat-Induced Autophagy via Endoplasmic Reticulum Stress. Toxicological Sciences, 2011, 119, 156-168.	1.4	48
259	Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases. Current Pharmaceutical Design, 2011, 17, 2036-2055.	0.9	41

#	Article	IF	Citations
260	A New (Old) Treatment Option for Depression in Parkinson's Disease. American Journal of Psychiatry, 2011, 168, 1015-1016.	4.0	4
261	Analysis of Parkinsonâ€™s Disease and Subsequent Cancer Risk in Taiwan: A Nationwide Population-Based Cohort Study. Neuroepidemiology, 2011, 37, 114-119.	1.1	31
262	Levodopaâ€“carbidopa intestinal gel for treatment of advanced Parkinsonâ€™s disease. Current Medical Research and Opinion, 2011, 27, 907-919.	0.9	62
263	Evaluation of 3RT1 cell quantity by a multimodal optical approach. , 2011, , .		0
264	Long-term Group Exercise for People With Parkinson's Disease. Journal of Neurologic Physical Therapy, 2011, 35, 122-128.	0.7	32
265	Impact of nonmotor symptoms on disability in patients with Parkinsonâ€™s disease. International Journal of Rehabilitation Research, 2011, 34, 316-320.	0.7	15
266	GDNF and protection of adult central catecholaminergic neurons. Journal of Molecular Endocrinology, 2011, 46, R83-R92.	1.1	59
267	ParkDB: a Parkinson's disease gene expression database. Database: the Journal of Biological Databases and Curation, 2011, 2011, bar007-bar007.	1.4	28
268	Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca ²⁺. FASEB Journal, 2011, 25, 2563-2573.	0.2	72
269	Association of Blood Pressure and Hypertension With the Risk of Parkinson Disease. Hypertension, 2011, 57, 1094-1100.	1.3	121
270	LRRK2 Parkinsonâ€™s disease: from animal models to cellular mechanisms. Reviews in the Neurosciences, 2011, 22, 411-8.	1.4	9
271	Cell Based Therapies in Parkinsonâ€™s Disease. Annals of Neurosciences, 2011, 18, 76-83.	0.9	9
272	Clinical overview and phenomenology of movement disorders. , 2011, , 1-35.		7
274	Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease. Archives of Neurology, 2011, 68, 932.	4.9	146
275	Factors Associated With Exercise Behavior in People With Parkinson Disease. Physical Therapy, 2011, 91, 1838-1848.	1.1	134
276	Using the WHOQOL-DIS to Measure Quality of Life in Persons with Physical Disabilities Caused by Neurodegenerative Disorders. Neurodegenerative Diseases, 2011, 8, 178-186.	0.8	21
277	Role of Familial, Environmental and Occupational Factors in the Development of Parkinsonâ€™s Disease. Neurodegenerative Diseases, 2011, 8, 345-351.	0.8	24
278	A National Registry to Determine the Distribution and Prevalence of Parkinsonâ€™s Disease in Thailand: Implications of Urbanization and Pesticides as Risk Factors for Parkinsonâ€™s Disease. Neuroepidemiology, 2011, 37, 222-230.	1.1	32

#	Article	IF	Citations
279	Intensive voice treatment in Parkinsonâ€™s disease: Lee Silverman Voice Treatment. Expert Review of Neurotherapeutics, 2011, 11, 815-830.	1.4	93
280	Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology, 2011, 77, 1048-1054.	1.5	268
281	Determining the Efficacy of Rasagiline in Reducing Bradykinesia Among Parkinson's Disease Patients: A Review. International Journal of Neuroscience, 2011, 121, 485-489.	0.8	2
282	How to Tackle Tremor â€“ Systematic Review of the Literature and Diagnostic Work-Up. Frontiers in Neurology, 2012, 3, 146.	1.1	19
283	Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database. PLoS Genetics, 2012, 8, e1002548.	1.5	495
284	The Impact of Familial Structure on Parkinson's Disease in Istanbul Medical School, Turkey. International Journal of Neuroscience, 2012, 122, 102-105.	0.8	0
285	Chelators in the Treatment of Iron Accumulation in Parkinson's Disease. International Journal of Cell Biology, 2012, 2012, 1-12.	1.0	62
286	Psychiatric, nonmotor aspects of Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 106, 477-490.	1.0	5
287	Six Novel Susceptibility Loci for Early-Onset Androgenetic Alopecia and Their Unexpected Association with Common Diseases. PLoS Genetics, 2012, 8, e1002746.	1.5	92
288	Contribution of Yeast Models to Neurodegeneration Research. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-12.	3.0	39
289	N-Methyl D-Aspartate (NMDA) Receptor Antagonists and Memantine Treatment for Alzheimerâ€™s Disease, Vascular Dementia and Parkinsonâ€™s Disease. Current Alzheimer Research, 2012, 9, 746-758.	0.7	277
290	In Vivo Dopamine Transporter Imaging in a Unilateral 6-Hydroxydopamine Rat Model of Parkinson Disease Using ¹¹C-Methylphenidate PET. Journal of Nuclear Medicine, 2012, 53, 813-822.	2.8	15
291	A randomized recruitment intervention trial in Parkinsonâ€™s disease to increase participant diversity: early stopping for lack of efficacy. Clinical Trials, 2012, 9, 188-197.	0.7	26
292	Use of Calcium Channel Blockers and Parkinsonâ€™s Disease. American Journal of Epidemiology, 2012, 175, 627-635.	1.6	134
293	Clinical Characteristics of Exacerbations in Parkinson Disease. Neurologist, 2012, 18, 120-124.	0.4	43
294	Dopamine-derived Quinones Affect the Structure of the Redox Sensor DJ-1 through Modifications at Cys-106 and Cys-53. Journal of Biological Chemistry, 2012, 287, 18738-18749.	1.6	61
295	Treatment of Parkinson Disease. JAMA - Journal of the American Medical Association, 2012, 307, 2305.	3.8	31
296	Clinical Approach to Parkinson's Disease: Features, Diagnosis, and Principles of Management. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a008870-a008870.	2.9	288

#	Article	IF	Citations
297	Therapeutic potential of targeting metabotropic glutamate receptors for Parkinsonâ€™s disease. Neurodegenerative Disease Management, 2012, 2, 221-232.	1.2	25
298	QSAR and Molecular Docking Techniques for the Discovery of Potent Monoamine Oxidase B Inhibitors: Computer-Aided Generation of New Rasagiline Bioisosteres. Current Topics in Medicinal Chemistry, 2012, 12, 1734-1747.	1.0	10
299	Retrospective Assessment of Occupational Exposure to Whole-Body Vibration for a Case-Control Study. Journal of Occupational and Environmental Hygiene, 2012, 9, 371-380.	0.4	13
300	Lack of Association Between CX3CR1 V249I and T280M Polymorphisms and Risk of Parkinson's Disease in a Greek Population. Genetic Testing and Molecular Biomarkers, 2012, 16, 974-977.	0.3	3
301	White Matter Alteration of the Cingulum in Parkinson Disease with and without Dementia: Evaluation by Diffusion Tensor Tractâ€“Specific Analysis. American Journal of Neuroradiology, 2012, 33, 890-895.	1.2	86
302	Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology, 2012, 78, 696-701.	1.5	125
303	Anxiety Disorders, Physical Illnesses, and Health Care Utilization in Older Male Veterans With Parkinson Disease and Comorbid Depression. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 233-239.	1.2	33
304	Activation of Transcription Factor MEF2D by Bis(3)-cognitin Protects Dopaminergic Neurons and Ameliorates Parkinsonian Motor Defects. Journal of Biological Chemistry, 2012, 287, 34246-34255.	1.6	38
305	Accuracy and Sensitivity of Parkinsonian Disorder Diagnoses in Two Swedish National Health Registers. Neuroepidemiology, 2012, 38, 186-193.	1.1	58
306	Molecular Imaging in Parkinsonâ€™s Disease. Neuromethods, 2012, , 359-375.	0.2	1
307	Therapeutic Potential of Metabotropic Glutamate Receptor Modulators. Current Neuropharmacology, 2012, 10, 12-48.	1.4	88
308	Neurological disorders and therapeutics targeted to surmount the blood–brain barrier. International Journal of Nanomedicine, 2012, 7, 3259.	3.3	84
309	Parkinson Disease. Southern Medical Journal, 2012, 105, 650-656.	0.3	39
310	Cognitive Behavioral Therapy for Depression and Anxiety in Parkinson's Disease: A Clinical Review. Journal of Parkinson's Disease, 2012, 2, 135-151.	1.5	45
311	Generation of Induced Pluripotent Stem Cells from Asian Patients with Chronic Neurodegenerative Diseases. Journal of Reproduction and Development, 2012, 58, 515-521.	0.5	7
314	Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. Nature Neuroscience, 2012, 15, 1414-1421.	7.1	144
315	Cutting Edge: IL-13RÎ±1 Expression in Dopaminergic Neurons Contributes to Their Oxidative Stressâ€“Mediated Loss following Chronic Peripheral Treatment with Lipopolysaccharide. Journal of Immunology, 2012, 189, 5498-5502.	0.4	64
316	Inflammation in Parkinson's Disease. Advances in Protein Chemistry and Structural Biology, 2012, 88, 69-132.	1.0	154

#	Article	IF	Citations
317	New concepts in the early and preclinical detection of Parkinsonâ€™s disease: therapeutic implications. Expert Review of Neurotherapeutics, 2012, 12, 1429-1438.	1.4	18
318	Exercise for People in Early- or Mid-Stage Parkinson Disease: A 16-Month Randomized Controlled Trial. Physical Therapy, 2012, 92, 1395-1410.	1.1	166
319	Substantia nigra depigmentation and exposure to encephalitis lethargica. Annals of Neurology, 2012, 72, 912-917.	2.8	7
320	Ubiquitin proteasome system in Parkinson's disease: A keeper or a witness?. Experimental Neurology, 2012, 238, 89-99.	2.0	37
321	Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson diseaseâ€"resemblance to the effect of amphetamine drugs of abuse. Free Radical Biology and Medicine, 2012, 53, 1791-1806.	1.3	89
322	DNA Methylation in Neurodegenerative Disorders. Current Geriatrics Reports, 2012, 1, 199-205.	1.1	3
324	What are the issues facing Parkinson's disease patients at ten years of disease and beyond?: Data from the NPF-QII study. Parkinsonism and Related Disorders, 2012, 18, S10-S14.	1.1	42
325	Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for costâ€“effectiveness in early Parkinsonâ€™s disease. Expert Review of Clinical Pharmacology, 2012, 5, 1-4.	1.3	2
326	Association of Catechol-O-Methyltransferase Polymorphism (Val108/158Met) With Parkinson's Disease: A Meta-Analysis. Journal of Motor Behavior, 2012, 44, 365-372.	0.5	5
327	Gene expression profiling and therapeutic interventions in neurodegenerative diseases: a comprehensive study on potentiality and limits. Expert Opinion on Drug Discovery, 2012, 7, 245-259.	2.5	18
328	Dl-3-n-butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson's disease. Neurobiology of Aging, 2012, 33, 1777-1791.	1.5	92
329	Centrosomal aggregates and Golgi fragmentation disrupt vesicular trafficking of DAT. Neurobiology of Aging, 2012, 33, 2462-2477.	1.5	11
330	Parkinsonâ€™s disease and risk of hip fracture: An 8-year follow-up study in Taiwan. Parkinsonism and Related Disorders, 2012, 18, 506-509.	1.1	46
331	Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism and Related Disorders, 2012, 18, 753-758.	1.1	200
332	Neurologic Diseases. , 2012, , 251-295.		5
333	Caffeine for treatment of Parkinson disease. Neurology, 2012, 79, 651-658.	1.5	252
334	GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology, 2012, 79, 1944-1950.	1.5	138
335	The influence of electrical stimulation of vagus nerve on elemental composition of dopamine related brain structures in rats. Neurochemistry International, 2012, 61, 156-165.	1.9	12

#	Article	IF	Citations
336	Meta-analysis of the influence of Parkin p.Asp394Asn variant on the susceptibility of Parkinson's disease. Neuroscience Letters, 2012, 524, 60-64.	1.0	6
337	Salidroside protects PC12 cells from MPP+-induced apoptosis via activation of the PI3K/Akt pathway. Food and Chemical Toxicology, 2012, 50, 2591-2597.	1.8	53
338	Effect of co-morbidities on fracture risk: Findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone, 2012, 50, 1288-1293.	1.4	129
339	The decrease of dopamine D2/D3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB1 cannabinoid receptors in Parkinson's disease: A preliminary autoradiographic study with the selective dopamine D2/D3 antagonist [3H]raclopride and the novel CB1 inverse agonist [125I]SD7015. Brain Research Bulletin, 2012, 87, 504-510.	1.4	20
342	Healthcare utilization in patients with Parkinson's disease: A population-based analysis. Parkinsonism and Related Disorders, 2012, 18, 930-935.	1.1	26
345	N9 microglial cells polarized by LPS and IL4 show differential responses to secondary environmental stimuli. Cellular Immunology, 2012, 278, 84-90.	1.4	51
346	A multi-modal approach to computer-assisted deep brain stimulation trajectory planning. International Journal of Computer Assisted Radiology and Surgery, 2012, 7, 687-704.	1.7	71
347	Systems Biology of Parkinson's Disease. , 2012, , .		8
348	Neuroprevention: A new challenge?. Revue Neurologique, 2012, 168, 796-801.	0.6	6
349	Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera. PLoS ONE, 2012, 7, e32383.	1.1	118
350	Evaluation of the Role of SNCA Variants in Survival without Neurological Disease. PLoS ONE, 2012, 7, e42877.	1.1	7
351	Quantitative Analysis of Î±-Synuclein Solubility in Living Cells Using Split GFP Complementation. PLoS ONE, 2012, 7, e43505.	1.1	21
352	Non-Motor Symptoms in Patients with Parkinsonâ€™s Disease â€“ Correlations with Inflammatory Cytokines in Serum. PLoS ONE, 2012, 7, e47387.	1.1	180
353	Efeito de uma intervenÃ§Ã£o cognitivo-motora sobre os sintomas depressivos de pacientes com doenÃ§a de Parkinson. Jornal Brasileiro De Psiquiatria, 2012, 61, 78-83.	0.2	9
354	Neuroprotection and Neuroregeneration in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2012, 2012, 1-1.	1.1	2
355	Hormone Replacement Therapy and Risk for Neurodegenerative Diseases. International Journal of Alzheimer's Disease, 2012, 2012, 1-18.	1.1	64
356	Inflammatory Pathways in Parkinsonâ€™s Disease; A BNE Microarray Study. Parkinson's Disease, 2012, 2012, 1-16.	0.6	51
357	Impact of changes in balance and walking capacity on the quality of life in patients with Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2012, 70, 119-124.	0.3	31

#	Article	IF	Citations
358	Adenosine A2A receptor antagonist istradefylline for levodopa-induced complications in Parkinson's disease. The Cochrane Library, 2012, , .	1.5	0
359	Feature Extraction Methods for Studying Surface Electromyography and Kinematic Measurements in Parkinsonâ€™s Disease. , 0, , .		0
360	Fault-Tolerant Energy-Efficient Priority-Based Routing Scheme for the Multisink Healthcare Sensor Networks. , 2012, 2012, 1-11.		1
361	Factors influencing the development of early- or late-onset Parkinsonâ€™s disease in a cohort of South African patients. South African Medical Journal, 2012, 102, 848.	0.2	12
362	Pathology of Neurodegenerative Diseases. , 0, , .		3
363			

#	Article	IF	Citations
377	Voltage-gated calcium channels and Parkinson's disease. , 2012, 133, 324-333.		37
378	Dietary patterns and risk of Parkinsonâ€™s disease: a caseâ€“control study in Japan. European Journal of Neurology, 2012, 19, 681-688.	1.7	48
379	Synaptic vesicle trafficking and Parkinson's disease. Developmental Neurobiology, 2012, 72, 134-144.	1.5	83
380	Lack of association between p.Ser167Asn variant of Parkin and Parkinson's disease: A metaâ€analysis of 15 studies involving 2,280 cases and 2,459 controls. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 38-47.	1.1	8
381	Nigral pathology and parkinsonian signs in elders without Parkinson disease. Annals of Neurology, 2012, 71, 258-266.	2.8	171
382	Transgenic expression and activation of PGC-1Î± protect dopaminergic neurons in the MPTP mouse model of Parkinsonâ€™s disease. Cellular and Molecular Life Sciences, 2012, 69, 1153-1165.	2.4	260
383	Kynurenines in Parkinsonâ€™s disease: therapeutic perspectives. Journal of Neural Transmission, 2012, 119, 275-283.	1.4	34
384	The impact of motor and non motor symptoms on health state values in newly diagnosed idiopathic Parkinsonâ€™s disease. Journal of Neurology, 2012, 259, 462-468.	1.8	49
385	Loss of temporal retinal nerve fibers in Parkinson disease: a mitochondrial pattern?. European Journal of Neurology, 2013, 20, 198-201.	1.7	92
386	Subthalamic deep brain stimulation improves smooth pursuit and saccade performance in patients with Parkinsonâ€™s disease. Journal of NeuroEngineering and Rehabilitation, 2013, 10, 33.	2.4	38
387	SERT-to-DAT ratios in early Parkinsonâ€™s disease do not correlate with the development of dyskinesias. EJNMMI Research, 2013, 3, 44.	1.1	10
388	Lycopene Protects Against MPP+-Induced Cytotoxicity by Maintaining Mitochondrial Function in SH-SY5Y Cells. Neurochemical Research, 2013, 38, 1747-1757.	1.6	52
389	Therapeutic Effects of Rapamycin on MPTP-Induced Parkinsonism in Mice. Neurochemical Research, 2013, 38, 201-207.	1.6	97
390	Reprint of: Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson diseaseâ€”resemblance to the effect of amphetamine drugs of abuse. Free Radical Biology and Medicine, 2013, 62, 186-201.	1.3	97
391	Alzheimer's disease and Parkinson's disease genome-wide association study top hits and risk of Parkinson's disease in Korean population. Neurobiology of Aging, 2013, 34, 2695.e1-2695.e7.	1.5	45
392	Melanin affinity and its possible role in neurodegeneration. Journal of Neural Transmission, 2013, 120, 1623-1630.	1.4	39
393	Advances in the genetics of Parkinson disease. Nature Reviews Neurology, 2013, 9, 445-454.	4.9	414
394	Cognitive, motor and tyrosine hydroxylase temporal impairment in a model of parkinsonism induced by reserpine. Behavioural Brain Research, 2013, 253, 68-77.	1.2	71

#	Article	IF	Citations
395	Parkinson's Disease and Sleep. , 2013, , 345-349.		0
396	Epidemiology of complementary and alternative medicine use in patients with Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2013, 20, 1062-1067.	0.8	49
397	Epidemiology of neurologically disabling disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 110, 77-92.	1.0	8
398	Neurorehabilitation in Parkinson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 110, 435-442.	1.0	26
399	Development and Screening of Contrast Agents for In Vivo Imaging of Parkinsonâ€™s Disease. Molecular Imaging and Biology, 2013, 15, 585-595.	1.3	21
400	Insights on altered mitochondrial function and dynamics in the pathogenesis of neurodegeneration. Translational Neurodegeneration, 2013, 2, 12.	3.6	57
401	Changes in Timing and kinematics of goal directed eye-hand movements in early-stage Parkinsonâ€™s disease. Translational Neurodegeneration, 2013, 2, 1.	3.6	26
402	Bumping Up Kinase Activity with an ATP-Derived Neo-Substrate. Cell, 2013, 154, 716-718.	13.5	2
403	Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinsonâ€™s disease. Bioorganic and Medicinal Chemistry, 2013, 21, 5480-5487.	1.4	33
404	Robotic implantation of intracerebral electrodes for Deep Brain Stimulation. , 2013, , .		2
405	Rapid eye movement sleep behavior disorder as a biomarker for neurodegeneration: The past 10years. Sleep Medicine, 2013, 14, 763-767.	0.8	76
406	Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Research, 2013, 23, 746-758.	5.7	187
407	Specific needs of dopamine neurons for stimulation in order to survive: implication for Parkinson disease. FASEB Journal, 2013, 27, 3414-3423.	0.2	59
408	Scalp acupuncture for Parkinsonâ€™s disease: A systematic review of randomized controlled trials. Chinese Journal of Integrative Medicine, 2013, 19, 297-306.	0.7	38
409	Genetic analysis of the FBXO48 gene in Chinese Han patients with Parkinson disease. Neuroscience Letters, 2013, 541, 224-226.	1.0	10
410	Good and bad sides of diet in Parkinson's disease. Nutrition, 2013, 29, 474-475.	1.1	7
411	Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Animal Models for Parkinson's Disease. , 2013, , 633-650.		2
412	Parkinsonâ€™s disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 116, 469-483.	1.0	8

#	Article	IF	Citations
413	Pesticide-Induced Gene Mutations and Parkinson Disease Risk: A Meta-Analysis. Genetic Testing and Molecular Biomarkers, 2013, 17, 826-832.	0.3	20
414	Epigenetic Landscape of Parkinson's Disease: Emerging Role in Disease Mechanisms and Therapeutic Modalities. Neurotherapeutics, 2013, 10, 698-708.	2.1	69
415	Dietary and lifestyle variables in relation to incidence of Parkinsonâ€™s disease in Greece. European Journal of Epidemiology, 2013, 28, 67-77.	2.5	110
416	Geneâ€“environment interactions in Parkinson's disease: Specific evidence in humans and mammalian models. Neurobiology of Disease, 2013, 57, 38-46.	2.1	158
417	New Pharmacological Options for Treating Advanced Parkinsonâ€™s Disease. Clinical Therapeutics, 2013, 35, 1640-1652.	1.1	36
418	EMG signal morphology in essential tremor and Parkinson's disease. , 2013, 2013, 5765-8.		7
419	Diffusion tensor imaging and correlations to Parkinson rating scales. Journal of Neurology, 2013, 260, 2823-2830.	1.8	42
420	Genetic analysis of the FBXO42 gene in Chinese Han patients with Parkinsonâ€™s disease. BMC Neurology, 2013, 13, 125.	0.8	1
421	In vitro neuroprotective potential of four medicinal plants against rotenone-induced toxicity in SH-SY5Y neuroblastoma cells. BMC Complementary and Alternative Medicine, 2013, 13, 353.	3.7	32
422	Alcohol use disorders and risk of Parkinsonâ€™s disease: findings from a Swedish national cohort study 1972â€“2008. BMC Neurology, 2013, 13, 190.	0.8	39
423	Molecular chaperones and protein folding as therapeutic targets in Parkinsonâ€™s disease and other synucleinopathies. Acta Neuropathologica Communications, 2013, 1, 79.	2.4	73
424	Collection and Analysis of a Parkinson Speech Dataset With Multiple Types of Sound Recordings. IEEE Journal of Biomedical and Health Informatics, 2013, 17, 828-834.	3.9	459
425	Parkinson's Disease â€“ the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis. Journal of Parkinson's Disease, 2013, 3, 1-11.	1.5	79
426	Neuroprotective effects of mercaptoethylleonurine and mercaptoethylguanidine analogs on hydrogen peroxide-induced apoptosis in human neuronal SH-SY5Y cells. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1793-1796.	1.0	5
427	Occupational pesticide exposure and screening tests for neurodegenerative disease among an elderly population in Costa Rica. Environmental Research, 2013, 120, 96-101.	3.7	31
428	Towards an implantale intelligent CMOS neurotrophic factor delivery micro neural prosthetic for Parkinson's disease. , 2013, , .		5
429	Structure-based design and analysis of MAO-B inhibitors for Parkinsonâ€™s disease: using in silico approaches. Molecular Diversity, 2013, 17, 111-122.	2.1	11
430	Risk prediction for complex diseases: application to Parkinson disease. Genetics in Medicine, 2013, 15, 361-367.	1.1	14

#	Article	IF	Citations
431	Shining a light on seizure controlâ€"optogenetic approach shows promise for treatment and prevention of epilepsies. Nature Reviews Neurology, 2013, 9, 1-1.	4.9	4
432	Epigenetics in Parkinsonâ€™s and Alzheimerâ€™s Diseases. Sub-Cellular Biochemistry, 2013, 61, 507-525.	1.0	33
433	100 years of Lewy pathology. Nature Reviews Neurology, 2013, 9, 13-24.	4.9	939
434	Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: Age-relationship to safety and tolerability. Parkinsonism and Related Disorders, 2013, 19, 37-42.	1.1	30
435	Simvastatin Inhibited the Apoptosis of PC12 Cells Induced by 1-Methyl-4-Phenylpyridinium Ion via Inhibiting Reactive Oxygen Species Production. Cellular and Molecular Neurobiology, 2013, 33, 69-73.	1.7	9
436	C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain, 2013, 136, 385-391.	3.7	143
437	DJ1 analysis in a large cohort of Italian early onset Parkinson Disease patients. Neuroscience Letters, 2013, 557, 165-170.	1.0	11
438	MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates. Neuropharmacology, 2013, 66, 355-364.	2.0	57
439	Meta-analysis supports association of a functional SNP (rs1801133) in the MTHFR gene with Parkinson's disease. Gene, 2013, 531, 78-83.	1.0	11
440	Predictors of road crossing safety in pedestrians with Parkinson's disease. Accident Analysis and Prevention, 2013, 51, 202-207.	3.0	11
441	Î±7 Nicotinic receptor agonist reactivates neurogenesis in adult brain. Biochemical Pharmacology, 2013, 86, 1099-1104.	2.0	33
442	Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys. Neuropharmacology, 2013, 73, 216-231.	2.0	52
443	Pesticides, Microglial NOX2, and Parkinson's Disease. Journal of Biochemical and Molecular Toxicology, 2013, 27, 137-149.	1.4	50
444	A new modality for quantitative evaluation of Parkinson's disease: In-air movement. , 2013, , .		36
445	Diffusional kurtosis imaging of cingulate fibers in Parkinson disease: Comparison with conventional diffusion tensor imaging. Magnetic Resonance Imaging, 2013, 31, 1501-1506.	1.0	76
447	The identification of dysfunctional crosstalk of pathways in Parkinson disease. Gene, 2013, 515, 159-162.	1.0	13
448	The impact of motor and depressive symptoms on quality of life in patients with Parkinson's disease. Tzu Chi Medical Journal, 2013, 25, 175-178.	0.4	2
449	Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1974-1977.	1.0	28

#	Article	IF	Citations
450	Striatal shape in Parkinson's disease. Neurobiology of Aging, 2013, 34, 2510-2516.	1.5	60
451	Identification of Regulatory Relationships in Parkinson's Disease. Journal of Molecular Neuroscience, 2013, 51, 9-12.	1.1	3
452	Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat. European Journal of Neuroscience, 2013, 37, 231-241.	1.2	20
453	An ERcentric view of Parkinson's disease. Trends in Molecular Medicine, 2013, 19, 165-175.	3.5	169
454	Vascular Degeneration in <scp>P</scp>arkinson's Disease. Brain Pathology, 2013, 23, 154-164.	2.1	136
455	Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinsonâ€™s disease. Neurochemistry International, 2013, 62, 803-819.	1.9	250
456	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurology, The, 2013, 12, 514-524.	4.9	126
457	Statistical theories of functions and the problem of epidemic disease. Biology and Philosophy, 2013, 28, 423-438.	0.7	26
458	Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Metallomics, 2013, 5, 91.	1.0	64
459	Mitophagy and Parkinson's disease: Be eaten to stay healthy. Molecular and Cellular Neurosciences, 2013, 55, 37-43.	1.0	87
460	Probing and Regulating Dysfunctional Circuits Using Deep Brain Stimulation. Neuron, 2013, 77, 406-424.	3.8	519
461	The VPS35 gene and Parkinson's disease. Movement Disorders, 2013, 28, 569-575.	2.2	82
462	alpha-Synuclein and intracellular trafficking: impact on the spreading of Parkinsonâ€™s disease pathology. Journal of Molecular Medicine, 2013, 91, 693-703.	1.7	55
463	A metaâ€analysis of the relationship of the Parkin p.Val380Leu polymorphism to Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 235-244.	1.1	9
464	Solid-State 13C NMR Reveals Annealing of Raft-Like Membranes Containing Cholesterol by the Intrinsically Disordered Protein Î±-Synuclein. Journal of Molecular Biology, 2013, 425, 2973-2987.	2.0	60
465	Epigenetic targeting of histone deacetylase: Therapeutic potential in Parkinson's disease?. , 2013, 140, 34-52.		193
466	Psoriasis is associated with an increased risk of parkinsonism: A population-based 5-year follow-up study. Journal of the American Academy of Dermatology, 2013, 68, 992-999.	0.6	33
467	Incidence and Pathology of Synucleinopathies and Tauopathies Related to Parkinsonism. JAMA Neurology, 2013, 70, 859.	4.5	140

#	Article	IF	Citations
468	InÂVitro Study of Î±-Synuclein Protofibrils by Cryo-EM Suggests aÂCu2+-Dependent Aggregation Pathway. Biophysical Journal, 2013, 104, 2706-2713.	0.2	35
469	Neurosteroid and neurotransmitter alterations in Parkinsonâ€™s disease. Frontiers in Neuroendocrinology, 2013, 34, 132-142.	2.5	39
470	Behavioral and structural effects of unilateral intrastriatal injections of botulinum neurotoxin a in the rat model of Parkinson's disease. Journal of Neuroscience Research, 2013, 91, 838-847.	1.3	32
471	Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease. Brain Research, 2013, 1513, 103-116.	1.1	49
472	Parkinsonâ€™s disease in patients and obligate carriers of Gaucher disease. Parkinsonism and Related Disorders, 2013, 19, 129-131.	1.1	13
474	Evolving classifiers to inform clinical assessment of Parkinson's disease. , 2013, , .		8
475	Prediction potential of different handwriting tasks for diagnosis of Parkinson's. , 2013, , .		37
476	Risk factors for Parkinson's disease may differ in men and women: an exploratory study. Hormones and Behavior, 2013, 63, 308-314.	1.0	55
477	Substantia Nigra Hyperechogenicity as a Marker for Parkinson's Disease: A Population-Based Study. Neurodegenerative Diseases, 2013, 12, 212-218.	0.8	28
478	Chicken DT40 cell line lacking DJ-1, the gene responsible for familial Parkinson's disease, displays mitochondrial dysfunction. Neuroscience Research, 2013, 77, 228-233.	1.0	6
479	Methylphenidate. CNS Drugs, 2013, 27, 1-14.	2.7	40
480	Targeting the Chameleon: a Focused Look at Î±-Synuclein and Its Roles in Neurodegeneration. Molecular Neurobiology, 2013, 47, 446-459.	1.9	22
481	Mutations in GBA and risk of Parkinsonâ€™s disease: a meta-analysis based on 25 case-control studies. Neurological Research, 2013, 35, 873-878.	0.6	21
482	The effects of a mindfulness-based lifestyle programme for adults with Parkinsonâ€™s disease: protocol for a mixed methods, randomised two-group control study. BMJ Open, 2013, 3, e003326.	0.8	16
483	Safinamide: a novel anti-Parkinsonian drug with multiple actions. Neurodegenerative Disease Management, 2013, 3, 231-240.	1.2	6
484	Potentiation of response to low doses of levodopa in MPTP-injected monkeys by chemical unilateral subthalamotomy. Journal of Neurosurgery, 2013, 118, 180-191.	0.9	9
485	Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease. International Journal of Neuropsychopharmacology, 2013, 16, 1251-1258.	1.0	23
486	Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinsonâ€™s disease patients. Eye, 2013, 27, 507-514.	1.1	93

#	Article	IF	Citations
487	CLASSIFICATION OF PARKINSON'S DISEASE PATIENTS USING NONLINEAR PHONETIC FEATURES AND MEL-FREQUENCY CEPSTRAL ANALYSIS. Biomedical Engineering - Applications, Basis and Communications, 2013, 25, 1350001.	0.3	12
488	Unchanged safety outcomes in deep brain stimulation surgery for Parkinson disease despite a decentralization of care. Journal of Neurosurgery, 2013, 119, 1546-1555.	0.9	20
489	Vocabulary influences older and younger listeners' processing of dysarthric speech. Journal of the Acoustical Society of America, 2013, 134, 1358-1368.	0.5	42
490	Risk of Parkinson disease after depression. Neurology, 2013, 81, 1538-1544.	1.5	120
491	Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration. Journal of Parkinson's Disease, 2013, 3, 415-459.	1.5	68
492	Management of patients with Parkinson disease. Nurse Practitioner, 2013, 38, 34-43.	0.2	17
493	Genetic Variations of GAK in Two Chinese Parkinsonâ€™s Disease Populations: A Case-Control Study. PLoS ONE, 2013, 8, e67506.	1.1	18
494	Non-Linear EMG Parameters for Differential and Early Diagnostics of Parkinsonâ€™s Disease. Frontiers in Neurology, 2013, 4, 135.	1.1	41
495	Cross-cultural adaptation and analysis of the psychometric properties of the Balance Evaluation Systems Test and MiniBESTest in the elderly and individuals with Parkinson's disease: application of the Rasch model. Brazilian Journal of Physical Therapy, 2013, 17, 195-217.	1.1	70
496	A phenotypic model recapitulating the neuropathology of <scp>P</scp>arkinson's disease. Brain and Behavior, 2013, 3, 351-366.	1.0	26
497	The hallmarks of <scp>P</scp>arkinson's disease. FEBS Journal, 2013, 280, 5981-5993.	2.2	214
498	Predicting neurodegenerative disease in idiopathic rapid eye movement (REM) sleep behavior disorder: Conference proceedings, REM Sleep Behavior Symposium 2011. Sleep and Biological Rhythms, 2013, 11, 75-81.	0.5	5
499	Getting from whiteboard to white matter: Translational research tools for investigating neurological disease. , 2013, , .		0
501	Concise Review: Adult Mesenchymal Stem Cells, Adult Neural Crest Stem Cells, and Therapy of Neurological Pathologies: A State of Play. Stem Cells Translational Medicine, 2013, 2, 284-296.	1.6	69
502	Parkinson's Disease: From Genetics to Treatments. Cell Transplantation, 2013, 22, 639-652.	1.2	21
503	Glial Cell Line-Derived Neurotrophic Factor Partially Ameliorates Motor Symptoms without Slowing Neurodegeneration in Mice with Respiratory Chain-Deficient Dopamine Neurons. Cell Transplantation, 2013, 22, 1529-1539.	1.2	5
504	A cohort study on diet and the risk of Parkinson's disease: the role of food groups and diet quality. British Journal of Nutrition, 2013, 109, 329-337.	1.2	66
505	Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Movement Disorders, 2013, 28, 216-219.	2.2	112

#	Article	IF	Citations
506	Levodopa does not change cerebral vasoreactivity in Parkinson's disease. Movement Disorders, 2013, 28, 469-475.	2.2	15
507	Parkinsonâ€™s disease: dopaminergic nerve cell model is consistent with experimental finding of increased extracellular transport of Î±-synuclein. BMC Neuroscience, 2013, 14, 136.	0.8	16
508	Found in transcription: Accurate Parkinson's disease classification in peripheral blood. Journal of Parkinson's Disease, 2013, 3, 19-29.	1.5	27
509	Parkinson's and Alzheimer's diseases in Costa Rica: a feasibility study toward a national screening program. Global Health Action, 2013, 6, 23061.	0.7	6
510	Nitric Oxide Synthase, Green Tea Catechins and Parkinsonâ€™s Disease. , 2013, , 1425-1431.		0
511	Assessment of cardiorespiratory fitness using submaximal protocol in older adults with mood disorder and Parkinson's disease. Revista De Psiquiatria Clinica, 2013, 40, 88-92.	0.6	6
512	Neural Fate of Mesenchymal Stem Cells and Neural Crest Stem Cells: Which Ways to Get Neurons for Cell Therapy Purpose?. , 0, , .		5
513	Homocysteine and Parkinsonâ€™s Disease: A Complex Relationship. Journal of Neurological Disorders, 2013, 01, .	0.1	4
516	Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes. Degenerative Neurological and Neuromuscular Disease, 2013, 3, 33.	0.7	9
517	A Comparative White Matter Study with Parkinsonâ€²s disease,Parkinsonâ€²s Disease with Dementia and Alzheimerâ€²s Disease. , 2013, 03, 123.		18
518	Tom70 Is Essential for PINK1 Import into Mitochondria. PLoS ONE, 2013, 8, e58435.	1.1	49
519	Substitution p.A350V in Na+/Mg2+ Exchanger SLC41A1, Potentially Associated with Parkinson's Disease, Is a Gain-of-Function Mutation. PLoS ONE, 2013, 8, e71096.	1.1	60
520	Epidemiological Survey-Based Formulae to Approximate Incidence and Prevalence of Neurological Disorders in the United States: a Meta-Analysis. PLoS ONE, 2013, 8, e78490.	1.1	39
521	Alpha-Synuclein Expression in Patients with Parkinson's Disease: A Clinician's Perspective. Experimental Neurobiology, 2013, 22, 77-83.	0.7	31
522	DNA methylation, a hand behind neurodegenerative diseases. Frontiers in Aging Neuroscience, 2013, 5, 85.	1.7	140
523	From Human Past to Human Future. Humanities, 2013, 2, 20-55.	0.1	2
524	Motor Complications in Parkinsonâ€™s Disease: A Comprehensive Review of Emergent Management Strategies. CNS and Neurological Disorders - Drug Targets, 2013, 12, 1017-1049.	0.8	8
525	Differential Effects of Methyl-4-Phenylpyridinium Ion, Rotenone, and Paraquat on Differentiated SH-SY5Y Cells. Journal of Toxicology, 2013, 2013, 1-10.	1.4	29

#	Article	IF	Citations
526	SOD1 and DJ-1 Converge at Nrf2 Pathway: A Clue for Antioxidant Therapeutic Potential in Neurodegeneration. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-12.	1.9	101
527	The Demise of Poskanzer and Schwabâ€™s Influenza Theory on the Pathogenesis of Parkinsonâ€™s Disease. Parkinson's Disease, 2013, 2013, 1-7.	0.6	7
528	Domperidone in Parkinsonâ€™s Disease: A Perilous Arrhythmogenic or the Gold Standard?. Current Drug Safety, 2013, 8, 63-68.	0.3	37
529	Eryptosis as a marker of Parkinson's disease. Aging, 2014, 6, 788-819.	1.4	84
530	What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinsonâ€™s disease? Is the Significance Diagnostic or Prognostic?. Experimental Neurobiology, 2014, 23, 352-364.	0.7	16
531	Parkinsonâ€™s Disease and Risk of Fracture: A Meta-Analysis of Prospective Cohort Studies. PLoS ONE, 2014, 9, e94379.	1.1	32
532	Activation of MAPK and FoxO by Manganese (Mn) in Rat Neonatal Primary Astrocyte Cultures. PLoS ONE, 2014, 9, e94753.	1.1	40
533	Risk for Femoral Fractures in Parkinsonâ€™s Disease Patients with and without Severe Functional Impairment. PLoS ONE, 2014, 9, e97073.	1.1	33
534	Active Aging for Individuals with Parkinsonâ€™s Disease: Definitions, Literature Review, and Models. Parkinson's Disease, 2014, 2014, 1-8.	0.6	8
535	Mathematical Analysis of a Series of 4-Acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines: A Simple Way to Relate Quantum Similarity to Local Chemical Reactivity Using the Gaussian Orbitals Localized Theory. Journal of Theoretical Chemistry, 2014, 2014, 1-13.	1.5	7
536	Oral Rehabilitation of Parkinsonâ€™s Disease Patient: A Review and Case Report. Case Reports in Dentistry, 2014, 2014, 1-4.	0.2	6
537	Using the Satisfaction with Life Scale in People with Parkinsonâ€™s Disease: A Validation Study in Different European Countries. Scientific World Journal, The, 2014, 2014, 1-7.	0.8	27
538	Measuring Hemoglobin Levels in the Optic Disc of Parkinsonâ€™s Disease Patients Using New Colorimetric Analysis Software. Parkinson's Disease, 2014, 2014, 1-8.	0.6	7
539	An age-related shift of resting-state functional connectivity of the subthalamic nucleus: a potential mechanism for compensating motor performance decline in older adults. Frontiers in Aging Neuroscience, 2014, 6, 178.	1.7	27
540	Targeting GTPases in ParkinsonÃ¢â‚¬â„¢s disease: comparison to the historic path of kinase drug discovery and perspectives. Frontiers in Molecular Neuroscience, 2014, 7, 52.	1.4	12
541	Economic burden associated with chronic constipation in Sweden: a retrospective cohort study. ClinicoEconomics and Outcomes Research, 2014, 6, 369.	0.7	21
542	Proposed Motor Scoring System in a Porcine Model of Parkinsonâ€™s Disease induced by Chronic Subcutaneous Injection of MPTP. Experimental Neurobiology, 2014, 23, 258-265.	0.7	10
543	Effects of physical exercise on articular range of motion of the lower limb in the Parkinson's disease individuals. Fisioterapia E Pesquisa, 2014, 21, 167-173.	0.3	1

#	Article	IF	Citations
544	Applications of yoga in Parkinson's disease: a systematic literature review. Journal of Parkinsonism and Restless Legs Syndrome, 2014, , 1.	0.8	25
545	Mutations in PRKN and SNCA Genes Important for the Progress of Parkinsonâ€™s Disease. Current Genomics, 2014, 14, 502-517.	0.7	64
546	Possible Relation Between Trace Element Status and Clinical Outcomes in Parkinson Syndrome. , 2014, , .		0
547	The Role of Atg8 Homologue in Lewy Body Disease. , 2014, , 383-389.		0
548	Solving the puzzle of Parkinsonâ€™s disease using induced pluripotent stem cells. Experimental Biology and Medicine, 2014, 239, 1421-1432.	1.1	16
549	Catecholamine metabolism drives generation of mitochondrial DNA deletions in dopaminergic neurons. Brain, 2014, 137, 354-365.	3.7	41
550	Muscle artifacts in single trial EEG data distinguish patients with Parkinson's disease from healthy individuals. , 2014, 2014, 3292-5.		3
551	Systematic Review of Traditional Chinese Medicine for Depression in Parkinson's Disease. The American Journal of Chinese Medicine, 2014, 42, 1035-1051.	1.5	42
552	Disease Penetrance of Late-Onset Parkinsonism. JAMA Neurology, 2014, 71, 1535.	4.5	86
553	Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with Parkinsonâ€™s disease and Atypical Parkinsonian syndromes using DaTSCANÂ® SPECT. Annals of Nuclear Medicine, 2014, 28, 851-859.	1.2	29
554	Comorbidity and Chronic Conditions in the National Social Life, Health and Aging Project (NSHAP), Wave 2. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2014, 69, S154-S165.	2.4	86
555	Ethical Focal Points in the International Practice of Deep Brain Stimulation. AJOB Neuroscience, 2014, 5, 65-80.	0.6	21
556	Depression and Cognitive Impairment in Parkinson's Disease: A Role for Inflammation and Immunomodulation?. NeuroImmunoModulation, 2014, 21, 88-94.	0.9	45
558	Nanomedicine-Based Neuroprotective Strategies in Patient Specific-iPSC and Personalized Medicine. International Journal of Molecular Sciences, 2014, 15, 3904-3925.	1.8	15
559	Neuroprotective effect of Tinospora cordifolia ethanol extract on 6-hydroxy dopamine induced Parkinsonism. Indian Journal of Pharmacology, 2014, 46, 176.	0.4	76
560	Experience in Evaluating AAL Solutions in Living Labs. Sensors, 2014, 14, 7277-7311.	2.1	22
561	Involvement of Endocytosis and Alternative Splicing in the Formation of the Pathological Process in the Early Stages of Parkinsonâ€™s Disease. BioMed Research International, 2014, 2014, 1-6.	0.9	33
562	A Differential Item Functioning (DIF) Analysis of the Communicative Participation Item Bank (CPIB): Comparing Individuals With Parkinson's Disease From the United States and New Zealand. Journal of Speech, Language, and Hearing Research, 2014, 57, 90-95.	0.7	20

#	Article	IF	Citations
563	Cognitiveâ€“Perceptual Examination of Remediation Approaches to Hypokinetic Dysarthria. Journal of Speech, Language, and Hearing Research, 2014, 57, 1268-1283.	0.7	19
564	Recent Mitochondrial DNA Mutations Increase the Risk of Developing Common Late-Onset Human Diseases. PLoS Genetics, 2014, 10, e1004369.	1.5	131
565	Feasibility Study of a Wearable System Based on a Wireless Body Area Network for Gait Assessment in Parkinsonâ€™s Disease Patients. Sensors, 2014, 14, 4618-4633.	2.1	51
566	Molecular Chaperone Dysfunction in Neurodegenerative Diseases and Effects of Curcumin. BioMed Research International, 2014, 2014, 1-14.	0.9	94
567	Theoretical approach to setup a multi-antenna system for brain implants. , 2014, , .		1
568	<i>UCH-L1</i> S18Y Variant and Risk of Parkinson's Disease in Asian Populations: An Updated Meta-Analysis. Neurodegenerative Diseases, 2014, 14, 194-203.	0.8	4
570	Reproductive factors and Parkinson's disease risk in Danish women. European Journal of Neurology, 2014, 21, 1168.	1.7	23
571	Dynamic tension EMG to characterize the effects of DBS treatment of advanced Parkinson's disease. , 2014, 2014, 3248-51.		7
572	Initial management of Parkinson's disease. BMJ, The, 2014, 349, g6258-g6258.	3.0	52
573	In vitrodopaminergic neurotoxicity of pesticides: a link with neurodegeneration?. Veterinary Quarterly, 2014, 34, 120-131.	3.0	12
574	Designing auditory cues for Parkinson's disease gait rehabilitation. , 2014, 2014, 5852-5.		12
575	Smartphone application for classification of motor impairment severity in Parkinson's disease. , 2014, 2014, 2686-9.		36
576	The screening of the 3â€²UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinsonâ€™s disease. Journal of Human Genetics, 2014, 59, 346-348.	1.1	14
577	Safinamide for the treatment of Parkinsonâ€™s disease. Expert Review of Clinical Pharmacology, 2014, 7, 747-759.	1.3	17
578	Proposal of a Kinect^{TM}-based system for gait assessment and rehabilitation in Parkinson's disease. , 2014, 2014, 4519-22.		13
579	Proteomics as a new paradigm to tackle Parkinsonâ€™s disease research challenges. Translational Proteomics, 2014, 4-5, 1-17.	1.2	11
580	Review: The future of cell therapies and brain repair: <scp>P</scp>arkinson's disease leads the way. Neuropathology and Applied Neurobiology, 2014, 40, 60-70.	1.8	71
581	Relative Mortality in U.S. Medicare Beneficiaries with Parkinson Disease and Hip and Pelvic Fractures. Journal of Bone and Joint Surgery - Series A, 2014, 96, e27.	1.4	36

#	Article	IF	Citations
582	SNCA variants rs2736990 and rs356220 as risk factors for Parkinsonâ€™s disease but not for amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population. Neurobiology of Aging, 2014, 35, 2882.e1-2882.e6.	1.5	30
583	Transcriptional regulation of human <scp>USP</scp>24 gene expression by NFâ€kappa B. Journal of Neurochemistry, 2014, 128, 818-828.	2.1	11
584	Objective quantification of upper extremity motor functions in Unified Parkinson's Disease Rating Scale Test. , 2014, 2014, 5345-8.		5
585	Genetics and genomics of Parkinsonâ€™s disease. Genome Medicine, 2014, 6, 48.	3.6	152
586	Increased Risk of Parkinson's Disease in Patients with End-Stage Renal Disease: A Retrospective Cohort Study. Neuroepidemiology, 2014, 42, 204-210.	1.1	29
587	Protein Conformational Dynamics and Signaling in Evolution and Pathophysiology. , 2014, , 209-249.		4
588	A laboratory-based study on patients with Parkinsonâ€™s disease and seborrheic dermatitis: the presence and density of Malassezia yeasts, their different species and enzymes production. BMC Dermatology, 2014, 14, 5.	2.1	56
589	Substantial telomere shortening in the substantia nigra of telomerase-deficient mice does not increase susceptibility to MPTP-induced dopamine depletion. NeuroReport, 2014, 25, 335-339.	0.6	4
590	Effects of 24 wk of Treadmill Training on Gait Performance in Parkinsonâ€™s Disease. Medicine and Science in Sports and Exercise, 2014, 46, 645-655.	0.2	77
591	Clinicopathological Outcomes of Prospectively Followed Normal Elderly Brain Bank Volunteers. Journal of Neuropathology and Experimental Neurology, 2014, 73, 244-252.	0.9	65
592	Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 549-560.	1.5	99
593	The ubiquitin proteasome system in glia and its role in neurodegenerative diseases. Frontiers in Molecular Neuroscience, 2014, 7, 73.	1.4	99
594	Tremor. JAMA - Journal of the American Medical Association, 2014, 311, 948.	3.8	105
595	Tetranectin Knockout Mice Develop Features of Parkinson Disease. Cellular Physiology and Biochemistry, 2014, 34, 277-287.	1.1	24
596	Relationship and factor structure in multisystem neurodegeneration in Parkinson's disease. Acta Neurologica Scandinavica, 2014, 130, 347-353.	1.0	12
597	Inhibition of polyisoprenylated methylated protein methyl esterase by synthetic musks induces cell degeneration. Environmental Toxicology, 2014, 29, 466-477.	2.1	13
598	Genetic screens in Caenorhabditis elegans models for neurodegenerative diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1951-1959.	1.8	51
599	A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. Neurobiology of Aging, 2014, 35, 1125-1131.	1.5	83

#	Article	IF	Citations
600	Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporosis International, 2014, 25, 85-95.	1.3	66
601	Genetic analysis of the ATP1B4 gene in Chinese Han patients with Parkinsonâ€™s disease. Molecular Biology Reports, 2014, 41, 2307-2311.	1.0	4
602	Sexual dimorphism in xenobiotic genetic variants-mediated risk for Parkinsonâ€™s disease. Neurological Sciences, 2014, 35, 897-903.	0.9	7
603	Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration. Cellular and Molecular Life Sciences, 2014, 71, 1607-1622.	2.4	124
604	Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants. EMBO Journal, 2014, 33, 341-355.	3.5	65
605	A preliminary diffusional kurtosis imaging study of Parkinson disease: comparison with conventional diffusion tensor imaging. Neuroradiology, 2014, 56, 251-258.	1.1	94
606	Economic Evaluation of Ropinirole Prolonged Release for Treatment of Parkinsonâ€™s Disease in The Netherlands. Drugs and Aging, 2014, 31, 193-201.	1.3	8
607	Corynoxine, a Natural Autophagy Enhancer, Promotes the Clearance of Alpha-Synuclein via Akt/mTOR Pathway. Journal of NeuroImmune Pharmacology, 2014, 9, 380-387.	2.1	78
608	Roles for the TGFÎ² Superfamily in the Development and Survival of Midbrain Dopaminergic Neurons. Molecular Neurobiology, 2014, 50, 559-573.	1.9	32
609	Protective effects of Althaea officinalis L. extract in 6-hydroxydopamine-induced hemi-Parkinsonism model: behavioral, biochemical and histochemical evidence. Journal of Physiological Sciences, 2014, 64, 171-176.	0.9	12
610	Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?. Ageing Research Reviews, 2014, 14, 19-30.	5.0	681
611	Advances in the Genetics of Parkinson's Disease: A Guide for the Clinician. Movement Disorders Clinical Practice, 2014, 1, 3-13.	0.8	17
612	Alzheimer's and Parkinson's diseases: An environmental proteomic point of view. Journal of Proteomics, 2014, 104, 24-36.	1.2	7
613	Number and Brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 2014-2024.	1.1	72
614	A mutation in Drosophila methuselah resists paraquat induced Parkinson-like phenotypes. Neurobiology of Aging, 2014, 35, 2419.e1-2419.e16.	1.5	37
615	Levodopa Fractionation in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 89-96.	1.5	14
616	EMG signal morphology and kinematic parameters in essential tremor and Parkinsonâ€™s disease patients. Journal of Electromyography and Kinesiology, 2014, 24, 300-306.	0.7	44
617	Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 6804-6809.	3.3	183

#	Article	IF	Citations
618	Sleep disordered breathing in Parkinson's disease: A critical appraisal. Sleep Medicine Reviews, 2014, 18, 173-178.	3.8	62
619	Genetics of essential tremor: From phenotype to genes, insights from both human and mouse studies. Progress in Neurobiology, 2014, 119-120, 1-19.	2.8	27
620	Advanced Age, Cardiovascular Risk Burden, and Timed Up and Go Test Performance in Parkinson Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 1569-1575.	1.7	12
621	Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinsonâ€™s disease patients. Pharmacogenomics Journal, 2014, 14, 289-294.	0.9	27
622	Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development. Acta Neuropathologica, 2014, 127, 151-173.	3.9	44
623	The influence of cannabinoids on generic traits of neurodegeneration. British Journal of Pharmacology, 2014, 171, 1347-1360.	2.7	57
624	The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiology of Aging, 2014, 35, 266.e5-266.e14.	1.5	36
625	Neuronal calcium signaling: function and dysfunction. Cellular and Molecular Life Sciences, 2014, 71, 2787-2814.	2.4	501
626	Association between PITX3 promoter polymorphism and risk of Parkinson's disease: The impact of ethnicity and onset age. Neuroscience Letters, 2014, 561, 128-133.	1.0	6
627	MicroRNA-494 reduces DJ-1 expression and exacerbates neurodegeneration. Neurobiology of Aging, 2014, 35, 705-714.	1.5	93
628	Depression and impulse control disorders in Parkinson's disease: Two sides of the same coin?. Neuroscience and Biobehavioral Reviews, 2014, 38, 60-71.	2.9	86
629	Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet, The, 2014, 383, 1138-1146.	6.3	368
630	Alpha-synuclein interferes with cAMP/PKA-dependent upregulation of dopamine Î²-hydroxylase and is associated with abnormal adaptive responses to immobilization stress. Experimental Neurology, 2014, 252, 63-74.	2.0	34
631	The Novel Tetramethylpyrazine Bis-nitrone (TN-2) Protects Against MPTP/MPP+-Induced Neurotoxicity via Inhibition of Mitochondrial-Dependent Apoptosis. Journal of NeuroImmune Pharmacology, 2014, 9, 245-258.	2.1	35
632	Low power CMOS neurochemical biosensor application in an implantable intelligent neurotrophic factor delivery hybrid microsystem for Parkinson's. , 2014, , .		2
633	Methyl Yellow: A Potential Drug Scaffold for Parkinson's Disease. ChemBioChem, 2014, 15, 1591-1598.	1.3	7
634	Targeting the low-hanging fruit of neurodegeneration. Neurology, 2014, 83, 1470-1473.	1.5	19
635	Nourish the roots while picking the fruit. Neurology, 2014, 83, 1473-1475.	1.5	0

#	Article	IF	Citations
636	Destabilization of survival factor MEF2D <scp>mRNA</scp> by neurotoxin in models of Parkinson's disease. Journal of Neurochemistry, 2014, 130, 720-728.	2.1	27
637	Parkinson's disease pharmacogenomics: new findings and perspectives. Pharmacogenomics, 2014, 15, 1253-1271.	0.6	35
638	In Vivo Detection of Monoaminergic Degeneration in Early Parkinson Disease by ¹⁸F-9-Fluoropropyl-(+)-Dihydrotetrabenzazine PET. Journal of Nuclear Medicine, 2014, 55, 73-79.	2.8	48
639	A new Drosophila model to study the interaction between genetic and environmental factors in Parkinson×3s disease. Brain Research, 2014, 1583, 277-286.	1.1	27
640	Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinsonâ€™s-like movement disorder. Nature Communications, 2014, 5, 4930.	5.8	118
641	Neurological Disorders in the Arab World. , 2014, , .		5
642	Multiple sclerosis and risk of <scp>P</scp>arkinson's disease: a <scp>D</scp>anish nationwide cohort study. European Journal of Neurology, 2014, 21, 107-111.	1.7	16
643	Intrastriatal Transplantation of Retinal Pigment Epithelial Cells for the Treatment of Parkinson Disease: In Vivo Longitudinal Molecular Imaging with¹⁸F-P3BZA PET/CT. Radiology, 2014, 272, 174-183.	3.6	12
644	FABP3 Protein Promotes Î±-Synuclein Oligomerization Associated with 1-Methyl-1,2,3,6-tetrahydropiridine-induced Neurotoxicity. Journal of Biological Chemistry, 2014, 289, 18957-18965.	1.6	71
645	Electrical Stimuli in the Central Nervous System Microenvironment. Annual Review of Biomedical Engineering, 2014, 16, 397-430.	5.7	86
646	Genomic aspects of sporadic neurodegenerative diseases. Biochemical and Biophysical Research Communications, 2014, 452, 221-225.	1.0	20
647	Proteome analysis reveals roles of L-DOPA in response to oxidative stress in neurons. BMC Neuroscience, 2014, 15, 93.	0.8	28
648	The rise of mortality from mental and neurological diseases in Europe, 1979â€“2009: observational study. BMC Public Health, 2014, 14, 840.	1.2	21
649	Calcium signaling in Parkinsonâ€™s disease. Cell and Tissue Research, 2014, 357, 439-454.	1.5	100
650	A further update on the role of excitotoxicity in the pathogenesis of Parkinsonâ€™s disease. Journal of Neural Transmission, 2014, 121, 849-859.	1.4	160
651	The PD-associated alpha-synuclein promoter Rep1 allele 2 shows diminished frequency in restless legs syndrome. Neurogenetics, 2014, 15, 189-192.	0.7	15
652	Fibroblast growth factor 20 (FGF20) gene polymorphism and risk of Parkinsonâ€™s disease: a meta-analysis. Neurological Sciences, 2014, 35, 1889-1894.	0.9	14
653	Reduced risk of Parkinsonâ€™s disease associated with lower body mass index and heavy leisure-time physical activity. European Journal of Epidemiology, 2014, 29, 285-292.	2.5	60

#	Article	IF	Citations
654	Considerations on the role of environmental toxins in idiopathic Parkinsonâ€™s disease pathophysiology. Translational Neurodegeneration, 2014, 3, 10.	3.6	36
656	Dopa-decarboxylase gene polymorphisms affect the motor response to l-dopa in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 170-175.	1.1	50
657	Knowledge and attitudes towards genetic testing in those affected with Parkinsonâ€™s disease. Journal of Community Genetics, 2014, 5, 167-177.	0.5	16
658	Intracranial Applications of Magnetic Resonance-guided Focused Ultrasound. Neurotherapeutics, 2014, 11, 593-605.	2.1	55
659	Challenges and Promises in the Development of Neurotrophic Factor-Based Therapies for Parkinsonâ€™s Disease. Drugs and Aging, 2014, 31, 239-261.	1.3	25
660	The association between ambient exposure to organophosphates and Parkinson's disease risk. Occupational and Environmental Medicine, 2014, 71, 275-281.	1.3	87
661	Preventing Î±-synuclein aggregation: The role of the small heat-shock molecular chaperone proteins. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1830-1843.	1.8	70
662	Parkinson's disease and mitochondrial gene variations: A review. Journal of the Neurological Sciences, 2014, 346, 11-19.	0.3	26
663	Antioxidant action of 7,8-dihydroxyflavone protects PC12 cells against 6-hydroxydopamine-induced cytotoxicity. Neurochemistry International, 2014, 64, 18-23.	1.9	66
664	SLC6A3 is a risk factor for Parkinson's disease: A meta-analysis of sixteen yearsâ€™ studies. Neuroscience Letters, 2014, 564, 99-104.	1.0	33
665	Where are we with surgical therapies for Parkinson's disease?. Parkinsonism and Related Disorders, 2014, 20, S187-S191.	1.1	37
666	Neuromuscular Problems in Foot and Ankle. Foot and Ankle Clinics, 2014, 19, 1-16.	0.5	5
667	Mitochondrial impairment observed in fibroblasts from South African Parkinsonâ€™s disease patients with parkin mutations. Biochemical and Biophysical Research Communications, 2014, 447, 334-340.	1.0	27
668	Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet, The, 2014, 384, 545-555.	6.3	336
669	Stemming the Hype: What Can We Learn from iPSC Models of Parkinson's Disease and How Can We Learn It?. Journal of Parkinson's Disease, 2014, 4, 15-27.	1.5	14
670	Stem Cells on the Brain: Modeling Neurodevelopmental and Neurodegenerative Diseases Using Human Induced Pluripotent Stem Cells. Journal of Neurogenetics, 2014, 28, 5-29.	0.6	52
671	Discovery of Vinyl Sulfones as a Novel Class of Neuroprotective Agents toward Parkinsonâ€™s Disease Therapy. Journal of Medicinal Chemistry, 2014, 57, 1473-1487.	2.9	205
672	Impulsive and Compulsive Behaviors in Parkinson's Disease. Annual Review of Clinical Psychology, 2014, 10, 553-580.	6.3	54

#	Article	IF	Citations
673	The chaperone-like protein 14-3-3Î· interacts with human Î±-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing Î±-synuclein cellular toxicity. Human Molecular Genetics, 2014, 23, 5615-5629.	1.4	56
674	A cyclodextrin-based approach for selective detection of catecholamine hormone mixtures. Micro and Nano Systems Letters, 2014, 2, .	1.7	13
675	Guanosine exerts neuroprotective effects by reversing mitochondrial dysfunction in a cellular model of Parkinsonâ€™s disease. International Journal of Molecular Medicine, 2014, 34, 1358-1364.	1.8	21
676	The â€˜Swallow Tailâ€™ Appearance of the Healthy Nigrosome â€“ A New Accurate Test of Parkinson's Disease: A Case-Control and Retrospective Cross-Sectional MRI Study at 3T. PLoS ONE, 2014, 9, e93814.	1.1	252
677	Effects of Balance and Gait Training on the Recovery of the Motor Function in an Animal Model of Parkinsonâ€™s Disease. Journal of Physical Therapy Science, 2014, 26, 905-908.	0.2	6
678	Interventions for improving medication adherence in patients with idiopathic Parkinson's disease. The Cochrane Library, 0, , .	1.5	1
679	A Novel 6-Item Screening Questionnaire for Parkinsonism: Validation and Comparison Between Different Instruments. Neuroepidemiology, 2014, 43, 178-193.	1.1	14
680	Mortality in Parkinson's disease: A systematic review and metaâ€analysis. Movement Disorders, 2014, 29, 1615-1622.	2.2	229
682	Prominent extensor truncal dystonia in egyptian patients with Wilson's disease. Movement Disorders, 2014, 29, 151-153.	2.2	2
683	Relation of clinical subtypes in Parkinson's disease with survival. Movement Disorders, 2014, 29, 150-151.	2.2	32
684	An algorithm for processing and analysis of Gas Chromatography-Mass Spectrometry (GC-MS) signals for early detection of Parkinson's disease. , 2014, , .		1
685	Creatine for Parkinson's disease. The Cochrane Library, 2014, , CD009646.	1.5	8
686	Non-motor symptoms: the core of multi-morbid Parkinson's disease. British Journal of Hospital Medicine (London, England: 2005), 2014, 75, 18-24.	0.2	38
687	Bypassing the bloodâ€“brian barrier using established skull base reconstruction techniques. World Journal of Otorhinolaryngology - Head and Neck Surgery, 2015, 1, 11-16.	0.7	7
688	Measurement of anteriorly flexed trunk posture in Parkinson's disease (PD): a systematic review. Physical Therapy Reviews, 2015, 20, 225-232.	0.3	6
689	MDS research criteria for prodromal Parkinson's disease. Movement Disorders, 2015, 30, 1600-1611.	2.2	1,033
690	Exercise as medicine â€“ evidence for prescribing exercise as therapy in 26 different chronic diseases. Scandinavian Journal of Medicine and Science in Sports, 2015, 25, 1-72.	1.3	2,111
691	Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinsonâ€™s disease. Scientific Reports, 2015, 5, 13888.	1.6	116

#	Article	IF	Citations
692	Tianma Gouteng Yin, a Traditional Chinese Medicine decoction, exerts neuroprotective effects in animal and cellular models of Parkinsonâ€™s disease. Scientific Reports, 2015, 5, 16862.	1.6	53
693	Dopaminergic Modulation of Arm Swing During Gait Among Parkinson's Disease Patients. Journal of Parkinson's Disease, 2015, 5, 141-150.	1.5	41
694	Non-invasive brain stimulation for Parkinsonâ€™s disease: Current concepts and outlook 2015. NeuroRehabilitation, 2015, 37, 11-24.	0.5	52
695	Unveiling transient protein-protein interactions that modulate inhibition of alpha-synuclein aggregation by beta-synuclein, a pre-synaptic protein that co-localizes with alpha-synuclein. Scientific Reports, 2015, 5, 15164.	1.6	53
696	Impact in oral health and the prevalence of temporomandibular disorder in individuals with Parkinsonâ€™s disease. Journal of Physical Therapy Science, 2015, 27, 887-891.	0.2	19
697	Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson's disease. The Cochrane Library, 0, , .	1.5	0
698	Is Parkinsonâ€™s Disease Truly a Prion-Like Disorder? An Appraisal of Current Evidence. Neurology Research International, 2015, 2015, 1-8.	0.5	23
699	Adverse Reactions to Antipsychotics in Parkinson Disease. Clinical Neuropharmacology, 2015, 38, 69-84.	0.2	20
700	Nonlinear parameters of surface electromyogram for diagnostics of neuromuscular disorders and normal conditions of the human motor system. Human Physiology, 2015, 41, 672-679.	0.1	6
701	Bioinformatic analysis of microRNA expression in Parkinsonâ€™s disease. Molecular Medicine Reports, 2015, 11, 1079-1084.	1.1	13
702	Evidence-based treatment of voice and speech disorders in Parkinson disease. Current Opinion in Otolaryngology and Head and Neck Surgery, 2015, 23, 209-215.	0.8	71
703	Sleep disorders in Parkinson's disease. Postepy Psychiatrii I Neurologii, 2015, 24, 147-155.	0.2	0
704	Protective effect of a novel herbmedicine, Hepad, on apoptosis of SH-SY5Y cells and a rat model of Parkinsonâ€™s disease. Molecular and Cellular Toxicology, 2015, 11, 223-230.	0.8	6
705	Interaction between SNCA, LRRK2 and GAK increases susceptibility to Parkinson's disease in a Chinese population. ENeurologicalSci, 2015, 1, 3-6.	0.5	9
706	Sleep in Neurodegenerative Disorders. Current Sleep Medicine Reports, 2015, 1, 81-90.	0.7	8
707	Wearable multimodal sensors for evaluation of patients with Parkinson disease. , 2015, , .		16
708	PDON: Parkinsonâ€™s disease ontology for representation and modeling of the Parkinsonâ€™s disease knowledge domain. Theoretical Biology and Medical Modelling, 2015, 12, 20.	2.1	29
709	The associations between Parkinsonâ€™s disease and cancer: the plot thickens. Translational Neurodegeneration, 2015, 4, 20.	3.6	77

#	Article	IF	Citations
710	Scanning laser polarimetry and spectral domain optical coherence tomography for the detection of retinal changes in Parkinson's disease. Acta Ophthalmologica, 2015, 93, e672-7.	0.6	21
712	Lâ€dopa increases Î±â€synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro. Movement Disorders, 2015, 30, 1794-1801.	2.2	81
713	TheEIF4G1gene and Parkinson's disease. Acta Neurologica Scandinavica, 2015, 132, 73-78.	1.0	34
714	Exploring the Relationship Between Activity and Physical Participation in Older Adults With Parkinson's Disease. Topics in Geriatric Rehabilitation, 2015, 31, 145-151.	0.2	4
715	A Multipurpose Ligninâ€based Adsorbent for Metallic Ions, Nanoparticles and Various Organophosphate Pesticides in Hexane. Journal of the Chinese Chemical Society, 2015, 62, 875-888.	0.8	6
716	Genetic analysis of SLC41A1 in Chinese Parkinson's disease patients. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015, 168, 706-711.	1.1	13
717	Modeling Neuronal Pathology in Yeast: Insights into the Molecular Basis of Parkinsonâ€™s Disease. Israel Journal of Chemistry, 2015, 55, 1252-1259.	1.0	0
718	Familial aggregation of Parkinson's disease in the Faroe Islands. Movement Disorders, 2015, 30, 538-544.	2.2	15
719	The Brainstem Pathologies of Parkinson's Disease and Dementia with Lewy Bodies. Brain Pathology, 2015, 25, 121-135.	2.1	214
720	DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients. European Journal of Neurology, 2015, 22, 1323-1325.	1.7	21
721	Prevalence and Risk Factors of Cognitive Impairment in Parkinson Disease. Medicine (United States), 2015, 94, e782.	0.4	4
722	Risk of developing <scp>P</scp>arkinson's disease among patients with asthma: a nationwide longitudinal study. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1605-1612.	2.7	35
723	Constitutional Study of Parkinson's Disease Patients Based on Traditional Chinese Medicine Pattern Differentiation. Integrative Medicine International, 2015, 1, 170-175.	0.6	2
725	Parkinsonâ€™s disease: A population-based investigation of life satisfaction and employment. Journal of Rehabilitation Medicine, 2015, 47, 45-51.	0.8	29
726	Markers of ParkinsonÃ‚â€™s Disease Progression Using Cerebrovascular, Autonomic and Small Fiber Polyneuropathy Features. Journal of Neurological Disorders, 2015, 03, .	0.1	0
727	The Significance of Experiences of Nature for People with Parkinsonâ€™s Disease, with Special Focus on Freezing of Gaitâ€"The Necessity for a Biophilic Environment. A Multi-Method Single Subject Study. International Journal of Environmental Research and Public Health, 2015, 12, 7274-7299.	1.2	12
728	Clinical neurorestorative progress in Parkinson's disease. Journal of Neurorestoratology, 0, , 101.	1.1	7
729	Chronic HIV-1 Tat and HIV Reduce Rbfox3/NeuN: Evidence for Sex- Related Effects. Current HIV Research, 2015, 13, 10-20.	0.2	13

#	Article	IF	Citations
730	Recent Patents and Advances in Regenerative Medicine and Stem Cell Therapies for Diabetes, Cardiovascular and Neurodegenerative Diseases. Recent Patents on Regenerative Medicine, 2015, 5, 36-54.	0.4	0
731	Nanotechnology platforms in Parkinsonâ€™s Disease. ADMET and DMPK, 2015, 3, .	1.1	16
732	Obstructive sleep apnea and neurodegenerative diseases: A bidirectional relation. Dementia E Neuropsychologia, 2015, 9, 9-15.	0.3	12
733	Treating patients with movement disorders using MRI-guided focused ultrasound: recent developments and challenges. Research and Reports in Focused Ultrasound, 2015, , 5.	0.2	1
734	Protective Effects of Lycium barbarum Polysaccharide on 6-OHDA-Induced Apoptosis in PC12 Cells through the ROS-NO Pathway. Molecules, 2015, 20, 293-308.	1.7	69
735	Associations between B Vitamins and Parkinsonâ€™s Disease. Nutrients, 2015, 7, 7197-7208.	1.7	89
736	Technologies for Assessment of Motor Disorders in Parkinsonâ€™s Disease: A Review. Sensors, 2015, 15, 21710-21745.	2.1	56
737	Force Variability during Dexterous Manipulation in Individuals with Mild to Moderate Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2015, 7, 151.	1.7	13
738	GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for ParkinsonÃ¢â‚¬â„¢s disease. Frontiers in Neuroanatomy, 2015, 9, 10.	0.9	78
739	CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. Frontiers in Neurology, 2015, 6, 91.	1.1	60
740	Morphological alterations in the caudate, putamen, pallidum, and thalamus in Parkinson's disease. Frontiers in Neuroscience, 2015, 9, 101.	1.4	55
741	Olfactory Dysfunction and Neurotransmitter Disturbance in Olfactory Bulb of Transgenic Mice Expressing Human A53T Mutant Î±-Synuclein. PLoS ONE, 2015, 10, e0119928.	1.1	57
742	Effects of Resistance Training on Measures of Muscular Strength in People with Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0132135.	1.1	46
743	Enrichment of Minor Alleles of Common SNPs and Improved Risk Prediction for Parkinson's Disease. PLoS ONE, 2015, 10, e0133421.	1.1	26
744	Genetic Variants of SNCA Are Associated with Susceptibility to Parkinsonâ€™s Disease but Not Amyotrophic Lateral Sclerosis or Multiple System Atrophy in a Chinese Population. PLoS ONE, 2015, 10, e0133776.	1.1	34
745	An Effective Method to Identify Shared Pathways and Common Factors among Neurodegenerative Diseases. PLoS ONE, 2015, 10, e0143045.	1.1	35
746	Parkinsonâ€™s Disease Prevalence and Proximity to Agricultural Cultivated Fields. Parkinson's Disease, 2015, 2015, 1-7.	0.6	7
747	Rapid Screening for Cognitive Impairment in Parkinsonâ€™s Disease: A Pilot Study. Parkinson's Disease, 2015, 2015, 1-6.	0.6	6

#	Article	IF	Citations
748	Potential of Neural Stem Cell-Based Therapy for Parkinsonâ€™s Disease. Parkinson's Disease, 2015, 2015, 1-9.	0.6	29
749	German Translation and Validation of the â€œFreezing of Gait Questionnaireâ€•in Patients with Parkinsonâ€™s Disease. Parkinson's Disease, 2015, 2015, 1-5.	0.6	20
750	Reduced Risk of Parkinsonâ€™s Disease in Users of Calcium Channel Blockers: A Meta-Analysis. International Journal of Chronic Diseases, 2015, 2015, 1-7.	1.9	33
751	Clinical Features Associated with Frozen Shoulder Syndrome in Parkinsonâ€™s Disease. Parkinson's Disease, 2015, 2015, 1-7.	0.6	3
752	Physical Training Regulates Mitochondrial Parameters and Neuroinflammatory Mechanisms in an Experimental Model of Parkinsonâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-10.	1.9	61
754	Mobile health and Parkinson: what is the future?. Journal of Innovation in Health Informatics, 2015, 22, 377-378.	0.9	1
755	Sleep Disturbances in Essential Tremor and Parkinson Disease: A Polysomnographic Study. Journal of Clinical Sleep Medicine, 2015, 11, 655-662.	1.4	26
756	A 5-Year Follow-up Study on the Relationship between Obstructive Sleep Apnea and Parkinson Disease. Journal of Clinical Sleep Medicine, 2015, 11, 1403-1408.	1.4	43
757	Imaging amyloidopathy in Parkinson disease and parkinsonian dementia syndromes. Clinical and Translational Imaging, 2015, 3, 57-64.	1.1	22
758	Ginkgo for Alzheimer×³s Disease, Tai Chi for Parkinson×³s Disease Revisited, Acupuncture for Postoperative Vomiting, Cranberry for Urinary Tract Infection, Curcuma domestica for knee osteoarthritis. Explore: the Journal of Science and Healing, 2015, 11, 326-330.	0.4	0
759	A New Evolutionary Fuzzy Instance-Based Learning Approach: Application for Detection of Parkinsonâ€™s Disease. Lecture Notes in Computer Science, 2015, , 42-50.	1.0	2
760	Hippocampal Neurogenesis in Neurodegenerative Movement Disorders. Pancreatic Islet Biology, 2015, , 79-105.	0.1	0
761	A Systematic Review of Key Issues in Public Health. , 2015, , .		6
763	Correlating Parkinsonâ€™s disease motor symptoms with three-dimensional [18F]FP-CIT PET. Japanese Journal of Radiology, 2015, 33, 609-618.	1.0	8
764	Occupational exposures and Parkinson's disease mortality in a prospective Dutch cohort. Occupational and Environmental Medicine, 2015, 72, 448-455.	1.3	48
765	To operate or not?: A literature review of surgical outcomes in 95 patients with Parkinson's disease undergoing spine surgery. Clinical Neurology and Neurosurgery, 2015, 134, 122-125.	0.6	31
766	Microcirculation of the brain: morphological assessment in degenerative diseases and restoration processes. Reviews in the Neurosciences, 2015, 26, 75-93.	1.4	20
767	Ventral midbrain dopaminergic neurons: From neurogenesis to neurodegeneration. FEBS Letters, 2015, 589, 3691-3692.	1.3	3

#	Article	IF	Citations
768	Autonomic nervous system response to L-dopa in patients with advanced Parkinson's disease. , 2015, 2015, 6162-5.		3
769	Tetranectin gene deletion induces Parkinson's disease by enhancing neuronal apoptosis. Biochemical and Biophysical Research Communications, 2015, 468, 400-407.	1.0	16
770	A constraint-based modelling approach to metabolic dysfunction in Parkinson's disease. Computational and Structural Biotechnology Journal, 2015, 13, 484-491.	1.9	5
771	La maladie de ParkinsonÂ: un facteur de risque dâ€™ostÃ©oporose. Revue Du Rhumatisme (Edition Francaise), 2015, 82, 368-372.	0.0	0
772	Computational approaches for understanding the diagnosis and treatment of Parkinson's disease. IET Systems Biology, 2015, 9, 226-233.	0.8	15
773	Elevated excretion of biopyrrin as a new marker for idiopathic Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 1371-1372.	1.1	17
774	EchoWear. , 2015, , .		39
775	Memory Similarities Between Essential Tremor and Parkinsonâ€™s Disease: A Final Common Pathway?. Clinical Neuropsychologist, 2015, 29, 985-1001.	1.5	13
776	Control of ventricular excitability by neurons of the dorsal motor nucleus of the vagus nerve. Heart Rhythm, 2015, 12, 2285-2293.	0.3	82
777	Protective effects of apigenin against 1-methyl-4-phenylpyridinium ion-induced neurotoxicity in PC12 cells. International Journal of Molecular Medicine, 2015, 35, 739-746.	1.8	25
778	Validation of Secondary Data Sources to Identify Parkinson Disease Against Clinical Diagnostic Criteria. American Journal of Epidemiology, 2015, 181, 185-190.	1.6	16
779	Management of constipation in Parkinsonâ€™s disease. Expert Opinion on Pharmacotherapy, 2015, 16, 547-557.	0.9	45
780	A Review of the Potential Role of Nano-Enabled Drug Delivery Technologies in Amyotrophic Lateral Sclerosis: Lessons Learned from Other Neurodegenerative Disorders. Journal of Pharmaceutical Sciences, 2015, 104, 1213-1229.	1.6	28
781	Characterizing gait asymmetry via frequency sub-band components of the ground reaction force. Biomedical Signal Processing and Control, 2015, 18, 56-60.	3.5	38
782	Macronutrients intake and risk of <scp>P</scp>arkinson's disease: A metaâ€analysis. Geriatrics and Gerontology International, 2015, 15, 606-616.	0.7	30
783	Selenium reduces bradykinesia and DNA damage in a rat model of Parkinson's disease. Nutrition, 2015, 31, 359-365.	1.1	39
784	Systematic review and meta-analysis of hydrocarbon exposure and the risk of Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 243-248.	1.1	11
785	Effects of Omega-3 on Neurodegenerative Diseases and Stroke. , 2015, , 187-201.		0

#	Article	IF	Citations
786	Effects of Repetitive Transcranial Magnetic Stimulation on Motor Symptoms in Parkinson Disease. JAMA Neurology, 2015, 72, 432.	4.5	169
787	LCâ€“MS-Based Urinary Metabolite Signatures in Idiopathic Parkinsonâ€™s Disease. Journal of Proteome Research, 2015, 14, 467-478.	1.8	114
788	Grip Force Modulation Characteristics as a Marker for Clinical Disease Progression in Individuals With Parkinson Disease: Case-Control Study. Physical Therapy, 2015, 95, 369-379.	1.1	28
789	Metacognitions, anxiety, and distress related to motor fluctuations in Parkinson's disease. Journal of Psychosomatic Research, 2015, 78, 143-148.	1.2	32
790	Rodent Models of Autosomal Dominant Parkinson Disease. , 2015, , 307-328.		0
791	Risk and adverse outcomes of fractures in patients with Parkinsonâ€™s disease: two nationwide studies. Osteoporosis International, 2015, 26, 1723-1732.	1.3	29
792	Nanoparticle technology for treatment of Parkinson's disease: the role of surface phenomena in reaching the brain. Drug Discovery Today, 2015, 20, 824-837.	3.2	77
793	Experiences of apathy in people with Parkinsonâ€™s disease: a qualitative exploration. Disability and Rehabilitation, 2015, 37, 611-619.	0.9	14
794	Dietary cholesterol, fats and risk of Parkinson's disease in the Singapore Chinese Health Study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-310065.	0.9	27
795	Evidence for a common biological pathway linking three Parkinson's diseaseâ€causing genes: parkin, PINK1 and DJâ€1. European Journal of Neuroscience, 2015, 41, 1113-1125.	1.2	87
796	Low-frequency repetitive transcranial magnetic stimulation on Parkinson motor function: a meta-analysis of randomised controlled trials. Acta Neuropsychiatrica, 2015, 27, 82-89.	1.0	27
797	The epigenetics of aging and neurodegeneration. Progress in Neurobiology, 2015, 131, 21-64.	2.8	334
798	Therapeutic potential of PACAP for neurodegenerative diseases. Cellular and Molecular Biology Letters, 2015, 20, 265-78.	2.7	33
799	Chaperone-mediated autophagy: roles in neuroprotection. Neuroscience Bulletin, 2015, 31, 452-458.	1.5	24
800	Edaravone leads to proteome changes indicative of neuronal cell protection in response to oxidative stress. Neurochemistry International, 2015, 90, 134-141.	1.9	38
801	Is early-life iron exposure critical in neurodegeneration?. Nature Reviews Neurology, 2015, 11, 536-544.	4.9	86
802	A Meta-Analysis of Mesenchymal Stem Cells in Animal Models of Parkinson's Disease. Stem Cells and Development, 2015, 24, 2082-2090.	1.1	26
803	Quercetin in brain diseases: Potential and limits. Neurochemistry International, 2015, 89, 140-148.	1.9	87

#	Article	IF	Citations
804	Neurobehavioral Sequelae of Psychostimulant Abuse. International Review of Neurobiology, 2015, 120, 161-177.	0.9	2
805	Tea Polyphenols in Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2015, 863, 117-137.	0.8	67
806	Validation and reliability of a modified sphygmomanometer for the assessment of handgrip strength in ParkinsonÂ´s disease. Brazilian Journal of Physical Therapy, 2015, 19, 137-145.	1.1	16
807	Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?. Frontiers in Psychiatry, 2015, 6, 32.	1.3	127
808	Neuronal adhesion, proliferation and differentiation of embryonic stem cells on hybrid scaffolds made of xanthan and magnetite nanoparticles. Biomedical Materials (Bristol), 2015, 10, 045002.	1.7	46
809	Channeled polymeric scaffolds with polypeptide gel filling for lengthwise guidance of neural cells. European Polymer Journal, 2015, 70, 331-341.	2.6	2
810	Fruit Fly Optimization Algorithm Based SVM Classifier for Efficient Detection of Parkinsonâ€™s Disease. Lecture Notes in Computer Science, 2015, , 98-106.	1.0	2
811	Utility of Autoantibodies as Biomarkers for Diagnosis and Staging of Neurodegenerative Diseases. International Review of Neurobiology, 2015, 122, 1-51.	0.9	39
812	Genetic analysis of the RAB39B gene in Chinese Han patients with Parkinson's disease. Neurobiology of Aging, 2015, 36, 2907.e11-2907.e12.	1.5	39
813	Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurology, The, 2015, 14, 795-803.	4.9	219
814	Epidemiology of early-onset Parkinson's disease in Finland. Parkinsonism and Related Disorders, 2015, 21, 938-942.	1.1	24
815	Natural Compounds as Therapeutic Agents for Amyloidogenic Diseases. Advances in Experimental Medicine and Biology, 2015, , .	0.8	7
816	Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinsonâ€™s disease in rats. Neuroscience Letters, 2015, 600, 220-225.	1.0	28
817	Understanding the Influence of Parkinson Disease on Adolf Hitler's Decision-Making during World War II. World Neurosurgery, 2015, 84, 1447-1452.	0.7	8
818	Parkinson's disease and intensive exercise therapy â€“ a systematic review and meta-analysis of randomized controlled trials. Journal of the Neurological Sciences, 2015, 353, 9-19.	0.3	151
819	Structural and functional neuroimaging in patients with Parkinson's disease and visual hallucinations: A critical review. Parkinsonism and Related Disorders, 2015, 21, 683-691.	1.1	85
820	Parkinsonâ€™s disease and enhanced inflammatory response. Experimental Biology and Medicine, 2015, 240, 1387-1395.	1.1	116
821	Parkinson's disease. Lancet, The, 2015, 386, 896-912.	6.3	4,079

#	Article	IF	Citations
822	Association of MTHFR C677T with total homocysteine plasma levels and susceptibility to Parkinsonâ€™s disease: a meta-analysis. Neurological Sciences, 2015, 36, 945-951.	0.9	26
823	Reliability of administrative data for the identification of Parkinsonâ€™s disease cohorts. Neurological Sciences, 2015, 36, 783-786.	0.9	23
824	A tripeptide isolated from Bothrops atrox venom has neuroprotective and neurotrophic effects on a cellular model of Parkinsonâ€™s disease. Chemico-Biological Interactions, 2015, 235, 10-16.	1.7	16
825	Comparing interventions and exploring neural mechanisms of exercise in Parkinson disease: a study protocol for a randomized controlled trial. BMC Neurology, 2015, 15, 9.	0.8	31
826	Transcription factor myocyte enhancer factor 2D regulates interleukin-10 production in microglia to protect neuronal cells from inflammation-induced death. Journal of Neuroinflammation, 2015, 12, 33.	3.1	39
827	The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinsonâ€™s disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Research, 2015, 5, 12.	1.1	91
828	Peripheral Vagus Nerve Stimulation Significantly Affects Lipid Composition and Protein Secondary Structure Within Dopamine-Related Brain Regions in Rats. NeuroMolecular Medicine, 2015, 17, 178-191.	1.8	19
829	Control of Autophagy in Parkinsonâ€™s Disease. Current Topics in Neurotoxicity, 2015, , 91-122.	0.4	1
830	Protein Misfolding, Neurodegeneration and Tau. , 2015, , 1-38.		0
831	Rab11 modulates Î±-synuclein-mediated defects in synaptic transmission and behaviour. Human Molecular Genetics, 2015, 24, 1077-1091.	1.4	94
833	Dietary Supplementation of Walnut Partially Reverses 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Induced Neurodegeneration in a Mouse Model of Parkinsonâ€™s Disease. Neurochemical Research, 2015, 40, 1283-1293.	1.6	23
834	Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinsonâ€™s disease. Brain, 2015, 138, 1271-1283.	3.7	51
835	History and Perspectives of A_{2A}Adenosine Receptor Antagonists as Potential Therapeutic Agents. Medicinal Research Reviews, 2015, 35, 790-848.	5.0	88
836	Deep brain stimulation for treating Parkinsonâ€™s disease. , 2015, , 341-359.		2
837	Adult Neurogenesis in Neurodegenerative Diseases: Figure 1.. Cold Spring Harbor Perspectives in Biology, 2015, 7, a021287.	2.3	258
839	Computer-Aided Diagnosis of Parkinsonâ€™s Disease Using Enhanced Probabilistic Neural Network. Journal of Medical Systems, 2015, 39, 179.	2.2	122
840	Evolvable Hardware. Natural Computing Series, 2015, , .	2.2	14
841	Wireless power distribution system for brain implants. , 2015, , .		3

#	Article	IF	Citations
842	Bent out of shape: Î±â€Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. FEBS Letters, 2015, 589, 3749-3759.	1.3	50
843	A Clinical Study of Integrating Acupuncture and Western Medicine in Treating Patients with Parkinson's Disease. The American Journal of Chinese Medicine, 2015, 43, 407-423.	1.5	34
844	Parkinson's disease proteins: Novel mitochondrial targets for cardioprotection. , 2015, 156, 34-43.		48
845	Neurodegenerative Disorders as Systemic Diseases. , 2015, , .		2
846	Animal models of Parkinson's disease: An updated overview. Revue Neurologique, 2015, 171, 750-761.	0.6	83
847	TCEANC2 rs10788972 and rs12046178 variants in the PARK10 region in Chinese Han patients with sporadic Parkinson's disease. Neurobiology of Aging, 2015, 36, 3335.e1-3335.e2.	1.5	11
848	Estimating the direct and indirect costs associated with Parkinsonâ€™s disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 889-911.	0.7	56
849	G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system. Journal of Neural Transmission, 2015, 122, 1645-1657.	1.4	12
850	Î±-Synuclein and nonhuman primate models of Parkinson's disease. Journal of Neuroscience Methods, 2015, 255, 38-51.	1.3	29
851	Association between cigarette smoking and Parkinsonâ€™s disease: A meta-analysis. Archives of Gerontology and Geriatrics, 2015, 61, 510-516.	1.4	119
852	Challenges and strategies of medication adherence in Parkinson's disease: A qualitative study. Geriatric Nursing, 2015, 36, 192-196.	0.9	32
853	Entacapone and <scp>P</scp>rostate <scp>C</scp>ancer <scp>R</scp>isk in <scp>P</scp>atients <scp>W</scp>ith <scp>P</scp>arkinson's <scp>D</scp>isease. Movement Disorders, 2015, 30, 724-728.	2.2	6
854	Monitoring Parkinson's Disease from phonation improvement by Log Likelihood Ratios. , 2015, , .		0
855	Biomarker sources for Parkinson's disease: Time to shed tears?. Basal Ganglia, 2015, 5, 63-69.	0.3	21
856	Synapses and Î±-synuclein signalling in disease. Cogent Biology, 2015, 1, 1085295.	1.7	2
857	Caffeine and Neuroprotection in Parkinsonâ€™s Disease. Current Topics in Neurotoxicity, 2015, , 233-272.	0.4	1
858	Combined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinsonâ€™s disease dementia. Neuroscience Letters, 2015, 606, 13-17.	1.0	15
859	MicroRNA-214 participates in the neuroprotective effect of Resveratrol via inhibiting Î±-synuclein expression in MPTP-induced Parkinsonâ€™s disease mouse. Biomedicine and Pharmacotherapy, 2015, 74, 252-256.	2.5	100

#	Article	IF	Citations
860	Contribution of different handwriting modalities to differential diagnosis of Parkinson's Disease. , 2015, , .		29
861	Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Experimental Neurology, 2015, 273, 36-44.	2.0	58
862	Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinsonâ€™s Disease. CNS Drugs, 2015, 29, 433-441.	2.7	81
863	The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. Parkinsonism and Related Disorders, 2015, 21, 1067-1071.	1.1	55
864	Interactions of sex and aging on spatiotemporal metrics in non-pathological gait: a descriptive meta-analysis. Physiotherapy, 2015, 101, 266-272.	0.2	72
865	A time to be stressed? Time perspectives and cortisol dynamics among healthy adults. Biological Psychology, 2015, 111, 90-99.	1.1	38
866	Early detection of Parkinson's disease through shape based features from ¹²³I-Ioflupane SPECT imaging. , 2015, , .		10
867	Luteolin as an anti-inflammatory and neuroprotective agent: A brief review. Brain Research Bulletin, 2015, 119, 1-11.	1.4	317
868	Prevalence of neurogenetic disorders in the North of England. Neurology, 2015, 85, 1195-1201.	1.5	26
870	Gout is not associated with a lower risk of Parkinson's disease: A systematic review and meta-analysis. Parkinsonism and Related Disorders, 2015, 21, 1238-1242.	1.1	24
871	Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention â€“ A Comparison with Parkinsonâ€™s Disease. Neuropsychology Review, 2015, 25, 424-438.	2.5	42
872	Selective toxicity of L-DOPA to dopamine transporter-expressing neurons and locomotor behavior in zebrafish larvae. Neurotoxicology and Teratology, 2015, 52, 51-56.	1.2	27
873	Parkinson's disease: A risk factor for osteoporosis. Joint Bone Spine, 2015, 82, 406-410.	0.8	42
874	D620N mutation in the VPS35 gene and R1205H mutation in the EIF4G1 gene are uncommon in the Greek population. Neuroscience Letters, 2015, 606, 113-116.	1.0	7
875	Aging Mechanisms. , 2015, , .		4
877	The contribution of GIGYF2 to Parkinsonâ€™s disease: a meta-analysis. Neurological Sciences, 2015, 36, 2073-2079.	0.9	26
878	Taste function in early stage treated and untreated Parkinsonâ€™s disease. Journal of Neurology, 2015, 262, 547-557.	1.8	43
879	Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. International Journal of Neuroscience, 2015, 125, 645-654.	0.8	145

#	Article	IF	Citations
880	Parkinson's disease, genetic variability and the Faroe Islands. Parkinsonism and Related Disorders, 2015, 21, 75-78.	1.1	11
881	Therapeutic strategies in Parkinson's disease: what we have learned from animal models. Annals of the New York Academy of Sciences, 2015, 1338, 16-37.	1.8	27
882	RelaciÃ³n entre el polimorfismo DRD2/ANKK1 y el desarrollo de complicaciones motoras en enfermedad de Parkinson. Neurologia Argentina, 2015, 7, 28-33.	0.1	3
883	Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease. Environment International, 2015, 75, 144-150.	4.8	75
884	Genetic Counseling for Adult Neurogenetic Disease. , 2015, , .		1
886	Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinsonâ€™s disease in the UK and Germany. Journal of Medical Economics, 2015, 18, 155-165.	1.0	37
887	Impulse control disorders in Parkinsonâ€™s disease: an overview from neurobiology to treatment. Journal of Neurology, 2015, 262, 7-20.	1.8	20
888	Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior. Brain Structure and Function, 2015, 220, 605-623.	1.2	74
889	Neurodegenerative diseases â€“ Understanding their molecular bases and progress in the development of potential treatments. Coordination Chemistry Reviews, 2015, 284, 298-312.	9.5	48
890	Use of an entacapone-containing drug combination and risk of death: Analysis of the FDA AERS (FAERS) database. Saudi Pharmaceutical Journal, 2015, 23, 28-32.	1.2	6
893	Genetics of Parkinson Disease. American Journal of Neuroradiology, 2015, 36, 445-447.	1.2	3
894	Decision Support Framework for Parkinsonâ€™s Disease Based on Novel Handwriting Markers. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2015, 23, 508-516.	2.7	121
895	Two-Year Exercise Program Improves Physical Function in Parkinsonâ€™s Disease. Neurorehabilitation and Neural Repair, 2015, 29, 112-122.	1.4	78
896	Recent Advances in Wearable Sensors for Health Monitoring. IEEE Sensors Journal, 2015, 15, 3119-3126.	2.4	250
897	An overview of the molecular mechanisms and novel roles of Nrf2 in neurodegenerative disorders. Cytokine and Growth Factor Reviews, 2015, 26, 47-57.	3.2	68
898	Synphilin-1A is a Phosphoprotein Phosphatase 1-Interacting Protein and Affects PPP1 Sorting to Subcellular Compartments. Journal of Molecular Neuroscience, 2015, 55, 385-395.	1.1	1
899	Protective Effects of Salidroside in the MPTP/MPP+-Induced Model of Parkinson's Disease through ROSâ€“NO-Related Mitochondrion Pathway. Molecular Neurobiology, 2015, 51, 718-728.	1.9	89
900	Role of SIRT1 in autoimmune demyelination and neurodegeneration. Immunologic Research, 2015, 61, 187-197.	1.3	52

#	Article	IF	Citations
901	Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinsonâ€™s disease. Expert Opinion on Investigational Drugs, 2015, 24, 219-227.	1.9	28
902	Curcumin and Neurological/Brain Disorders. , 2015, , 197-204.		1
903	Effect of monocrotophos, an organophosphorus insecticide, on the striatal dopaminergic system in a mouse model of Parkinsonâ€™s disease. Toxicology and Industrial Health, 2016, 32, 1153-1165.	0.6	11
904	The correlation between Toxoplasma gondii infection and Parkinsonâ€™s disease: a case-control study. Journal of Parasitic Diseases, 2016, 40, 872-876.	0.4	22
905	Pharmacotherapeutic Challenges in Parkinsonâ€™s Disease Inpatients. , 0, , .		1
906	Cell-Based Therapies for Parkinsonâ€™s Disease: Preclinical and Clinical Perspectives. , 2016, , .		0
907	TelerreabilitaÃ§Ã£o vocal na doenÃ§a de Parkinson. CoDAS, 2016, 28, 176-181.	0.2	39
908	Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases. International Journal of Molecular Sciences, 2016, 17, 26.	1.8	7
909	Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's		

#	Article	IF	Citations
919	Pathophysiology of Motor Dysfunction in Parkinsonâ€™s Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinson's Disease, 2016, 2016, 1-18.	0.6	161
920	Risk of Parkinsonâ€™s Disease in the Users of Antihypertensive Agents: An Evidence from the Meta-Analysis of Observational Studies. Journal of Neurodegenerative Diseases, 2016, 2016, 1-8.	1.1	16
921	Efficacies of globus pallidus stimulation and subthalamic nucleus stimulation for advanced Parkinson's disease: a meta-analysis of randomized controlled trials. Clinical Interventions in Aging, 2016, 11, 777.	1.3	23
923	Effects of Nordic walking on Parkinsonâ€™s disease: a systematic review of randomized clinical trials. Fisioterapia E Pesquisa, 2016, 23, 439-447.	0.3	5
924	Biological functions of selenium and its potential influence on Parkinson's disease. Anais Da Academia Brasileira De Ciencias, 2016, 88, 1655-1674.	0.3	64
925	Environmental Toxicants-Induced Immune Responses in the Olfactory Mucosa. Frontiers in Immunology, 2016, 7, 475.	2.2	49
926	A Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future Prospects. Frontiers in Aging Neuroscience, 2016, 8, 117.	1.7	20
927	Simultaneous Detection of Both GDNF and GFRÎ±1 Expression Patterns in the Mouse Central Nervous System. Frontiers in Neuroanatomy, 2016, 10, 73.	0.9	13
928	Functional Magnetic Resonance Imaging Neurofeedback-guided Motor Imagery Training and Motor Training for Parkinsonâ€™s Disease: Randomized Trial. Frontiers in Behavioral Neuroscience, 2016, 10, 111.	1.0	49
929	Protection of Primary Dopaminergic Midbrain Neurons by GPR139 Agonists Supports Different Mechanisms of MPP+ and Rotenone Toxicity. Frontiers in Cellular Neuroscience, 2016, 10, 164.	1.8	17
930	Early Degeneration of Both Dopaminergic and Serotonergic Axons â€“ A Common Mechanism in Parkinsonâ€™s Disease. Frontiers in Cellular Neuroscience, 2016, 10, 293.	1.8	92
931	microRNAs: Emerging Targets Regulating Oxidative Stress in the Models of Parkinson's Disease. Frontiers in Neuroscience, 2016, 10, 298.	1.4	36
932	Astaxanthin and Docosahexaenoic Acid Reverse the Toxicity of the Maxi-K (BK) Channel Antagonist Mycotoxin Penitrem A. Marine Drugs, 2016, 14, 208.	2.2	15
933	The Role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic Review. PLoS ONE, 2016, 11, e0167201.	1.1	90
934	Comparing the Incidence of Falls/Fractures in Parkinsonâ€™s Disease Patients in the US Population. PLoS ONE, 2016, 11, e0161689.	1.1	59
935	Gene Expression Differences in Peripheral Blood of Parkinsonâ€™s Disease Patients with Distinct Progression Profiles. PLoS ONE, 2016, 11, e0157852.	1.1	36
936	Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinsonâ€™s Disease? The Potential Role of Zolpidem in the Treatment of Parkinsonâ€™s Disease. Parkinson's Disease, 2016, 2016, 1-14.	0.6	13
937	The effect of magnetic nanoparticles on neuronal differentiation of induced pluripotent stem cell-derived neural precursors. International Journal of Nanomedicine, 2016, Volume 11, 6267-6281.	3.3	16

#	Article	IF	Citations
938	Deficits in the Mimicry of Facial Expressions in Parkinson's Disease. Frontiers in Psychology, 2016, 7, 780.	1.1	40
939	Parkinson';s Disease, Diabetes and Cognitive Impairment. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2016, 10, 11-21.	0.7	52
940	Randomized controlled trials for Alzheimer disease and Parkinson disease. Frontiers in Bioscience - Elite, 2016, 8, 378-389.	0.9	4
941	Risk factors for pneumonia among patients with Parkinson's disease: a Taiwan nationwide population-based study. Neuropsychiatric Disease and Treatment, 2016, 12, 1037.	1.0	19
942	Communication impairment in patients with Parkinson's disease: challenges and solutions. Journal of Parkinsonism and Restless Legs Syndrome, 0, , 45.	0.8	6
943	Nrf2 Signaling: An Adaptive Response Pathway for Neurodegenerative Disorders. , 0, , .		0
944	Introduction to Parkinson disease (PD) and its complications. Mental Health Clinician, 2016, 6, 229-235.	0.5	9
945	L'ipotensione. Italian Journal of Medicine, 2016, 4, 1.	0.2	1
946	Outcomes After Non-neurological Surgery in Patients With Parkinson's Disease. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	19
947	<scp>MiR</scp>â€124 Regulates Apoptosis and Autophagy Process in <scp>MPTP</scp> Model of <scp>P</scp>arkinson's Disease by Targeting to <scp>B</scp>im. Brain Pathology, 2016, 26, 167-176.	2.1	157
948	Increased Risk of Parkinson's Disease in Patients With Obstructive Sleep Apnea. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	57
949	Mild <scp>MPP</scp>⁺ exposure impairs autophagic degradation through a novel lysosomal acidityâ€independent mechanism. Journal of Neurochemistry, 2016, 139, 294-308.	2.1	28
950	Micronutrients and Risk of Parkinsonâ€™s Disease. Gerontology and Geriatric Medicine, 2016, 2, 233372141664428.	0.8	9
951	High-Convexity Tightness Predicts the Shunt Response in Idiopathic Normal Pressure Hydrocephalus. American Journal of Neuroradiology, 2016, 37, 1831-1837.	1.2	60
952	Neuroâ€<scp>Q</scp>oL healthâ€related quality of life measurement system: <scp>V</scp>alidation in <scp>P</scp>arkinson's disease. Movement Disorders, 2016, 31, 725-733.	2.2	46
953	Parkinson's Disease and Pesticides Exposure: New Findings From a Comprehensive Study in Nebraska, USA. Journal of Rural Health, 2016, 32, 303-313.	1.6	26
954	Comparison of Bilateral vs. Staged Unilateral Deep Brain Stimulation (DBS) in Parkinsonâ€™s Disease in Patients Under 70 Years of Age. Neuromodulation, 2016, 19, 31-37.	0.4	27
955	Serum 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk. Movement Disorders, 2016, 31, 972-978.	2.2	50

#	Article	IF	Citations
956	Emotional dysfunctions in neurodegenerative diseases. Journal of Comparative Neurology, 2016, 524, 1727-1743.	0.9	25
957	Lung Function Testing On and Off Dopaminergic Medication in Parkinson's Disease Patients With and Without Dysphagia. Movement Disorders Clinical Practice, 2016, 3, 146-150.	0.8	7
958	Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?. Movement Disorders, 2016, 31, 937-946.	2.2	99
959	Estimating the prevalence of Parkinson's disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data. International Journal of Geriatric Psychiatry, 2016, 31, 938-943.	1.3	42
960	Genetic Variants in MicroRNAs and Their Binding Sites Are Associated with the Risk of Parkinson Disease. Human Mutation, 2016, 37, 292-300.	1.1	52
961	Test-Retest Reliability and Minimal Detectable Change for the 10-Meter Walk Test in Older Adults With Parkinson's disease. Journal of Geriatric Physical Therapy, 2016, 39, 165-170.	0.6	77
962	Can we use peripheral tissue biopsies to diagnose Parkinson's disease? A review of the literature. European Journal of Neurology, 2016, 23, 247-261.	1.7	80
963	Quantitative analysis in the digital Luria's alternating series tests. , 2016, , .		13
964	Geographical distribution of mortality by Parkinson's disease and its association with air lead levels in Spain. Medicina ClÃnica (English Edition), 2016, 147, 481-487.	0.1	3
965	Spanish version of the Parkinsonâ€™s Disease Questionnaireâ€“Carer (PDQ-Carer). Health and Quality of Life Outcomes, 2016, 14, 154.	1.0	3
966	Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinsonâ€™s Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators. Journal of Alzheimer's Disease, 2016, 50, 733-740.	1.2	41
967	Newly Diagnosed Anemia Increases Risk of Parkinsonâ€™s disease: A Population-Based Cohort Study. Scientific Reports, 2016, 6, 29651.	1.6	35
968	Modified serpinA1 as risk marker for Parkinsonâ€™s disease dementia: Analysis of baseline data. Scientific Reports, 2016, 6, 26145.	1.6	24
969	Identifying Pilots with Parkinsonâ€™s Disease. Aerospace Medicine and Human Performance, 2016, 87, 545-549.	0.2	1
970	Connecting Ca2+ and Lysosomes to Parkinson Disease. Messenger (Los Angeles, Calif: Print), 2016, 5, 76-86.	0.3	5
971	Optimal Short Distance Electrode Locations for Impedance Pneumography Measurement from the Frontal Thoracic Area. IFMBE Proceedings, 2016, , 1144-1149.	0.2	5
972	Design and Development of a Mobile Application to Explore Cognitive Skills in Parkinsonâ€™s Disease Patients. IFMBE Proceedings, 2016, , 1150-1155.	0.2	1
973	Partial neurorescue effects of DHA following a 6-OHDA lesion of the mouse dopaminergic system. Journal of Nutritional Biochemistry, 2016, 30, 133-142.	1.9	27

#	Article	IF	Citations
974	The construct validity of the Dutch version of the activity card sort. Disability and Rehabilitation, 2016, 38, 1943-1951.	0.9	14
975	Effects of an Ai Chi fall prevention programme for patients with Parkinson's disease. NeurologÃa (English Edition), 2016, 31, 176-182.	0.2	4
976	The role of magnetic resonance imaging in the diagnosis of Parkinson's disease: a review. Clinical Imaging, 2016, 40, 987-996.	0.8	26
977	Parkinsonâ€™s disease and colorectal cancer riskâ€”A nested case control study. Cancer Epidemiology, 2016, 43, 9-14.	0.8	20
978	Early-onset vs. Late-onset Parkinsonâ€™s disease: A Clinical-pathological Study. Canadian Journal of Neurological Sciences, 2016, 43, 113-119.	0.3	66
979	Admittance-Based Voluntary-Driven Motion With Speed-Controlled Tremor Rejection. IEEE/ASME Transactions on Mechatronics, 2016, 21, 2108-2119.	3.7	22
980	Evaluation of handwriting kinematics and pressure for differential diagnosis of Parkinson's disease. Artificial Intelligence in Medicine, 2016, 67, 39-46.	3.8	203
981	Protective effects of DJ-1 medicated Akt phosphorylation on mitochondrial function are promoted by Da-Bu-Yin-Wan in 1-methyl-4-phenylpyridinium-treated human neuroblastoma SH-SY5Y cells. Journal of Ethnopharmacology, 2016, 187, 83-93.	2.0	13
982	Association Between Tuberculosis and Parkinson Disease. Medicine (United States), 2016, 95, e2883.	0.4	33
983	A promising therapeutic potential of cerebrolysin in 6-OHDA rat model of Parkinson's disease. Life Sciences, 2016, 155, 174-179.	2.0	19
984	Impact of limiting visual input on gait: Individuals with Parkinson disease, age-matched controls, and healthy young participants. Somatosensory & Motor Research, 2016, 33, 29-34.	0.4	5
985	Predicting Parkinson disease in the community using a nonmotor risk score. European Journal of Epidemiology, 2016, 31, 679-684.	2.5	15
986	Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opinion on Drug Delivery, 2016, 13, 1121-1131.	2.4	99
987	Neuro-protective Mechanisms of Lycium barbarum. NeuroMolecular Medicine, 2016, 18, 253-263.	1.8	49
988	Contributory Factors to Caregiver Burden in Parkinson Disease. Journal of the American Medical Directors Association, 2016, 17, 626-632.	1.2	81
989	Exploring coumarin potentialities: development of new enzymatic inhibitors based on the 6-methyl-3-carboxamidocoumarin scaffold. RSC Advances, 2016, 6, 49764-49768.	1.7	13
990	Regenerative effects of peptide nanofibers in an experimental model of Parkinsonâ€™s disease. Acta Biomaterialia, 2016, 46, 79-90.	4.1	22
991	Voice assessments for detecting patients with Parkinsonâ€™s diseases using PCA and NPCA. International Journal of Speech Technology, 2016, 19, 743-754.	1.4	26

#	Article	IF	Citations
992	Epidemiology of Parkinson Disease. Neurologic Clinics, 2016, 34, 955-965.	0.8	242
993	Genetic Analysis of the ZNF512B, SLC41A1, and ALDH2 Polymorphisms in Parkinson's Disease in the Iranian Population. Genetic Testing and Molecular Biomarkers, 2016, 20, 629-632.	0.3	18
994	SLC6A3 rs28363170 and rs3836790 variants in Han Chinese patients with sporadic Parkinsonâ€™s disease. Neuroscience Letters, 2016, 629, 48-51.	1.0	6
995	Quality of life outcomes following cervical decompression for coexisting Parkinson's disease and cervical spondylotic myelopathy. Spine Journal, 2016, 16, 1358-1366.	0.6	15
996	Concurrent transcranial direct current stimulation and progressive resistance training in Parkinsonâ€™s disease: study protocol for a randomised controlled trial. Trials, 2016, 17, 326.	0.7	8
997	Facial Behaviour Analysis in Parkinsonâ€™s Disease. Lecture Notes in Computer Science, 2016, , 329-339.	1.0	3
998	TDP-43/FUS in motor neuron disease: Complexity and challenges. Progress in Neurobiology, 2016, 145-146, 78-97.	2.8	93
999	The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurology, The, 2016, 15, 1257-1272.	4.9	1,233
1000	Insulin resistance and Parkinsonâ€™s disease: A new target for disease modification?. Progress in Neurobiology, 2016, 145-146, 98-120.	2.8	220
1001	Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus. Parkinsonism and Related Disorders, 2016, 33, 115-121.	1.1	72
1002	Computerized analysis of the distribution of occlusal contacts in individuals with Parkinson's disease and temporomandibular disorder. Cranio - Journal of Craniomandibular Practice, 2016, 34, 358-362.	0.6	7
1003	Evaluation of depth perception in elder with Parkinson's disease. , 2016, , .		0
1004	Neuroprotective effects of nitidine in Parkinson's disease models through inhibiting microglia activation: role of the Jak2â€“Stat3 pathway. RSC Advances, 2016, 6, 71328-71337.	1.7	21
1005	The best medicine? The influence of physical activity and inactivity on Parkinson's disease. Movement Disorders, 2016, 31, 1444-1454.	2.2	89
1006	Infusion treatments and deep brain stimulation in Parkinson's Disease: The role of nursing. Geriatric Nursing, 2016, 37, 434-439.	0.9	6
1007	<i>LRRK2, GBA </i>and<i> SMPD1 </i>Founder Mutations and Parkinson's Disease in Ashkenazi Jews. Dementia and Geriatric Cognitive Disorders, 2016, 42, 1-6.	0.7	17
1008	Model systems of protein-misfolding diseases reveal chaperone modifiers of proteotoxicity. DMM Disease Models and Mechanisms, 2016, 9, 823-838.	1.2	45
1009	Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited. Revue Neurologique, 2016, 172, 512-523.	0.6	6

#	Article	IF	Citations
1010	Parkinson's disease: Autoimmunity and neuroinflammation. Autoimmunity Reviews, 2016, 15, 1005-1011.	2.5	275
1012	Epidemiology of Parkinson's Disease: A Population-Based Study in Primary Care in Italy. Neuroepidemiology, 2016, 47, 38-45.	1.1	21
1013	Medical Imaging and Augmented Reality. Lecture Notes in Computer Science, 2016, , .	1.0	8
1014	Neurodegenerative and neurological disorders by small inhaled particles. NeuroToxicology, 2016, 56, 94-106.	1.4	246
1015	The genetic background of Parkinson's disease: current progress and future prospects. Acta Neurologica Scandinavica, 2016, 134, 314-326.	1.0	205
1016	Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. British Journal of Clinical Pharmacology, 2016, 82, 461-472.	1.1	35
1017	Quantifying rigidity of Parkinson's disease in relation to laxative treatment: a service evaluation. British Journal of Clinical Pharmacology, 2016, 82, 441-450.	1.1	9
1018	Induced pluripotent stem cells and Parkinson's disease: modelling and treatment. Cell Proliferation, 2016, 49, 14-26.	2.4	13
1019	New insights on the mitochondrial proteome plasticity in Parkinson's disease. Proteomics - Clinical Applications, 2016, 10, 416-429.	0.8	11
1020	The clinical symptoms of Parkinson's disease. Journal of Neurochemistry, 2016, 139, 318-324.	2.1	830
1021	Review: Sporadic Parkinson's disease: development and distribution of Î±â€synuclein pathology. Neuropathology and Applied Neurobiology, 2016, 42, 33-50.	1.8	309
1022	Characterizing structural neural networks in de novo Parkinson disease patients using diffusion tensor imaging. Human Brain Mapping, 2016, 37, 4500-4510.	1.9	75
1023	Event-related potentials and cognition in Parkinsonâ€™s disease: An integrative review. Neuroscience and Biobehavioral Reviews, 2016, 71, 691-714.	2.9	77
1024	Vitamin D receptor polymorphisms and Parkinsonâ€™s disease in a Korean population: Revisited. Neuroscience Letters, 2016, 628, 230-235.	1.0	14
1025	Genetic analysis of the CHCHD2 gene in a cohort of Chinese patients with Parkinson disease. Neuroscience Letters, 2016, 629, 116-118.	1.0	5
1026	Functional Status of Elderly Nursing Home Residents With Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2016, 6, 617-624.	1.5	7
1027	Bone mass and vitamin D levels in Parkinsonâ€™s disease: is there any difference between genders?. Journal of Physical Therapy Science, 2016, 28, 2204-2209.	0.2	20
1028	Higher levels of apomorphine and rotigotine prescribing reduce overall secondary healthcare costs in Parkinson's disease. International Journal of Clinical Practice, 2016, 70, 907-915.	0.8	7

#	Article	IF	Citations
1029	New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinsonâ€™s Disease. Current Pharmacology Reports, 2016, 2, 253-261.	1.5	13
1031	Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease. , 2016, , .		10
1032	PARKIN/PINK1 Pathway for the Selective Isolation and Degradation of Impaired Mitochondria. , 2016, , 159-182.		3
1033	Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases. Neurobiology of Disease, 2016, 95, 210-224.	2.1	98
1035	Nurr1 and PPARÎ³ protect PC12 cells against MPP+ toxicity: involvement of selective genes, anti-inflammatory, ROS generation, and antimitochondrial impairment. Molecular and Cellular Biochemistry, 2016, 420, 29-42.	1.4	21
1036	Typeâ€1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease. Glia, 2016, 64, 1590-1604.	2.5	71
1038	ParkinsoNET: Estimation of UPDRS Score Using Hubness-Aware Feedforward Neural Networks. Applied Artificial Intelligence, 2016, 30, 541-555.	2.0	16
1039	VoxTester, software for digital evaluation of speech changes in Parkinson disease. , 2016, , .		24
1040	Meclizine-induced enhanced glycolysis is neuroprotective in Parkinson disease cell models. Scientific Reports, 2016, 6, 25344.	1.6	42
1041	Monitoring of motor and non-motor symptoms of Parkinson's disease through a mHealth platform. , 2016, 2016, 663-666.		30
1042	Eating Behaviors and Dietary Changes in Patients With Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 706-716.	0.9	49
1043	Genetics of Parkinson's disease. Molecular and Cellular Probes, 2016, 30, 386-396.	0.9	282
1044	Are interlimb interactions disturbed in patients with Parkinsonâ€™s disease? A study under unloading conditions. Human Physiology, 2016, 42, 529-538.	0.1	0
1045	Î±-lipoic acid exerts neuroprotective effects on neuronal cells by upregulating the expression of PCNA via the P53 pathway in neurodegenerative conditions. Molecular Medicine Reports, 2016, 14, 4360-4366.	1.1	14
1046	Living with chronic illness scale: international validation of a new self-report measure in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2016, 2, 16022.	2.5	14
1047	Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model. Acta Neuropathologica Communications, 2016, 4, 87.	2.4	40
1048	Transcription factor Pitx3 mutant mice as a model for Parkinsonâ€™s disease. Frontiers in Biology, 2016, 11, 427-438.	0.7	7
1049	Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review. Gerontology, 2016, 62, 371-380.	1.4	19

#	Article	IF	Citations
1050	Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study. Clinical Neuropharmacology, 2016, 39, 227-231.	0.2	24
1051	Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2016, 6, 109-117.	1.5	40
1052	Possible role of Epoxyeicosatrienoic acid in prevention of oxidative stress mediated neuroinflammation in Parkinson disorders. Medical Hypotheses, 2016, 93, 161-165.	0.8	19
1053	Medication Therapy Management Service for Patients with Parkinsonâ€™s Disease: A Before-and-After Study. Neurology and Therapy, 2016, 5, 85-99.	1.4	26
1054	Inertial BSN-Based Characterization and Automatic UPDRS Evaluation of the Gait Task of Parkinsonians. IEEE Transactions on Affective Computing, 2016, 7, 258-271.	5.7	28
1055	Melanin and neuromelanin binding of drugs and chemicals: toxicological implications. Archives of Toxicology, 2016, 90, 1883-1891.	1.9	55
1056	Genetic risk of Parkinsonâ€™s disease in the general population. Parkinsonism and Related Disorders, 2016, 29, 54-59.	1.1	11
1057	Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion. Neurobiology of Disease, 2016, 94, 213-225.	2.1	25
1058	ACTUALIZACIÃ“N EN LA ENFERMEDAD DE PARKINSON. Revista MÃ©dica ClÃnica Las Condes, 2016, 27, 363-379.	0.2	14
1059	Trends in the Incidence of Parkinson Disease in the General Population. American Journal of Epidemiology, 2016, 183, 1018-1026.	1.6	50
1060	Altered expression of Mg2+ transport proteins during Parkinson's disease-like dopaminergic cell degeneration in PC12 cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 1979-1984.	1.9	16
1061	An efficient hybrid kernel extreme learning machine approach for early diagnosis of Parkinson×³s disease. Neurocomputing, 2016, 184, 131-144.	3.5	222
1062	Preparation and evaluation of rotigotine-loaded implant for the treatment of Parkinsonâ€™s disease and its evolution study. Saudi Pharmaceutical Journal, 2016, 24, 363-370.	1.2	11
1063	An update on the diagnosis and treatment of Parkinson disease. Cmaj, 2016, 188, 1157-1165.	0.9	286
1064	Efficient derivation of dopaminergic neurons from SOX1â^' floor plate cells under defined culture conditions. Journal of Biomedical Science, 2016, 23, 34.	2.6	7
1065	Association between FGF20 rs12720208 gene polymorphism and Parkinsonâ€™s disease: a meta-analysis. Neurological Sciences, 2016, 37, 1119-1126.	0.9	4
1066	Genomic mechanisms underlying PARK2 large deletions identified in a cohort of patients with PD. Neurology: Genetics, 2016, 2, e73.	0.9	22
1067	Measurement of tremor transmission during microsurgery. International Journal of Medical Robotics and Computer Assisted Surgery, 2016, 12, 585-597.	1.2	9

#	Article	IF	Citations
1068	Meta-analysis of the association between serum iron levels and Parkinson's disease: Evidence from 11 publications. Brain Research, 2016, 1646, 490-493.	1.1	19
1069	Association of four new candidate genetic variants with Parkinson's disease in a Han Chinese population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 342-347.	1.1	18
1070	Alphaâ€Synuclein as a Biomarker for Parkinson's Disease. Brain Pathology, 2016, 26, 410-418.	2.1	217
1071	Cognitive profile of Parkinson's disease patients: a comparative study between early-onset and late-onset Parkinson's disease. International Journal of Neuroscience, 2016, 126, 227-234.	0.8	26
1072	Association of the MTHFR rs1801131 and rs1801133 variants in sporadic Parkinsonâ€™s disease patients. Neuroscience Letters, 2016, 616, 26-31.	1.0	20
1073	Prevalence of parkinsonism estimated using the drug prescription archive: a possible method to estimate the prevalence of a chronic neurological disease?. Journal of Neural Transmission, 2016, 123, 415-420.	1.4	1
1074	NMR-Based Metabolomics Reveal a Recovery from Metabolic Changes in the Striatum of 6-OHDA-Induced Rats Treated with Basic Fibroblast Growth Factor. Molecular Neurobiology, 2016, 53, 6690-6697.	1.9	23
1075	Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience. European Neurology, 2015, 74, 227-236.	0.6	17
1076	Stereological approaches to dementia research using human brain tissue. Journal of Chemical Neuroanatomy, 2016, 76, 73-81.	1.0	5
1078	Genetic analysis of MC1R variants in Chinese Han patients with sporadic Parkinsonâ€™s disease. Neuroscience Letters, 2016, 611, 101-105.	1.0	12
1079	Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline. Neurological Sciences, 2016, 37, 227-234.	0.9	9
1080	Beta-cyfluthrin induced neurobehavioral impairments in adult rats. Chemico-Biological Interactions, 2016, 243, 19-28.	1.7	19
1081	Obstructive Sleep Apnea and Cognition in Parkinson's disease. Sleep Medicine, 2016, 21, 28-34.	0.8	62
1082	Physical exercise counteracts MPTP-induced changes in neural precursor cell proliferation in the hippocampus and restores spatial learning but not memory performance in the water maze. Behavioural Brain Research, 2016, 307, 227-238.	1.2	34
1083	Medicinal plant Combretum leprosum mart ameliorates motor, biochemical and molecular alterations in a Parkinson's disease model induced by MPTP. Journal of Ethnopharmacology, 2016, 185, 68-76.	2.0	11
1084	Sudden unexpected death in Parkinson's disease: Perspectives on what we have learned about sudden unexpected death in epilepsy (SUDEP). Epilepsy and Behavior, 2016, 57, 124-125.	0.9	8
1085	The Association Between Parkinson's Disease Motor Impairments and Pain. Pain Medicine, 2016, 17, pme12898.	0.9	18
1086	Generation and evaluation of an ultra-high-field atlas with applications in DBS planning. Proceedings of SPIE, 2016, , .	0.8	8

#	Article	IF	Citations
1087	Mutations of glucocerebrosidase gene and susceptibility to Parkinsonâ€™s disease: An updated meta-analysis in a European population. Neuroscience, 2016, 320, 239-246.	1.1	33
1088	Identifying clinical measures that most accurately reflect the progression of disability in Parkinson disease. Parkinsonism and Related Disorders, 2016, 25, 65-71.	1.1	54
1089	Age at onset and Parkinson disease phenotype. Neurology, 2016, 86, 1400-1407.	1.5	245
1090	Selenoprotein T Exerts an Essential Oxidoreductase Activity That Protects Dopaminergic Neurons in Mouse Models of Parkinson's Disease. Antioxidants and Redox Signaling, 2016, 24, 557-574.	2.5	91
1091	Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism. Molecular Neurobiology, 2016, 53, 7284-7297.	1.9	11
1092	Genome-Wide Epigenetic Studies in Neurologic Diseases. , 2016, , 209-234.		1
1093	Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress. Nutritional Neuroscience, 2016, 19, 237-246.	1.5	77
1094	Neuroprotective effect of fucoidan from Turbinaria decurrens in MPTP intoxicated Parkinsonic mice. International Journal of Biological Macromolecules, 2016, 86, 425-433.	3.6	47
1095	Discriminating Between Patients With Parkinsonâ€™s and Neurological Diseases Using Cepstral Analysis. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2016, 24, 1100-1108.	2.7	76
1096	Maladie de Parkinson et facteurs de risque professionnels et environnementauxÂ: enquÃªte cas-tÃ©moins dans lâ€™ouest algÃ©rien. Archives Des Maladies Professionnelles Et De L'Environnement, 2016, 77, 21-26.	0.1	3
1097	Efectos de un programa de prevenciÃ³n de caÃdas con Ai Chi acuÃ¡tico en pacientes diagnosticados de parkinson. NeurologÃa, 2016, 31, 176-182.	0.3	22
1098	Association of three candidate genetic variants in RAB7L1/NUCKS1, MCCC1 and STK39 with sporadic Parkinsonâ€™s disease in Han Chinese. Journal of Neural Transmission, 2016, 123, 425-430.	1.4	15
1099	What lysosomes actually tell us about Parkinsonâ€™s disease?. Ageing Research Reviews, 2016, 32, 140-149.	5.0	19
1100	Aging of perennial cells and organ parts according to the programmed aging paradigm. Age, 2016, 38, 35.	3.0	26
1101	Parkinsonâ€™s Disease: Update on Medication Management. Journal for Nurse Practitioners, 2016, 12, e81-e89.	0.4	2
1102	Influence of urinary urgency and other urinary disturbances on falls in Parkinson's disease. Journal of the Neurological Sciences, 2016, 360, 153-157.	0.3	31
1103	Genetic analysis of TREM2 variants in Chinese Han patients with sporadic Parkinsonâ€™s disease. Neuroscience Letters, 2016, 612, 189-192.	1.0	23
1104	The analysis of association between SNCA, HUSEYO and CSMD1 gene variants and Parkinsonâ€™s disease in Iranian population. Neurological Sciences, 2016, 37, 731-736.	0.9	20

#	Article	IF	Citations
1105	Direct intranigral injection of dopaminochrome causes degeneration of dopamine neurons. Neuroscience Letters, 2016, 612, 178-184.	1.0	13
1106	Curcumin improves neurofunctions of 6-OHDA-induced parkinsonian rats. Pathology Research and Practice, 2016, 212, 247-251.	1.0	37
1107	Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. Parkinsonism and Related Disorders, 2016, 23, 1-9.	1.1	307
1108	Conformational ensemble of human Î±-synuclein physiological form predicted by molecular simulations. Physical Chemistry Chemical Physics, 2016, 18, 5702-5706.	1.3	32
1109	Design of shRNA and miRNA for Delivery to the CNS. Methods in Molecular Biology, 2016, 1382, 67-80.	0.4	15
1110	Intrastriatal injection of botulinum neurotoxin-A is not cytotoxic in rat brainÂâ€“ A histological and stereological analysis. Brain Research, 2016, 1630, 18-24.	1.1	19
1111	Nrf2â€“ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. , 2016, 157, 84-104.		463
1112	Gene Therapy for Neurological Disorders. Methods in Molecular Biology, 2016, , .	0.4	3
1113	Reduction of dopamine in basal ganglia and its effects on syllable sequencing in speech: A computer simulation study. Basal Ganglia, 2016, 6, 7-17.	0.3	16
1114	Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis. International Journal of Neuroscience, 2016, 126, 771-776.	0.8	64
1115	Fibroblast Biomarkers of Sporadic Parkinsonâ€™s Disease and LRRK2 Kinase Inhibition. Molecular Neurobiology, 2016, 53, 5161-5177.	1.9	60
1116	The relationship between essential tremor and Parkinson's disease. Parkinsonism and Related Disorders, 2016, 22, S162-S165.	1.1	103
1117	Sustained attention training reduces spatial bias in Parkinsonâ€™s disease: a pilot case series. Neurocase, 2016, 22, 179-186.	0.2	9
1118	Comparison of Human Primary with Human iPS Cell-Derived Dopaminergic Neuron Grafts in the Rat Model for Parkinsonâ€™s Disease. Stem Cell Reviews and Reports, 2016, 12, 105-120.	5.6	18
1119	Immunohistochemical Detection of Oxidized Forms of 5-Methylcytosine in Embryonic and Adult Brain Tissue. Neuromethods, 2016, , 125-137.	0.2	2
1120	Epigenetic Methods in Neuroscience Research. Neuromethods, 2016, , .	0.2	2
1121	Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage. Neuroscience, 2016, 312, 247-259.	1.1	13
1122	Chronic restraint stress triggers dopaminergic and noradrenergic neurodegeneration: Possible role of chronic stress in the onset of Parkinsonâ€™s disease. Brain, Behavior, and Immunity, 2016, 51, 39-46.	2.0	71

#	Article	IF	Citations
1123	Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery. Journal of Medicinal Chemistry, 2016, 59, 2-15.	2.9	31
1124	Pharmacophore model prediction, 3D-QSAR and molecular docking studies on vinyl sulfones targeting Nrf2-mediated gene transcription intended for anti-Parkinson drug design. Journal of Biomolecular Structure and Dynamics, 2016, 34, 1282-1297.	2.0	40
1125	InÂvivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease. Neuropharmacology, 2016, 100, 106-115.	2.0	24
1126	FLZ Attenuates Î±-Synuclein-Induced Neurotoxicity by Activating Heat Shock Protein 70. Molecular Neurobiology, 2017, 54, 349-361.	1.9	20
1127	Oxidative Modification and Its Implications for the Neurodegeneration of Parkinsonâ€™s Disease. Molecular Neurobiology, 2017, 54, 1404-1418.	1.9	40
1128	Expression of the Parkinsonâ€™s Disease-Associated Gene Alpha-Synuclein is Regulated by the Neuronal Cell Fate Determinant TRIM32. Molecular Neurobiology, 2017, 54, 4257-4270.	1.9	11
1129	Development of a Prolonged-Release Pramipexole Transdermal Patch: In Vitro and In Vivo Evaluation. AAPS PharmSciTech, 2017, 18, 738-748.	1.5	5
1130	Yeast buddies helping to unravel the complexity of neurodegenerative disorders. Mechanisms of Ageing and Development, 2017, 161, 288-305.	2.2	34
1131	Altered Long Noncoding RNA Expression Precedes the Course of Parkinsonâ€™s Diseaseâ€”a Preliminary Report. Molecular Neurobiology, 2017, 54, 2869-2877.	1.9	116
1132	Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinsonâ€™s Disease. Molecular Neurobiology, 2017, 54, 3618-3632.	1.9	6
1133	Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review. Acta Neurologica Scandinavica, 2017, 135, 34-56.	1.0	96
1134	Noggin Along with a Self-Assembling Peptide Nanofiber Containing Long Motif of Laminin Induces Tyrosine Hydroxylase Gene Expression. Molecular Neurobiology, 2017, 54, 4609-4616.	1.9	21
1135	Reliability and Validity of Nonradiologic Measures of Forward Flexed Posture in Parkinson Disease. Archives of Physical Medicine and Rehabilitation, 2017, 98, 508-516.	0.5	12
1136	REM sleep behaviour disorder: prodromal and mechanistic insights for Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 445-451.	0.9	33
1137	Context-sensitive network-based disease genetics prediction and its implications in drug discovery. Bioinformatics, 2017, 33, 1031-1039.	1.8	20
1138	Epidemiology of Parkinsonâ€™s disease. Journal of Neural Transmission, 2017, 124, 901-905.	1.4	1,593
1139	Auxilin Underlies Progressive Locomotor Deficits and Dopaminergic Neuron Loss in a Drosophila Model of Parkinsonâ€™s Disease. Cell Reports, 2017, 18, 1132-1143.	2.9	68
1140	Autophagic modulation by rosuvastatin prevents rotenone-induced neurotoxicity in an in vitro model of Parkinsonâ€™s disease. Neuroscience Letters, 2017, 642, 20-26.	1.0	43

#	Article	IF	Citations
1141	Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinsonâ€™s: a systematic review. Quality of Life Research, 2017, 26, 1-23.	1.5	16
1143	Caseâ€“control association mapping by proxy using family history of disease. Nature Genetics, 2017, 49, 325-331.	9.4	192
1144	Multi-View Ensemble Classification of Brain Connectivity Images for Neurodegeneration Type Discrimination. Neuroinformatics, 2017, 15, 199-213.	1.5	37
1145	Gait Disturbances in Movement Disorders: A Motor-Cognitive Problem. , 2017, , 129-141.		0
1146	Dopaminergic modulation of performance monitoring in Parkinsonâ€™s disease: An event-related potential study. Scientific Reports, 2017, 7, 41222.	1.6	21
1147	Improving Prospective Memory in Persons With Parkinson Disease: A Randomized Controlled Trial. Neurorehabilitation and Neural Repair, 2017, 31, 451-461.	1.4	16
1148	Association of IGF1 gene polymorphism with Parkinson's disease in a Han Chinese population. Journal of Gene Medicine, 2017, 19, e2949.	1.4	7
1149	Parkinsonâ€™s Disease and Gait Asymmetry. , 2017, , 161-175.		0
1150	Treatment of Older Parkinson's Disease. International Review of Neurobiology, 2017, 132, 381-405.	0.9	15
1151	A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers. Stem Cell Reports, 2017, 8, 728-742.	2.3	57
1152	Detection of Motor Impairment in Parkinson's Disease Via Mobile Touchscreen Typing. IEEE Transactions on Biomedical Engineering, 2017, 64, 1994-2002.	2.5	81
1153	Functional connectivity disruptions correlate with cognitive phenotypes in Parkinson's disease. NeuroImage: Clinical, 2017, 14, 591-601.	1.4	87
1154	Sigma-1 (Ïƒ1) Receptor in Memory and Neurodegenerative Diseases. Handbook of Experimental Pharmacology, 2017, 244, 81-108.	0.9	43
1155	Opicapone for the treatment of Parkinsonâ€™s disease. Expert Opinion on Pharmacotherapy, 2017, 18, 445-453.	0.9	12
1156	Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of <scp>l</scp>â€<scp>DOPA</scp> treatment and changes in levodopaâ€induced dyskinesia. Journal of Neurochemistry, 2017, 141, 614-625.	2.1	31
1157	The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinsonâ€™s Disease in Rats. Neurochemical Research, 2017, 42, 1104-1115.	1.6	125
1158	Amentoflavone protects dopaminergic neurons in MPTP-induced Parkinson's disease model mice through PI3K/Akt and ERK signaling pathways. Toxicology and Applied Pharmacology, 2017, 319, 80-90.	1.3	97
1159	<scp>M</scp>itochondrial <scp>DNA</scp> and primary mitochondrial dysfunction in <scp>P</scp>arkinson's disease. Movement Disorders, 2017, 32, 346-363.	2.2	115

#	Article	IF	Citations
1160	Walking in fully immersive virtual environments: an evaluation of potential adverse effects in older adults and individuals with Parkinsonâ€™s disease. Journal of NeuroEngineering and Rehabilitation, 2017, 14, 16.	2.4	128
1161	Detecting multiple system atrophy, Parkinson and other neurological disorders using voice analysis. International Journal of Speech Technology, 2017, 20, 281-288.	1.4	6
1162	Clinical Features and Differential Diagnosis of Parkinsonâ€™s Disease. , 2017, , 103-115.		5
1163	RAB7L1 promoter polymorphism and risk of Parkinsonâ€™s disease; a case-control study. Neurological Research, 2017, 39, 468-471.	0.6	12
1164	Immunochemical Detection of Î±-Synuclein Autoantibodies in Parkinsonâ€™s Disease: Correlation between Plasma and Cerebrospinal Fluid Levels. ACS Chemical Neuroscience, 2017, 8, 1170-1176.	1.7	52
1165	Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases. , 2017, 177, 32-43.		36
1166	Resting-state functional reorganization in Parkinson's disease: An activation likelihood estimation meta-analysis. Cortex, 2017, 92, 119-138.	1.1	101
1167	Prevalence of Parkinson symptoms in patients with different peripheral vestibular disorders. Journal of Neurology, 2017, 264, 1287-1289.	1.8	4
1168	Gut microbes augment neurodegeneration. Nature, 2017, 544, 304-305.	13.7	31
1169	Dopamine Transporter Imaging has no Impact on Functional Outcomes in de Novo Probable Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2017, 7, 279-287.	1.5	5
1171	Varied pathological and therapeutic response effects associated with CHCHD2 mutant and risk variants. Human Mutation, 2017, 38, 978-987.	1.1	21
1172	Ablative surgery for Parkinsonâ€™s disease: Is there still a role for pallidotomy in the deep brain stimulation era?. Clinical Neurology and Neurosurgery, 2017, 158, 33-39.	0.6	10
1173	Advances in the Clinical Differential Diagnosis of Parkinson's Disease. International Review of Neurobiology, 2017, 132, 79-127.	0.9	4
1174	Automated analysis of connected speech reveals early biomarkers of Parkinsonâ€™s disease in patients with rapid eye movement sleep behaviour disorder. Scientific Reports, 2017, 7, 12.	1.6	245
1175	Cannabinoid Therapeutics in Parkinsonâ€™s Disease: Promise and Paradox. Journal of Herbs, Spices and Medicinal Plants, 2017, 23, 231-248.	0.5	10
1176	Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism. JAMA Neurology, 2017, 74, 839.	4.5	68
1177	Glaucoma correlates with increased risk of Parkinsonâ€™s disease in the elderly: a national-based cohort study in Taiwan. Current Medical Research and Opinion, 2017, 33, 1511-1516.	0.9	30
1178	A comparison between aquatic and land-based physical exercise on postural sway and quality of life in people with Parkinsonâ€™s disease: a randomized controlled pilot study. Sport Sciences for Health, 2017, 13, 341-348.	0.4	9

#	Article	IF	Citations
1179	Succinate dehydrogenase in Parkinsonâ€™s disease. Frontiers in Biology, 2017, 12, 175-182.	0.7	7
1180	Bee venom for the treatment of Parkinsonâ€™s disease: How far is it possible?. Biomedicine and Pharmacotherapy, 2017, 91, 295-302.	2.5	23
1181	Involvement of the cerebellum in Parkinson disease and dementia with Lewy bodies. Annals of Neurology, 2017, 81, 898-903.	2.8	44
1182	Acceptance of technology-based tools in a sample of Parkinsonâ€™s patients. Chronic Illness, 2017, 13, 3-13.	0.6	4
1183	Outdoor Ambient Air Pollution and Neurodegenerative Diseases: the Neuroinflammation Hypothesis. Current Environmental Health Reports, 2017, 4, 166-179.	3.2	142
1184	BNN-20, a synthetic microneurotrophin, strongly protects dopaminergic neurons in the â€œweaverâ€• mouse, a genetic model of dopamine-denervation, acting through the TrkB neurotrophin receptor. Neuropharmacology, 2017, 121, 140-157.	2.0	18
1185	Aberrant regional homogeneity in Parkinsonâ€™s disease: A voxel-wise meta-analysis of resting-state functional magnetic resonance imaging studies. Neuroscience and Biobehavioral Reviews, 2017, 72, 223-231.	2.9	68
1186	Association between Parkinson's disease and risk of colorectal cancer. Parkinsonism and Related Disorders, 2017, 35, 42-47.	1.1	18
1187	Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes. Journal of the American Medical Directors Association, 2017, 18, 791-796.	1.2	7
1188	Clinical Outcomes Following Surgical Management of Coexisting Parkinson Disease and Cervical Spondylotic Myelopathy. Neurosurgery, 2017, 81, 350-356.	0.6	8
1189	Editorâ€™s Highlight: Nlrp3 Is Required for Inflammatory Changes and Nigral Cell Loss Resulting From Chronic Intragastric Rotenone Exposure in Mice. Toxicological Sciences, 2017, 159, 64-75.	1.4	45
1190	Bone Health in Parkinsonâ€™s Disease. Clinical Reviews in Bone and Mineral Metabolism, 2017, 15, 99-114.	1.3	3
1191	FGF18 protects against 6-hydroxydopamine-induced nigrostriatal damage in a rat model of Parkinsonâ€™s disease. Neuroscience, 2017, 356, 229-241.	1.1	12
1192	Immunopathology of the Nervous System. Molecular and Integrative Toxicology, 2017, , 123-219.	0.5	0
1193	Epigenetics in Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2017, 978, 363-390.	0.8	50
1194	Upper limb robotics applied to neurorehabilitation: An overview of clinical practice. NeuroRehabilitation, 2017, 41, 5-15.	0.5	13
1195	Effects of 2 Years of Exercise on Gait Impairment in People With Parkinson Disease: The PRET-PD Randomized Trial. Journal of Neurologic Physical Therapy, 2017, 41, 21-30.	0.7	40
1196	Sudden unexpected death in Parkinsonâ€™s disease (SUDPAR): sleep apnea increases risk of heart attack. Sleep and Breathing, 2017, 21, 965-966.	0.9	6

#	Article	IF	Citations
1197	Skewed X-chromosome inactivation and XIST locus methylation levels do not contribute to the lower prevalence of Parkinson's disease in females. Neurobiology of Aging, 2017, 57, 248.e1-248.e5.	1.5	11
1198	SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinsonâ€™s disease. BMC Neuroscience, 2017, 18, 46.	0.8	140
1199	Structural changes of gut microbiota in Parkinsonâ€™s disease and its correlation with clinical features. Science China Life Sciences, 2017, 60, 1223-1233.	2.3	316
1200	Gait analysis and quantitative drug effect evaluation in Parkinson disease by jointly EEG-EMG monitoring. , 2017, , .		17
1201	Associations of Spatial Disparities of Alzheimerâ€™s Disease Mortality Rates with Soil Selenium and Sulfur Concentrations and Four Common Risk Factors in the United States. Journal of Alzheimer's Disease, 2017, 58, 897-907.	1.2	12
1202	Psychosocial difficulties in patients with Parkinsonâ€™s disease. International Journal of Rehabilitation Research, 2017, 40, 112-118.	0.7	13
1203	Endocannabinoid system in neurodegenerative disorders. Journal of Neurochemistry, 2017, 142, 624-648.	2.1	148
1204	Classification of advanced stages of Parkinsonâ€™s disease: translation into stratified treatments. Journal of Neural Transmission, 2017, 124, 1015-1027.	1.4	64
1205	Î±-Synuclein Enhances Cadmium Uptake and Neurotoxicity via Oxidative Stress and Caspase Activated Cell Death Mechanisms in a Dopaminergic Cell Model of Parkinsonâ€™s Disease. Neurotoxicity Research, 2017, 32, 231-246.	1.3	11
1206	Continuous cerebroventricular administration of dopamine: A new treatment for severe dyskinesia in Parkinson's disease?. Neurobiology of Disease, 2017, 103, 24-31.	2.1	17
1207	Sirt3 protects dopaminergic neurons from mitochondrial oxidative stress. Human Molecular Genetics, 2017, 26, 1915-1926.	1.4	76
1208	The factor structure of the Brief Symptom Inventory-18 (BSI-18) in Parkinson disease patients. Journal of Psychosomatic Research, 2017, 96, 21-26.	1.2	13
1209	Intrastriatal Transplantation of Human Neural Stem Cells Restores the Impaired Subventricular Zone in Parkinsonian Mice. Stem Cells, 2017, 35, 1519-1531.	1.4	27
1210	The small heat shock proteins Î±B-crystallin (HSPB5) and Hsp27 (HSPB1) inhibit the intracellular aggregation of Î±-synuclein. Cell Stress and Chaperones, 2017, 22, 589-600.	1.2	42
1211	Motor learning in animal models of Parkinson's disease: Aberrant synaptic plasticity in the motor cortex. Movement Disorders, 2017, 32, 487-497.	2.2	25
1212	Trajectories of prediagnostic functioning in Parkinsonâ€™s disease. Brain, 2017, 140, 429-441.	3.7	124
1213	The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Neurochemistry International, 2017, 108, 183-189.	1.9	106
1214	Parkinson's disease monitoring by biomechanical instability of phonation. Neurocomputing, 2017, 255, 3-16.	3.5	17

#	Article	IF	Citations
1215	Genetic Analysis of FBXO2, FBXO6, FBXO12, and FBXO41 Variants in Han Chinese Patients with Sporadic Parkinsonâ€™s Disease. Neuroscience Bulletin, 2017, 33, 510-514.	1.5	18
1216	Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2017, 8, 1519-1529.	1.7	47
1218	Evolution and complications after surgery for spine deformation in patients with Parkinson's disease. Orthopaedics and Traumatology: Surgery and Research, 2017, 103, 517-522.	0.9	24
1219	Copper increases the ability of 6â€hydroxydopamine to generate oxidative stress and the ability of ascorbate and glutathione to potentiate this effect: potential implications in Parkinson's disease. Journal of Neurochemistry, 2017, 141, 738-749.	2.1	21
1220	Short-term air pollution exposure aggravates Parkinsonâ€™s disease in a population-based cohort. Scientific Reports, 2017, 7, 44741.	1.6	59
1221	Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinsonâ€™s Disease: A Meta-Analysis. Journal of Alzheimer's Disease, 2017, 56, 1229-1239.	1.2	21
1222	Non-pharmacological Approaches Based on Mind-Body Medicine to Enhancement of Cognitive and Brain Reserve in Humans. , 2017, , 129-151.		0
1223	TMEM230 in Parkinson's disease. Neurobiology of Aging, 2017, 56, 212.e1-212.e3.	1.5	9
1224	Glucose-rich diet aggravates monocrotophos-induced dopaminergic neuronal dysfunction inCaenorhabditis elegans. Journal of Applied Toxicology, 2017, 37, 772-780.	1.4	13
1225	Analysis of Extrastriatal ¹²³I-FP-CIT Binding Contributes to the Differential Diagnosis of Parkinsonian Diseases. Journal of Nuclear Medicine, 2017, 58, 1117-1123.	2.8	35
1226	Simvastatin is associated with decreased risk of <scp>P</scp>arkinson disease. Annals of Neurology, 2017, 81, 329-330.	2.8	12
1227	Gender effect on non-motor symptoms in Parkinson's disease: are men more at risk?. Parkinsonism and Related Disorders, 2017, 35, 69-74.	1.1	53
1228	Imposed Faster and Slower Walking Speeds Influence Gait Stability Differently in Parkinson Fallers. Archives of Physical Medicine and Rehabilitation, 2017, 98, 639-648.	0.5	23
1229	Genetic analysis of the TMEM230 gene in Chinese patients with familial Parkinson disease. Parkinsonism and Related Disorders, 2017, 36, 105-106.	1.1	11
1230	Movement Disorders Rehabilitation. , 2017, , .		1
1231	Opening up the DNA methylome of dementia. Molecular Psychiatry, 2017, 22, 485-496.	4.1	59
1233	Role of the VPS35 D620N mutation in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 36, 10-18.	1.1	24
1234	Diminished stress resistance and defective adaptive homeostasis in age-related diseases. Clinical Science, 2017, 131, 2573-2599.	1.8	32

#	Article	IF	Citations
1235	Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico-basal ganglia loop circuit in vivo in experimental parkinsonism. Experimental Neurology, 2017, 298, 122-133.	2.0	20
1236	Anti-Parkinsonian effects of Î²-amyrin are regulated via LGG-1 involved autophagy pathway in Caenorhabditis elegans. Phytomedicine, 2017, 36, 118-125.	2.3	41
1237	The Influence of Parkinson Disease on Lumbar Decompression Surgery: A Retrospective Case Control Study. World Neurosurgery, 2017, 108, 513-518.	0.7	8
1238	An Efficient Text Entry Model for Scanning Ambiguous Keyboard. , 2017, , .		2
1239	Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinsonâ€™s disease motor symptoms without neuronal degeneration in adult mice. Scientific Reports, 2017, 7, 12432.	1.6	15
1240	Dancing with Parkinson's: a London hospice's experience of running a dance programme. International Journal of Palliative Nursing, 2017, 23, 498-500.	0.2	2
1242	Neuroprotective strategies to prevent and treat Parkinsonâ€™s disease based on its pathophysiological mechanism. Archives of Pharmacal Research, 2017, 40, 1117-1128.	2.7	16
1243	Detection and application of neurochemical profile by multiple regional ¹Hâ€MRS in Parkinson's disease. Brain and Behavior, 2017, 7, e00792.	1.0	15
1244	NCEH-1 modulates cholesterol metabolism and protects against Î±-synuclein toxicity in a C. elegans model of Parkinsonâ€™s disease. Human Molecular Genetics, 2017, 26, 3823-3836.	1.4	26
1245	Epigenetic approach to early-onset Parkinsonâ€™s disease: low methylation status of SNCA and PARK2 promoter regions. Neurological Research, 2017, 39, 965-972.	0.6	29
1246	Mitochondrial-Associated Membranes in Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2017, 997, 157-169.	0.8	26
1247	Applications for Treatment of Neurodegenerative Diseases. Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques, 2017, , 99-134.	0.6	5
1248	Measurement Characteristics and Clinical Utility of the Freezing of Gait Questionnaire in Individuals With Parkinson Disease. Archives of Physical Medicine and Rehabilitation, 2017, 98, 2106-2107.	0.5	2
1249	Regenerative Medicine: Advances from Developmental to Degenerative Diseases. Advances in Experimental Medicine and Biology, 2017, 1007, 225-239.	0.8	3
1250	Association between SNCA rs2736990 polymorphism and Parkinsonâ€™s disease: a meta-analysis. Neuroscience Letters, 2017, 658, 102-107.	1.0	2
1251	Prescribing Pattern for Parkinsonâ€™s Disease in Indian Community before Referral to Tertiary Center. Canadian Journal of Neurological Sciences, 2017, 44, 705-710.	0.3	8
1252	Gender Differences of Nonmotor Symptoms Affecting Quality of Life in Parkinson Disease. Neurodegenerative Diseases, 2017, 17, 276-280.	0.8	25
1253	Crafting a View of Self-Tracking Data in the Clinical Visit. , 2017, , .		68

#	Article	IF	Citations
1254	Mitochondrial dynamics in Parkinson's disease: a role for Î±-synuclein?. DMM Disease Models and Mechanisms, 2017, 10, 1075-1087.	1.2	134
1255	Comparative Patient Satisfaction and Feasibility of a Pilot Parkinsonâ€™s Disease Enrichment Program. Journal of Geriatric Psychiatry and Neurology, 2017, 30, 253-260.	1.2	3
1256	ACRâ€“ACNM Practice Parameter for the Performance of Dopamine Transporter (DaT) Single Photon Emission Computed Tomography (SPECT) Imaging for Movement Disorders. Clinical Nuclear Medicine, 2017, 42, 847-852.	0.7	13
1257	ER Stress and Neurodegenerative Disease: A Cause or Effect Relationship?. Current Topics in Microbiology and Immunology, 2017, 414, 131-157.	0.7	29
1258	Measurement of spontaneous blinks in patients with Parkinson's disease using a new high-speed blink analysis system. Journal of the Neurological Sciences, 2017, 380, 200-204.	0.3	14
1259	Dopaminergic Modulation of Biological Motion Perception in patients with Parkinsonâ€™s disease. Scientific Reports, 2017, 7, 10159.	1.6	5
1260	Does supplementation with carnosine improve cardiometabolic health and cognitive function in patients with pre-diabetes and type 2 diabetes? study protocol for a randomised, double-blind, placebo-controlled trial. BMJ Open, 2017, 7, e017691.	0.8	12
1261	Ã‰volution et complications des arthrodÃ¨ses pour dÃ©formation rachidienne majeure chez les patients parkinsoniens. Revue De Chirurgie Orthopedique Et Traumatologique, 2017, 103, 364-370.	0.0	0
1262	Abnormal energy metabolism and tau phosphorylation in the brains of middle-aged mice in response to atmospheric PM2.5 exposure. Journal of Environmental Sciences, 2017, 62, 145-153.	3.2	26
1263	Downregulation of blood serum microRNA 29 family in patients with Parkinsonâ€™s disease. Scientific Reports, 2017, 7, 5411.	1.6	89
1264	Wearable platform for automatic recognition of Parkinson Disease by muscular implication monitoring. , 2017, , .		5
1265	Occurrence of spleen qi deficiency as defined by Chinese medicine in Parkinson disease. Journal of Traditional Chinese Medical Sciences, 2017, 4, 24-30.	0.1	3
1266	Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?. Journal of Medicinal Chemistry, 2017, 60, 7206-7212.	2.9	47
1267	Reproductive factors and risk of Parkinsonâ€™s disease in women: A meta-analysis of observational studies. Behavioural Brain Research, 2017, 335, 103-110.	1.2	27
1268	Parkinson's disease-associated pathogenic VPS35 mutation causes complex I deficits. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 2791-2795.	1.8	40
1269	Head trauma and Parkinsonâ€™s disease: results from an Italian case-control study. Neurological Sciences, 2017, 38, 1835-1839.	0.9	11
1270	Nested caseâ€“control study designs for leftâ€truncated survival data. Canadian Journal of Statistics, 2017, 45, 4-28.	0.6	0
1271	Prevalence, Duration and Severity of Parkinson's Disease in Germany: A Combined Meta-Analysis from Literature Data and Outpatient Samples. European Neurology, 2017, 78, 128-136.	0.6	16

#	Article	IF	Citations
1272	Contribution of language studies to the understanding of cognitive impairment and its progression over time in Parkinsonâ€™s disease. Neuroscience and Biobehavioral Reviews, 2017, 80, 657-672.	2.9	51
1273	Automated PDF highlighting to support faster curation of literature for Parkinsonâ€™s and Alzheimerâ€™s disease. Database: the Journal of Biological Databases and Curation, 2017, 2017, .	1.4	1
1274	Melatonin as a mitochondrial protector in neurodegenerative diseases. Cellular and Molecular Life Sciences, 2017, 74, 3999-4014.	2.4	57
1275	Evidence for association between hepatitis C virus and Parkinsonâ€™s disease. Neurological Sciences, 2017, 38, 1913-1920.	0.9	16
1276	Does assisted cycling improve function in those with Parkinsonâ€™s disease?. Physical Therapy Reviews, 2017, 22, 243-253.	0.3	3
1277	Glaucocalyxin B Alleviates Lipopolysaccharide-Induced Parkinsonâ€™s Disease by Inhibiting TLR/NF-Î²B and Activating Nrf2/HO-1 Pathway. Cellular Physiology and Biochemistry, 2017, 44, 2091-2104.	1.1	45
1278	Exploring the microbiome in health and disease. Toxicology Research and Application, 2017, 1, 239784731774188.	0.7	36
1279	The significance of uric acid in the diagnosis and treatment of Parkinson disease. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlo	0.4	36
1281	Ultrasound targeted CNS gene delivery for Parkinson's disease treatment. Journal of Controlled Release, 2017, 261, 246-262.	4.8	68
1282	Biomarkers in Neurodegenerative Diseases. Advances in Neurobiology, 2017, 15, 491-528.	1.3	69
1283	Subclinical vascular disease and the risk of parkinsonism: The Rotterdam Study. Parkinsonism and Related Disorders, 2017, 43, 27-32.	1.1	4
1284	Evaluation of the Parkinsonâ€™s KinetiGraph in monitoring and managing Parkinsonâ€™s disease. Expert Review of Medical Devices, 2017, 14, 583-591.	1.4	25
1285	Structural changes in Parkinsonâ€™s disease: voxel-based morphometry and diffusion tensor imaging analyses based on 123I-MIBG uptake. European Radiology, 2017, 27, 5073-5079.	2.3	6
1286	Voice assessments for detecting patients with neurological diseases using PCA and NPCA. International Journal of Speech Technology, 2017, 20, 673-683.	1.4	10
1287	Excessive early-life dietary exposure: a potential source of elevated brain iron and a risk factor for Parkinsonâ€™s disease. Npj Parkinson's Disease, 2017, 3, 1.	2.5	60
1288	Integrated molecular landscape of Parkinsonâ€™s disease. Npj Parkinson's Disease, 2017, 3, 14.	2.5	92
1289	Sensors for Parkinson's disease evaluation. , 2017, , .		2
1290	Co-morbidity and polypharmacy in Parkinsonâ€™s disease: insights from a large Scottish primary care database. BMC Neurology, 2017, 17, 126.	0.8	80

#	Article	IF	Citations
1291	Long non-coding RNA MALAT1 contributes to cell apoptosis by sponging miR-124 in Parkinson disease. Cell and Bioscience, 2017, 7, 19.	2.1	114
1292	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADYâ€PD III). Annals of Clinical and Translational Neurology, 2017, 4, 360-368.	1.7	59
1293	The role of endoplasmic reticulum stress in neurodegenerative disease. Apoptosis: an International Journal on Programmed Cell Death, 2017, 22, 1-26.	2.2	185
1294	Factors associated with life satisfaction in Parkinson's disease. Acta Neurologica Scandinavica, 2017, 136, 64-71.	1.0	38
1295	Î±-synuclein aggregation and its modulation. International Journal of Biological Macromolecules, 2017, 100, 37-54.	3.6	106
1296	Symmetrical aryl linked bis-iminothiazolidinones as new chemical entities for the inhibition of monoamine oxidases: Synthesis, in vitro biological evaluation and molecular modelling analysis. Bioorganic Chemistry, 2017, 70, 17-26.	2.0	17
1297	Cognitive phenotypes in parkinson's disease differ in terms of brainâ€network organization and connectivity. Human Brain Mapping, 2017, 38, 1604-1621.	1.9	84
1298	Stem Cells for Modeling and Therapy of Parkinson's Disease. Human Gene Therapy, 2017, 28, 85-98.	1.4	35
1299	Molecular Imaging of Extrapyramidal Movement Disorders. Seminars in Nuclear Medicine, 2017, 47, 18-30.	2.5	4
1300	Ageing, masculinity and Parkinson's disease: embodied perspectives. Sociology of Health and Illness, 2017, 39, 532-546.	1.1	9
1301	Epidemiology and associated risk factors of Parkinson's disease among the north Indian population. Clinical Epidemiology and Global Health, 2017, 5, 8-13.	0.9	12
1302	Neuromuscular Impairments Are Associated With Impaired Head and Trunk Stability During Gait in Parkinson Fallers. Neurorehabilitation and Neural Repair, 2017, 31, 34-47.	1.4	35
1303	Association of the DRD2 CA n -STR and DRD3 Ser9Gly polymorphisms with Parkinson's disease and response to dopamine agonists. Journal of the Neurological Sciences, 2017, 372, 433-438.	0.3	19
1304	Back to the tubule: microtubule dynamics in Parkinsonâ€™s disease. Cellular and Molecular Life Sciences, 2017, 74, 409-434.	2.4	114
1305	(Neuro)degenerated Mitochondria-ER contacts. Biochemical and Biophysical Research Communications, 2017, 483, 1096-1109.	1.0	28
1306	<scp>DJ</scp>â€1 modulates mitochondrial response to oxidative stress: clues from a novel diagnosis of <scp>PARK7</scp>. Clinical Genetics, 2017, 92, 18-25.	1.0	34
1307	Neuroprotective mechanisms of plant extracts against MPTP induced neurotoxicity: Future applications in Parkinsonâ€™s disease. Biomedicine and Pharmacotherapy, 2017, 85, 635-645.	2.5	72
1308	Assessment of Speech Intelligibility in Parkinsonâ€™s Disease Using a Speech-To-Text System. IEEE Access, 2017, 5, 22199-22208.	2.6	68

#	Article	IF	Citations
1309	Stereological Evaluation of the Brains in Patients with Parkinsonâ€™s disease Compared to Controls. Romanian Journal of Laboratory Medicine, 2017, 25, 265-274.	0.1	3
1310	Effects of Quercetin on Neurodegenerative and Compensatory Processes in the Nigrostriatal System in a Model of the Preclinical Stage of Parkinsonâ€™s Disease in Rats. Neuroscience and Behavioral Physiology, 2017, 47, 1029-1036.	0.2	5
1311	Excessive burden of lysosomal storage disorder gene variants in Parkinsonâ€™s disease. Brain, 2017, 140, 3191-3203.	3.7	323
1312	Discovering the 3â€² UTR-mediated regulation of alpha-synuclein. Nucleic Acids Research, 2017, 45, 12888-12903.	6.5	32
1313	Towards a personal at-home lab for motion video tracking in patients with Parkinson's disease. , 2017, , .		12
1314	The Age-Related Effect of Nicotine on the Expression of Neuroprotective Genes in Ventral Tegmental Area and Substantia Nigra. IEEE Life Sciences Letters, 2017, 3, 13-16.	1.2	1
1315	On mobile personalized healthcare services for human involvement into prevention, therapy, mutual support, and social rehabilitation. , 2017, , .		6
1316	Associations Between Lifestyle Factors And Parkinsonâ€™s Disease In An Urban Sri Lankan Clinic Study. International Archive of Medicine, 2017, 10, .	1.2	7
1317	Speech Impairment, Phonation, Writing, Salivation, and Swallowing in Patients with Parkinsonâ€™s Disease. , 0, , .		0
1318	Endothelial Degeneration of Parkinson's Disease is Related to Alpha-Synuclein Aggregation. , 2017, 7, .		11
1319	Rodent Model of Parkinsonâ€™s Disease: Unilateral or Bilateral?. , 2017, 07, .		3
1320	PREDITORES DO DESEMPENHO NO TESTE DE ALCANCE FUNCIONAL EM PESSOAS COM DOENÃ‡A DE PARKINSON. Journal of Physical Education (Maringa), 2017, 28, .	0.1	1
1321	Safety and Efficacy of Rotigotine for Treating Parkinsonâ€™s Disease: A Meta-Analysis of Randomised Controlled Trials. Journal of Pharmacy and Pharmaceutical Sciences, 2017, 20, 285.	0.9	9
1322	Support System to Improve Reading Activity in Parkinsonâ€™s Disease and Essential Tremor Patients. Sensors, 2017, 17, 1006.	2.1	3
1323	Biomarker Research in Parkinsonâ€™s Disease Using Metabolite Profiling. Metabolites, 2017, 7, 42.	1.3	107
1324	Variants in SNCA Gene Are Associated with Parkinsonâ€™s Disease Risk and Cognitive Symptoms in a Brazilian Sample. Frontiers in Aging Neuroscience, 2017, 9, 198.	1.7	40
1325	The Role of Microglia in Retinal Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma. Frontiers in Aging Neuroscience, 2017, 9, 214.	1.7	348
1326	Exercise-Induced Neuroprotection of the Nigrostriatal Dopamine System in Parkinson's Disease. Frontiers in Aging Neuroscience, 2017, 9, 358.	1.7	64

#	Article	IF	Citations
1327	Biological and Clinical Implications of Comorbidities in Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2017, 9, 394.	1.7	67
1328	Parkinson Disease: An Evolutionary Perspective. Frontiers in Neurology, 2017, 8, 157.	1.1	39
1329	Aerobic-Strength Exercise Improves Metabolism and Clinical State in Parkinsonâ€™s Disease Patients. Frontiers in Neurology, 2017, 8, 698.	1.1	23
1330	Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target. Frontiers in Neuroscience, 2017, 11, 30.	1.4	154
1331	The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. Frontiers in Neuroscience, 2017, 11, 254.	1.4	277
1332	Adenosine A1-A2A Receptor Heteromer as a Possible Target for Early-Onset Parkinson's Disease. Frontiers in Neuroscience, 2017, 11, 652.	1.4	10
1333	Can coffee consumption lower the risk of Alzheimerâ€™s disease and Parkinsonâ€™s disease? A literature review. Archives of Medical Science, 2017, 3, 507-514.	0.4	35
1334	Body Posture, Postural Stability, and Metabolic Age in Patients with Parkinsonâ€™s Disease. BioMed Research International, 2017, 2017, 1-9.	0.9	19
1335	Salidroside Protects against MPP+-Induced Neuronal Injury through DJ-1-Nrf2 Antioxidant Pathway. Evidence-based Complementary and Alternative Medicine, 2017, 2017, 1-11.	0.5	13
1336	A Randomized Controlled Trial of Chinese Medicine on Nonmotor Symptoms in Parkinsonâ€™s Disease. Parkinson's Disease, 2017, 2017, 1-8.	0.6	13
1337	Genetic Variants in SNCA and the Risk of Sporadic Parkinsonâ€™s Disease and Clinical Outcomes: A Review. Parkinson's Disease, 2017, 2017, 1-11.	0.6	32
1338	Protective effect of tangeritin in transgenic Drosophila model of Parkinson rsquo s disease. Frontiers in Bioscience - Elite, 2017, 9, 44-53.	0.9	17
1339	Consensus on the Definition of Advanced Parkinsonâ€™s Disease: A Neurologists-Based Delphi Study (CEPA Study). Parkinson's Disease, 2017, 2017, 1-8.	0.6	53
1340	Chaperone-Based Therapies for Disease Modification in Parkinsonâ€™s Disease. Parkinson's Disease, 2017, 2017, 1-11.	0.6	32
1341	Noradrenergic Modulation of Cognition in Health and Disease. Neural Plasticity, 2017, 2017, 1-14.	1.0	154
1342	Altered GABAergic Signaling in Brain Disease at Various Stages of Life. Experimental Neurobiology, 2017, 26, 122-131.	0.7	49
1343	The Effect of Balance Training on Postural Control in Patients with Parkinsonâ€™s Disease Using a Virtual Rehabilitation System. Methods of Information in Medicine, 2017, 56, 138-144.	0.7	29
1344	Ultra high-field SWI of the substantia nigra at 7T: reliability and consistency of the swallow-tail sign. BMC Neurology, 2017, 17, 194.	0.8	35

#	Article	IF	Citations
1345	Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. BMC Neurology, 2017, 17, 198.	0.8	55
1346	Lack of interleukin-13 receptor Î±1 delays the loss of dopaminergic neurons during chronic stress. Journal of Neuroinflammation, 2017, 14, 88.	3.1	24
1347	The PD COMM trial: a protocol for the process evaluation of a randomised trial assessing the effectiveness of two types of SLT for people with Parkinsonâ€™s disease. Trials, 2017, 18, 397.	0.7	6
1348	The Pocket-4-Life project, bioavailability and beneficial properties of the bioactive compounds of espresso coffee and cocoa-based confectionery containing coffee: study protocol for a randomized cross-over trial. Trials, 2017, 18, 527.	0.7	13
1349	Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases. Translational Neurodegeneration, 2017, 6, 20.	3.6	104
1350	Direct conversion from skin fibroblasts to functional dopaminergic neurons for biomedical application. Biomedical Dermatology, 2017, 1, .	7.6	4
1351	Refinement of a neuronal differentiation protocol predominantly yields human iPS cell-derived dopaminergic neurons for the investigation of neurodegenerative pathomechanisms in vitro. Journal of Cellular Biotechnology, 2017, 3, 61-80.	0.1	0
1352	Stem Cell Applications in Parkinsonâ€™s Disease. , 2017, 07, .		0
1353	Neurotoxin 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Induced Animal Models of Parkinsonâ€™s Disease. , 2017, , 1087-1108.		4
1354	Mitochondrial Respiration in Intact Peripheral Blood Mononuclear Cells and Sirtuin 3 Activity in Patients with Movement Disorders. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-10.	1.9	8
1355	Is Decompressive Surgery for Cervical Spondylotic Myelopathy Effective in Patients Suffering from Concomitant Multiple Sclerosis or Parkinsonâ€™s Disease?. Brain Sciences, 2017, 7, 39.	1.1	8
1356	Average annual cost of Parkinson’s disease in São Paulo, Brazil, with a focus on disease-related motor symptoms. Clinical Interventions in Aging, 2017, Volume 12, 2095-2108.	1.3	22
1357	Prevalence of depression and receipt of antidepressant pharmacotherapy among patients with Parkinson’s disease: a national assessment of US office-based physician visits. Journal of Parkinsonism and Restless Legs Syndrome, 2017, Volume 7, 79-84.	0.8	1
1358	Modification of Î±-Synuclein by Phosphorylation: A Pivotal Event in the Cellular Pathogenesis of Parkinsonâ€™s Disease. , 2017, , .		1
1359	Parkinsonâ€™s Disease Impulsive-Compulsive Disorders Questionnaire â€“ Current Short (QUIP-CS) â€“ Translation and validation of content of Portuguese Version. Jornal Brasileiro De Psiquiatria, 2017, 66, 111-115.	0.2	6
1360	Skin disorders in Parkinson’s disease: potential biomarkers and risk factors. Clinical, Cosmetic and Investigational Dermatology, 2017, Volume 10, 87-92.	0.8	45
1361	Resolvin D1 Attenuates Mpp+-Induced Parkinson Disease via Inhibiting Inflammation in PC12 Cells. Medical Science Monitor, 2017, 23, 2684-2691.	0.5	30
1362	DinÃ¢mica da fronteira agrÃ¢cola do Mato Grosso e implicaÃ§Ãµes para a saÃºde. Estudos Avancados, 2017, 31, 323-338.	0.2	4

#	Article	IF	Citations
1363	Î±-Syn-PMCA in cerebrospinal fluid has diagnostic potential in Parkinsonâ€™s disease. Journal of Xiangya Medicine, 0, 2, 78-78.	0.2	0
1364	Inpatient morbidity after spinal deformity surgery in patients with movement disorders. Journal of Spine Surgery, 2017, 3, 601-608.	0.6	9
1365	Parkinsonâ€™s disease and the risk of osteoporotic vertebral compression fracture: a nationwide population-based study. Osteoporosis International, 2018, 29, 1117-1124.	1.3	11
1367	Optimizing Parkinsonâ€™s disease diagnosis: the role of a dual nuclear imaging algorithm. Npj Parkinson's Disease, 2018, 4, 5.	2.5	18
1368	Parkinson's Disease: Patientsâ€™ Knowledge, Attitudes, and Interest in Genetic Counseling. Journal of Genetic Counseling, 2018, 27, 1200-1209.	0.9	18
1369	Differential scanning calorimetry study of early and advanced stages in Parkinsonâ€™s disease using human blood serum. Thermochimica Acta, 2018, 662, 64-68.	1.2	8
1370	Association between physical fitness, cardiovascular risk factors, and Parkinson's disease. European Journal of Preventive Cardiology, 2018, 25, 1409-1415.	0.8	14
1371	Impact of the Aged Brain Environment on Gene Therapy for Parkinsonâ€™s Disease. , 2018, , 647-657.		0
1373	Obstructive Sleep Apnea in Parkinsonâ€™s Diseaseâ€”a Mini-Review. Current Sleep Medicine Reports, 2018, 4, 118-124.	0.7	0
1374	Detecting neurodegenerative disorders from web search signals. Npj Digital Medicine, 2018, 1, 8.	5.7	36
1375	Exosomes and Stem Cells in Degenerative Disease Diagnosis and Therapy. Cell Transplantation, 2018, 27, 349-363.	1.2	111
1376	Gallic Acid Protects 6-OHDA Induced Neurotoxicity by Attenuating Oxidative Stress in Human Dopaminergic Cell Line. Neurochemical Research, 2018, 43, 1150-1160.	1.6	65
1377	Comparison of Awake vs. Asleep Surgery for Subthalamic Deep Brain Stimulation in Parkinsonâ€™s Disease. Neuromodulation, 2018, 21, 541-547.	0.4	27
1378	Application of the Movement Disorder Society prodromal criteria in healthy G2019Sâ€LRRK2 carriers. Movement Disorders, 2018, 33, 966-973.	2.2	44
1379	Gastrodin microinjection suppresses 6-OHDA-induced motor impairments in parkinsonian rats: insights into oxidative balance and microglial activation in SNc. Inflammopharmacology, 2018, 26, 1305-1316.	1.9	21
1380	Restorative effect of l-Dopa treatment against Ochratoxin A induced neurotoxicity. Neurochemistry International, 2018, 118, 252-263.	1.9	24
1381	Refolding of helical soluble Î±â€synuclein through transient interaction with lipid interfaces. FEBS Letters, 2018, 592, 1464-1472.	1.3	38
1382	Descriptive epidemiology of parkinsonism in the Canton of Geneva, Switzerland. Parkinsonism and Related Disorders, 2018, 54, 30-39.	1.1	42

#	Article	IF	Citations
1383	Parkinson's disease, epileptic seizures, and sudden death: Three faces of the same coin. Epilepsy and Behavior, 2018, 83, 239-241.	0.9	3
1384	Degradation of alpha-synuclein by dendritic cell factor 1 delays neurodegeneration and extends lifespan in Drosophila. Neurobiology of Aging, 2018, 67, 67-74.	1.5	11
1385	Pluripotent stem cell-based therapy for Parkinsonâ€™s disease: Current status and future prospects. Progress in Neurobiology, 2018, 168, 1-20.	2.8	84
1386	Cognitive Flexibility Deficits Following 6-OHDA Lesions of the Rat Dorsomedial Striatum. Neuroscience, 2018, 374, 80-90.	1.1	51
1387	Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model. Neurochemistry International, 2018, 114, 71-79.	1.9	27
1388	Carvacrol prevents impairments in motor and neurochemical parameters in a model of progressive parkinsonism induced by reserpine. Brain Research Bulletin, 2018, 139, 9-15.	1.4	25
1389	Sleep disorders and Parkinson disease; lessons from genetics. Sleep Medicine Reviews, 2018, 41, 101-112.	3.8	35
1390	Transcriptional alterations in skin fibroblasts from Parkinson's disease patients with parkin mutations. Neurobiology of Aging, 2018, 65, 206-216.	1.5	13
1391	Longitudinal assessment of falls in patients with Parkinsonâ€™s disease using inertial sensors and the Timed Up and Go test. Journal of Rehabilitation and Assistive Technologies Engineering, 2018, 5, 205566831775081.	0.6	16
1392	A meta-analysis of diffusion tensor imaging of substantia nigra in patients with Parkinsonâ€™s disease. Scientific Reports, 2018, 8, 2941.	1.6	23
1393	Voice quality outcomes of idiopathic Parkinson's disease medical treatment: A systematic review. Clinical Otolaryngology, 2018, 43, 882-903.	0.6	16
1394	Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinsonâ€™s Disease: a Network Meta-Analysis. Cellular Physiology and Biochemistry, 2018, 45, 119-130.	1.1	22
1395	Release and uptake of pathologic alpha-synuclein. Cell and Tissue Research, 2018, 373, 175-182.	1.5	57
1396	Genetic Modifiers in Neurodegeneration. Current Genetic Medicine Reports, 2018, 6, 11-19.	1.9	11
1397	Feature-based information filtering in visual working memory is impaired in Parkinson's disease. Neuropsychologia, 2018, 111, 317-323.	0.7	9
1398	Orphan G protein-coupled receptors: The role in CNS disorders. Biomedicine and Pharmacotherapy, 2018, 98, 222-232.	2.5	70
1399	Step length determines minimum toe clearance in older adults and people with Parkinsonâ€™s disease. Journal of Biomechanics, 2018, 71, 30-36.	0.9	37
1400	Neurodegenerative Disorders and Sleep. Sleep Medicine Clinics, 2018, 13, 63-70.	1.2	85

#	Article	IF	Citations
1401	Measuring quality of life in individuals with Parkinsonâ€™s disease attending a self-help club: cross-sectional study in Hungary. International Journal of Rehabilitation Research, 2018, 41, 81-83.	0.7	1
1402	Garcinia kola seed biflavonoid fraction (Kolaviron), increases longevity and attenuates rotenone-induced toxicity in Drosophila melanogaster. Pesticide Biochemistry and Physiology, 2018, 145, 39-45.	1.6	43
1403	Reprogramming neurodegeneration in the big data era. Current Opinion in Neurobiology, 2018, 48, 167-173.	2.0	5
1404	Genetics and Treatment Response in Parkinsonâ€™s Disease: An Update on Pharmacogenetic Studies. NeuroMolecular Medicine, 2018, 20, 1-17.	1.8	43
1405	Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinsonâ€™s disease. Cellular and Molecular Life Sciences, 2018, 75, 2075-2091.	2.4	16
1406	Effect of physical activity on cognitive flexibility, depression and RBD in healthy elderly. Clinical Neurology and Neurosurgery, 2018, 165, 88-93.	0.6	26
1407	Implementation of a multidisciplinary psychoeducational intervention for Parkinsonâ€™s disease patients and carers in the community: study protocol. BMC Family Practice, 2018, 19, 45.	2.9	9
1408	An inducible MAO-B mouse model of Parkinsonâ€™s disease: a tool towards better understanding basic disease mechanisms and developing novel therapeutics. Journal of Neural Transmission, 2018, 125, 1651-1658.	1.4	23
1409	Plasma Î±-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study. Neurobiology of Disease, 2018, 116, 53-59.	2.1	29
1410	Evidence of Neurobiological Changes in the Presymptomatic PINK1 Knockout Rat. Journal of Parkinson's Disease, 2018, 8, 281-301.	1.5	22
1412	Subjective and psychological well-being in Parkinson's Disease: A systematic review. Acta Neurologica Scandinavica, 2018, 138, 12-23.	1.0	30
1413	Cardiac abnormalities in Parkinsonâ€™s disease and Parkinsonism. Journal of Clinical Neuroscience, 2018, 53, 1-5.	0.8	100
1414	Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process. Cellular and Molecular Neurobiology, 2018, 38, 1153-1178.	1.7	102
1415	Functional results and patient satisfaction after long fusion for spinal deformity in Parkinson's disease. Orthopaedics and Traumatology: Surgery and Research, 2018, 104, 417-420.	0.9	6
1416	Dynamic balance control during stair negotiation for older adults and people with Parkinson disease. Human Movement Science, 2018, 59, 30-36.	0.6	12
1417	Neurologic Disorders and Maxillofacial Surgery. , 2018, , 243-262.		1
1418	Genetic risk factors in Parkinsonâ€™s disease. Cell and Tissue Research, 2018, 373, 9-20.	1.5	159
1419	FPGA-Based Embedded Cyber-Physical Platform to Assess Gait and Postural Stability in Parkinsonâ€™s Disease. IEEE Transactions on Components, Packaging and Manufacturing Technology, 2018, 8, 1167-1179.	1.4	33

#	Article	IF	Citations
1420	The Convergence of Dopamine and Î±-Synuclein: Implications for Parkinsonâ€™s Disease. Journal of Experimental Neuroscience, 2018, 12, 117906951876136.	2.3	16
1421	miR-494-3p modulates the progression of in vitro and in vivo Parkinsonâ€™s disease models by targeting SIRT3. Neuroscience Letters, 2018, 675, 23-30.	1.0	48
1422	Cytokine modulation in response to acute and chronic aquatic therapy intervention in Parkinson disease individuals: A pilot study. Neuroscience Letters, 2018, 674, 30-35.	1.0	12
1423	The role of regulatory T cells in nervous system pathologies. Journal of Neuroscience Research, 2018, 96, 951-968.	1.3	64
1424	Association of soil selenium, strontium, and magnesium concentrations with Parkinsonâ€™s disease mortality rates in the USA. Environmental Geochemistry and Health, 2018, 40, 349-357.	1.8	22
1425	Modulation of ARTS and XIAP by Parkin Is Associated with Carnosic Acid Protects SH-SY5Y Cells against 6-Hydroxydopamine-Induced Apoptosis. Molecular Neurobiology, 2018, 55, 1786-1794.	1.9	15
1426	Assessment of residential environmental exposure to pesticides from agricultural fields in the Netherlands. Journal of Exposure Science and Environmental Epidemiology, 2018, 28, 173-181.	1.8	34
1427	Depressive symptoms in Parkinsonâ€™s disease are related to decreased left hippocampal volume: correlation with the 15-item shortened version of the Geriatric Depression Scale. Acta Radiologica, 2018, 59, 341-345.	0.5	18
1428	Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease. Parkinsonism and Related Disorders, 2018, 46, S15-S18.	1.1	14
1429	Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harbor Perspectives in Biology, 2018, 10, a033118.	2.3	616
1430	Diagnosis of Parkinsonâ€™s disease and the level of oxidized DJ-1 protein. Neuroscience Research, 2018, 128, 58-62.	1.0	15
1431	Deep learning for freezing of gait detection in Parkinsonâ€™s disease patients in their homes using a waist-worn inertial measurement unit. Knowledge-Based Systems, 2018, 139, 119-131.	4.0	151
1432	5â€HT_{1F} receptorâ€mediated mitochondrial biogenesis for the treatment of Parkinson's disease. British Journal of Pharmacology, 2018, 175, 348-358.	2.7	31
1433	Sensitivity analysis of discharge patterns of subthalamic nucleus in the model of basal ganglia in Parkinson disease. Journal of Integrative Neuroscience, 2018, 16, 441-452.	0.8	5
1434	A review of genomeâ€wide transcriptomics studies in Parkinson's disease. European Journal of Neuroscience, 2018, 47, 1-16.	1.2	99
1435	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
1436	Deciphering the pathways that protect from IL-13-mediated potentiation of oxidative stress-induced dopaminergic nerve cell death. Cytokine, 2018, 103, 114-120.	1.4	10
1437	Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders. Journal of Drug Delivery Science and Technology, 2018, 43, 295-310.	1.4	86

#	Article	IF	Citations
1438	Rehabilitation of Ageing People with Neurological Disorders. Practical Issues in Geriatrics, 2018, , 305-329.	0.3	0
1439	Intrastriatal Chromospheresâ€™ Transplant Reduces Nociception in Hemiparkinsonian Rats. Neuroscience, 2018, 387, 123-134.	1.1	16
1440	In mammalian skeletal muscle, phosphorylation of TOMM22 by protein kinase CSNK2/CK2 controls mitophagy. Autophagy, 2018, 14, 311-335.	4.3	51
1441	Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats. Neurotoxicity Research, 2018, 33, 549-559.	1.3	9
1442	APOE, thought disorder, and SPAREâ€AD predict cognitive decline in established Parkinson's disease. Movement Disorders, 2018, 33, 289-297.	2.2	35
1443	Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy. Molecular and Cellular Neurosciences, 2018, 86, 65-71.	1.0	35
1444	Small molecule SUMOylation activators are novel neuroprotective agents. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 405-409.	1.0	10
1445	Mobility monitoring using smart technologies for Parkinsonâ€™s disease in free-living environment. Collegian, 2018, 25, 549-560.	0.6	16
1446	Association of circulating manganese levels with Parkinsonâ€™s disease: A meta-analysis. Neuroscience Letters, 2018, 665, 92-98.	1.0	18
1447	Costs of informal nursing care for patients with neurologic disorders. Neurology, 2018, 90, 28-34.	1.5	7
1448	Genetics of Parkinsonâ€™s disease and related disorders. Journal of Medical Genetics, 2018, 55, 73-80.	1.5	55
1449	Severely Affected by Parkinson Disease: The Patientâ€™s View and Implications for Palliative Care. American Journal of Hospice and Palliative Medicine, 2018, 35, 579-585.	0.8	16
1450	Efficacy and safety of perampanel in Parkinsonâ€™s disease. A systematic review with meta-analysis. Journal of Neurology, 2018, 265, 733-740.	1.8	25
1451	Pharmacokinetics, Pharmacodynamics, and Safety of Rasagiline Transdermal Patch: A Preliminary Study in Healthy Chinese Subjects. Clinical Drug Investigation, 2018, 38, 125-133.	1.1	10
1452	Residential exposure to air pollution and incidence of Parkinsonâ€™s disease in a large metropolitan cohort. Environmental Epidemiology, 2018, 2, e023.	1.4	24
1453	Dysfunction of mitochondria as the basis of Parkinsonâ€™s disease. Medical Journal of Cell Biology (discontinued), 2018, 6, 174-181.	0.2	1
1454	ELECTROPHYSIOLOGICAL SIGNAL PROCESSING FOR INTRAOPERATIVE LOCALIZATION OF SUBTHALAMIC NUCLEUS DURING DEEP BRAIN STIMULATION SURGERY. , 2018, , .		3
1455	Cerebral Microbleeds are Associated with Postural Instability and Gait Disturbance Subtype in People with Parkinsonâ€™s Disease. European Neurology, 2018, 80, 335-340.	0.6	12

#	Article	IF	Citations
1456	Healthy and Parkinson voices discrimination based on compensation/normalization cepstral features. , 2018, , .		0
1457	EstimulaciÃ³n cerebral profunda en enfermedad de Parkinson. Iatreia, 2018, 31, 262-273.	0.1	3
1458	The study of health-related quality of life using PDQ39 in patients with Parkinson's disease treated with advanced therapies. Revista CientÃfica De La Sociedad De EnfermerÃa NeurolÃ³gica (English Ed), 2018, 48, 9-14.	0.0	0
1459	Neuroengineering and neuroprosthetics. Brain and Neuroscience Advances, 2018, 2, 239821281881749.	1.8	9
1460	Dopamine and Early Onset Parkinsonâ€™s Disease. , 0, , .		1
1461	Development of Neural Stem Cell-Based Therapies for Parkinsonâ€™s Disease. , 2018, , .		0
1462	Exploring causality of the association between smoking and Parkinsonâ€™s disease. International Journal of Epidemiology, 2019, 48, 912-925.	0.9	70
1463	Pioglitazone use and Parkinsonâ€™s disease: a retrospective cohort study in Taiwan. BMJ Open, 2018, 8, e023302.	0.8	23
1464	Optimization of mechanical properties of chitosan/phenol formaldehyde composite. Bayero Journal of Pure and Applied Sciences, 2018, 11, 229-235.	0.1	0
1465	The Discrepancy of Neurological Diseases between China and Western Countries in Recent Two Decades. Chinese Medical Journal, 2018, 131, 886-891.	0.9	4
1466	C-SAK: Chinese Scanning Ambiguous Keyboard for Parkinson's Disease Patients. , 2018, , .		0
1467	Endoplasmic reticulum stress and apoptosis induced by manganese trigger Î±-synuclein accumulation. Tropical Journal of Pharmaceutical Research, 2018, 17, 1497.	0.2	4
1468	Diagnostic accuracy of imaging brain vesicular monoamine transporter type 2 (VMAT2) in clinically uncertain parkinsonian syndrome (CUPS): a 3-year follow-up study in community patients. BMJ Open, 2018, 8, e025533.	0.8	10
1469	Factors associated with depression in patients with Parkinsonâ€™s disease A multicenter study in Lima, Peru. Dementia E Neuropsychologia, 2018, 12, 292-298.	0.3	7
1471	The imbalance of serotonergic circuitry impairing the crop supercontractile muscle activity and the mitochondrial morphology of PD PINK1B9 Drosophila melanogaster are rescued by Mucuna pruriens. Journal of Insect Physiology, 2018, 111, 32-40.	0.9	7
1472	Ensemble Classifier to Enhance Computer Aided Diagnosis of Parkinson Disease. , 2018, , .		0
1473	Cognitive Impairment in Parkinson s Disease. International Journal of School and Cognitive Psychology, 2018, 05, .	0.2	0
1474	Data-driven, voxel-based analysis of brain PET images: Application of PCA and LASSO methods to visualize and quantify patterns of neurodegeneration. PLoS ONE, 2018, 13, e0206607.	1.1	14

#	Article	IF	Citations
1475	Enfermedad de Parkinson: fisiopatologÃa, diagnÃ³stico y tratamiento. Revista De La Universidad Industrial De Santander Salud, 2018, 50, 79-92.	0.0	7
1476	Metals and Parkinson's Disease: Mechanisms and Biochemical Processes. Current Medicinal Chemistry, 2018, 25, 2198-2214.	1.2	136
1477	Estudio de calidad de vida con la PDQ39 en pacientes con enfermedad de Parkinson tratados con terapias avanzadas. Revista CientÃfica De La Sociedad EspaÃ±ola De EnfermerÃa NeurolÃ³gica, 2018, 48, 9-14.	0.1	0
1478	COMPARISON OF SPATIO-TEMPORAL GAIT VARIABLES IN PATIENTS WITH PARKINSONâ€™S DISEASE AND SWEDD. Journal of Mechanics in Medicine and Biology, 2018, 18, 1840023.	0.3	3
1479	Quantifying Dynamic Balance in Young, Elderly and Parkinson's Individuals: A Systematic Review. Frontiers in Aging Neuroscience, 2018, 10, 387.	1.7	46
1480	Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics. PLoS Biology, 2018, 16, e2006265.	2.6	44
1481	Schizophrenia-associated mt-DNA SNPs exhibit highly variable haplogroup affiliation and nuclear ancestry: Bi-genomic dependence raises major concerns for link to disease. PLoS ONE, 2018, 13, e0208828.	1.1	15
1482	Sex-Specific Transcriptome Differences in Substantia Nigra Tissue: A Meta-Analysis of Parkinsonâ€™s Disease Data. Genes, 2018, 9, 275.	1.0	16
1483	A Meta-Analysis of Î±-Synuclein Multiplication in Familial Parkinsonism. Frontiers in Neurology, 2018, 9, 1021.	1.1	82
1484	Skin Disease and Neurological Conditions of the Elderly. Current Geriatrics Reports, 2018, 7, 238-242.	1.1	0
1485	Ageing, the autonomic nervous system and arrhythmia: From brain to heart. Ageing Research Reviews, 2018, 48, 40-50.	5.0	40
1486	Systematic analysis of genetic variants in patients with essential tremor. Brain and Behavior, 2018, 8, e01100.	1.0	8
1487	Competing Endogenous RNA Regulations in Neurodegenerative Disorders: Current Challenges and Emerging Insights. Frontiers in Molecular Neuroscience, 2018, 11, 370.	1.4	52
1488	Repetitive transcranial magnetic stimulation therapy for motor recovery in Parkinson's disease: A Metaâ€analysis. Brain and Behavior, 2018, 8, e01132.	1.0	72
1489	Epigenetic Study in Parkinsonâ€™s Disease: A Pilot Analysis of DNA Methylation in Candidate Genes in Brain. Cells, 2018, 7, 150.	1.8	25
1490	Global, regional, and national burden of Parkinson's disease, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2018, 17, 939-953.	4.9	1,573
1491	Prevalent cerebrovascular and cardiovascular disease in people with Parkinson’s disease: a meta-analysis. Clinical Epidemiology, 2018, Volume 10, 1147-1154.	1.5	29
1492	A Review of Stem Cell Therapy for Acquired Brain Injuries and Neurodegenerative Central Nervous System Diseases. PM and R, 2018, 10, S151-S156.	0.9	15

#	Article	IF	Citations
1493	Triglyceride Form of Docosahexaenoic Acid Mediates Neuroprotection in Experimental Parkinsonism. Frontiers in Neuroscience, 2018, 12, 604.	1.4	26
1494	Commentary. Neurosurgery, 2018, 83, E244-E256.	0.6	6
1495	Structural MRI in Idiopathic Parkinson's Disease. International Review of Neurobiology, 2018, 141, 405-438.	0.9	12
1496	Unraveling connectivity changes due to dopaminergic therapy in chronically treated Parkinsonâ€™s disease patients. Scientific Reports, 2018, 8, 14328.	1.6	18
1497	The Role of Exercise in the Management of Parkinson's Disease. Strength and Conditioning Journal, 2018, 40, 120-125.	0.7	2
1498	Early predictors of mortality in parkinsonism and Parkinson disease. Neurology, 2018, 91, e2045-e2056.	1.5	111
1499	Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinsonâ€™s Disease. Metabolites, 2018, 8, 71.	1.3	35
1500	Coding mutations inNUS1contribute to Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 11567-11572.	3.3	78
1501	Medaka Fish Model of Parkinsonâ€™s Disease. , 2018, , 235-249.		2
1502	Parameters of Surface Electromyogram Suggest That Dry Immersion Relieves Motor Symptoms in Patients With Parkinsonism. Frontiers in Neuroscience, 2018, 12, 667.	1.4	12
1503	Zebrafish, Medaka, and Other Small Fishes. , 2018, , .		4
1504	Positive and Negative Affect Schedule (PANAS). , 2018, , 2722-2724.		2
1505	Hearing handicap perception and hearing alterations in individuals with Parkinson's disease. Revista CEFAC: ActualizaÃ§Ã£o CientÃfica Em Fonoaudiologia, 2018, 20, 135-144.	0.2	1
1507	Sex ratio in dementia with Lewy bodies balanced between Alzheimerâ€™s disease and Parkinsonâ€™s disease dementia: a cross-sectional study. Alzheimer's Research and Therapy, 2018, 10, 92.	3.0	33
1508	Regulation of the Unfolded Protein Response in Disease: Cellular Stress and microRNAs. Current Immunology Reviews, 2018, 14, 3-14.	1.2	1
1509	A Patient Suffering From Neurodegenerative Disease May Have a Strengthened Fractal Gait Rhythm. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2018, 26, 1765-1772.	2.7	7
1510	High prevalence of parkinsonism in patients with MCI or mild Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1615-1622.	0.4	22
1511	Genetic analysis of ATP13A2, PLA2G6 and FBXO7 in a cohort of Chinese patients with early-onset Parkinsonâ€™s disease. Scientific Reports, 2018, 8, 14028.	1.6	11

#	Article	IF	Citations
1512	Genome Editing and the Problem of Tetraploidy in Cell Modeling of the Genetic Form of Parkinsonism. Biochemistry (Moscow), 2018, 83, 1040-1045.	0.7	0
1513	Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease. Human Gene Therapy Clinical Development, 2018, 29, 148-155.	3.2	92
1514	Information Content and Efficiency in the Spoken Discourse of Individuals With Parkinson's Disease. Journal of Speech, Language, and Hearing Research, 2018, 61, 2259-2274.	0.7	28
1515	Periodic flashing coordinated reset stimulation paradigm reduces sensitivity to ON and OFF period durations. PLoS ONE, 2018, 13, e0203782.	1.1	8
1516	Platform for Model-Based Design and Testing for Deep Brain Stimulation. , 2018, , .		10
1517	AMPA-induced extracellular Zn2+ influx into nigral dopaminergic neurons causes movement disorder in rats. NeuroToxicology, 2018, 69, 23-28.	1.4	25
1518	Comprehensive Examination of Therapies for Pain in Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology, 2018, 51, 190-206.	1.1	29
1519	FPGA-Embedded Serial SVM Classifier for Neuromuscular Disorders Assessment. , 2018, , .		0
1520	Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET. NeuroImage: Clinical, 2018, 19, 652-660.	1.4	23
1521	The 100 most-cited articles in Parkinsonâ€™s disease. Neurological Sciences, 2018, 39, 1537-1545.	0.9	19
1522	Adipose-derived Stem Cells Stimulated with n-Butylidenephthalide Exhibit Therapeutic Effects in a Mouse Model of Parkinsonâ€™s Disease. Cell Transplantation, 2018, 27, 456-470.	1.2	34
1523	The Role of Gene Editing in Neurodegenerative Diseases. Cell Transplantation, 2018, 27, 364-378.	1.2	11
1524	Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for?. Current Neurology and Neuroscience Reports, 2018, 18, 37.	2.0	27
1525	Drooling in Parkinsonâ€™s Disease: Evidence of a Role for Divided Attention. Dysphagia, 2018, 33, 809-817.	1.0	26
1526	Tai Chi for Reducing Dual-task Gait Variability, a Potential Mediator of Fall Risk in Parkinsonâ€™s Disease: A Pilot Randomized Controlled Trial. Global Advances in Health and Medicine, 2018, 7, 216495611877538.	0.7	42
1527	Using virtual environments to assess visual perception judgements in patients with Parkinsonâ€™s disease. Transportation Research Part F: Traffic Psychology and Behaviour, 2018, 56, 322-332.	1.8	5
1528	A multiple treatment comparison metaâ€analysis of monoamine oxidase type B inhibitors for Parkinson's disease. British Journal of Clinical Pharmacology, 2018, 84, 1917-1927.	1.1	54
1529	New HSF1 inducer as a therapeutic agent in a rodent model of Parkinson's disease. Experimental Neurology, 2018, 306, 199-208.	2.0	41

#	Article	IF	Citations
1530	Singing Exercises for Speech and Vocal Abilities in Individuals with Hypokinetic Dysarthria: A Feasibility Study. Music Therapy Perspectives, 2018, 36, 40-49.	0.2	10
1531	Biochemical Profiling of the Brain and Blood Metabolome in a Mouse Model of Prodromal Parkinsonâ€™s Disease Reveals Distinct Metabolic Profiles. Journal of Proteome Research, 2018, 17, 2460-2469.	1.8	56
1532	Nrf2 Pathway in Age-Related Neurological Disorders: Insights into MicroRNAs. Cellular Physiology and Biochemistry, 2018, 47, 1951-1976.	1.1	77
1533	Validation of a simple screening tool for early diagnosis of advanced Parkinsonâ€™s disease in daily practice: the CDEPA questionnaire. Npj Parkinson's Disease, 2018, 4, 20.	2.5	19
1534	Neuronal Proteomic Analysis of the Ubiquitinated Substrates of the Disease-Linked E3 Ligases Parkin and Ube3a. BioMed Research International, 2018, 2018, 1-14.	0.9	12
1535	Evidence of Oropharyngeal Dysfunction in Feeding in the Rat Rotenone Model of Parkinsonâ€™s Disease. Parkinson's Disease, 2018, 2018, 1-8.	0.6	6
1536	Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinsonâ€™s disease patients. Journal of Neurology, 2018, 265, 1976-1984.	1.8	7
1537	Combination of Multifocal Electroretinogram and Spectral-Domain OCT Can Increase Diagnostic Efficacy of Parkinsonâ€™s Disease. Parkinson's Disease, 2018, 2018, 1-7.	0.6	8
1538	Parkinsonâ€™s Disease Model. Advances in Experimental Medicine and Biology, 2018, 1076, 41-61.	0.8	16
1539	Therapy With Mesenchymal Stem Cells in Parkinson Disease. Neurologist, 2018, 23, 141-147.	0.4	45
1540	Drosophila Models for Human Diseases. Advances in Experimental Medicine and Biology, 2018, , .	0.8	13
1541	Gait alterations on irregular surface in people with Parkinson's disease. Clinical Biomechanics, 2018, 57, 93-98.	0.5	27
1542	Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 56, 9-15.	1.1	58
1543	The Effect of Parkinsonâ€™s Disease on Patients Undergoing Lumbar Spine Surgery. Parkinson's Disease, 2018, 2018, 1-7.	0.6	4
1544	C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease. CNS and Neurological Disorders - Drug Targets, 2018, 17, 14-21.	0.8	28
1545	Inoculation of Î±-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. Molecular Neurodegeneration, 2018, 13, 21.	4.4	206
1546	An Intelligent Parkinsonâ€™s Disease Diagnostic System Based on a Chaotic Bacterial Foraging Optimization Enhanced Fuzzy KNN Approach. Computational and Mathematical Methods in Medicine, 2018, 2018, 1-24.	0.7	92
1547	How Well Do Caregivers Detect Depression and Anxiety in Patients With Parkinson Disease?. Journal of Geriatric Psychiatry and Neurology, 2018, 31, 227-236.	1.2	14

#	Article	IF	Citations
1548	Circulating levels of neurotrophic factors are unchanged in patients with Parkinson's disease. Arquivos De Neuro-Psiquiatria, 2018, 76, 310-315.	0.3	6
1549	Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy. Frontiers in Pharmacology, 2018, 9, 325.	1.6	42
1550	Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies. Frontiers in Pharmacology, 2018, 9, 417.	1.6	42
1551	Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing. Frontiers in Pharmacology, 2018, 9, 422.	1.6	63
1552	Association between Open-Angle Glaucoma and the Risks of Alzheimerâ€™s and Parkinsonâ€™s Diseases in South Korea: A 10-year Nationwide Cohort Study. Scientific Reports, 2018, 8, 11161.	1.6	53
1553	Natural Molecules From Chinese Herbs Protecting Against Parkinsonâ€™s Disease via Anti-oxidative Stress. Frontiers in Aging Neuroscience, 2018, 10, 246.	1.7	19
1554	The Therapeutic Potential of Metformin in Neurodegenerative Diseases. Frontiers in Endocrinology, 2018, 9, 400.	1.5	203
1555	Levodopa-Induced Changes in Electromyographic Patterns in Patients with Advanced Parkinsonâ€™s Disease. Frontiers in Neurology, 2018, 9, 35.	1.1	21
1556	Non-Motor Symptoms of Parkinsonâ€™s Disease and Their Impact on Quality of Life in a Cohort of Moroccan Patients. Frontiers in Neurology, 2018, 9, 170.	1.1	78
1557	Dopaminergic Therapy Increases Go Timeouts in the Go/No-Go Task in Patients with Parkinsonâ€™s Disease. Frontiers in Human Neuroscience, 2017, 11, 642.	1.0	9
1558	Can Interactions Between Î±-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?. Frontiers in Neuroscience, 2018, 12, 161.	1.4	62
1559	Cold Shock Induced Protein RBM3 but Not Mild Hypothermia Protects Human SH-SY5Y Neuroblastoma Cells From MPP+-Induced Neurotoxicity. Frontiers in Neuroscience, 2018, 12, 298.	1.4	9
1560	Degenerative Movement Disorders of the Central Nervous System. , 2018, , 321-325.e3.		0
1561	pTSara-NatB, an improved N-terminal acetylation system for recombinant protein expression in E. coli. PLoS ONE, 2018, 13, e0198715.	1.1	4
1562	Informed Consent Decision-Making in Deep Brain Stimulation. Brain Sciences, 2018, 8, 84.	1.1	7
1563	Dopamine and Levodopa Prodrugs for the Treatment of Parkinsonâ€™s Disease. Molecules, 2018, 23, 40.	1.7	100
1564	The Role of Magnesium in Neurological Disorders. Nutrients, 2018, 10, 730.	1.7	178
1565	Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease. Frontiers in Neurology, 2018, 9, 260.	1.1	12

#	Article	IF	Citations
1566	Does nephrotic syndrome without chronic kidney disease increase the risk of Parkinsonâ€™s disease and secondary parkinsonism? A nationwide population-based study in Taiwan. BMJ Open, 2018, 8, e020821.	0.8	4
1567	Unlocking Human Brain Metabolism by Genome-Scale and Multiomics Metabolic Models: Relevance for Neurology Research, Health, and Disease. OMICS A Journal of Integrative Biology, 2018, 22, 455-467.	1.0	14
1568	New Targets for Parkinson's Disease: Adhesion G Protein-Coupled Receptor B1 is Downregulated by AMP-Activated Protein Kinase Activation. OMICS A Journal of Integrative Biology, 2018, 22, 493-501.	1.0	7
1569	Concurrent exergaming and transcranial direct current stimulation to improve balance in people with Parkinsonâ€™s disease: study protocol for a randomised controlled trial. Trials, 2018, 19, 387.	0.7	15
1570	The Familial Î±-Synuclein A53E Mutation Enhances Cell Death in Response to Environmental Toxins Due to a Larger Population of Oligomers. Biochemistry, 2018, 57, 5014-5028.	1.2	19
1571	Determinants of dopaminergic neuron loss in Parkinson's disease. FEBS Journal, 2018, 285, 3657-3668.	2.2	251
1572	Inhibition of microRNA-505 suppressed MPP+â€¯-induced cytotoxicity of SHSY5Y cells in an in vitro Parkinson's disease model. European Journal of Pharmacology, 2018, 835, 11-18.	1.7	22
1573	Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: can mitochondria be targeted therapeutically?. Biochemical Society Transactions, 2018, 46, 891-909.	1.6	131
1574	A novel device for continuous monitoring of tremor and other motor symptoms. Neurological Sciences, 2018, 39, 1333-1343.	0.9	18
1576	A pervasive and sensor-free Deep Learning system for Parkinsonian gait analysis. , 2018, , .		13
1577	Automatic multi-trajectory planning solution for steerable catheters. , 2018, , .		3
1578	Association between allopurinol use and Parkinsonâ€™s disease in older adults. European Geriatric Medicine, 2018, 9, 377-381.	1.2	2
1579	Acceptance of Cognitive Games through Smart TV Applications in Patients with Parkinson's Disease. , 2018, , .		6
1580	Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2018, 9, 620.	1.1	28
1581	Patterns of physical activity in individuals with Parkinsonâ€™s disease. , 2018, , .		0
1582	Recent progress in therapeutic strategies for microglia-mediated neuroinflammation in neuropathologies. Expert Opinion on Therapeutic Targets, 2018, 22, 765-781.	1.5	47
1583	Tubulin and Tau: Possible targets for diagnosis of Parkinsonâ€™s and Alzheimerâ€™s diseases. PLoS ONE, 2018, 13, e0196436.	1.1	21
1584	Parkinson Matters. Journal of Parkinson's Disease, 2018, 8, 495-498.	1.5	22

#	Article	IF	Citations
1585	A novel analytical approach to assess dyskinesia in patients with Parkinson disease. , 2018, , .		6
1586	Feature Extraction in Sit-to-Stand Task Using M-IMU Sensors and Evaluatiton in Parkinson's Disease. , 2018, , .		9
1587	The Acute Effects of Cigarette Smoking on the Functional State of High Density Lipoprotein. American Journal of the Medical Sciences, 2018, 356, 374-381.	0.4	4
1588	Intranasal carnosine attenuates transcriptomic alterations and improves mitochondrial function in the Thy1-aSyn mouse model of Parkinson's disease. Molecular Genetics and Metabolism, 2018, 125, 305-313.	0.5	16
1589	Sex: A Significant Risk Factor for Neurodevelopmental and Neurodegenerative Disorders. Brain Sciences, 2018, 8, 154.	1.1	124
1590	NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinsonâ€™s disease. Npj Parkinson's Disease, 2018, 4, 24.	2.5	108
1591	Mapping movement, mood, motivation and mentation in the subthalamic nucleus. Royal Society Open Science, 2018, 5, 171177.	1.1	29
1592	Quality of life in Parkinsonâ€™s disease: Italian validation of the Parkinsonâ€™s Disease Questionnaire (PDQ-39-IT). Neurological Sciences, 2018, 39, 1903-1909.	0.9	32
1593	Identification of Critical Genes and miRNAs Associated with the Development of Parkinsonâ€™s Disease. Journal of Molecular Neuroscience, 2018, 65, 527-535.	1.1	12
1594	A role for viral infections in Parkinsonâ€™s etiology?. Neuronal Signaling, 2018, 2, NS20170166.	1.7	37
1595	Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinsonâ€™s disease. Molecular Neurodegeneration, 2018, 13, 26.	4.4	39
1596	Implicit Detection of Motor Impairment in Parkinson's Disease from Everyday Smartphone Interactions. , 2018, , .		3
1597	ER Lipid Defects in Neuropeptidergic Neurons Impair Sleep Patterns in Parkinsonâ€™s Disease. Neuron, 2018, 98, 1155-1169.e6.	3.8	77
1598	Intermittent, low dose carbon monoxide exposure enhances survival and dopaminergic differentiation of human neural stem cells. PLoS ONE, 2018, 13, e0191207.	1.1	20
1599	Early detection of Parkinson's disease through multimodal features using machine learning approaches. International Journal of Signal and Imaging Systems Engineering, 2018, 11, 31.	0.6	6
1600	Association of thiazolidinedione with a lower risk of Parkinsonâ€™s disease in a population with newly-diagnosed diabetes mellitus. Annals of Medicine, 2018, 50, 430-436.	1.5	10
1601	Potential antiparkinsonian agents derived from South African medicinal plants. Journal of Herbal Medicine, 2018, 13, 1-7.	1.0	6
1602	Behavioral and neurochemical responses derived from dopaminergic intrastriatal grafts in hemiparkinsonian rats engaged in a novel motor task. Journal of Neuroscience Methods, 2018, 307, 149-163.	1.3	1

#	Article	IF	Citations
1603	Copper Increases Brain Oxidative Stress and Enhances the Ability of 6-Hydroxydopamine to Cause Dopaminergic Degeneration in a Rat Model of Parkinsonâ€™s Disease. Molecular Neurobiology, 2019, 56, 2845-2854.	1.9	34
1604	Mercury Involvement in Neuronal Damage and in Neurodegenerative Diseases. Biological Trace Element Research, 2019, 187, 341-356.	1.9	108
1605	Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. Chemical Reviews, 2019, 119, 1221-1322.	23.0	360
1606	Functional and morphological assessment of ocular structures and follow-up of patients with early-stage Parkinsonâ€™s disease. International Ophthalmology, 2019, 39, 1255-1262.	0.6	17
1607	Prediction of Gait Freezing in Parkinsonian Patients: A Binary Classification Augmented With Time Series Prediction. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2019, 27, 1909-1919.	2.7	34
1608	Patients with Inflammatory Bowel Disease Are at an Increased Risk of Parkinsonâ€™s Disease: A South Korean Nationwide Population-Based Study. Journal of Clinical Medicine, 2019, 8, 1191.	1.0	60
1609	Parkinsonâ€™s Disease and Aging. Advances in Gerontology, 2019, 9, 164-173.	0.1	11
1610	Radiomics approach in the neurodegenerative brain. Aging Clinical and Experimental Research, 2021, 33, 1709-1711.	1.4	31
1611	Treatment Patterns in Patients with Incident Parkinsonâ€™s Disease in the United States. Journal of Parkinson's Disease, 2019, 9, 749-759.	1.5	6
1612	Changes in visual function and retinal structure in the progression of Alzheimer's disease. PLoS ONE, 2019, 14, e0220535.	1.1	64
1613	Image Caption Generation With Adaptive Transformer. , 2019, , .		10
1614	Atypical antipsychotics for Parkinsonâ€™s disease psychosis: a systematic review and meta-analysis . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2137-2149.	1.0	29
1615	The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinsonâ€™s disease. BMC Neurology, 2019, 19, 160.	0.8	74
1616	Fuzzy Classification Methods Based Diagnosis of Parkinsonâ€™s disease from Speech Test Cases. Current Aging Science, 2019, 12, 100-120.	0.4	14
1617	Severity of Caregiver Stress in Relation to Severity of Disease in Persons with Parkinsonâ€™s. Cureus, 2019, 11, e4358.	0.2	13
1618	Oligomeric Î±-synuclein is increased in basal tears of Parkinsonâ€™s patients. Biomarkers in Medicine, 2019, 13, 941-952.	0.6	40
1619	What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinsonâ€™s Disease Patients and Healthy Subjects with Parkinsonâ€™s-Associated LRRK2 Mutations?. Journal of Parkinson's Disease, 2019, 9, 467-488.	1.5	10
1620	Palliative care for persons with Parkinsonâ€™s disease: a qualitative study on the experiences of health care professionals. BMC Palliative Care, 2019, 18, 53.	0.8	24

#	Article	IF	Citations
1622	Nicotinamide and Demographic and Disease transitions: Moderation is Best. International Journal of Tryptophan Research, 2019, 12, 117864691985594.	1.0	4
1623	Role of Dietary Supplements in the Management of Parkinsonâ€™s Disease. Biomolecules, 2019, 9, 271.	1.8	51
1624	Harnessing ionic mechanisms to achieve disease modification in neurodegenerative disorders. Pharmacological Research, 2019, 147, 104343.	3.1	6
1625	Non-cell autonomous mechanism of Parkinsonâ€™s disease pathology caused by G2019S LRRK2 mutation in Ashkenazi Jewish patient: Single cell analysis. Brain Research, 2019, 1722, 146342.	1.1	8
1626	Dysregulation of Respiratory Center Drive (P0.1) and Muscle Strength in Patients With Early Stage Idiopathic Parkinson's Disease. Frontiers in Neurology, 2019, 10, 724.	1.1	22
1627	The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease. Neurobiology of Disease, 2019, 132, 104545.	2.1	13
1628	Revealing Adenosine A2A-Dopamine D2 Receptor Heteromers in Parkinsonâ€™s Disease Post-Mortem Brain through a New AlphaScreen-Based Assay. International Journal of Molecular Sciences, 2019, 20, 3600.	1.8	40
1629	Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinsonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2348-2357.	3.3	21
1630	Tandem mass spectrometric analysis of novel caffeine scaffoldâ€based bifunctional compounds for Parkinson's disease. Rapid Communications in Mass Spectrometry, 2019, 33, 1792-1803.	0.7	7
1631	Evaluation of Î±-synuclein and apolipoprotein E as potential biomarkers in cerebrospinal fluid to monitor pharmacotherapeutic efficacy in dopamine dictated disease states of Parkinsonâ€™s disease and schizophrenia . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2073-2085.	1.0	4
1632	How to Select Balance Measures Sensitive to Parkinsonâ€™s Disease from Body-Worn Inertial Sensorsâ€”Separating the Trees from the Forest. Sensors, 2019, 19, 3320.	2.1	44
1633	Neurotoxic effects of acrylamide on dopaminergic neurons in primary mesencephalic cell culture. Folia Neuropathologica, 2019, 57, 196-204.	0.5	7
1634	Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinsonâ€™s disease. Journal of Psychiatric Research, 2019, 117, 116-121.	1.5	8
1635	Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease. Movement Disorders, 2019, 34, 1440-1451.	2.2	81
1636	Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism and Related Disorders, 2019, 67, 74-89.	1.1	59
1638	Linking Individual Patient Data to Estimate Incidence and Prevalence of Parkinson's Disease by Comparing Reports of Neurological Services and Pharmacy Prescription Refills at a Nationwide Level. Frontiers in Neurology, 2019, 10, 640.	1.1	9
1639	Emerging therapeutic potentials of dualâ€acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases. Archiv Der Pharmazie, 2019, 352, e1900177.	2.1	99
1640	Examining the Reserve Hypothesis in Parkinson's Disease: A Longitudinal Study. Movement Disorders, 2019, 34, 1663-1671.	2.2	30

#	Article	IF	Citations
1641	Sestrin2 as Serum Protein Marker and Potential Therapeutic Target for Parkinsonâ€™s Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 690-695.	1.7	16
1642	Power vs strength training to improve muscular strength, power, balance and functional movement in individuals diagnosed with Parkinson's disease. Experimental Gerontology, 2019, 128, 110740.	1.2	24
1643	Fatty Acid-Binding Protein 3 is Critical for Î±-Synuclein Uptake and MPP+-Induced Mitochondrial Dysfunction in Cultured Dopaminergic Neurons. International Journal of Molecular Sciences, 2019, 20, 5358.	1.8	39
1644	Parkin truncating variants result in a loss-of-function phenotype. Scientific Reports, 2019, 9, 16150.	1.6	4
1645	GDNF-expressing macrophages restore motor functions at a severe late-stage, and produce long-term neuroprotective effects at an early-stage of Parkinsonâ€™s disease in transgenic Parkin Q311X(A) mice. Journal of Controlled Release, 2019, 315, 139-149.	4.8	25
1646	DNA damage and repair in neuropsychiatric disorders. What do we know and what are the future perspectives?. Mutagenesis, 2020, 35, 79-106.	1.0	14
1647	A Systematic Review of the Neurocognitive Effects of Cannabis Use in Older Adults. Current Addiction Reports, 2019, 6, 443-455.	1.6	22
1648	A machine learning algorithm successfully screens for Parkinson's in web users. Annals of Clinical and Translational Neurology, 2019, 6, 2503-2509.	1.7	15
1650	Dopaminergic dysfunction in neuropsychiatric disorders. Pathophysiology, current therapeutics, and future perspectives. Neuropsychiatria I Neuropsychologia, 2019, 14, 39-47.	0.3	1
1651	Genetic and Environmental Factors Contributing to Parkinson's Disease: A Case-Control Study in the Cypriot Population. Frontiers in Neurology, 2019, 10, 1047.	1.1	20
1652	Polymeric Nanomedicine. , 2019, , 233-267.		1
1653	A Two-Stage Tremor Detection Algorithm for Wearable Inertial Sensors During Normal Daily Activities. , 2019, 2019, 2535-2538.		6
1654	The neuroprotective effect of schisandrol A on 6-OHDA-induced PD mice may be related to PI3K/AKT and IKK/Iº Bî±/NF-ºB pathway. Experimental Gerontology, 2019, 128, 110743.	1.2	43
1655	Circulating amino acid signature in older people with Parkinson's disease: A metabolic complement to the EXosomes in PArkiNson Disease (EXPAND) study. Experimental Gerontology, 2019, 128, 110766.	1.2	32
1656	Associations Between Cognitive Functions and Physical Frailty in Patients With Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 283.	1.7	11
1657	Bergenin Ameliorates MPTP-Induced Parkinsonâ€™s Disease by Activating PI3K/Akt Signaling Pathway. Journal of Alzheimer's Disease, 2019, 72, 823-833.	1.2	27
1658	Stroke in Parkinsonâ€™s disease. QJM - Monthly Journal of the Association of Physicians, 2019, 112, 269-274.	0.2	9
1659	Brain Iron Metabolism and CNS Diseases. Advances in Experimental Medicine and Biology, 2019, , .	0.8	11

#	Article	IF	Citations
1660	Herpes simplex virus-1 (HSV-1) infection induces a potent but ineffective IFN-Î» production in immune cells of AD and PD patients. Journal of Translational Medicine, 2019, 17, 286.	1.8	14
1661	Sudden unexpected death in Parkinsonâ€™s disease: why is drinking water important?. Neurodegenerative Disease Management, 2019, 9, 241-246.	1.2	7
1662	Current Progress of Mitochondrial Quality Control Pathways Underlying the Pathogenesis of Parkinsonâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-11.	1.9	27
1663	The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. Medical Science Monitor, 2019, 25, 666-674.	0.5	61
1664	Functional Connectivity Signatures of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2019, 9, 637-652.	1.5	79
1665	A Novel Small Molecule Supports the Survival of Cultured Dopamine Neurons and May Restore the Dopaminergic Innervation of the Brain in the MPTP Mouse Model of Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 4337-4349.	1.7	10
1666	Association between MTHFR genetic polymorphism and Parkinsonâ€™s disease susceptibility: a meta-analysis. Open Medicine (Poland), 2019, 14, 613-624.	0.6	6
1667	Metal coordination and peripheral substitution modulate the activity of cyclic tetrapyrroles on Î±S aggregation: a structural and cell-based study. Journal of Biological Inorganic Chemistry, 2019, 24, 1269-1278.	1.1	2
1668	High-intensity interval training prevents cognitive-motor impairment and serum BDNF level reduction in parkinson mice model. Sport Sciences for Health, 2019, 15, 681-687.	0.4	6
1669	Bioenergetics and Autophagic Imbalance in Patients-Derived Cell Models of Parkinson Disease Supports Systemic Dysfunction in Neurodegeneration. Frontiers in Neuroscience, 2019, 13, 894.	1.4	29
1670	Risky behaviors and Parkinson disease. Neurology, 2019, 93, e1412-e1424.	1.5	18
1672	Functional and Neuroprotective Role of Striatal Adenosine A_{2A}Receptor Heterotetramers. Journal of Caffeine and Adenosine Research, 2019, 9, 89-97.	0.8	26
1674	Association between Parkinsonâ€™s Disease and Risk of Cancer: A PRISMA-compliant Meta-analysis. ACS Chemical Neuroscience, 2019, 10, 4430-4439.	1.7	23
1675	Botulinum toxin A injection into the entopeduncular nucleus improves dynamic locomotory parameters in hemiparkinsonian rats. PLoS ONE, 2019, 14, e0223450.	1.1	6
1676	Solid Lipid Nanoparticles: A Modern Approach for the Treatment of Neurodegenerative Diseases. , 2019, , 209-225.		1
1677	Fishing for Parkinsonâ€™s Disease: A review of the literature. Journal of Clinical Neuroscience, 2019, 62, 1-6.	0.8	19
1678	Contributions of VPS35 Mutations to Parkinsonâ€™s Disease. Neuroscience, 2019, 401, 1-10.	1.1	39
1679	An NMR-based lipidomic approach to identify Parkinson's disease-stage specific lipoproteinâ€“lipid signatures in plasma. Analyst, The, 2019, 144, 1334-1344.	1.7	9

#	Article	IF	Citations
1680	Distinct Stress Response and Altered Striatal Transcriptome in Alpha-Synuclein Overexpressing Mice. Frontiers in Neuroscience, 2018, 12, 1033.	1.4	8
1681	BST1 rs4698412 allelic variant increases the risk of gait or balance deficits in patients with Parkinsonâ€™s disease. CNS Neuroscience and Therapeutics, 2019, 25, 422-429.	1.9	15
1682	Osthole alleviates MPTP-induced Parkinsonâ€™s disease mice by suppressing Notch signaling pathway. International Journal of Neuroscience, 2019, 129, 833-841.	0.8	19
1683	An Integrative Approach to Treat Parkinson's Disease: Ukgansan Complements L-Dopa by Ameliorating Dopaminergic Neuronal Damage and L-Dopa-Induced Dyskinesia in Mice. Frontiers in Aging Neuroscience, 2018, 10, 431.	1.7	9
1684	Hippocampal subfield atrophy of CA1 and subicular structures predict progression to dementia in idiopathic Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 681-687.	0.9	24
1685	Are we listening to everything the PARK genes are telling us?. Journal of Comparative Neurology, 2019, 527, 1527-1540.	0.9	13
1686	Loss of nuclear REST/NRSF in aged-dopaminergic neurons in Parkinsonâ€™s disease patients. Neuroscience Letters, 2019, 699, 59-63.	1.0	38
1687	The Use and Efficacy of Transcranial Direct Current Stimulation in Individuals with Neurodegenerative Dementias. , 2019, , 473-507.		2
1688	Paraquat as an Environmental Risk Factor in Parkinsonâ€™s Disease Accelerates Age-Related Degeneration Via Rapid Influx of Extracellular Zn2+ into Nigral Dopaminergic Neurons. Molecular Neurobiology, 2019, 56, 7789-7799.	1.9	18
1689	Metabolomicsâ€driven identification of adenosine deaminase as therapeutic target in a mouse model of Parkinson's disease. Journal of Neurochemistry, 2019, 150, 282-295.	2.1	20
1690	The roles of galectin-3 and galectin-4 in the idiopatic Parkinson disease and its progression. Clinical Neurology and Neurosurgery, 2019, 184, 105373.	0.6	21
1691	Resting functional connectivity and mild cognitive impairment in Parkinsonâ€™s disease. An electroencephalogram study. Future Neurology, 2019, 14, FNL18.	0.9	8
1692	What Can Gestures Tell?. , 2019, , .		15
1693	Impulse control disorders in Parkinsonâ€™s disease: A systematic review on the psychometric properties of the existing measures. PLoS ONE, 2019, 14, e0217700.	1.1	4
1694	Rs2015 Polymorphism in miRNA Target Site of Sirtuin2 Gene Is Associated with the Risk of Parkinsonâ€™s Disease in Chinese Han Population. BioMed Research International, 2019, 2019, 1-8.	0.9	10
1695	Assessment of the Levels of Level of Biomarkers of Bone Matrix Glycoproteins and Inflammatory Cytokines from Saudi Parkinson Patients. BioMed Research International, 2019, 2019, 1-6.	0.9	15
1696	Cancer risk in patients with Parkinsonâ€™s disease in South Korea: A nationwide, population-based cohort study. European Journal of Cancer, 2019, 117, 5-13.	1.3	37
1697	A metabolomic signature of treated and drug-naÃ¯ve patients with Parkinsonâ€™s disease: a pilot study. Metabolomics, 2019, 15, 90.	1.4	14

#	Article	IF	Citations
1698	Glial HMOX1 expression promotes central and peripheral Î±â€synuclein dysregulation and pathogenicity in parkinsonian mice. Glia, 2019, 67, 1730-1744.	2.5	25
1699	Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinsonâ€™s disease. Neuroscience and Biobehavioral Reviews, 2019, 103, 305-315.	2.9	87
1700	Deep Brain Stimulation for the Treatment of Juvenile Parkinsonism: Case Report. Brazilian Neurosurgery, 2019, 38, 124-127.	0.0	1
1701	Loss of FBXO7 results in a Parkinson'sâ€like dopaminergic degeneration via an RPL23â€“MDM2â€“TP53 pathway. Journal of Pathology, 2019, 249, 241-254.	2.1	24
1702	(Neuro)Psychological Interventions for Non-Motor Symptoms in the Treatment of Patients with Parkinsonâ€™s Disease: a Systematic Umbrella Review. Neuropsychology Review, 2019, 29, 166-180.	2.5	15
1703	Interrogating Parkinson's disease associated redox targets: Potential application of CRISPR editing. Free Radical Biology and Medicine, 2019, 144, 279-292.	1.3	18
1704	Effects ofin vivoconditions on amyloid aggregation. Chemical Society Reviews, 2019, 48, 3946-3996.	18.7	148
1705	The association between Parkinsonâ€™s disease and temporomandibular disorder. PLoS ONE, 2019, 14, e0217763.	1.1	10
1706	Bipolar disorder and risk of Parkinson disease. Neurology, 2019, 92, e2735-e2742.	1.5	22
1707	Mitochondrial Neurodegenerative Disorders I: Parkinsonism and Cognitive Deficits. , 2019, , 223-239.		0
1708	Tissue engineering scaffolds in the treatment of brain disorders in geriatric patients. Artificial Organs, 2019, 43, 947-960.	1.0	5
1709	Iron and other metals in the pathogenesis of Parkinson's disease: Toxic effects and possible detoxification. Journal of Inorganic Biochemistry, 2019, 199, 110717.	1.5	39
1710	RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinson's iPSC-derived astrocytes. Neurobiology of Disease, 2019, 129, 56-66.	2.1	55
1711	Explaining Pathogenicity of Congenital Zika and Guillainâ€“BarrÃ© Syndromes: Does Dysregulation of RNA Editing Play a Role?. BioEssays, 2019, 41, 1800239.	1.2	14
1712	The Role of the Antioxidant Response in Mitochondrial Dysfunction in Degenerative Diseases: Cross-Talk between Antioxidant Defense, Autophagy, and Apoptosis. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-26.	1.9	92
1713	Use of Magnetic Resonance Imaging and Artificial Intelligence in Studies of Diagnosis of Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 2658-2667.	1.7	25
1714	Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations. NeuroImage: Clinical, 2019, 23, 101856.	1.4	21
1715	Neuroplasticity and Neuroprotective Effect of Treadmill Training in the Chronic Mouse Model of Parkinsonâ€™s Disease. Neural Plasticity, 2019, 2019, 1-14.	1.0	23

#	Article	IF	Citations
1717	Impulsive-Compulsive Behaviours in Belgian-Flemish Parkinsonâ€™s Disease Patients: A Questionnaire-Based Study. Parkinson's Disease, 2019, 2019, 1-5.	0.6	1
1718	Deficits in tapping accuracy and variability in tremor patients. Journal of NeuroEngineering and Rehabilitation, 2019, 16, 54.	2.4	7
1719	Earliest Mechanisms of Dopaminergic Neurons Sufferance in a Novel Slow Progressing Ex Vivo Model of Parkinson Disease in Rat Organotypic Cultures of Substantia Nigra. International Journal of Molecular Sciences, 2019, 20, 2224.	1.8	15
1720	Intranasal drug delivery: Novel delivery route for effective management of neurological disorders. Journal of Drug Delivery Science and Technology, 2019, 52, 130-137.	1.4	13
1721	Treadmill training and kinesiotherapy versus conventional physiotherapy in Parkinsonâ€™s disease: a pragmatic study. Fisioterapia Em Movimento, 2019, 32, .	0.4	4
1722	Physical activity sustains memory retrieval in dopamine-depleted mice previously treated with L-Dopa. Behavioural Brain Research, 2019, 369, 111915.	1.2	2
1723	Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 235-241.	1.1	12
1724	Î±â€synuclein oligomers enhance astrocyteâ€induced synapse formation through TGFâ€Î²1 signaling in a Parkinson's disease model. Journal of Neurochemistry, 2019, 150, 138-157.	2.1	27
1725	Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 831-838.	1.0	17
1726	Substance P Saliva Reduction Predicts Pharyngeal Dysphagia in Parkinson's Disease. Frontiers in Neurology, 2019, 10, 386.	1.1	28
1727	E46K-like Î±-synuclein mutants increase lipid interactions and disrupt membrane selectivity. Journal of Biological Chemistry, 2019, 294, 9799-9812.	1.6	32
1728	MicroRNA-135b alleviates MPP+-mediated Parkinsonâ€™s disease in in vitro model through suppressing FoxO1-induced NLRP3 inflammasome and pyroptosis. Journal of Clinical Neuroscience, 2019, 65, 125-133.	0.8	59
1729	2D-DIGE as a strategy to identify serum protein biomarkers to monitor pharmacological efficacy in dopamine-dictated states of Parkinson’s disease and schizophrenia . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1031-1044.	1.0	7
1730	Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments. International Journal of Molecular Sciences, 2019, 20, 1829.	1.8	43
1731	Chronic renal dysfunction, proteinuria, and risk of Parkinson's disease in the elderly. Movement Disorders, 2019, 34, 1184-1191.	2.2	33
1732	Association of HIF1A and Parkinsonâ€™s disease in a Han Chinese population demonstrated by molecular inversion probe analysis. Neurological Sciences, 2019, 40, 1927-1931.	0.9	15
1733	Parkinsonâ€™s Disease as Risk Factor in Osteoporosis and Osteoporotic Vertebral Fracture : Prevalence Study Using National Inpatient Sample Database in Korea. Journal of Korean Neurosurgical Society, 2019, 62, 71-82.	0.5	9
1734	Identification of Differentially Expressed Genes and Long Noncoding RNAs Associated with Parkinsonâ€™s Disease. Parkinson's Disease, 2019, 2019, 1-7.	0.6	33

#	Article	IF	Citations
1735	Serum levels of chromogranins and secretogranins correlate with the progress and severity of Parkinson's disease. Kaohsiung Journal of Medical Sciences, 2019, 35, 146-150.	0.8	5
1736	Nanoparticles for drug delivery targeting neurodegeneration in brain and eye. , 2019, , 149-183.		1
1737	Anti-ageing and anti-Parkinsonian effects of natural flavonol, tambulin from Zanthoxyllum aramatum promotes longevity in Caenorhabditis elegans. Experimental Gerontology, 2019, 120, 50-61.	1.2	45
1738	Dopamine neuronal protection in the mouse Substantia nigra by GHSR is independent of electric activity. Molecular Metabolism, 2019, 24, 120-138.	3.0	7
1739	Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinsonâ€™s disease pathogenesis. Nature Communications, 2019, 10, 973.	5.8	217
1740	Covalent Modification and Regulation of the Nuclear Receptor Nurr1 by a Dopamine Metabolite. Cell Chemical Biology, 2019, 26, 674-685.e6.	2.5	41
1741	The influence of dopaminergic medication on gait automaticity in Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2019, 65, 71-76.	0.8	5
1742	Familial early onset Parkinson's disease caused by a homozygous frameshift variant in PARK7: Clinical features and literature update. Parkinsonism and Related Disorders, 2019, 64, 308-311.	1.1	7
1743	Sex Differences in Rotenone Sensitivity Reflect the Male-to-Female Ratio in Human Parkinsonâ€™s Disease Incidence. Toxicological Sciences, 2019, 170, 133-143.	1.4	41
1744	A Parkinsonâ€™s Disease Patient without Corpus Callosum. Journal of Parkinson's Disease, 2019, 9, 441-442.	1.5	0
1745	Dementia and Parkinson's Disease: Similar and Divergent Challenges in Providing Palliative Care. Frontiers in Neurology, 2019, 10, 54.	1.1	17
1746	Î±-Synuclein misfolding and aggregation: Implications in Parkinsonâ€™s disease pathogenesis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 890-908.	1.1	241
1747	Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review. Movement Disorders Clinical Practice, 2019, 6, 282-290.	0.8	25
1748	Postoperative Confusion in Patients with Parkinson Disease Undergoing Deep Brain Stimulation of the Subthalamic Nucleus. World Neurosurgery, 2019, 125, e966-e971.	0.7	8
1749	Classic animal models of Parkinsonâ€™s disease: a historical perspective. Behavioural Pharmacology, 2019, 30, 291-310.	0.8	23
1750	Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease. Biology of the Cell, 2019, 111, 161-168.	0.7	36
1751	The Parkinsonâ€™s disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4. Scientific Reports, 2019, 9, 4515.	1.6	22
1752	Polycaprolactone-based neurotherapeutic delivery of rasagiline targeting behavioral and biochemical deficits in Parkinsonâ€™s disease. Drug Delivery and Translational Research, 2019, 9, 891-905.	3.0	8

#	Article	IF	Citations
1753	Glial phagocytic clearance in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2019, 14, 16.	4.4	104
1754	Diet and medical foods in Parkinsonâ€™s disease. Food Science and Human Wellness, 2019, 8, 83-95.	2.2	22
1755	Multi-year whole-blood transcriptome data for the study of onset and progression of Parkinsonâ€™s Disease. Scientific Data, 2019, 6, 20.	2.4	8
1756	Combination therapy of scalp electro-acupuncture and medication for the treatment of Parkinson's disease: A systematic review and meta-analysis. Journal of Traditional Chinese Medical Sciences, 2019, 6, 26-34.	0.1	4
1757	Calcium, Dopamine and Neuronal Calcium Sensor 1: Their Contribution to Parkinsonâ€™s Disease. Frontiers in Molecular Neuroscience, 2019, 12, 55.	1.4	29
1758	Involvement of aberrant regulation of epigenetic mechanisms in the pathogenesis of Parkinson's disease and epigeneticâ€based therapies. Journal of Cellular Physiology, 2019, 234, 19307-19319.	2.0	40
1759	Imaging in Neurodegeneration: Movement Disorders. IEEE Transactions on Radiation and Plasma Medical Sciences, 2019, 3, 262-274.	2.7	4
1760	Association of statin use with Parkinson's disease: Doseâ€“response relationship. Movement Disorders, 2019, 34, 1014-1021.	2.2	45
1761	Influencing factors when living with Parkinsonâ€™s disease: A crossâ€sectional study. Journal of Clinical Nursing, 2019, 28, 3168-3176.	1.4	25
1762	Safety and Tolerability of Pharmacotherapies for Parkinsonâ€™s Disease in Geriatric Patients. Drugs and Aging, 2019, 36, 511-530.	1.3	38
1763	Roco Proteins: GTPases with a Baroque Structure and Mechanism. International Journal of Molecular Sciences, 2019, 20, 147.	1.8	31
1764	The influence of dopaminergic medication on balance automaticity in Parkinsonâ€™s disease. Gait and Posture, 2019, 70, 98-103.	0.6	18
1765	Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD. Neurology, 2019, 92, e1468-e1478.	1.5	16
1766	DAPHNE: A Novel e-Health System for the Diagnosis and the Treatment of Parkinsonâ€™s Disease. Lecture Notes in Electrical Engineering, 2019, , 271-288.	0.3	0
1767	Association between Hypertension and the Risk of Parkinsonâ€™s Disease: A Meta-Analysis of Analytical Studies. Neuroepidemiology, 2019, 52, 181-192.	1.1	37
1768	A Multi-Layer Gaussian Process for Motor Symptom Estimation in People With Parkinson's Disease. IEEE Transactions on Biomedical Engineering, 2019, 66, 3038-3049.	2.5	5
1769	General and abdominal adiposity and the risk of Parkinson's disease: A prospective cohort study. Parkinsonism and Related Disorders, 2019, 62, 98-104.	1.1	7
1770	Lack of Association Between DJ-1 Gene Promoter Polymorphism and the Risk of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 24.	1.7	5

#	Article	IF	Citations
1771	Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinsonâ€™s disease. Brain, 2019, 142, 512-525.	3.7	194
1772	Blood pressure circadian rhythm alterations in alpha-synucleinopathies. Journal of Neurology, 2019, 266, 1141-1152.	1.8	25
1773	Roles of microRNAs in Parkinsonâ€™s and other neurodegenerative diseases. , 2019, , 209-232.		3
1774	Sex-Specific Patient Journeys in Early Parkinson's Disease in the Netherlands. Frontiers in Neurology, 2019, 10, 794.	1.1	6
1775	Classification of Parkinson disease data with artificial neural networks. IOP Conference Series: Materials Science and Engineering, 2019, 675, 012031.	0.3	12
1777	Pathophysiology and management of parkinson disease: a review. Bayero Journal of Pure and Applied Sciences, 2019, 11, 238.	0.1	0
1778	miRNAâ€‘384â€‘5p regulates the progression of Parkinson'sï¿½disease by targeting SIRT1 in mice and SHâ€‘SY5Y cell. International Journal of Molecular Medicine, 2019, 45, 441-450.	1.8	14
1779	In-the-Wild End-to-End Detection of Speech Affecting Diseases. , 2019, , .		4
1780	Role of MicroRNAs in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2019, 20, 5649.	1.8	134
1781	Autonomic dysfunction: Diagnosis and management. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 123-137.	1.0	23
1782	Epidemiology of aging and associated cognitive disorders: Prevalence and incidence of Alzheimer's disease and other dementias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 139-148.	1.0	85
1783	Enfermedad de Parkinson y parkinsonismos. Medicine, 2019, 12, 4273-4284.	0.0	1
1785	How to approach a patient with parkinsonism â€“ red flags for atypical parkinsonism. International Review of Neurobiology, 2019, 149, 1-34.	0.9	4
1786	InÂVivo Protein Complementation Demonstrates Presynaptic Î±-Synuclein Oligomerization and Age-Dependent Accumulation of 8â€“16-mer Oligomer Species. Cell Reports, 2019, 29, 2862-2874.e9.	2.9	26
1787	Unsupervised Clustering of Micro-Electrophysiological Signals for localization of Subthalamic Nucleus during DBS Surgery. , 2019, , .		2
1788	Aging With a Progressive Neurologic Disease. Topics in Geriatric Rehabilitation, 2019, 35, 172-182.	0.2	3
1789	Association between the DRD2 TaqIA gene polymorphism and Parkinson disease risk: an updated meta-analysis. Medicine (United States), 2019, 98, e17136.	0.4	3
1790	The Challenge and Opportunity to Diagnose Parkinson's Disease in Midlife. Frontiers in Neurology, 2019, 10, 1328.	1.1	16

#	Article	IF	Citations
1791	Trends in the incidence and prevalence of Parkinsonâ€™s disease in Korea: a nationwide, population-based study. BMC Geriatrics, 2019, 19, 320.	1.1	61
1792	PhoneMD: Learning to Diagnose Parkinsonâ€™s Disease from Smartphone Data. Proceedings of the AAAI Conference on Artificial Intelligence, 2019, 33, 1118-1125.	3.6	27
1793	Delayed Dopamine Dysfunction and Motor Deficits in Female Parkinson Model Mice. International Journal of Molecular Sciences, 2019, 20, 6251.	1.8	17
1794	Experiences of people with Parkinson's disease and their views on physical activity interventions: a qualitative systematic review. JBI Database of Systematic Reviews and Implementation Reports, 2019, 17, 548-613.	1.7	17
1795	Long-Term Home-Monitoring Sensor Technology in Patients with Parkinsonâ€™s Diseaseâ€”Acceptance and Adherence. Sensors, 2019, 19, 5169.	2.1	40
1796	Is Parkinsonâ€™s Disease Associated with Increased Mortality, Poorer Outcomes Scores, and Revision Risk After THA? Findings from the Swedish Hip Arthroplasty Register. Clinical Orthopaedics and Related Research, 2019, 477, 1347-1355.	0.7	13
1797	Use of radiomic features and support vector machine to distinguish Parkinsonâ€™s disease cases from normal controls. Annals of Translational Medicine, 2019, 7, 773-773.	0.7	49
1798	Long-Term Voluntary Physical Exercise Exerts Neuroprotective Effects and Motor Disturbance Alleviation in a Rat Model of Parkinsonâ€™s Disease. Behavioural Neurology, 2019, 2019, 1-10.	1.1	8
1799	Schinus terebinthifoliusEssential Oil Attenuates Scopolamine-Induced Memory Deficits via Cholinergic Modulation and Antioxidant Properties in a Zebrafish Model. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-11.	0.5	34
1800	New insights into the complex role of mitochondria in Parkinsonâ€™s disease. Progress in Neurobiology, 2019, 177, 73-93.	2.8	268
1801	Nanoneuromedicine for management of neurodegenerative disorder. Journal of Drug Delivery Science and Technology, 2019, 49, 477-490.	1.4	34
1802	Multidisciplinary care for people with Parkinsonâ€™s disease: the new kids on the block!. Expert Review of Neurotherapeutics, 2019, 19, 145-157.	1.4	45
1803	Apolipoprotein E Polymorphisms and Parkinson Disease With or Without Dementia: A Meta-Analysis Including 6453 Participants. Journal of Geriatric Psychiatry and Neurology, 2019, 32, 3-15.	1.2	11
1804	Iatrogenic hypertension: a bioinformatic analysis. Pharmacogenomics Journal, 2019, 19, 337-346.	0.9	4
1805	Auditory and visual hallucination prevalence in Parkinson's disease and dementia with Lewy bodies: a systematic review and meta-analysis. Psychological Medicine, 2019, 49, 2342-2353.	2.7	49
1806	Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson's disease. European Journal of Neuroscience, 2019, 49, 525-532.	1.2	32
1807	Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation. European Journal of Clinical Pharmacology, 2019, 75, 351-361.	0.8	9
1808	Guanosine Protects Striatal Slices Against 6-OHDA-Induced Oxidative Damage, Mitochondrial Dysfunction, and ATP Depletion. Neurotoxicity Research, 2019, 35, 475-483.	1.3	18

#	Article	IF	Citations
1809	The role of monogenic genes in idiopathic Parkinsonâ€™s disease. Neurobiology of Disease, 2019, 124, 230-239.	2.1	97
1810	In search of early neuroradiological biomarkers for Parkinsonâ€™s Disease: Alterations in resting state functional connectivity and gray matter microarchitecture in PINK1 â˜’/â˜’ rats. Brain Research, 2019, 1706, 58-67.	1.1	19
1811	Nonhypoxic pharmacological stabilization of Hypoxia Inducible Factor 1Î±: Effects on dopaminergic differentiation of human neural stem cells. European Journal of Neuroscience, 2019, 49, 497-509.	1.2	2
1812	Alpha-synuclein in salivary gland as biomarker for Parkinsonâ€™s disease. Reviews in the Neurosciences, 2019, 30, 455-462.	1.4	19
1813	Hypericum perforatum in the treatment of psychiatric and neurodegenerative disorders: Current evidence and potential mechanisms of action. Journal of Cellular Physiology, 2019, 234, 8496-8508.	2.0	74
1814	Nanotechnology: Applications in Energy, Drug and Food. , 2019, , .		8
1815	A low-cost quantitative continuous measurement of movements in the extremities of people with Parkinson's disease. MethodsX, 2019, 6, 169-189.	0.7	20
1816	The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimerâ€™s Disease and Other Neurodegenerative Disorders. Molecular Neurobiology, 2019, 56, 5436-5455.	1.9	181
1817	Pretreatment with crocin along with treadmill exercise ameliorates motor and memory deficits in hemiparkinsonian rats by anti-inflammatory and antioxidant mechanisms. Metabolic Brain Disease, 2019, 34, 459-468.	1.4	20
1818	The usual suspects, dopamine and alphaâ€synuclein, conspire to cause neurodegeneration. Movement Disorders, 2019, 34, 167-179.	2.2	62
1819	Effects of Substantia Nigra pars compacta lesion on the behavioral sequencing in the 6-OHDA model of Parkinsonâ€™s disease. Behavioural Brain Research, 2019, 362, 28-35.	1.2	22
1820	Parkinsonâ€™s pain is more aching and interfering with social life in Caucasians compared to Indians. International Journal of Neuroscience, 2019, 129, 746-753.	0.8	1
1821	Gout and the risk of Parkinsonâ€™s disease in older adults: a study of U.S. Medicare data. BMC Neurology, 2019, 19, 4.	0.8	23
1822	Recent advances and perspectives of metabolomics-based investigations in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2019, 14, 3.	4.4	176
1823	Treatment of Parkinsonâ€™s Disease through Personalized Medicine and Induced Pluripotent Stem Cells. Cells, 2019, 8, 26.	1.8	82
1824	Blockade of Rapid Influx of Extracellular Zn2+ into Nigral Dopaminergic Neurons Overcomes Paraquat-Induced Parkinsonâ€™s Disease in Rats. Molecular Neurobiology, 2019, 56, 4539-4548.	1.9	20
1825	Nanoengineered biomaterial for brain tissue reconstruction and functional repairment. , 2019, , 145-166.		3
1826	Association between ambient air pollution and Parkinson's disease: Systematic review and meta-analysis. Environmental Research, 2019, 168, 448-459.	3.7	61

#	Article	IF	Citations
1827	Parkinson's disease prevalence and the association with rurality and agricultural determinants. Parkinsonism and Related Disorders, 2019, 61, 198-202.	1.1	13
1828	Pharmacogenetics and levodopa induced motor complications. International Journal of Neuroscience, 2019, 129, 384-392.	0.8	14
1829	Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives. Molecular Neurobiology, 2019, 56, 4799-4811.	1.9	28
1830	Neuropalliative Care. , 2019, , .		16
1831	Utility and implications of exome sequencing in earlyâ€onset Parkinson's disease. Movement Disorders, 2019, 34, 133-137.	2.2	36
1832	Marmosets in Neurologic Disease Research. , 2019, , 415-435.		1
1833	Parkinson's disease in Nigeria: A review of published studies and recommendations for future research. Parkinsonism and Related Disorders, 2019, 62, 36-43.	1.1	12
1834	Ethical issues in susceptibility genetic testing for lateâ€onset neurodegenerative diseases. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 609-621.	1.1	11
1835	Dysregulation of Transcription Factors: A Key Culprit Behind Neurodegenerative Disorders. Neuroscientist, 2019, 25, 548-565.	2.6	6
1836	Quantification of discrete behavioral components of the MDS-UPDRS. Journal of Clinical Neuroscience, 2019, 61, 174-179.	0.8	6
1837	Promises and Challenges ofÂMSC-Based Therapies: Parkinson Disease and Parkinsonism. , 2019, , 297-320.		0
1839	Laryngopharyngeal motor dysfunction and obstructive sleep apnea in Parkinsonâ€™s disease. Sleep and Breathing, 2019, 23, 543-550.	0.9	20
1840	Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration. Free Radical Biology and Medicine, 2019, 133, 221-233.	1.3	312
1841	Measuring activities of daily living in Parkinsonâ€™s disease: On a road to nowhere and back again?. Measurement: Journal of the International Measurement Confederation, 2019, 132, 109-124.	2.5	17
1842	Inherited Neurodegenerative Disorders. , 2019, , 73-79.		0
1843	Beneficial effects of dietary restriction in aging brain. Journal of Chemical Neuroanatomy, 2019, 95, 123-133.	1.0	35
1844	Long-term effects of Lee Silverman Voice Treatment on daily voice use in Parkinsonâ€™s disease as measured with a portable voice accumulator. Logopedics Phoniatrics Vocology, 2019, 44, 124-133.	0.5	13
1845	Retinal vessel diameter obtained by optical coherence tomography is spared in Parkinsonâ€™s disease. International Ophthalmology, 2019, 39, 813-819.	0.6	9

#	Article	IF	Citations
1846	Mindfulness-based lifestyle programs for the self-management of Parkinsonâ€™s disease in Australia. Health Promotion International, 2019, 34, 668-676.	0.9	10
1847	Assessing visual attributes of handwriting for prediction of neurological disordersâ€”A case study on Parkinsonâ€™s disease. Pattern Recognition Letters, 2019, 121, 19-27.	2.6	74
1848	Extracellular Zn2+ Influx into Nigral Dopaminergic Neurons Plays a Key Role for Pathogenesis of 6-Hydroxydopamine-Induced Parkinsonâ€™s Disease in Rats. Molecular Neurobiology, 2019, 56, 435-443.	1.9	26
1850	Nuevos modelos transgÃ©nicos para el estudio de la enfermedad de Parkinson basados en sistemas de ediciÃ³n con nucleasas. NeurologÃa, 2020, 35, 486-499.	0.3	2
1851	Effects of depression and exercise on health-related quality of life in patients with Parkinson's disease. Chronic Illness, 2020, 16, 190-200.	0.6	3
1852	Feasibility and informativeness of the Patient-Specific Functional Scale with patients with Parkinsonâ€™s disease. Physiotherapy Theory and Practice, 2020, 36, 1241-1244.	0.6	6
1853	Coordinate based meta-analysis of motor functional imaging in Parkinsonâ€™s: disease-specific patterns and modulation by dopamine replacement and deep brain stimulation. Brain Imaging and Behavior, 2020, 14, 1263-1280.	1.1	7
1854	Automated detection of Parkinson's disease using minimum average maximum tree and singular value decomposition method with vowels. Biocybernetics and Biomedical Engineering, 2020, 40, 211-220.	3.3	76
1855	Active information storage in Parkinsonâ€™s disease: a resting state fMRI study over the sensorimotor cortex. Brain Imaging and Behavior, 2020, 14, 1143-1153.	1.1	4
1856	Age-dependent accumulation of oligomeric SNCA/Î±-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA). Autophagy, 2020, 16, 347-370.	4.3	116
1857	Predictors of Residue and Airway Invasion in Parkinsonâ€™s Disease. Dysphagia, 2020, 35, 220-230.	1.0	42
1858	Cognitive profiles and optimal cutâ€offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition. Psychogeriatrics, 2020, 20, 20-27.	0.6	4
1859	Analysis and Discrimination of Surface Electromyographic Features for Parkinsonâ€™s Disease during Elbow Flexion Movements. Journal of Motor Behavior, 2020, 52, 625-633.	0.5	6
1860	Diagnosis of Parkinsonâ€™s Disease at an Early Stage Using Volume Rendering SPECT Image Slices. Arabian Journal for Science and Engineering, 2020, 45, 2799-2811.	1.7	9
1861	An in silico analysis of deleterious single nucleotide polymorphisms and molecular dynamics simulation of disease linked mutations in genes responsible for neurodegenerative disorder. Journal of Biomolecular Structure and Dynamics, 2020, 38, 4259-4272.	2.0	11
1862	Dopamine betaâ€hydroxylase and its genetic variants in human health and disease. Journal of Neurochemistry, 2020, 152, 157-181.	2.1	47
1863	Accuracy of Dopamine Transporter Imaging with ¹²³I-Ioflupane in Hispanic and Non-Hispanic Patients. Journal of Nuclear Medicine Technology, 2020, 48, 154-157.	0.4	2
1864	The interplay between agingâ€associated loss of protein homeostasis and extracellular vesicles in neurodegeneration. Journal of Neuroscience Research, 2020, 98, 262-283.	1.3	21

#	Article	IF	Citations
1865	Early Postnatal Exposure to Paraquat and Maneb in Mice Increases Nigrostriatal Dopaminergic Susceptibility to a Re-challenge with the Same Pesticides at Adulthood: Implications for Parkinsonâ€™s Disease. Neurotoxicity Research, 2020, 37, 210-226.	1.3	20
1867	Effectiveness of SaeboReJoyce in the Evaluation of the Improvement of the Occupational Performance in Parkinsonâ€™s Disease: An Outcome Research. Advances in Intelligent Systems and Computing, 2020, , 63-70.	0.5	1
1868	RIP1/RIP3/MLKL mediates dopaminergic neuron necroptosis in a mouse model of Parkinson disease. Laboratory Investigation, 2020, 100, 503-511.	1.7	55
1869	New transgenic models of Parkinson's disease using genome editing technology. NeurologÃa (English) Tj ETQq1 1 0.784314 rgBT /Ov	0.2	1
1870	Neurologic Disorders of the Maxillofacial Region. Dental Clinics of North America, 2020, 64, 255-278.	0.8	1
1871	Occupational exposure to chronic ionizing radiation increases risk of Parkinson's disease incidence in Russian Mayak workers. International Journal of Epidemiology, 2020, 49, 435-447.	0.9	48
1872	Assessment of copper, iron, zinc and manganese status and speciation in patients with Parkinsonâ€™s disease: A pilot study. Journal of Trace Elements in Medicine and Biology, 2020, 59, 126423.	1.5	36
1873	The impact of traumatic brain injury on cognitive and neuropsychiatric symptoms of Parkinsonâ€™s disease. International Review of Psychiatry, 2020, 32, 46-60.	1.4	6
1874	Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. European Journal of Pharmacology, 2020, 871, 172914.	1.7	13
1875	Whole-exome sequencing in early-onset Parkinson's disease among ethnic Chinese. Neurobiology of Aging, 2020, 90, 150.e5-150.e11.	1.5	29
1876	Metaâ€Analysis of Copper and Iron in Parkinson's Disease Brain and Biofluids. Movement Disorders, 2020, 35, 662-671.	2.2	51
1877	The effects of chronic subthalamic stimulation on nonmotor symptoms in advanced Parkinsonâ€™s disease, revealed by an online questionnaire program. Acta Neurochirurgica, 2020, 162, 247-255.	0.9	9
1878	What we can learn from iPSC-derived cellular models of Parkinson's disease. Progress in Brain Research, 2020, 252, 3-25.	0.9	11
1879	Do patients with PD benefit from music assisted therapy plus treadmill-based gait training? An exploratory study focused on behavioral outcomes. International Journal of Neuroscience, 2020, 130, 933-940.	0.8	15
1880	Evolving nanoformulation strategies for diagnosis and clinical interventions for Parkinsonâ€™s disease. Drug Discovery Today, 2020, 25, 392-405.	3.2	7
1881	Essential Current Concepts in Stem Cell Biology. Learning Materials in Biosciences, 2020, , .	0.2	2
1883	Assessment of the Neuroprotective Potential of Glucose-Regulated Heat Shock Protein in a Model of Parkinsonâ€™s Disease in Rats. Neuroscience and Behavioral Physiology, 2020, 50, 119-125.	0.2	1
1884	Serum growth differentiation factor 15, but not lactate, is elevated in patients with Parkinson's disease. Journal of the Neurological Sciences, 2020, 409, 116616.	0.3	7

#	Article	IF	Citations
1885	CHARACTERIZATION BY FRACTAL DIMENSION ANALYSIS OF THE RETINAL CAPILLARY NETWORK IN PARKINSON DISEASE. Retina, 2020, 40, 1483-1491.	1.0	42
1886	Mitochondrial remodeling in human skin fibroblasts from sporadic male Parkinson's disease patients uncovers metabolic and mitochondrial bioenergetic defects. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165615.	1.8	24
1887	Apigenin exhibits anti-inflammatory effects in LPS-stimulated BV2 microglia through activating GSK3Î²/Nrf2 signaling pathway. Immunopharmacology and Immunotoxicology, 2020, 42, 9-16.	1.1	30
1888	Is Parkinsonâ€™s Disease a Very Rare Pathology in Centenarians? A Clinical Study in a Cohort of Subjects. Journal of Alzheimer's Disease, 2020, 73, 73-76.	1.2	4
1889	The incidence rates and risk factors of Parkinson disease in patients with psoriasis: A nationwide population-based cohort study. Journal of the American Academy of Dermatology, 2020, 83, 1688-1695.	0.6	15
1890	Associations between long-term exposure to ambient air pollution and Parkinson's disease prevalence: A cross-sectional study. Neurochemistry International, 2020, 133, 104615.	1.9	25
1891	Delayed Clinical Manifestation of Parkinsonâ€™s Disease Among Physically Active: Do Participants in a Long-Distance Ski Race Have a Motor Reserve?1. Journal of Parkinson's Disease, 2020, 10, 267-274.	1.5	11
1892	Patients with Parkinsonâ€™s Disease and Myasthenia Gravisâ€”A Report of Three New Cases and Review of the Literature. Medicina (Lithuania), 2020, 56, 5.	0.8	6
1893	Brain Mitochondrial Impairment in Earlyâ€Onset Parkinson's Disease With or Without PINK1 Mutation. Movement Disorders, 2020, 35, 504-507.	2.2	21
1894	Imbalance of Lysine Acetylation Contributes to the Pathogenesis of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 7182.	1.8	21
1895	A Splice Intervention Therapy for Autosomal Recessive Juvenile Parkinsonâ€™s Disease Arising from Parkin Mutations. International Journal of Molecular Sciences, 2020, 21, 7282.	1.8	8
1896	The PARK2 Mutation Associated with Parkinsonâ€™s Disease Enhances the Vulnerability of Peripheral Blood Lymphocytes to Paraquat. BioMed Research International, 2020, 2020, 1-9.	0.9	7
1897	Neuroprotective Effect of Curcumin on the Nigrostriatal Pathway in a 6-Hydroxydopmine-Induced Rat Model of Parkinsonâ€™s Disease is Mediated by Î±7-Nicotinic Receptors. International Journal of Molecular Sciences, 2020, 21, 7329.	1.8	41
1898	Dysfunctional proteins in neuropsychiatric disorders: From neurodegeneration to autism spectrum disorders. Neurochemistry International, 2020, 141, 104853.	1.9	14
1899	Parkinsonâ€™s Disease-Related Risk of Suicide and Effect of Deep Brain Stimulation: Meta-Analysis. Parkinson's Disease, 2020, 2020, 1-10.	0.6	9
1900	Neuromodulation of Glial Function During Neurodegeneration. Frontiers in Cellular Neuroscience, 2020, 14, 278.	1.8	35
1901	VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology. Neurobiology of Disease, 2020, 145, 105056.	2.1	19
1902	DJ-1 (Park7) affects the gut microbiome, metabolites and the development of innate lymphoid cells (ILCs). Scientific Reports, 2020, 10, 16131.	1.6	16

#	Article	IF	Citations
1903	Performance of Force-Field- and Machine Learning-Based Scoring Functions in Ranking MAO-B Proteinâ€“Inhibitor Complexes in Relevance to Developing Parkinsonâ€™s Therapeutics. International Journal of Molecular Sciences, 2020, 21, 7648.	1.8	9
1904	Diffusion Tensor Imaging in Parkinson's Disease and Parkinsonian Syndrome: A Systematic Review. Frontiers in Neurology, 2020, 11, 531993.	1.1	43
1905	Risk of Parkinsonâ€™s disease following gout: a population-based retrospective cohort study in Taiwan. BMC Neurology, 2020, 20, 338.	0.8	14
1906	Compensatory neuritogenesis of serotonergic afferents within the striatum of a transgenic rat model of Parkinsonâ€™s disease. Brain Research, 2020, 1748, 147119.	1.1	6
1907	Detecting Oxidative Stress Biomarkers in Neurodegenerative Disease Models and Patients. Methods and Protocols, 2020, 3, 66.	0.9	19
1908	The Role of Lipids in the Initiation of Î±-Synuclein Misfolding. Frontiers in Cell and Developmental Biology, 2020, 8, 562241.	1.8	29
1909	Effect of vibration frequency on frictional resistance of brain tissue during vibration-assisted needle insertion. Medical Engineering and Physics, 2020, 86, 35-40.	0.8	5
1910	Neuroprotective potential of Myrica esulenta in Haloperidol induced Parkinsonâ€™s disease. Journal of Ayurveda and Integrative Medicine, 2020, 11, 448-454.	0.9	11
1911	Transplanted Whartonâ€™s jelly mesenchymal stem cells improve memory and brain hippocampal electrophysiology in rat model of Parkinsonâ€™s disease. Journal of Chemical Neuroanatomy, 2020, 110, 101865.	1.0	13
1912	A natural product solution to aging and aging-associated diseases. , 2020, 216, 107673.		26
1913	Metformin rescues Parkinsonâ€™s disease phenotypes caused by hyperactive mitochondria. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26438-26447.	3.3	95
1914	Repeatability of Spatio-Temporal Gait Measurements in Parkinsonâ€™s Disease. , 2020, , .		11
1915	Evaluating the Role of <scp>SNCA</scp>, <scp>LRRK2</scp>, and <scp>GBA</scp> in Chinese Patients With <scp>Earlyâ€Onset</scp> Parkinson's Disease. Movement Disorders, 2020, 35, 2046-2055.	2.2	30
1916	A real-time tracking system for tremor and trajectory estimation in Parkinsonâ€™s disease affected patients. , 2020, , .		6
1917	Î±-Synuclein aggregation and transmission in Parkinsonâ€™s disease: a link to mitochondria and lysosome. Science China Life Sciences, 2020, 63, 1850-1859.	2.3	16
1918	NfL as a biomarker for neurodegeneration and survival in Parkinson disease. Neurology, 2020, 95, e827-e838.	1.5	73
1919	Prodromal Parkinson disease in patients with idiopathic hyposmia. Journal of Neurology, 2020, 267, 3673-3682.	1.8	12
1920	Identification of vital regulatory genes with network pathways among Huntingtonâ€™s, Parkinsonâ€™s, and Alzheimerâ€™s diseases. Network Modeling Analysis in Health Informatics and Bioinformatics, 2020, 9, 1.	1.2	3

#	Article	IF	Citations
1921	Current Evidence for a Bidirectional Loop Between the Lysosome and Alpha-Synuclein Proteoforms. Frontiers in Cell and Developmental Biology, 2020, 8, 598446.	1.8	18
1922	Alpha-Synuclein in the Gastrointestinal Tract as a Potential Biomarker for Early Detection of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 8666.	1.8	13
1923	A systems biology approach to identifying genetic factors affected by aging, lifestyle factors, and type 2 diabetes that influences Parkinson's disease progression. Informatics in Medicine Unlocked, 2020, 21, 100448.	1.9	3
1924	Both Intracranial and Intravenous Administration of Functionalized Carbon Nanotubes Protect Dopaminergic Neuronal Death from 6-Hydroxydopamine . International Journal of Nanomedicine, 2020, Volume 15, 7615-7626.	3.3	4
1925	Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort. Frontiers in Neurology, 2020, 11, 578924.	1.1	1
1926	Longitudinal analysis of premotor anthropometric and serological markers of Parkinsonâ€™s disease. Scientific Reports, 2020, 10, 20524.	1.6	0
1927	Isradipine Versus Placebo in Early Parkinson Disease. Annals of Internal Medicine, 2020, 172, 591-598.	2.0	117
1928	The Experience of Persons with Parkinsonâ€™s Disease: a Hermeneutic-Phenomenological Exploration. Journal of Phenomenological Psychology, 2020, 51, 16-43.	0.7	0
1929	Identification of Freezing of Gait in Parkinsonâ€™s Patients Using Instrumented Shoes and Artificial Neural Networks. , 2020, , .		3
1930	Parkinsonâ€™s Disease, Periodontitis and Patient-Related Outcomes: A Cross-Sectional Study. Medicina (Lithuania), 2020, 56, 383.	0.8	18
1931	Female reproductive factors and the risk of Parkinsonâ€™s disease: a nationwide cohort study. European Journal of Epidemiology, 2020, 35, 871-878.	2.5	29
1932	Multimorbidity and Frailty: Tackling Complexity in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, S85-S91.	1.5	18
1933	GLP-1 receptor agonists for Parkinson's disease. The Cochrane Library, 2020, 2020, CD012990.	1.5	24
1934	Deep representation learning of electronic health records to unlock patient stratification at scale. Npj Digital Medicine, 2020, 3, 96.	5.7	90
1935	Effects of interactive video-gameâ€“based exercise on balance in older adults with mild-to-moderate Parkinsonâ€™s disease. Journal of NeuroEngineering and Rehabilitation, 2020, 17, 91.	2.4	33
1936	From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinsonâ€™s Disease: Lessons From LRRK2. Frontiers in Cellular Neuroscience, 2020, 14, 158.	1.8	15
1937	Relationship between Blood and Standard Biochemistry Levels with Periodontitis in Parkinsonâ€™s Disease Patients: Data from the NHANES 2011â€“2012. Journal of Personalized Medicine, 2020, 10, 69.	1.1	21
1938	Lipid Metabolism is the common pathologic mechanism between Type 2 Diabetes Mellitus and Parkinson's disease. International Journal of Medical Sciences, 2020, 17, 1723-1732.	1.1	6

#	Article	IF	Citations
1939	Phytochemical andrographolide modulates NF-ÎºB and JNK in human neuroblastoma SH-SY5Y cells, a cell model for Parkinson's disease. Heliyon, 2020, 6, e04121.	1.4	10
1940	The P2X7 Receptor: Central Hub of Brain Diseases. Frontiers in Molecular Neuroscience, 2020, 13, 124.	1.4	87
1941	Microglia and astrocyte dysfunction in parkinson's disease. Neurobiology of Disease, 2020, 144, 105028.	2.1	177
1942	Addressing knowledge gaps in Parkinsonâ€™s disease: a report on the Movement Disorder Societyâ€™s Centre-to-Centre initiative to improve Parkinsonâ€™s disease services in Lao Peopleâ€™s Democratic Republic. BMC Medical Education, 2020, 20, 239.	1.0	4
1943	Characteristics of initial symptoms and symptoms at diagnosis in probable dementia with Lewy body disease: incidence of symptoms and gender differences. Psychogeriatrics, 2020, 20, 737-745.	0.6	31
1944	Effects of gold nanoparticles administration through behavioral and oxidative parameters in animal model of Parkinsonâ€™s disease. Colloids and Surfaces B: Biointerfaces, 2020, 196, 111302.	2.5	18
1945	Membrane insertion exacerbates the Î±-Synuclein-Cu(II) dopamine oxidase activity: Metallothionein-3 targets and silences all Î±-synuclein-Cu(II) complexes. Free Radical Biology and Medicine, 2020, 158, 149-161.	1.3	11
1946	A Comparative Study of Anti Tremor Devices. , 2020, , .		1
1947	Associations between concussion and risk of diagnosis of psychological and neurological disorders: a retrospective population-based cohort study. Family Medicine and Community Health, 2020, 8, e000390.	0.6	16
1948	Cardiovascular evaluation of female rats with 6-OHDA-induced parkinsonism: Possible protection by ovarian hormones and participation of nitric oxide. Life Sciences, 2020, 259, 118259.	2.0	7
1949	A Senescence-Centric View of Aging: Implications for Longevity and Disease. Trends in Cell Biology, 2020, 30, 777-791.	3.6	138
1950	Docosahexaenoic acid-acylated astaxanthin ester exhibits superior performance over non-esterified astaxanthin in preventing behavioral deficits coupled with apoptosis in MPTP-induced mice with Parkinson's disease. Food and Function, 2020, 11, 8038-8050.	2.1	32
1951	Gut Microbiota Approachâ€"A New Strategy to Treat Parkinsonâ€™s Disease. Frontiers in Cellular and Infection Microbiology, 2020, 10, 570658.	1.8	24
1952	Dopamine, Alpha-Synuclein, and Mitochondrial Dysfunctions in Parkinsonian Eyes. Frontiers in Neuroscience, 2020, 14, 567129.	1.4	31
1953	Effects of Medical Comorbidities on the Surgical Outcomes of Deep Brain Stimulation for Parkinson Disease: A Retrospective, Single-Institution Study. World Neurosurgery, 2020, 144, e347-e352.	0.7	1
1954	Therapeutic effect of a histone demethylase inhibitor in Parkinsonâ€™s disease. Cell Death and Disease, 2020, 11, 927.	2.7	31
1955	Biomarker detection of Parkinsonâ€™s disease: therapy and treatment using nanomaterials. , 2020, , 479-523.		0
1956	MonParLoc: A Speech-Based System for Parkinsonâ€™s Disease Analysis and Monitoring. IEEE Access, 2020, 8, 188243-188255.	2.6	12

#	Article	IF	Citations
1957	Female mice are resilient to age-related decline of substantia nigra dopamine neuron firing parameters. Neurobiology of Aging, 2020, 95, 195-204.	1.5	15
1958	Neuroprotective Properties of Green Tea (Camellia sinensis) in Parkinsonâ€™s Disease: A Review. Molecules, 2020, 25, 3926.	1.7	46
1959	A Critical LRRK at the Synapse? The Neurobiological Function and Pathophysiological Dysfunction of LRRK2. Frontiers in Molecular Neuroscience, 2020, 13, 153.	1.4	21
1960	Plasma Exosomal Brain-Derived Neurotrophic Factor Correlated with the Postural Instability and Gait Disturbanceâ€“Related Motor Symptoms in Patients with Parkinsonâ€™s Disease. Diagnostics, 2020, 10, 684.	1.3	17
1961	Effects of an Innovative Telerehabilitation Intervention for People With Parkinson's Disease on Quality of Life, Motor, and Non-motor Abilities. Frontiers in Neurology, 2020, 11, 846.	1.1	58
1962	Detection of early Parkinsonâ€™s disease with wavelet features using finger typing movements on a keyboard. SN Applied Sciences, 2020, 2, 1.	1.5	6
1963	Prodromal Markers of Parkinson's Disease in Patients With Essential Tremor. Frontiers in Neurology, 2020, 11, 874.	1.1	9
1964	The experiences of carers looking after people with Parkinsonâ€™s disease who exhibit impulsive and compulsive behaviours: An exploratory qualitative study. Journal of Clinical Nursing, 2020, 29, 4623-4632.	1.4	7
1965	Gut metagenomics-derived genes as potential biomarkers of Parkinsonâ€™s disease. Brain, 2020, 143, 2474-2489.	3.7	72
1966	Association of Tooth Loss with New-Onset Parkinsonâ€™s Disease: A Nationwide Population-Based Cohort Study. Parkinson's Disease, 2020, 2020, 1-8.	0.6	16
1967	The Effect of a Secondary Task on Kinematics during Turning in Parkinsonâ€™s Disease with Mild to Moderate Impairment. Symmetry, 2020, 12, 1284.	1.1	2
1968	L444P Gba1 mutation increases formation and spread of Î±-synuclein deposits in mice injected with mouse Î±-synuclein pre-formed fibrils. PLoS ONE, 2020, 15, e0238075.	1.1	20
1969	Explorative Combined Lipid and Transcriptomic Profiling of Substantia Nigra and Putamen in Parkinsonâ€™s Disease. Cells, 2020, 9, 1966.	1.8	29
1970	A Modified Maximum Relevance Minimum Redundancy Feature Selection Method Based on Tabu Search For Parkinsonâ€™s Disease Mining. International Journal of Artificial Intelligence & Applications, 2020, 11, 1-14.	0.3	0
1971	Evaluation of train and test performance of machine learning algorithms and Parkinson diagnosis with statistical measurements. Medical and Biological Engineering and Computing, 2020, 58, 2775-2788.	1.6	30
1972	Role of HSP in the Pathogenesis of Age-Related Inflammatory Diseases. Heat Shock Proteins, 2020, , 1.	0.2	0
1973	The cis-Regulatory Element of SNCA Intron 4 Modulates Susceptibility to Parkinsonâ€™s Disease in Han Chinese. Frontiers in Genetics, 2020, 11, 590365.	1.1	0
1974	Evaluating a frontostriatal working-memory updating-training paradigm in Parkinsonâ€™s disease: the iPARK trial, a double-blinded randomized controlled trial. BMC Neurology, 2020, 20, 337.	0.8	0

#	Article	IF	Citations
1975	Multiclass machine learning classification of functional brain images for Parkinson's disease stage prediction. Statistical Analysis and Data Mining, 2020, 13, 508-523.	1.4	17
1976	The Role of Architecture and Design in the Management of Parkinsonâ€™s Disease: A Systematic Review. Journal of Parkinson's Disease, 2020, 10, 1301-1314.	1.5	5
1977	Manganese-induced neurodegenerative diseases and possible therapeutic approaches. Expert Review of Neurotherapeutics, 2020, 20, 1109-1121.	1.4	35
1978	Muscle activation and deactivation dynamics in Parkinsonâ€™s disease patients. Gait and Posture, 2020, 81, 299-300.	0.6	0
1979	Neurofilament light chain level in plasma extracellular vesicles and Parkinsonâ€™s disease. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642097591.	1.5	20
1980	Zonisamide for the Treatment of Parkinson Disease: A Current Update. Frontiers in Neuroscience, 2020, 14, 574652.	1.4	25
1981	Screening Patients with Early Stage Parkinsonâ€™s Disease Using a Machine Learning Technique: Measuring the Amount of Iron in the Basal Ganglia. Applied Sciences (Switzerland), 2020, 10, 8732.	1.3	0
1982	An IoT Smart Environment in Support of Disease Diagnosis Decentralization. Electronics (Switzerland), 2020, 9, 2108.	1.8	2
1983	Competing Endogenous RNA Networks as Biomarkers in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2020, 21, 9582.	1.8	73
1984	Prevalence of Alzheimer's Disease and Parkinson's Disease in China: An Updated Systematical Analysis. Frontiers in Aging Neuroscience, 2020, 12, 603854.	1.7	53
1985	Evaluation of Prescription Practices of Domperidone in Parkinsonâ€™s Disease: A Cross Sectional Study Among French Neurologists. CNS Drugs, 2020, 34, 1267-1274.	2.7	1
1986	Istradefylline to Treat Patients with Parkinsonâ€™s Disease Experiencing â€œOffâ€•Episodes: A Comprehensive Review. Neurology International, 2020, 12, 109-129.	1.3	22
1987	Radon Exposure and Neurodegenerative Disease. International Journal of Environmental Research and Public Health, 2020, 17, 7439.	1.2	8
1988	Stem Cell-Based Therapies for Parkinson Disease. International Journal of Molecular Sciences, 2020, 21, 8060.	1.8	41
1989	Metabolic Profiling of CSF from People Suffering from Sporadic and LRRK2 Parkinsonâ€™s Disease: A Pilot Study. Cells, 2020, 9, 2394.	1.8	8
1990	Constipation and sleep behaviour disorder associate with processing speed and attention in males with Parkinsonâ€™s disease over five years follow-up. Scientific Reports, 2020, 10, 19014.	1.6	15
1991	Beneficial Effects of Coconut Oil in Treatment of Parkinsonâ€™s Disease. Neurophysiology, 2020, 52, 169-175.	0.2	1
1992	Does glitazone treatment have a role on the prevention of Parkinsonâ€™s disease in adult diabetic population? A systematic review. Metabolic Brain Disease, 2020, 35, 1067-1075.	1.4	4

#	Article	IF	Citations
1993	Persistent Neurovascular Unit Dysfunction: Pathophysiological Substrate and Trigger for Late-Onset Neurodegeneration After Traumatic Brain Injury. Frontiers in Neuroscience, 2020, 14, 581.	1.4	21
1994	Neuroprotective Effect of Ropinirole Lipid Nanoparticles Enriched Hydrogel for Parkinsonâ€™s Disease: In Vitro, Ex Vivo, Pharmacokinetic and Pharmacodynamic Evaluation. Pharmaceutics, 2020, 12, 448.	2.0	71
1995	Functional Pathway Identification With CRISPR/Cas9 Genome-wide Gene Disruption in Human Dopaminergic Neuronal Cells Following Chronic Treatment With Dieldrin. Toxicological Sciences, 2020, 176, 366-381.	1.4	14
1996	Nanotheranostic Applications for Detection and Targeting Neurodegenerative Diseases. Frontiers in Neuroscience, 2020, 14, 305.	1.4	41
1997	Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinsonâ€™s disease pathogenesis. Acta Neuropathologica Communications, 2020, 8, 63.	2.4	45
1998	Assessment of Genetic Association Between Parkinson Disease and Bipolar Disorder. JAMA Neurology, 2020, 77, 1034.	4.5	4
1999	Intramitochondrial proteostasis is directly coupled to Î±-synuclein and amyloid Î²1-42 pathologies. Journal of Biological Chemistry, 2020, 295, 10138-10152.	1.6	22
2000	Motor Dysfunction as a Prodrome of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 1067-1073.	1.5	6
2001	Alteration in the Expression of Parkinsonâ€™s-Related Genes in Rat Hippocampus by Exercise and Morphine Treatments. Russian Journal of Genetics, 2020, 56, 502-508.	0.2	1
2002	Pharmacological exploration of traditional plants for the treatment of neurodegenerative disorders. Phytotherapy Research, 2020, 34, 3089-3112.	2.8	25
2003	Actively targeted gold nanoparticle composites improve behavior and cognitive impairment in Parkinson's disease mice. Materials Science and Engineering C, 2020, 114, 111028.	3.8	25
2004	Recent technological advancements in stem cell research for targeted therapeutics. Drug Delivery and Translational Research, 2020, 10, 1147-1169.	3.0	8
2005	New insight into Parkinsonâ€™s disease pathogenesis from reactive oxygen species-mediated extracellular Zn2+ influx. Journal of Trace Elements in Medicine and Biology, 2020, 61, 126545.	1.5	6
2006	Building a Machine-Learning Framework to Remotely Assess Parkinson's Disease Using Smartphones. IEEE Transactions on Biomedical Engineering, 2020, 67, 3491-3500.	2.5	34
2007	Application of Machine Learning Technique to Distinguish Parkinsonâ€™s Disease Dementia and Alzheimerâ€™s Dementia: Predictive Power of Parkinsonâ€™s Disease-Related Non-Motor Symptoms and Neuropsychological Profile. Journal of Personalized Medicine, 2020, 10, 31.	1.1	11
2008	The effect of LRRK2 loss-of-function variants in humans. Nature Medicine, 2020, 26, 869-877.	15.2	79
2009	The Role of the Gastrointestinal Mucus System in Intestinal Homeostasis: Implications for Neurological Disorders. Frontiers in Cellular and Infection Microbiology, 2020, 10, 248.	1.8	109
2010	Intrastriatal administration of coenzyme Q10 enhances neuroprotection in a Parkinsonâ€™s disease rat model. Scientific Reports, 2020, 10, 9572.	1.6	35

#	Article	IF	Citations
2011	Evaluation of causality between ADHD and Parkinson's disease: Mendelian randomization study. European Neuropsychopharmacology, 2020, 37, 49-63.	0.3	5
2012	A wearable tool for selective and continuous monitoring of tremor and dyskinesia in Parkinsonian patients. Parkinsonism and Related Disorders, 2020, 77, 43-47.	1.1	11
2013	The Evolution-Driven Signature of Parkinsonâ€™s Disease. Trends in Neurosciences, 2020, 43, 475-492.	4.2	22
2014	Hand tremor suppression device for patients suffering from Parkinsonâ€™s disease. Journal of Medical Engineering and Technology, 2020, 44, 190-197.	0.8	11
2015	Optical Coherence Tomography Angiography in Neurodegenerative Disorders. Journal of Clinical Medicine, 2020, 9, 1706.	1.0	46
2016	Genetic Architecture of Parkinson's Disease in the Indian Population: Harnessing Genetic Diversity to Address Critical Gaps in Parkinson's Disease Research. Frontiers in Neurology, 2020, 11, 524.	1.1	23
2017	Serum microRNA expression levels in Turkish patients with Parkinsonâ€™s disease. International Journal of Neuroscience, 2021, 131, 1181-1189.	0.8	21
2018	Enhanced Hyaluronan Signaling and Autophagy Dysfunction by VPS35 D620N. Neuroscience, 2020, 441, 33-45.	1.1	8
2019	Dilated Perivascular Space in the Midbrain May Reflect Dopamine Neuronal Degeneration in Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 161.	1.7	21
2020	The generation of midbrain dopaminergic neurons. , 2020, , 369-398.		5
2021	The critical role of Faecalibacterium prausnitzii in human health: An overview. Microbial Pathogenesis, 2020, 149, 104344.	1.3	102
2022	The environmental toxicant ziram enhances neurotransmitter release and increases neuronal excitability via the EAG family of potassium channels. Neurobiology of Disease, 2020, 143, 104977.	2.1	3
2023	Depression Comorbid With Stroke, Traumatic Brain Injury, Parkinsonâ€™s Disease, and Multiple Sclerosis: Diagnosis and Treatment. Focus (American Psychiatric Publishing), 2020, 18, 150-161.	0.4	7
2024	Downregulation of Î±-Synuclein Protein Levels by an Intracellular Single-Chain Antibody. Journal of Parkinson's Disease, 2020, 10, 573-590.	1.5	5
2025	The effect of fatigue on balance performance in Parkinson's disease. Clinical Parkinsonism & Related Disorders, 2020, 3, 100047.	0.5	1
2026	Can the Executive Control Network be Used to Diagnose Parkinsonâ€™s Disease and as an Efficacy Indicator of Deep Brain Stimulation?. Parkinson's Disease, 2020, 2020, 1-6.	0.6	12
2027	Mechanistic evaluation of Ursolic acid against rotenone induced Parkinsonâ€™s diseaseâ€“ emphasizing the role of mitochondrial biogenesis. Brain Research Bulletin, 2020, 160, 150-161.	1.4	17
2028	Potential Roles of Exosomes in Parkinsonâ€™s Disease: From Pathogenesis, Diagnosis, and Treatment to Prognosis. Frontiers in Cell and Developmental Biology, 2020, 8, 86.	1.8	84

#	Article	IF	Citations
2029	PINK1/Parkin Mediated Mitophagy, Ca2+ Signalling, and ERâ€“Mitochondria Contacts in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 1772.	1.8	105
2030	ALFF and ReHo Mapping Reveals Different Functional Patterns in Early- and Late-Onset Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2020, 14, 141.	1.4	29
2031	Targeting the cholinergic system in Parkinsonâ€™s disease. Acta Pharmacologica Sinica, 2020, 41, 453-463.	2.8	25
2032	Effect of Virtual Reality on Balance in Individuals With Parkinson Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Physical Therapy, 2020, 100, 933-945.	1.1	38
2033	Anemia and the risk of Parkinsonâ€™s disease in Korean older adults: A nationwide population-based study. Scientific Reports, 2020, 10, 4268.	1.6	6
2034	CNTNAP4 deficiency in dopaminergic neurons initiates parkinsonian phenotypes. Theranostics, 2020, 10, 3000-3021.	4.6	21
2035	Epidemiology of neurological diseases in older adults. Revue Neurologique, 2020, 176, 642-648.	0.6	45
2036	Lipopolysaccharide animal models of Parkinsonâ€™s disease: Recent progress and relevance to clinical disease. Brain, Behavior, & Immunity - Health, 2020, 4, 100060.	1.3	48
2037	Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease. Neurobiology of Disease, 2020, 139, 104846.	2.1	8
2038	Small ubiquitin-related modifier (SUMO) 3 and SUMO4 gene polymorphisms in Parkinsonâ€™s disease. Neurological Research, 2020, 42, 451-457.	0.6	7
2039	Natural Killer Cell Alloreactivity Against Human Induced Pluripotent Stem Cells and Their Neuronal Derivatives into Dopaminergic Neurons. Stem Cells and Development, 2020, 29, 853-862.	1.1	5
2040	Altered Body Composition and Increased Resting Metabolic Rate Associated with the Postural Instability/Gait Difficulty Parkinsonâ€™s Disease Subtype. Parkinson's Disease, 2020, 2020, 1-9.	0.6	5
2041	A rapid liquid chromatography/tandem mass spectrometry method for simultaneous determination of levodopa, carbidopa, entacapone and their six related compounds in filmâ€coated tablets. Rapid Communications in Mass Spectrometry, 2020, 34, e8782.	0.7	8
2042	An Overview of Crucial Dietary Substances and Their Modes of Action for Prevention of Neurodegenerative Diseases. Cells, 2020, 9, 576.	1.8	20
2043	A preliminary study of Parkinsonâ€™s gene therapy via sono-magnetic sensing gene vector for conquering extra/intracellular barriers in mice. Brain Stimulation, 2020, 13, 786-799.	0.7	18
2045	The relationship between cognitive decline and motor dysfunction in Parkinsonâ€™s disease: A focused miniâ€review on cognitiveâ€locomotor dualâ€task interference. Neurology and Clinical Neuroscience, 2020, 8, 372-377.	0.2	3
2046	Parkinsonâ€™s Disease and the Gut: Future Perspectives for Early Diagnosis. Frontiers in Neuroscience, 2020, 14, 626.	1.4	18
2047	Parkinsonâ€™s disease case ascertainment in prospective cohort studies through combining multiple health information resources. PLoS ONE, 2020, 15, e0234845.	1.1	6

#	Article	IF	Citations
2048	Evaluation of the neuroprotective potential of caffeic acid phenethyl ester in a cellular model of Parkinson's disease. European Journal of Pharmacology, 2020, 883, 173342.	1.7	19
2049	Antidiabetic Agents for Treatment of Parkinsonâ€™s Disease: A Meta-Analysis. International Journal of Environmental Research and Public Health, 2020, 17, 4805.	1.2	20
2050	Focal alteration of the intraretinal layers in neurodegenerative disorders. Annals of Eye Science, 2020, 5, 8-8.	1.1	3
2051	Repeated intrastriatal application of botulinum neurotoxin-A did not influence choline acetyltransferase-immunoreactive interneurons in hemiparkinsonian rat brain â€“ A histological, stereological and correlational analysis. Brain Research, 2020, 1742, 146877.	1.1	5
2052	Leverage mechanical alterations during walking at self-selected speed in patients with Parkinsonâ€™s disease. Gait and Posture, 2020, 79, 175-182.	0.6	2
2053	Parkin, an E3 Ubiquitin Ligase, Plays an Essential Role in Mitochondrial Quality Control in Parkinsonâ€™s Disease. Cellular and Molecular Neurobiology, 2021, 41, 1395-1411.	1.7	24
2054	Is YouTube a useful tool for oral care in patients with Parkinson's disease?. Special Care in Dentistry, 2020, 40, 464-469.	0.4	11
2055	Epigenetic Vulnerability of Insulator CTCF Motifs at Parkinsonâ€™s Disease-Associated Genes in Response to Neurotoxicant Rotenone. Frontiers in Genetics, 2020, 11, 627.	1.1	5
2056	Phase II Dose Selection for Alpha Synucleinâ€“Targeting Antibody Cinpanemab (BIIB054) Based on Target Protein Binding Levels in the Brain. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 515-522.	1.3	21
2057	PERK-Mediated eIF2Î± Phosphorylation Contributes to The Protection of Dopaminergic Neurons from Chronic Heat Stress in Drosophila. International Journal of Molecular Sciences, 2020, 21, 845.	1.8	18
2058	The Challenge of Disease-Modifying Therapies in Parkinsonâ€™s Disease: Role of CSF Biomarkers. Biomolecules, 2020, 10, 335.	1.8	25
2059	Cerebellar Transcranial Direct Current Stimulation in People with Parkinsonâ€™s Disease: A Pilot Study. Brain Sciences, 2020, 10, 96.	1.1	32
2060	Soluble TREM2 is elevated in Parkinsonâ€™s disease subgroups with increased CSF tau. Brain, 2020, 143, 932-943.	3.7	49
2061	Early transcranial direct current stimulation treatment exerts neuroprotective effects on 6-OHDA-induced Parkinsonism in rats. Brain Stimulation, 2020, 13, 655-663.	0.7	18
2062	Multicenter study of levodopa carbidopa intestinal gel in Parkinson's disease: the Turkish experince. Turkish Journal of Medical Sciences, 2020, 50, 66-85.	0.4	2
2063	Spectral domain OCT can differentiate the retinal morphological changes of patients with Parkinsonâ€™s disease in clinical middle stages. Neurological Sciences, 2020, 41, 1909-1912.	0.9	4
2065	Immunotherapy for Parkinsonâ€™s disease. Neurobiology of Disease, 2020, 137, 104760.	2.1	57
2066	Phytochemicals as therapeutic interventions in neurodegenerative diseases. , 2020, , 161-178.		7

#	Article	IF	Citations
2067	Association between vitamin D receptor polymorphisms and susceptibility to Parkinson's disease: An updated meta-analysis. Neuroscience Letters, 2020, 720, 134778.	1.0	12
2068	Brain Organoids: A Promising Living Biobank Resource for Neuroscience Research. Biopreservation and Biobanking, 2020, 18, 136-143.	0.5	15
2069	Accelerometry-Based Digital Gait Characteristics for Classification of Parkinson's Disease: What Counts?. IEEE Open Journal of Engineering in Medicine and Biology, 2020, 1, 65-73.	1.7	34
2070	Vesicular Dysfunction and the Pathogenesis of Parkinsonâ€™s Disease: Clues From Genetic Studies. Frontiers in Neuroscience, 2019, 13, 1381.	1.4	20
2071	Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinsonâ€™s Disease. Molecules, 2020, 25, 453.	1.7	30
2072	Striatum Shape Hypertrophy in Early Stage Parkinsonâ€™s Disease With Excessive Daytime Sleepiness. Frontiers in Neuroscience, 2019, 13, 1353.	1.4	8
2073	Machine learning ensemble for neurological disorders. Neural Computing and Applications, 2020, 32, 12697-12714.	3.2	20
2074	Metabolomics in genetic testing. Advances in Clinical Chemistry, 2020, 94, 85-153.	1.8	15
2075	Improvements of Motor Performances in the Drosophila LRRK2 Loss-of-Function Model of Parkinsonâ€™s Disease: Effects of Dialyzed Leucocyte Extracts from Human Serum. Brain Sciences, 2020, 10, 45.	1.1	2
2076	The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. Journal of Parkinson's Disease, 2020, 10, 301-313.	1.5	35
2077	Neuropathology of Kynurenine Pathway of Tryptophan Metabolism. Current Pharmacology Reports, 2020, 6, 8-23.	1.5	14
2078	Automatic detection and quantification of hand movements toward development of an objective assessment of tremor and bradykinesia in Parkinson's disease. Journal of Neuroscience Methods, 2020, 333, 108576.	1.3	35
2079	Polydatin protects SH-SY5Y in models of Parkinson's disease by promoting Atg5-mediated but parkin-independent autophagy. Neurochemistry International, 2020, 134, 104671.	1.9	41
2080	Mitochondrial Dysfunction Combined with High Calcium Load Leads to Impaired Antioxidant Defense Underlying the Selective Loss of Nigral Dopaminergic Neurons. Journal of Neuroscience, 2020, 40, 1975-1986.	1.7	34
2081	Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's. Life Sciences, 2020, 245, 117394.	2.0	51
2082	Microglial Activation in the Retina of a Triple-Transgenic Alzheimerâ€™s Disease Mouse Model (3xTg-AD). International Journal of Molecular Sciences, 2020, 21, 816.	1.8	29
2083	Gait asymmetry in glucocerebrosidase mutation carriers with Parkinsonâ€™s disease. PLoS ONE, 2020, 15, e0226494.	1.1	8
2084	Exploring the multifaceted neuroprotective actions of gallic acid: a review. International Journal of Food Properties, 2020, 23, 736-752.	1.3	47

#	Article	IF	Citations
2085	Alcohol Consumption and Risk of Parkinson's Disease: Data From a Large Prospective European Cohort. Movement Disorders, 2020, 35, 1258-1263.	2.2	17
2086	LncRNA H19 Attenuates Apoptosis in MPTP-Induced Parkinsonâ€™s Disease Through Regulating miR-585-3p/PIK3R3. Neurochemical Research, 2020, 45, 1700-1710.	1.6	41
2087	Labelâ€Free Nanoimaging of Neuromelanin in the Brain by Soft Xâ€ray Spectromicroscopy. Angewandte Chemie - International Edition, 2020, 59, 11984-11991.	7.2	13
2088	Tianma Gouteng granules decreases the susceptibility of Parkinson's disease by inhibiting ALOX15-mediated lipid peroxidation. Journal of Ethnopharmacology, 2020, 256, 112824.	2.0	18
2089	Genetic analysis of N6-methyladenosine modification genes in Parkinson's disease. Neurobiology of Aging, 2020, 93, 143.e9-143.e13.	1.5	35
2090	Bilateral Subthalamic Nucleus Deep Brain Stimulation in Elderly Patients With Parkinson Disease: A Case-Control Study. Operative Neurosurgery, 2020, 19, 234-240.	0.4	2
2091	Measuring impulsivity in Parkinsonâ€™s disease: a correlational and structural neuroimaging study using different tests. European Journal of Neurology, 2020, 27, 1478-1486.	1.7	6
2092	Labelâ€Free Nanoimaging of Neuromelanin in the Brain by Soft Xâ€ray Spectromicroscopy. Angewandte Chemie, 2020, 132, 12082-12089.	1.6	0
2093	Latency of subthalamic nucleus deep brain stimulation-evoked cortical activity as a potential biomarker for postoperative motor side effects. Clinical Neurophysiology, 2020, 131, 1221-1229.	0.7	11
2094	Reviews on New Drug Targets in Age-Related Disorders. Advances in Experimental Medicine and Biology, 2020, , .	0.8	5
2095	Risk of Parkinson's disease in patients with hypothyroidism: A nationwide population-based cohort study. Parkinsonism and Related Disorders, 2020, 74, 28-32.	1.1	13
2096	The necroptosis pathway and its role in age-related neurodegenerative diseases: will it open up new therapeutic avenues in the next decade?. Expert Opinion on Therapeutic Targets, 2020, 24, 679-693.	1.5	13
2097	Parkinsonâ€™s Disease and Headaches: A Crossâ€Sectional Study. Headache, 2020, 60, 967-973.	1.8	7
2098	A double-blind, randomized controlled trial of duloxetine for pain in Parkinson's disease. Journal of the Neurological Sciences, 2020, 414, 116833.	0.3	9
2099	Parkinsonâ€™s disease and skin cancer risk: a nationwide populationâ€based cohort study in Korea. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2775-2780.	1.3	19
2100	Resolution of Inflammation in Neurodegenerative Diseases: The Role of Resolvins. Mediators of Inflammation, 2020, 2020, 1-10.	1.4	24
2101	Proactive and Integrated Management and Empowerment in Parkinsonâ€™s Disease: Designing a New Model of Care. Parkinson's Disease, 2020, 2020, 1-11.	0.6	29
2102	Update on the Management of Parkinsonâ€™s Disease for General Neurologists. Parkinson's Disease, 2020, 2020, 1-13.	0.6	33

#	Article	IF	Citations
2103	Parkinsonâ€™s Disease in the Middle East, North Africa, and South Asia: Consensus from the International Parkinson and Movement Disorder Society Task Force for the Middle East. Journal of Parkinson's Disease, 2020, 10, 729-741.	1.5	8
2104	NEURODEGENERATIVE DISEASES: AN OVERVIEW. International Research Journal of Pharmacy, 2020, 11, 20-24.	0.0	0
2105	Altered white matter microarchitecture in Parkinsonâ€™s disease: a voxel-based meta-analysis of diffusion tensor imaging studies. Frontiers of Medicine, 2021, 15, 125-138.	1.5	11
2106	Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's Disease. American Journal of Geriatric Psychiatry, 2021, 29, 35-47.	0.6	2
2107	Predictors of second-sided deep brain stimulation for Parkinsonâ€™s disease. Journal of Neurosurgery, 2021, 134, 386-392.	0.9	0
2108	A Comparative Study of Existing Machine Learning Approaches for Parkinson's Disease Detection. IETE Journal of Research, 2021, 67, 4-14.	1.8	51
2109	Neuroprotective benefits of grape seed and skin extract in a mouse model of Parkinsonâ€™s disease. Nutritional Neuroscience, 2021, 24, 197-211.	1.5	35
2110	Genomeâ€Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients. Movement Disorders, 2021, 36, 434-441.	2.2	12
2111	In vitro neuroprotective potential of Clivia miniata and Nerine humilis (Amaryllidaceae) in MPP+-induced neuronal toxicity in SH-SY5Y neuroblastoma cells. South African Journal of Botany, 2021, 136, 110-117.	1.2	12
2112	Autophagy-dependent removal of Î±-synuclein: a novel mechanism of GM1 ganglioside neuroprotection against Parkinsonâ€™s disease. Acta Pharmacologica Sinica, 2021, 42, 518-528.	2.8	35
2113	Analysis of the LRP10 gene in patients with Parkinsonâ€™s disease and dementia with Lewy bodies from Southern Italy. Neurological Sciences, 2021, 42, 305-308.	0.9	5
2114	Linking chronic kidney disease and Parkinsonâ€™s disease: a literature review. Metabolic Brain Disease, 2021, 36, 1-12.	1.4	18
2115	Is there a link between inorganic polyphosphate (polyP), mitochondria, and neurodegeneration?. Pharmacological Research, 2021, 163, 105211.	3.1	20
2116	Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders. Expert Opinion on Drug Discovery, 2021, 16, 373-389.	2.5	38
2117	Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study. Movement Disorders, 2021, 36, 255-260.	2.2	41
2118	Neurologic Emergencies at the Extremes of Age. Emergency Medicine Clinics of North America, 2021, 39, 47-65.	0.5	4
2119	Graph theory analysis of the dopamine D2 receptor network in Parkinsonâ€™s disease patients with cognitive decline. Journal of Neuroscience Research, 2021, 99, 947-965.	1.3	6
2120	Rare variant analysis of essential tremorâ€associated genes in earlyâ€onset Parkinsonâ€™s disease. Annals of Clinical and Translational Neurology, 2021, 8, 119-125.	1.7	4

#	Article	IF	Citations
2121	Patients With Parkinsonâ€™s Disease Have Poorer Function and More Flexion Contractures After Total Knee Arthroplasty. Journal of Arthroplasty, 2021, 36, 2325-2330.	1.5	10
2122	A long-term follow-up of safety and clinical efficacy of NTCELLÂ® [Immunoprotected (Alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2021, 82, 128-132.	1.1	7
2123	Fluorescent probes for bioimaging of potential biomarkers in Parkinson's disease. Chemical Society Reviews, 2021, 50, 1219-1250.	18.7	90
2124	Metabolomic Changes after Coffee Consumption: New Paths on the Block. Molecular Nutrition and Food Research, 2021, 65, 2000875.	1.5	11
2125	Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease. Movement Disorders, 2021, 36, 570-580.	2.2	32
2126	Upregulation of Cellular Palmitoylation Mitigates Î±â€Synuclein Accumulation and Neurotoxicity. Movement Disorders, 2021, 36, 348-359.	2.2	18
2127	A Comparative In Vitro Study of the Neuroprotective Effect Induced by Cannabidiol, Cannabigerol, and Their Respective Acid Forms: Relevance of the 5-HT1A Receptors. Neurotoxicity Research, 2021, 39, 335-348.	1.3	25
2128	Metabolic Syndrome and Parkinson's Disease Incidence: A Nationwide Study Using Propensity Score Matching. Metabolic Syndrome and Related Disorders, 2021, 19, 1-7.	0.5	13
2129	A Pragmatic Approach to the Perioperative Management of Parkinsonâ€™s Disease. Canadian Journal of Neurological Sciences, 2021, 48, 299-307.	0.3	9
2130	Gait Spatiotemporal Signal Analysis for Parkinsonâ€™s Disease Detection and Severity Rating. IEEE Sensors Journal, 2021, 21, 1838-1848.	2.4	33
2131	Factors explaining physical activity level in ParkinsonÂ´s disease: A gender focus. Physiotherapy Theory and Practice, 2021, 37, 507-516.	0.6	22
2132	Fractures in Parkinsonâ€™s Disease: injury patterns, hospitalization, and therapeutic aspects. European Journal of Trauma and Emergency Surgery, 2021, 47, 573-580.	0.8	17
2133	Positive impact of short-term gait rehabilitation in Parkinson patients: a combined approach based on statistics and machine learning. Mathematical Biosciences and Engineering, 2021, 18, 6995-7009.	1.0	28
2134	iPSCs and cell therapy for Parkinsonâ€™s disease. , 2021, , 23-47.		0
2135	Serotonergic imaging in Parkinson's disease. Progress in Brain Research, 2021, 261, 303-338.	0.9	11
2136	Poor outcomes of primary total knee arthroplasty in patients with Parkinsonâ€™s disease. International Orthopaedics, 2021, 45, 643-647.	0.9	6
2138	The contribution of gut microbiota in the pathogenesis of Parkinsonâ€™s disease. , 2021, , 123-141.		0
2139	Aging in the Human Species. Advances in Studies of Aging and Health, 2021, , 241-290.	0.2	0

#	Article	IF	Citations
2140	Characterizing Advanced Parkinsonâ€™s Disease: Romanian Subanalysis from the OBSERVE-PD Study. Parkinson's Disease, 2021, 2021, 1-12.	0.6	9
2141	Parkinson disease and sleep. , 2021, , .		0
2142	Reduction in Nesfatin-1 Levels in the Cerebrospinal Fluid and Increased Nigrostriatal Degeneration Following Ventricular Administration of Anti-nesfatin-1 Antibody in Mice. Frontiers in Neuroscience, 2021, 15, 621173.	1.4	5
2143	Epidemiology of Parkinsonâ€™s Disease in Chile. Neuroepidemiology, 2021, 55, 393-397.	1.1	3
2144	Urinary proteome profiling for stratifying patients with familial Parkinsonâ€™s disease. EMBO Molecular Medicine, 2021, 13, e13257.	3.3	88
2145	Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinsonâ€™s Disease. , 2021, 12, 1494.		21
2146	Data analytics for wearable IoT-based telemedicine. , 2021, , 357-378.		4
2147	Mitochondrial response to environmental toxicants. , 2021, , 61-97.		1
2148	People with mild PD have impaired force production in all lower limb muscle groups: A crossâ€sectional study. Physiotherapy Research International, 2021, 26, e1897.	0.7	6
2149	The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinsonâ€™s disease: meta-analysis of randomized controlled trials. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532098599.	1.2	7
2150	The Elderly Subjects and Their Troubles. Advances in Studies of Aging and Health, 2021, , 291-349.	0.2	0
2151	Proteomics for Target Identification in Psychiatric and Neurodegenerative Disorders. Advances in Experimental Medicine and Biology, 2021, 1286, 251-264.	0.8	3
2152	An automated cloud-based tool for Screening of Parkinsonâ€™s disease in Bangladesh. , 2021, , .		3
2153	Clinical overview and phenomenology of movement disorders. , 2021, , 1-51.e27.		3
2154	Ethnic and Immigrant Variations in the Time Trends of Dementia and Parkinsonism. Canadian Journal of Neurological Sciences, 2021, , 1-12.	0.3	2
2155	LncRNA SNHG1 promotes neuronal injury in Parkinsonâ€™s disease cell model by miR-181a-5p/CXCL12 axis. Journal of Molecular Histology, 2021, 52, 153-163.	1.0	19
2156	Degenerative Movement Disorders of the Central Nervous System. , 2021, , 972-982.		0
2157	Autonomic disorders in Parkinson disease: Disrupted hypothalamic connectivity as revealed from resting-state functional magnetic resonance imaging. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 182, 211-222.	1.0	3

#	Article	IF	Citations
2159	Environmental Aspects of Alzheimer's and Parkinson's Diseases Neuropathologies. , 2021, , 79-108.		0
2160	Recuperative effect of estrogen on rotenone-induced experimental model of Parkinsonâ€™s disease in rats. Environmental Science and Pollution Research, 2021, 28, 21266-21275.	2.7	4
2161	Detecting Effect of Levodopa in Parkinsonâ€™s Disease Patients Using Sustained Phonemes. IEEE Journal of Translational Engineering in Health and Medicine, 2021, 9, 1-9.	2.2	16
2162	Inflammation and regulatory T cell genes are differentially expressed in peripheral blood mononuclear cells of Parkinsonâ€™s disease patients. Scientific Reports, 2021, 11, 2316.	1.6	20
2164	Identification of potential Parkinsonâ€™s disease biomarkers using computational biology approaches. Network Modeling Analysis in Health Informatics and Bioinformatics, 2021, 10, 1.	1.2	0
2165	Regulation of Mitochondrial Dynamics in Parkinsonâ€™s Diseaseâ€”Is 2-Methoxyestradiol a Missing Piece?. Antioxidants, 2021, 10, 248.	2.2	4
2166	X-Vectors: New Quantitative Biomarkers for Early Parkinson's Disease Detection From Speech. Frontiers in Neuroinformatics, 2021, 15, 578369.	1.3	34
2167	Ginnalin A Binds to the Subpockets of Keap1 Kelch Domain To Activate the Nrf2-Regulated Antioxidant Defense System in SH-SY5Y Cells. ACS Chemical Neuroscience, 2021, 12, 872-882.	1.7	15
2168	Ecto-GPR37: a potential biomarker for Parkinsonâ€™s disease. Translational Neurodegeneration, 2021, 10, 8.	3.6	19
2169	Classification of Parkinson disease using binary Rao optimization algorithms. Expert Systems, 2021, 38, e12674.	2.9	21
2170	Integrative analysis identifies bHLH transcription factors as contributors to Parkinsonâ€™s disease risk mechanisms. Scientific Reports, 2021, 11, 3502.	1.6	1
2171	Physical interventions for people with Parkinson's disease: a systematic review and network meta-analysis. The Cochrane Library, 0, , .	1.5	3
2172	A wearable tool for continuous monitoring of movement disorders: clinical assessment and comparison with tremor scores. Neurological Sciences, 2021, 42, 4241-4248.	0.9	3
2173	Sexual Disorders and Quality of Life in Parkinson's Disease. Sexual Medicine, 2021, 9, 100280-100280.	0.9	16
2174	CUB and Sushi Multiple Domains (CSMD1) Gene Polymorphisms and Susceptibilities to Idiopathic Parkinsonâ€™s Disease in Northern Chinese Han Population: A Case-Control Study. Parkinson's Disease, 2021, 2021, 1-10.	0.6	2
2175	Representation of Parkinson's disease and atypical Parkinson's syndromes in the Czech Republicâ€”A nationwide retrospective study. PLoS ONE, 2021, 16, e0246342.	1.1	2
2176	Characterization of Retinal Microvascular and Choroidal Structural Changes in Parkinson Disease. JAMA Ophthalmology, 2021, 139, 182.	1.4	84
2177	Long Non-coding RNAs in Parkinsonâ€™s Disease. Neurochemical Research, 2021, 46, 1031-1042.	1.6	22

#	Article	IF	Citations
2178	The Function of the Metals in Regulating Epigenetics During Parkinsonâ€™s Disease. Frontiers in Genetics, 2020, 11, 616083.	1.1	8
2179	Blood Pressure Patterns in Patients with Parkinsonâ€™s Disease: A Systematic Review. Journal of Personalized Medicine, 2021, 11, 129.	1.1	10
2180	Peripheral electrical stimulation to reduce pathological tremor: a review. Journal of NeuroEngineering and Rehabilitation, 2021, 18, 33.	2.4	27
2181	Boxing with Parkinsonâ€™s Disease: findings from a qualitative study using self-determination theory. Disability and Rehabilitation, 2022, 44, 3880-3889.	0.9	5
2182	Changes in Step Characteristics Over a Known Outdoor Surface Transition: The Effect of Parkinson Disease. Journal of Applied Biomechanics, 2021, 37, 59-65.	0.3	3
2183	Tissue-Specific Landscape of Metabolic Dysregulation during Ageing. Biomolecules, 2021, 11, 235.	1.8	24
2184	Is Attention-Deficit/Hyperactivity Disorder a Risk Syndrome for Parkinsonâ€™s Disease?. Harvard Review of Psychiatry, 2021, 29, 142-158.	0.9	6
2185	Impulse Control Disorders in Parkinson's Disease: Epidemiology, Pathogenesis and Therapeutic Strategies. Frontiers in Psychiatry, 2021, 12, 635494.	1.3	15
2186	Î±-synuclein impairs autophagosome maturation through abnormal actin stabilization. PLoS Genetics, 2021, 17, e1009359.	1.5	49
2187	Multi target-directed imidazole derivatives for neurodegenerative diseases. Journal of Physics: Conference Series, 2021, 1853, 012066.	0.3	4
2189	Impact of anticholinergic drugs withdrawal on motor function in patients with Parkinsonâ€™s disease. Clinical Neurology and Neurosurgery, 2021, 202, 106480.	0.6	3
2190	Cytokine Profile in Plasma Extracellular Vesicles of Parkinsonâ€™s Disease and the Association with Cognitive Function. Cells, 2021, 10, 604.	1.8	21
2191	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models. European Journal of Medicinal Chemistry, 2021, 213, 113168.	2.6	17
2192	Early diagnosis of Parkinsonâ€™s disease based on non-motor symptoms: a descriptive and factor analysis. Journal of Ambient Intelligence and Humanized Computing, 0, , 1.	3.3	15
2193	Telerehabilitation for Individuals with Parkinsonâ€™s Disease and a History of Falls: A Pilot Study. Physiotherapy Canada Physiotherapie Canada, 2021, 73, 343-350.	0.3	6
2194	Age-related vulnerability to nigral dopaminergic degeneration in rats via Zn2+-permeable GluR2-lacking AMPA receptor activation. NeuroToxicology, 2021, 83, 69-76.	1.4	8
2195	Fatty Acid-Binding Protein 3 Expression in the Brain and Skin in Human Synucleinopathies. Frontiers in Aging Neuroscience, 2021, 13, 648982.	1.7	12
2196	Parkinsonâ€™s Disease Diagnosis in Cepstral Domain Using MFCC and Dimensionality Reduction with SVM Classifier. Mobile Information Systems, 2021, 2021, 1-10.	0.4	22

#	Article	IF	Citations
2197	Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders. Frontiers in Neuroscience, 2021, 15, 656921.	1.4	16
2198	Using Handwriting Evaluation Software to Predict and Increase Diagnosis for Parkinsonâ€™s. Journal of Student Research, 2021, 10, .	0.0	0
2199	VPS35 D620N knockin mice recapitulate cardinal features of Parkinsonâ€™s disease. Aging Cell, 2021, 20, e13347.	3.0	21
2200	Tremor, Hallucinations, and Cognitive Decline. , 2021, , 109-111.		0
2201	Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease. JAMA Neurology, 2021, 78, 312.	4.5	83
2202	The Importance of Drosophila melanogaster Research to UnCover Cellular Pathways Underlying Parkinsonâ€™s Disease. Cells, 2021, 10, 579.	1.8	17
2203	Targeting Î²-Arrestins in the Treatment of Psychiatric and Neurological Disorders. CNS Drugs, 2021, 35, 253-264.	2.7	8
2204	A dual-branch model for diagnosis of Parkinsonâ€™s disease based on the independent and joint features of the left and right gait. Applied Intelligence, 2021, 51, 7221-7232.	3.3	11
2205	Tablet-based patient educational interventions in care and management of complex movement disorders. Disability and Rehabilitation: Assistive Technology, 2021, , 1-8.	1.3	0
2206	Sex effects on clinical features in LRRK2 G2385R carriers and non-carriers in Parkinson's disease. BMC Neuroscience, 2021, 22, 22.	0.8	6
2207	The translocator protein (TSPO) is prodromal to mitophagy loss in neurotoxicity. Molecular Psychiatry, 2021, 26, 2721-2739.	4.1	10
2208	Combination targeting of subthalamic nucleus and ventral intermediate thalamic nucleus with a single trajectory in deep brain stimulation for tremor-dominant Parkinsonâ€™s disease. Journal of Clinical Neuroscience, 2021, 85, 92-100.	0.8	5
2209	A randomized single and multiple ascending dose study in healthy volunteers of LTIâ€291, a centrally penetrant glucocerebrosidase activator. British Journal of Clinical Pharmacology, 2021, 87, 3561-3573.	1.1	29
2210	Effects of Î±-Synuclein-Associated Post-Translational Modifications in Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2021, 12, 1061-1071.	1.7	35
2211	Neurotoxin-Induced Rodent Models of Parkinsonâ€™s Disease: Benefits and Drawbacks. Neurotoxicity Research, 2021, 39, 897-923.	1.3	21
2212	Bipolar Disorder and Parkinson's Disease: A 123I-Ioflupane Dopamine Transporter SPECT Study. Frontiers in Neurology, 2021, 12, 652375.	1.1	5
2213	Excessive daytime sleepiness in Parkinson's disease: A systematic review and meta-analysis. Parkinsonism and Related Disorders, 2021, 85, 133-140.	1.1	32
2214	What is the lived experience of anxiety for people with Parkinsonâ€™s? A phenomenological study. PLoS ONE, 2021, 16, e0249390.	1.1	5

#	Article	IF	Citations
2215	PINK1: A Bridge between Mitochondria and Parkinsonâ€™s Disease. Life, 2021, 11, 371.	1.1	20
2216	The Cell Biology of LRRK2 in Parkinson's Disease. Molecular and Cellular Biology, 2021, 41, .	1.1	44
2217	Sagittal alignment changes and postoperative complications following surgery for adult spinal deformity in patients with Parkinsonâ€™s disease: a multi-institutional retrospective cohort study. BMC Musculoskeletal Disorders, 2021, 22, 357.	0.8	3
2218	C-Phycocyanin-derived Phycocyanobilin as a Potential Nutraceutical Approach for Major Neurodegenerative Disorders and COVID-19- induced Damage to the Nervous System. Current Neuropharmacology, 2021, 19, 2250-2275.	1.4	28
2219	Herbal Resources to Combat a Progressive & Degenerative Nervous System Disorder- Parkinsonâ€™s Disease. Current Drug Targets, 2021, 22, 609-630.	1.0	13
2220	Genetic Modifiers of Age at Onset for Parkinson's Disease in Asians: A Genomeâ€Wide Association Study. Movement Disorders, 2021, 36, 2077-2084.	2.2	15
2221	Improved Classification Accuracy for Diagnosing the Early Stage of Parkinsonâ€™s Disease Using Alpha Stable Distribution. IETE Journal of Research, 2023, 69, 92-103.	1.8	2
2222	Microglia Specific Drug Targeting Using Natural Products for the Regulation of Redox Imbalance in Neurodegeneration. Frontiers in Pharmacology, 2021, 12, 654489.	1.6	24
2223	Rare homozygous PRKN exon 8 and 9 deletion in Malay familial early-onset Parkinsonâ€™s disease. Annals of the Academy of Medicine, Singapore, 2021, 50, 353-355.	0.2	2
2224	Association of Glycolysis-Enhancing Î±-1 Blockers With Risk of Developing Parkinson Disease. JAMA Neurology, 2021, 78, 407.	4.5	42
2225	Preparation, In Vitro characterization and stability studies of ropinirole lipid nanoparticles enriched hydrogel for treatment of neurodegeneration diseases. Journal of Drug Delivery and Therapeutics, 2021, 11, 66-75.	0.2	0
2226	Moxibustion Protects Dopaminergic Neurons in Parkinsonâ€™s Disease through Antiferroptosis. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-11.	0.5	6
2227	Early Detection of Parkinsonâ€™s and Alzheimerâ€™s Diseases using the VOT_Mean Feature. Engineering, Technology & Applied Science Research, 2021, 11, 6912-6918.	0.8	3
2228	Systemic Literature Review of the Use of Virtual Reality for Rehabilitation in Parkinson Disease. , 2021, 38, S20-S27.		2
2229	Multiple genetic pathways regulating lifespan extension are neuroprotective in a G2019S LRRK2 nematode model of Parkinson's disease. Neurobiology of Disease, 2021, 151, 105267.	2.1	7
2230	Current and Emerging MR Methods and Outcome in Rodent Models of Parkinsonâ€™s Disease: A Review. Frontiers in Neuroscience, 2021, 15, 583678.	1.4	1
2231	Changes in Drp1 Function and Mitochondrial Morphology Are Associated with the Î±-Synuclein Pathology in a Transgenic Mouse Model of Parkinsonâ€™s Disease. Cells, 2021, 10, 885.	1.8	27
2232	Laterality in Parkinsonâ€™s disease: A neuropsychological review. Applied Neuropsychology Adult, 2023, 30, 126-140.	0.7	6

#	Article	IF	Citations
2233	VGLUT2 Is a Determinant of Dopamine Neuron Resilience in a Rotenone Model of Dopamine Neurodegeneration. Journal of Neuroscience, 2021, 41, 4937-4947.	1.7	17
2234	Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinsonâ€™s disease. Journal of Pharmaceutical Investigation, 2021, 51, 465-481.	2.7	13
2235	The Role of the Dopamine Î²-hydroxylase Functional Polymorphism in Patients with Early-Onset Parkinsonâ€™s Disease in the Turkish Population. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2021, 27, 21-26.	0.1	0
2236	Tooth Loss and Blood Pressure in Parkinsonâ€™s Disease Patients: An Exploratory Study on NHANES Data. International Journal of Environmental Research and Public Health, 2021, 18, 5032.	1.2	11
2237	Incident Parkinsonâ€™s disease in kidney transplantation recipients: a nationwide population-based cohort study in Korea. Scientific Reports, 2021, 11, 10541.	1.6	1
2239	Imputation and Reanalysis of ExomeChip Data Identifies Novel, Conditional and Joint Genetic Effects on Parkinsonâ€™s Disease Risk. Genes, 2021, 12, 689.	1.0	8
2240	Effects of vibratory stimulation on balance and gait in Parkinson's disease: a systematic review and meta-analysis. European Journal of Physical and Rehabilitation Medicine, 2021, 57, 254-264.	1.1	11
2241	Dysfunction of Synaptic Vesicle Endocytosis in Parkinsonâ€™s Disease. Frontiers in Integrative Neuroscience, 2021, 15, 619160.	1.0	17
2242	Nicotine suppresses Parkinsonâ€™s disease like phenotypes induced by Synphilin-1 overexpression in Drosophila melanogaster by increasing tyrosine hydroxylase and dopamine levels. Scientific Reports, 2021, 11, 9579.	1.6	14
2243	Psychotherapy for the Treatment of Anxiety and Depression in Patients with Parkinson Disease: A Meta-Analysis of Randomized Controlled Trials. Journal of the American Medical Directors Association, 2021, 22, 2289-2295.e2.	1.2	13
2244	Mechanistic insights into the protective effect of paracetamol against rotenone-induced Parkinsonâ€™s disease in rats: Possible role of endocannabinoid system modulation. International Immunopharmacology, 2021, 94, 107431.	1.7	15
2245	Clinical Spectrum of Movement Disorders in Neurology Inpatients in a Tertiary Care Centre. Journal of Neurosciences in Rural Practice, 2021, 12, 581-585.	0.3	2
2246	MRI Signs of Parkinsonâ€™s Disease and Atypical Parkinsonism. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2021, 193, 1403-1410.	0.7	4
2247	Glucose Metabolic Dysfunction in Neurodegenerative Diseasesâ€”New Mechanistic Insights and the Potential of Hypoxia as a Prospective Therapy Targeting Metabolic Reprogramming. International Journal of Molecular Sciences, 2021, 22, 5887.	1.8	49
2248	The Neuroprotective Properties, Functions, and Roles of Cannabis sativa in Selected Diseases Related to the Nervous System. Central Nervous System Agents in Medicinal Chemistry, 2021, 21, 20-38.	0.5	2
2249	Anti-Muscle Specific Kinase (Anti-MuSK) Positive Myasthenia Gravis Overlapping With Parkinsonâ€™s Disease: A Challenging Diagnosis. Cureus, 2021, 13, e14839.	0.2	2
2250	Rá»‘i loáº¡n khá»£ nÄƒng váº¤n Ä‘á»™ng trÃªn mÃ´ hÃ¬nh ruá»“i giáº¥m biá»ƒu hiá»‡n Protein Alpha-Synuclein gÃ¢y bá»‡nh Parkinson. Ta Nghien Cuu Y Hoc, 2021, 138, 28-36.	0.0	0
2251	Edaravone Plays Protective Effects on LPS-Induced Microglia by Switching M1/M2 Phenotypes and Regulating NLRP3 Inflammasome Activation. Frontiers in Pharmacology, 2021, 12, 691773.	1.6	13

#	Article	IF	Citations
2252	Neurotoxic Mechanism and Shortcomings of MPTP, 6-OHDA, Rotenone and Paraquat-induced Parkinsonâ€™s Disease Animal Models. Venoms and Toxins, 2021, 1, 27-40.	0.3	2
2253	Plasma Extracellular Vesicle Î±-Synuclein Level in Patients with Parkinsonâ€™s Disease. Biomolecules, 2021, 11, 744.	1.8	16
2254	Association between VPS13C rs2414739 polymorphism and Parkinsonâ€™s disease risk: A meta-analysis. Neuroscience Letters, 2021, 754, 135879.	1.0	1
2255	Effect of gender in the onset and progression of Parkinson's disease. , 2021, , .		0
2256	Electromyography-informed modeling for estimating muscle activation and force alterations in Parkinsonâ€™s disease. Computer Methods in Biomechanics and Biomedical Engineering, 2022, 25, 14-26.	0.9	5
2257	Effect of orofacial physiotherapeutic and hygiene interventions on oral healthâ€“related quality of life in patients with Parkinsonâ€™s disease: A randomised controlled trial. Journal of Oral Rehabilitation, 2021, 48, 1035-1043.	1.3	9
2258	Functional variant rs17525453 within RAB35 gene promoter is possibly associated with increased risk of Parkinson's disease in Taiwanese population.. Neurobiology of Aging, 2021, 107, 189-196.	1.5	0
2259	Characterization of EMG time-frequency content during Parkinson walking: a pilot study. , 2021, , .		2
2260	A mechanistic review of Parkin activation. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129894.	1.1	13
2261	Mathematical model for early stage identification of Parkinsonâ€™s disease using neurotransmitter: GABA. International Journal of Information Technology (Singapore), 2022, 14, 265-273.	1.8	4
2262	Wearable Technology to Detect Motor Fluctuations in Parkinsonâ€™s Disease Patients: Current State and Challenges. Sensors, 2021, 21, 4188.	2.1	18
2263	Nociception alterations precede motor symptoms in a progressive model of parkinsonism induced by reserpine in middle-aged rats. Brain Research Bulletin, 2021, 171, 1-9.	1.4	4
2265	The cannabinoid system and microglia in health and disease. Neuropharmacology, 2021, 190, 108555.	2.0	49
2266	Parkinsonâ€™s Disease Patient Monitoring: A Real-Time Tracking and Tremor Detection System Based on Magnetic Measurements. Sensors, 2021, 21, 4196.	2.1	10
2267	Association between Temporomandibular Joint Disorder and Parkinsonâ€™s Disease. Brain Sciences, 2021, 11, 747.	1.1	7
2268	Association of Dynamic Changes in Metabolic Syndrome Status with the Risk of Parkinsonâ€™s Disease: A Nationwide Cohort Study. Journal of Parkinson's Disease, 2021, 11, 1-9.	1.5	3
2269	Precision Medicine on the Fly: Using Drosophila to Decipher Gene-Environment Interactions in Parkinsonâ€™s Disease. Toxicological Sciences, 2021, 182, 159-167.	1.4	8
2270	Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future Perspective. Current Neuropharmacology, 2022, 20, 158-178.	1.4	55

#	Article	IF	Citations
2271	Assessment of the Efficacy of Preventive Therapy with Chaperone Inducer U133 in a Model of the Preclinical Stage of Parkinsonâ€™s Disease in Elderly Rats. Neuroscience and Behavioral Physiology, 2021, 51, 673-680.	0.2	5
2272	Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson's Disease: A Systematic Review. Advances in Nutrition, 2021, 12, 2265-2287.	2.9	31
2273	Small Molecule Fisetin Modulates Alphaâ€“Synuclein Aggregation. Molecules, 2021, 26, 3353.	1.7	12
2274	The PINK1-Mediated Crosstalk between Neural Cells and the Underlying Link to Parkinsonâ€™s Disease. Cells, 2021, 10, 1395.	1.8	6
2275	A feasibility study of dual-task strategy training to improve gait performance in patients with Parkinsonâ€™s disease. Scientific Reports, 2021, 11, 12416.	1.6	10
2276	Advances in artificial neural networks as a disease prediction tool. Journal of Cancer Research & Therapy, 2021, 9, 1-11.	0.1	3
2278	Brainâ€derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson's disease. Brain and Behavior, 2021, 11, e2251.	1.0	18
2279	Speech Rhythm Variation in Early-Stage Parkinson's Disease: A Study on Different Speaking Tasks. Frontiers in Psychology, 2021, 12, 668291.	1.1	9
2280	Caprylic acid ameliorates rotenone induced inflammation and oxidative stress in the gut-brain axis in Zebrafish. Molecular Biology Reports, 2021, 48, 5259-5273.	1.0	25
2281	Trend of recognizing depression symptoms and antidepressants use in newly diagnosed Parkinson's disease: Populationâ€based study. Brain and Behavior, 2021, 11, e2228.	1.0	8
2282	Clinical and imaging features of surgically treated low lumbar osteoporotic vertebral collapse in patients with Parkinsonâ€™s disease. Scientific Reports, 2021, 11, 14235.	1.6	2
2283	TSPO imaging in animal models of brain diseases. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 49, 77-109.	3.3	37
2284	Neurodegenerative disorders and gut-brain interactions. Journal of Clinical Investigation, 2021, 131, .	3.9	55
2285	Managing Advanced Parkinson Disease. Journal of Geriatric Psychiatry and Neurology, 2021, 34, 289-300.	1.2	3
2286	Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2021, 22, 8196.	1.8	9
2287	Dual-task intervention based on trail making test: Effects on Parkinson's disease. Journal of Bodywork and Movement Therapies, 2021, 27, 628-633.	0.5	8
2288	Oxidative Stress, Mitochondrial Dysfunction, and Neuroprotection of Polyphenols with Respect to Resveratrol in Parkinsonâ€™s Disease. Biomedicines, 2021, 9, 918.	1.4	46
2289	Burden of Parkinsonâ€™s disease in Sicily: a health administrative database study. Neurological Sciences, 2022, 43, 1043-1046.	0.9	1

#	Article	IF	Citations
2290	Operative Treatment of Distal Radius Fractures in Patients With Parkinson Disease. Hand, 2021, , 155894472110289.	0.7	0
2291	Single-cell transcriptome and TCR profiling reveal activated and expanded T cell populations in Parkinsonâ€™s disease. Cell Discovery, 2021, 7, 52.	3.1	51
2292	DJ-1 inhibits microglial activation and protects dopaminergic neurons in vitro and in vivo through interacting with microglial p65. Cell Death and Disease, 2021, 12, 715.	2.7	19
2293	Small heterodimer partner (SHP) aggravates ER stress in Parkinsonâ€™s disease-linked LRRK2 mutant astrocyte by regulating XBP1 SUMOylation. Journal of Biomedical Science, 2021, 28, 51.	2.6	8
2294	Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinsonâ€™s Disease. Toxins, 2021, 13, 505.	1.5	9
2295	Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation. Journal of Medicinal Chemistry, 2021, 64, 9592-9638.	2.9	28
2297	Age-Related Characteristics of Sleep Impairments in a Model of the Preclinical Stage of Parkinsonâ€™s Disease in Rats. Neuroscience and Behavioral Physiology, 2021, 51, 704-710.	0.2	1
2298	Hot Topics in Recent Parkinsonâ€™s Disease Research: Where We are and Where We Should Go. Neuroscience Bulletin, 2021, 37, 1735-1744.	1.5	19
2299	Development of a Hydrophobicity-Controlled Delivery System Containing Levodopa Methyl Ester Hydrochloride Loaded into a Mesoporous Silica. Pharmaceutics, 2021, 13, 1039.	2.0	3
2300	Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinsonâ€™s Disease. Current Pharmaceutical Design, 2021, 27, 4008-4016.	0.9	11
2301	Mortality of People with Parkinson's Disease in a Large <scp>UK</scp>â€Based Cohort Study: Time Trends and Relationship to Disease Duration. Movement Disorders, 2021, 36, 2811-2820.	2.2	8
2302	Berberine Attenuates MPP+-Induced Neuronal Injury by Regulating LINC00943/miR-142-5p/KPNA4/NF-Î²B Pathway in SK-N-SH Cells. Neurochemical Research, 2021, 46, 3286-3300.	1.6	17
2303	Effectiveness of Telerehabilitation on Motor Impairments, Non-motor Symptoms and Compliance in Patients With Parkinson's Disease: A Systematic Review. Frontiers in Neurology, 2021, 12, 627999.	1.1	27
2304	Altered microstructural properties of superficial white matter in patients with Parkinsonâ€™s disease. Brain Imaging and Behavior, 2022, 16, 476-491.	1.1	2
2305	Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinsonâ€™s Disease and Levodopa-Induced Dyskinesia: A MicroPET Study. Journal of Parkinson's Disease, 2021, 11, 1257-1269.	1.5	2
2306	Nurr1 downregulation is caused by CREB inactivation in a Parkinsonâ€™s disease mouse model. Neuroscience Letters, 2021, 759, 136045.	1.0	6
2307	Cerebroventricular Microinjections of MPTP on Adult Zebrafish Induces Dopaminergic Neuronal Death, Mitochondrial Fragmentation, and Sensorimotor Impairments. Frontiers in Neuroscience, 2021, 15, 718244.	1.4	11
2308	Epidemiology of Parkinsonâ€™s Diseaseâ€”Current Understanding of Causation and Risk Factors. Series in Bioengineering, 2022, , 31-48.	0.3	0

#	Article	IF	Citations
2309	The C-terminal domain of the heavy chain of tetanus toxin prevents the oxidative and nitrosative stress induced by acute toxicity of 1-methyl-4-phenylpyridinium, a rat model of Parkinsonâ€™s disease. Neuroscience Research, 2022, 174, 36-45.	1.0	2
2311	Are Parkinsonâ€™s Disease Patients the Ideal Preclinical Population for Alzheimerâ€™s Disease Therapeutics?. Journal of Personalized Medicine, 2021, 11, 834.	1.1	3
2312	Early-Onset Parkinsonism and Early-Onset Parkinsonâ€™s Disease: A Population-Based Study (2010-2015). Journal of Parkinson's Disease, 2021, 11, 1197-1207.	1.5	29
2313	Continuous Identification of Freezing of Gait in Parkinsonâ€™s Patients Using Artificial Neural Networks and Instrumented Shoes. IEEE Transactions on Medical Robotics and Bionics, 2021, 3, 554-562.	2.1	4
2314	C9orf72-G4C2 Intermediate Repeats and Parkinsonâ€™s Disease; A Data-Driven Hypothesis. Genes, 2021, 12, 1210.	1.0	2
2316	Editorial: Integrated Motor-Cognitive Aerobic Rehabilitation Approaches in Parkinson's Disease. Frontiers in Neurology, 2021, 12, 677721.	1.1	0
2317	The Trajectory of Motor Deterioration to Death in Parkinson's Disease. Frontiers in Neurology, 2021, 12, 670567.	1.1	4
2318	Screening of LRP10 mutations in Parkinson's disease patients from Italy. Parkinsonism and Related Disorders, 2021, 89, 17-21.	1.1	5
2319	UPRmt activation protects against MPP+-induced toxicity in a cell culture model of Parkinson's disease. Biochemical and Biophysical Research Communications, 2021, 569, 17-22.	1.0	10
2320	Emerging contributions of formyl peptide receptors to neurodegenerative diseases. Biological Chemistry, 2022, 403, 27-41.	1.2	10
2321	Non-negative matrix factorization-based time-frequency feature extraction of voice signal for Parkinson's disease prediction. Computer Speech and Language, 2021, 69, 101216.	2.9	35
2322	A meta-analysis of the prevalence of the mutation LRRK2 G2019S in patients with Parkinson's disease in Africa. Gene Reports, 2021, 24, 101284.	0.4	1
2323	Neuroprotective Effect of 1,4-Naphthoquinones in an In Vitro Model of Paraquat and 6-OHDA-Induced Neurotoxicity. International Journal of Molecular Sciences, 2021, 22, 9933.	1.8	8
2324	Association of Parkinsonâ€™s disease with ischemic stroke in Korea: A nationwide longitudinal cohort study in Korea. Journal of Cerebrovascular and Endovascular Neurosurgery, 2021, 23, 233-239.	0.2	7
2325	Hypomimia May Influence the Facial Emotion Recognition Ability in Patients with Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 185-197.	1.5	7
2326	Mitofusin 2: A link between mitochondrial function and substrate metabolism?. Mitochondrion, 2021, 61, 125-137.	1.6	7
2327	Parkinson's disease and the gut: Models of an emerging relationship. Acta Biomaterialia, 2021, 132, 325-344.	4.1	15
2328	Cancer risk in Parkinson disease: An updated systematic review and metaâ€analysis. European Journal of Neurology, 2021, 28, 4219-4237.	1.7	12

#	Article	IF	Citations
2329	Mitochondrial dysfunction and apoptosis are attenuated through activation of AMPK/GSK-3Î²/PP2A pathway in Parkinson's disease. European Journal of Pharmacology, 2021, 907, 174202.	1.7	13
2330	Using novel method: Real Cepstral Discrete Cosine Transform, for detecting Parkinson from multiple system atrophy, other neurological diseases and healthy cases using voice analysis. International Journal of Speech Technology, 2022, 25, 163-172.	1.4	2
2331	Association between plasma neurofilament light chain levels and cognitive function in patients with Parkinson's disease. Journal of Neuroimmunology, 2021, 358, 577662.	1.1	15
2332	Plasma extracellular vesicles tau and Î²â€amyloid as biomarkers of cognitive dysfunction of Parkinson's disease. FASEB Journal, 2021, 35, e21895.	0.2	23
2333	Preliminary Studies on Optimization of Anti-Parkinson Drug Loaded Lipid Nanoparticles Enriched Hydrogel Formulations for Management of Parkinsonâ€™s Disease. Current Nanomedicine, 2021, 11, 112-126.	0.2	0
2334	Is there a special relationship between complex I activity and nigral neuronal loss in Parkinsonâ€™s disease? A critical reappraisal. Brain Research, 2021, 1767, 147434.	1.1	25
2335	Statistical shape analysis of putamen in early-onset Parkinsonâ€™s disease. Clinical Neurology and Neurosurgery, 2021, 209, 106936.	0.6	7
2336	Caveolin-1, a novel player in cognitive decline. Neuroscience and Biobehavioral Reviews, 2021, 129, 95-106.	2.9	15
2337	Natural products attenuate PI3K/Akt/mTOR signaling pathway: A promising strategy in regulating neurodegeneration. Phytomedicine, 2021, 91, 153664.	2.3	55
2338	PLA2G6 mutations cause motor dysfunction phenotypes of young-onset dystoniaâ€“parkinsonism type 14 and can be relieved by DHA treatment in animal models. Experimental Neurology, 2021, 346, 113863.	2.0	5
2339	Linguistic features of dysfluencies in Parkinson Disease. Journal of Fluency Disorders, 2021, 70, 105845.	0.7	5
2340	Potential applications of nanomedicine for treating Parkinson's disease. Journal of Drug Delivery Science and Technology, 2021, 66, 102793.	1.4	7
2341	Video Based Shuffling Step Detection for Parkinsonian Patients Using 3D Convolution. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2021, 29, 641-649.	2.7	9
2342	Biochemical markers for severity and risk in GBA and LRRK2 Parkinsonâ€™s disease. Journal of Neurology, 2021, 268, 1517-1525.	1.8	4
2343	Effects of concomitant use of hydrogen water and photobiomodulation on Parkinson disease. Medicine (United States), 2021, 100, e24191.	0.4	21
2344	Dietary Antioxidants and the Risk of Parkinson Disease. Neurology, 2021, 96, e895-e903.	1.5	36
2345	Exercise-Induced Autophagy and Parkinsonâ€™s Disease. , 2021, , 155-175.		0
2346	World brain day 2020 â€“ Challenges and opportunities in India. Annals of Indian Academy of Neurology, 2021, 24, 1.	0.2	4

#	Article	IF	Citations
2347	Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinsonâ€™s Disease. MDM Policy and Practice, 2021, 6, 238146832110213.	0.5	7
2348	Idiopathic Parkinson Disease : The Prevalence of in Edirne and Its Counties and Concomitant Non Motor Symptoms Determination of Feature.. Noropsikiyatri Arsivi, 2021, , .	0.2	0
2349	Comprehensive metabolic profiling of Parkinsonâ€™s disease by liquid chromatography-mass spectrometry. Molecular Neurodegeneration, 2021, 16, 4.	4.4	86
2350	Relationship between Muscular Activity and Postural Control Changes after Proprioceptive Focal Stimulation (EquistasiÂ®) in Middle-Moderate Parkinsonâ€™s Disease Patients: An Explorative Study. Sensors, 2021, 21, 560.	2.1	14
2351	Association between hyperthyroidism and risk of incident in Parkinsonâ€™s disease. Endocrine Connections, 2021, 10, 13-20.	0.8	8
2353	From the nose to the brain, nanomedicine drug delivery. , 2021, , 153-180.		2
2357	The Endocannabinoid System in the Physiology and Pathology of the Basal Ganglia. , 2008, , 423-483.		14
2358	Gene- and Cell-Based Approaches for Neurodegenerative Disease. Advances in Experimental Medicine and Biology, 2010, 671, 117-130.	0.8	10
2359	Mathematical Models of Dopamine Metabolism in Parkinsonâ€™s Disease. , 2012, , 151-171.		3
2361	DNA Methylation in Neuronal Development and Disease. RNA Technologies, 2019, , 103-140.	0.2	1
2363	The Interplay Between Proteostasis Systems and Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2020, 1233, 223-236.	0.8	6
2364	Polyphenols as an Effective Therapeutic Intervention Against Cognitive Decline During Normal and Pathological Brain Aging. Advances in Experimental Medicine and Biology, 2020, 1260, 159-174.	0.8	28
2365	Neurological Disease and Suicidal Behavior. , 2014, , 155-166.		2
2366	Parkinsonâ€™s Disease Monitoring from Phonation Biomechanics. Lecture Notes in Computer Science, 2015, , 238-248.	1.0	4
2367	Parkinsonâ€™s Disease and Aging. , 2016, , 229-255.		1
2368	The Delta-Opioid System in the Brain: A Neglected Element in Parkinsonâ€™s Disease?. , 2015, , 461-520.		2
2369	Automated Diagnosis of Parkinsonian Syndromes by Deep Sparse Filtering-Based Features. Smart Innovation, Systems and Technologies, 2016, , 249-258.	0.5	14
2370	Monitoring Parkinsonâ€™s Disease Rehabilitation from Phonation Biomechanics. Biosystems and Biorobotics, 2017, , 93-97.	0.2	1

#	Article	IF	Citations
2371	Postural Control and Somatosensory Information: Effects of Aging and Parkinsonâ€™s Disease. , 2017, , 307-322.		2
2372	Oscillatory Neural Models of the Basal Ganglia for Action Selection in Healthy and Parkinsonian Cases. Springer Series in Bio-/neuroinformatics, 2017, , 149-189.	0.1	3
2373	A 3D Convolutional Neural Network Approach for the Diagnosis of Parkinsonâ€™s Disease. Lecture Notes in Computer Science, 2017, , 324-333.	1.0	25
2374	Rough Set Data Mining Algorithms and Pursuit Eye Movement Measurements Help to Predict Symptom Development in Parkinsonâ€™s Disease. Lecture Notes in Computer Science, 2018, , 428-435.	1.0	4
2375	Parkinsonâ€™s Disease and Related Disorders. , 2019, , 59-72.		1
2376	Drug Development for Neurodegenerative Diseases. , 2015, , 183-216.		5
2377	Diagnostics and Treatments of Iron-Related CNS Diseases. Advances in Experimental Medicine and Biology, 2019, 1173, 179-194.	0.8	9
2378	Restoring dopamine levels in Parkinson's disease: neuronal pathways, agonists and antiinflammatory agents. , 2020, , 479-493.		1
2380	Parkinson Disease. , 2008, , 761-765.		1
2382	Unicompartmental knee arthroplasty in patients with Parkinson's disease. Knee, 2020, 27, 1325-1331.	0.8	3
2383	Long noncoding RNA NEAT1 knockdown inhibits MPP+-induced apoptosis, inï¬‚ammation and cytotoxicity in SK-N-SH cells by regulating miR-212-5p/RAB3IP axis. Neuroscience Letters, 2020, 731, 135060.	1.0	24
2384	Season-of-birth phenomenon in health and longevity: epidemiologic evidence and mechanistic considerations. Journal of Developmental Origins of Health and Disease, 2021, 12, 849-858.	0.7	13
2385	Nanotheranostic agents for neurodegenerative diseases. Emerging Topics in Life Sciences, 2020, 4, 645-675.	1.1	10
2386	The class II histone deacetylases as therapeutic targets for Parkinsonâ€™s disease. Neuronal Signaling, 2020, 4, NS20200001.	1.7	26
2387	Examination of Clear Speech in Parkinson Disease Using Measures of Working Vowel Space. Journal of Speech, Language, and Hearing Research, 2019, 62, 2082-2098.	0.7	19
2388	The Effect of SPEAK OUT! and The LOUD Crowd on Dysarthria Due to Parkinson's Disease. American Journal of Speech-Language Pathology, 2020, 29, 1448-1465.	0.9	19
2389	A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinsonâ€™s disease. Expert Opinion on Pharmacotherapy, 2018, 19, 937-945.	0.9	7
2394	Automatic detection of early stages of Parkinson's disease through acoustic voice analysis with mel-frequency cepstral coefficients. , 2017, , .		17

#	Article	IF	Citations
2395	Balance Rehabilitation System for Parkinson's Disease Patients based on Augmented Reality. , 2020, , .		8
2396	Sparse Adaptive Graph Convolutional Network for Leg Agility Assessment in Parkinsonâ€™s Disease. IEEE Transactions on Neural Systems and Rehabilitation Engineering, 2020, 28, 2837-2848.	2.7	29
2397	Removable prosthesis hygiene in elders with Parkinson's disease. Special Care in Dentistry, 2017, 37, 277-281.	0.4	4
2398	Automated Classification of Postural Control for Individuals With Parkinsonâ€™s Disease Using a Machine Learning Approach: A Preliminary Study. Journal of Applied Biomechanics, 2020, 36, 334-339.	0.3	4
2399	The horses are the first thought but one must not forget the zebras even if they are rare: Stiff person syndrome associated with malignant mesothelioma. BMJ Case Reports, 2014, 2014, bcr2013203455-bcr2013203455.	0.2	9
2400	COMPLEXITY OF MOLECULAR SIGNALING NETWORKS FOR VARIOUS TYPES OF CANCER AND NEUROLOGICAL DISEASES CORRELATES WITH PATIENT SURVIVABILITY. , 2014, , .		1
2401	Parkinsonâ€™s Symptoms and Caregiver Burden and Mental Health: A Cross-Cultural Mediational Model. Behavioural Neurology, 2019, 2019, 1-10.	1.1	25
2402	Ambulatory Activity Components Deteriorate Differently across Neurodegenerative Diseases: A Cross-Sectional Sensor-Based Study. Neurodegenerative Diseases, 2016, 16, 317-323.	0.8	11
2403	Human autologous iPSCâ€“derived dopaminergic progenitors restore motor function in Parkinsonâ€™s disease models. Journal of Clinical Investigation, 2020, 130, 904-920.	3.9	102
2404	Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons. Journal of Clinical Investigation, 2018, 128, 774-788.	3.9	72
2406	Diagnosing Parkinson Disease. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 1047-1063.	0.4	18
2407	Parkinson Disease. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 896-918.	0.4	34
2408	CD200 Inhibits Inflammatory Response by Promoting KATP Channel Opening in Microglia Cells in Parkinsonâ€™s Disease. Medical Science Monitor, 2016, 22, 1733-1741.	0.5	30
2409	Role of Paeonol in an Astrocyte Model of Parkinsonâ€™s Disease. Medical Science Monitor, 2017, 23, 4740-4748.	0.5	9
2410	IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian Primates. PLoS ONE, 2013, 8, e52680.	1.1	15
2411	Risk of Obstructive Sleep Apnea in Parkinsonâ€™s Disease: A Meta-Analysis. PLoS ONE, 2013, 8, e82091.	1.1	53
2412	Delirium and High Fever Are Associated with Subacute Motor Deterioration in Parkinson Disease: A Nested Case-Control Study. PLoS ONE, 2014, 9, e94944.	1.1	77
2413	Occupational Complexity and Risk of Parkinson's Disease. PLoS ONE, 2014, 9, e106676.	1.1	19

#	Article	IF	Citations
2414	Parkin (PARK 2) Mutations Are Rare in Czech Patients with Early-Onset Parkinson's Disease. PLoS ONE, 2014, 9, e107585.	1.1	14
2415	Sex Differences in Clinical Features of Early, Treated Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0133002.	1.1	48
2416	Baseline C-Reactive Protein Levels and Life Prognosis in Parkinson Disease. PLoS ONE, 2015, 10, e0134118.	1.1	51
2417	Genetic Variants in GAPDH Confer Susceptibility to Sporadic Parkinsonâ€™s Disease in a Chinese Han Population. PLoS ONE, 2015, 10, e0135425.	1.1	12
2418	Early-Life Factors and Risk of Parkinsonâ€™s Disease: A Register-Based Cohort Study. PLoS ONE, 2016, 11, e0152841.	1.1	8
2419	Rotenone Susceptibility Phenotype in Olfactory Derived Patient Cells as a Model of Idiopathic Parkinsonâ€™s Disease. PLoS ONE, 2016, 11, e0154544.	1.1	13
2420	Cognitive and Psychiatric Effects of STN versus GPi Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2016, 11, e0156721.	1.1	47
2421	Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinsonâ€™s Disease. PLoS ONE, 2016, 11, e0157755.	1.1	35
2422	Affective Disorders, Psychosis and Dementia in a Community Sample of Older Men with and without Parkinsonâ€™s Disease. PLoS ONE, 2016, 11, e0163781.	1.1	6
2423	Impact of Sjogren's syndrome on Parkinsonâ€™s disease: A nationwide case-control study. PLoS ONE, 2017, 12, e0175836.	1.1	13
2424	Differences of immune disorders between Alzheimerâ€™s disease and breast cancer based on transcriptional regulation. PLoS ONE, 2017, 12, e0180337.	1.1	10
2425	Antagonism of proteasome inhibitor-induced heme oxygenase-1 expression by PINK1 mutation. PLoS ONE, 2017, 12, e0183076.	1.1	12
2426	Mitochondrial superclusters influence age of onset of Parkinsonâ€™s disease in a gender specific manner in the Cypriot population: A case-control study. PLoS ONE, 2017, 12, e0183444.	1.1	19
2427	Recent Advances in the Development of Experimental Therapeutics for Levodopa-Induced Dyskinesia. Journal of Movement Disorders, 2019, 12, 161-165.	0.7	1
2428	A review on preventive role of ketogenic diet (KD) in CNS disorders from the gut microbiota perspective. Reviews in the Neurosciences, 2021, 32, 143-157.	1.4	35
2429	Protective Effect ofCelastrus orbiculatusThunb Extract on Cultured Neuroglial Cells Damaged by Manganese Dioxide, a Parkinsonism Inducer. Korean Journal of Clinical Laboratory Science, 2020, 52, 150-157.	0.1	1
2430	Tissue engineered organoids for neural network modelling. Advances in Tissue Engineering & Regenerative Medicine Open Access, 2017, 3, .	0.1	4
2431	Obstructive sleep apnea and Parkinson's disease: characteristics and associated factors. Arquivos De Neuro-Psiquiatria, 2019, 77, 609-616.	0.3	16

#	Article	IF	Citations
2432	Chronic pain and depression as factors associated with temporomandibular dysfunction in older adults with Parkinson's disease. Revista CEFAC: ActualizaÃ§Ã£o CientÃfica Em Fonoaudiologia, 2020, 22, .	0.2	1
2433	An Overview of Parkinson's Disease and Oxidative Stress: Herbal Scenario. Neuropathological Diseases, 2012, 1, 95-122.	0.1	1
2434	The Prevalence and Incidence of Parkinsonâ€²s Disease in South Korea: A 10-Year Nationwide Populationâ€“Based Study. Journal of the Korean Neurological Association, 2017, 35, 191-198.	0.0	31
2435	Restoration of Mitochondrial Dysfunction in 6-Hydroxydopamine Induced Parkinsonâ€™s disease: a Complete Review. , 2017, 1, 001-026.		8
2436	Health Economics and Cost of Illness in Parkinson's Disease. European Neurological Review, 2012, 8, 6.	0.5	21
2437	Integrated transcriptome expression profiling reveals a novel lncRNA associated with L-DOPA-induced dyskinesia in a rat model of Parkinsonâ€™s disease. Aging, 2020, 12, 718-739.	1.4	7
2438	Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinsonâ€™s disease models through activating the MEF2-PGC1Î± and BDNF/CREB pathways. Aging, 2020, 12, 14897-14917.	1.4	12
2439	Fbxo7 and Pink1 play a reciprocal role in regulating their protein levels. Aging, 2021, 13, 77-88.	1.4	12
2440	MicroRNA-6862 inhibition elevates sphingosine kinase 1 and protects neuronal cells from MPP+-induced apoptosis. Aging, 2021, 13, 1369-1382.	1.4	4
2441	Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson's disease. Oncotarget, 2016, 7, 54215-54227.	0.8	30
2442	Risk of lung cancer in Parkinson's disease. Oncotarget, 2016, 7, 77319-77325.	0.8	9
2443	PARK14 PLA2G6 mutants are defective in preventing rotenone-induced mitochondrial dysfunction, ROS generation and activation of mitochondrial apoptotic pathway. Oncotarget, 2017, 8, 79046-79060.	0.8	36
2444	Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose. Oncotarget, 2015, 6, 40480-40495.	0.8	11
2445	Preclinical progression of neurodegenerative diseases. Nagoya Journal of Medical Science, 2018, 80, 289-298.	0.6	32
2449	Identifying Distinctive Acoustic and Spectral Features in Parkinsonâ€™s Disease. , 0, , .		5
2450	Relationship between Perception and Production of Intonation of French in Parkinsonâ€™s Disease. , 0, , .		5
2451	MudanÃ§as Ambientais e SaÃºde PÃºblica: ObservaÃ§Ãµes sobre a trajetÃ³ria de uma fronteira agrÃcola amazÃ´nica. Fronteiras, 2015, 4, 209.	0.0	1
2452	Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinsonâ€™s Disease. Current Medicinal Chemistry, 2019, 26, 3719-3753.	1.2	45

#	Article	IF	Citations
2453	Neurodegenerative Diseases Associated with Mitochondrial DNA Mutations. Current Pharmaceutical Design, 2020, 26, 103-109.	0.9	7
2454	Liposomes: Novel Drug Delivery Approach for Targeting Parkinsonâ€™s Disease. Current Pharmaceutical Design, 2020, 26, 4721-4737.	0.9	24
2455	Can Trehalose Prevent Neurodegeneration? Insights from Experimental Studies. Current Drug Targets, 2014, 15, 551-557.	1.0	64
2456	Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines. Current Drug Targets, 2020, 21, 819-836.	1.0	7
2457	Parkinsonâ€™s Disease: A Review from Pathophysiology to Treatment. Mini-Reviews in Medicinal Chemistry, 2020, 20, 754-767.	1.1	103
2458	Gene Therapy in the Management of Parkinsonâ€™s Disease: Potential of GDNF as a Promising Therapeutic Strategy. Current Gene Therapy, 2020, 20, 207-222.	0.9	9
2459	QSAR and Molecular Docking Techniques for the Discovery of Potent Monoamine Oxidase B Inhibitors: Computer-Aided Generation of New Rasagiline Bioisosteres. Current Topics in Medicinal Chemistry, 2012, 12, 1734-1747.	1.0	37
2460	Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions. Current Topics in Medicinal Chemistry, 2015, 15, 2139-2151.	1.0	34
2461	Epigenetic Basis of Neuronal and Synaptic Plasticity. Current Topics in Medicinal Chemistry, 2017, 17, 771-793.	1.0	30
2462	Advantages of Structure-Based Drug Design Approaches in Neurological Disorders. Current Neuropharmacology, 2017, 15, 1136-1155.	1.4	23
2463	Computer-aided Drug Design Applied to Parkinson Targets. Current Neuropharmacology, 2018, 16, 865-880.	1.4	17
2464	Biopharmaceutical Potential of Selegiline Loaded Chitosan Nanoparticles in the Management of Parkinson's Disease. Current Drug Discovery Technologies, 2019, 16, 417-425.	0.6	23
2465	Does Parkinsonâ€™s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?. CNS and Neurological Disorders - Drug Targets, 2014, 13, 418-428.	0.8	50
2466	Multiple Intranigral Unilateral LPS Infusion Protocol Generates a Persistent Cognitive Impairment without Cumulative Dopaminergic Impairment. CNS and Neurological Disorders - Drug Targets, 2013, 12, 1002-1010.	0.8	5
2467	Effects of Exercise and Ferulic Acid on Alpha Synuclein and Neuroprotective Heat Shock Protein 70 in An Experimental Model of Parkinsonism Disease. CNS and Neurological Disorders - Drug Targets, 2019, 18, 156-169.	0.8	17
2468	Practical Guidance on How to Handle Levodopa/Carbidopa Intestinal Gel Therapy of Advanced PD in a Movement Disorder Clinic. The Open Neurology Journal, 2012, 6, 37-50.	0.4	21
2469	Orofacial Functions and Chewing Effiency in Elderly Patients with Parkinsonâ€™s Disease Rehabilitated with Removable Prostheses. Open Dentistry Journal, 2020, 14, 13-18.	0.2	5
2470	Quantifying Short-Term Dynamics of Parkinsonâ€™s Disease Using Self-reported Symptom Data From an Internet Social Network. Journal of Medical Internet Research, 2013, 15, e20.	2.1	34

#	Article	IF	Citations
2471	Detecting Motor Impairment in Early Parkinsonâ€™s Disease via Natural Typing Interaction With Keyboards: Validation of the neuroQWERTY Approach in an Uncontrolled At-Home Setting. Journal of Medical Internet Research, 2018, 20, e89.	2.1	46
2472	Web-Based Telemonitoring and Delivery of Caregiver Support for Patients With Parkinson Disease After Deep Brain Stimulation: Protocol. JMIR Research Protocols, 2015, 4, e30.	0.5	9
2473	Preoperative assessment and preparation of patients with neurologic disorders. Acta Chirurgica Iugoslavica, 2011, 58, 137-142.	0.0	5
2474	Current trends in etiology, prognosis and therapeutic aspects of Parkinson's disease: a review. Acta Biomedica, 2017, 88, 249-262.	0.2	20
2475	Prevalence of Parkinson Disease in Italy: a systematic review and meta-analysis. Acta Biomedica, 2020, 91, e2020088.	0.2	12
2476	Cellular models, genomic technologies and clinical practice: a synthesis of knowledge for the study of the mechanisms, diagnostics and treatment of Parkinson's disease. Genes and Cells, 2017, 12, 11-28.	0.2	4
2477	Traditional Chinese medicine-based neurorestorative therapy for Alzheimerâ€™s and Parkinsonâ€™s disease. Journal of Neurorestoratology, 2019, 7, 207-222.	1.1	16
2478	Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome. Frontiers in Bioscience - Landmark, 2007, 12, 1079.	3.0	88
2479	Functional foods and bioactive compounds: Roles in the prevention, treatment and management of neurodegenerative diseases. GSC Biological and Pharmaceutical Sciences, 2020, 11, 297-313.	0.1	7
2480	LC-MS determination of L-DOPA concentration in the leaf and flower tissues of six faba bean (Vicia) Tj ETQq1 1 0.784314 rgBT /Overlock 243.	0.3	12
2481	VALIDATION AND COMPARISON OF EQ-5D-3L AND SF-6D INSTRUMENTS IN A SPANISH PARKINSONÂ´S DISEASE POPULATION SAMPLE. Nutricion Hospitalaria, 2015, 32, 2808-21.	0.2	13
2482	Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinsonâ€™s disease: a large pragmatic randomised controlled trial (PD) Tj ETQq1 1 0.784314 rgBT /Over	0.3	60
2483	In vivo, in vitro and pharmacologic models of Parkinson's disease. Physiological Research, 2019, 68, 17-24.	0.4	40
2484	O mÃ©todo Lee Silverman para reabilitaÃ§Ã£o da fala na doenÃ§a de Parkinson. Revista Neurociencias, 2011, 19, 551-557.	0.0	3
2485	Evaluation of abnormal iron distribution in specific regions in the brains of patients with Parkinson's disease using quantitative susceptibility mapping and R2* mapping. Experimental and Therapeutic Medicine, 2020, 19, 3778-3786.	0.8	8
2486	Anticancer and Nutraceutical Potentialities of Phytase/Phytate. International Journal of Pharmacology, 2017, 13, 808-817.	0.1	7
2487	Serum Autoantibodies as Biomarkers for Parkinsons Disease: Background and Utility. AIMS Medical Science, 2015, 2, 316-327.	0.2	5
2488	The Effectiveness of Mashiningan for Constipation in Parkinson's Disease. Kampo Medicine, 2016, 67, 131-136.	0.1	2

#	Article	IF	Citations
2489	Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's		



#	Article	IF	Citations
2507	Parkinsonâ€™s disease among gardeners exposed to pesticides â€“ a Danish cohort study. Scandinavian Journal of Work, Environment and Health, 2012, 38, 65-69.	1.7	14
2508	Effects of 6-month, Multimodal Exercise Program on Clinical and Gait Parameters of Patients with Idiopathic Parkinson's Disease: A Pilot Study. ISRN Neurology, 2011, 2011, 1-7.	1.5	15
2509	Mobile Systems as a Challenge for Neurological Diseases Management â€“ The Case of Parkinson's Disease. , 0, , .		3
2510	Parkinsonâ€™s Disease and Parkin: Insights from Park2 Knockout Mice. , 0, , .		3
2511	Towards New Therapies for Parkinson's Disease. , 2011, , .		10
2512	Domperidone, Parkinson disease and sudden cardiac death: Mice and men show the way. Clinics, 2016, 70, 59-61.	0.6	13
2513	Classification of Neurodegenerative Disorders Based on Major Risk Factors Employing Machine Learning Techniques. International Journal of Engineering and Technology, 2010, 2, 350-355.	0.1	14
2514	Effective Management of Upper Limb Parkinsonian Tremor by IncobotulinumtoxinA Injections Using Sensor-based Biomechanical Patterns. Tremor and Other Hyperkinetic Movements, 2015, 5, 348.	1.1	23
2515	Pathogenic Factors and Treatment of Parkinsonâ€™s Disease. Bioprocess, 2021, 11, 67-75.	0.1	0
2516	A Hierarchical Architecture for Multisymptom Assessment of Early Parkinsonâ€™s Disease via Wearable Sensors. IEEE Transactions on Cognitive and Developmental Systems, 2022, 14, 1553-1563.	2.6	3
2517	RCSN Cell System for Identifying Dopaminergic Neurotoxicity. , 2021, , 1-16.		0
2518	Automatic Classification of Parkinson's Disease Using Best Parameters of Forward and Backward Walking. , 2021, , .		0
2519	Parkinson's disease: the nutrition perspective. Proceedings of the Nutrition Society, 2022, 81, 12-26.	0.4	9
2520	Macular microcirculation characteristics in Parkinsonâ€™s disease evaluated by OCT-Angiography: a literature review. Seminars in Ophthalmology, 2021, , 1-9.	0.8	4
2522	Dance Is an Accessible Physical Activity for People with Parkinsonâ€™s Disease. Parkinson's Disease, 2021, 2021, 1-20.	0.6	9
2523	Female Rats Are Resistant to Cognitive, Motor and Dopaminergic Deficits in the Reserpine-Induced Progressive Model of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 757714.	1.7	15
2524	The Neuroprotective Role of Polydatin: Neuropharmacological Mechanisms, Molecular Targets, Therapeutic Potentials, and Clinical Perspective. Molecules, 2021, 26, 5985.	1.7	18
2525	Use of Covariance Analysis in Electroencephalogram Reveals Abnormalities in Parkinsonâ€™s Disease. Applied Sciences (Switzerland), 2021, 11, 9633.	1.3	1

#	Article	IF	Citations
2526	Patients with Parkinsonâ€™s disease predict a lower incidence of colorectal cancer. BMC Geriatrics, 2021, 21, 564.	1.1	5
2527	Inhibitory effect of mitoquinone against the Î±-synuclein fibrillation and relevant neurotoxicity: possible role in inhibition of Parkinsonâ€™s disease. Biological Chemistry, 2022, 403, 253-263.	1.2	2
2528	Impact of Selenium on Biomarkers and Clinical Aspects Related to Ageing. A Review. Biomolecules, 2021, 11, 1478.	1.8	33
2529	Understanding Identity Negotiation of Parkinsonâ€™s Disease and Occupational Engagement Using Narrative Inquiry. Physical and Occupational Therapy in Geriatrics, 0, , 1-22.	0.2	2
2530	Parkinson HastalarÄ±nÄ±n Dikkat FonksiyonlarÄ±nÄ±n Cinsiyet AÃ§Ä±sÄ±ndan DeÄŸerlendirilmesi: Bir fMRG Ã‡alÄ±ÅŸmasÄ±. European Journal of Science and Technology, 0, , .	0.5	0
2531	Dual-task training to improve cognitive impairment and walking function in Parkinson's disease patients: A brief review. Sports Medicine and Health Science, 2021, 3, 202-206.	0.7	6
2532	Association of HLAâ€“DRB1, DQA1 and DQB1 alleles and haplotype in Parkinsonâ€™s disease from South India. Neuroscience Letters, 2021, 765, 136296.	1.0	6
2533	Parkinson's disease and microRNAs - Lessons from model organisms and human studies. Experimental Gerontology, 2021, 155, 111585.	1.2	5
2534	The Shaking Palsy - Advances in Our Understanding of Parkinson's Disease. Opticon1826, 2008, , .	0.0	0
2537	Epidemiologia descrittiva e analitica della malattia di Parkinson. , 2009, , 23-27.		1
2538	Treating Oxidative Neural Injury: Methionine Sulfoxide Reductase Therapy for Parkinsonâ€™s Disease. , 2009, , 193-206.		0
2540	ãƒ‘ãƒ¼ã‚ãƒ³ã‚½ãƒ³ç—…ã®åŽŸå› ãƒ»æ²»ç™‚ã«ã¤ã„ã¦. Juntendoì„ Igaku, 2010, 56, 438-443.	0.1	0
2543	Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients. , 2012, , 3-17.		0
2544	Single Nucleotide Polymorphisms of PARKIN Gene in Ten Indian Populations. , 2010, , 105-114.		0
2547	Symptoms of Parkinson's Disease. , 2011, , .		0
2549	Epidemiologia dei deficit neuropsicologici acquisiti dellâ€™adulto. , 2012, , 7-15.		0
2550	Sleep Disorders in Parkinsonâ€™s Disease and Parkinsonian Syndromes. , 2012, , 330-344.		0
2551	Manganese Speciation Related to Neurotoxicity in Humans. , 2012, , 569-589.		0

#	Article	IF	Citations
2552	The Impact of the BBB on the Pharmacokinetics of Drugs: Investigations by PET. , 2012, , 575-614.		0
2554	Update in Parkinsonâ€™s Disease. , 0, , .		2
2555	Brain Damage - Bridging Between Basic Research and Clinics. , 2012, , .		9
2556	Mental Disorder, Age and Adult Life Events. , 2013, , 249-278.		0
2557	Age-Related Changes in PLMS Characteristics of RLS Patients. , 2013, , 124-136.		0
2559	Basal ganglia disorders. , 2013, , 601-630.		5
2560	Can population genomics guide future therapeutic gene transfer strategies for Parkinsonâ€™s disease?. Open Journal of Genetics, 2013, 03, 19-29.	0.1	0
2562	Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients. , 2013, , 3-17.		0
2564	RCSN Cell System for Identifying Dopaminergic Neurotoxicity. , 2014, , 95-108.		0
2565	Dopamine Receptors and Levodopa-Induced Dyskinesia. , 2014, , 171-197.		0
2566	Fusion Models and â€œFusioningâ€•in Parkinsonism: Protection and Restoration by Exercise. , 2014, , 2047-2063.		0
2567	Role of Ionotropic Glutamate Receptors in Neurodegenerative and Other Disorders. , 2014, , 1039-1070.		0
2568	Voeding bij de ziekte van Parkinson. , 2014, , 89-105.		0
2570	Therapeutic Strategy for Parkinson^|^#39;s Disease. The Japanese Journal of Rehabilitation Medicine, 2014, 51, 700-704.	0.0	0
2571	Creatine supplementation and exercise as possible therapeutic treatments in Parkinsonâ€™s Disease: A review. Archives of Exercise in Health and Disease, 2014, 4, 286-298.	0.6	1
2573	Parkinsonâ€™s Disease, Nutrition, and Surgery in Context of Critical Care. , 2014, , 1-17.		0
2574	Treatments of Parkinson's disease, Epilepsy and Obsessive Compulsive Disorder with Deep Brain Stimulation. The Neuroscience Journal of Shefaye Khatam, 2014, 2, 95-100.	0.4	2
2575	Novel sEMG parameters for early diagnostics of neurological diseases and aging. Journal of Biomedical Technologies, 2014, , 2-9.	0.0	0

#	Article	IF	Citations
2576	Correlation of the Neuropsychological Screening Battery (NSB) and Neuroanatomy for the Parkinson's Disease with Mild Cognitive Impairment by Using the Analysis of Cerebral Cortex Thickness in the Brain MRI. Journal of the Korean Society of Radiology, 2014, 8, 163-170.	0.0	0
2577	Sleep Disorders in Neurodegenerative Disorders. Su'myeon, 2014, 11, 1-4.	0.2	0
2581	Sailing Stormy Seas: The Illness Experience of Persons with Parkinson's Disease. Qualitative Report, 0, , .	0.1	3
2583	Use of Induced Pluripotent Stem Cells in Aging Research. , 2015, , 67-78.		0
2585	Parkinsonâ€™s Disease, Nutrition and Surgery in Context of Critical Care. , 2015, , 713-726.		0
2586	Public Mental Health. , 2015, , 205-221.		2
2587	Poverty and Slowness of Voluntary Movement. , 2016, , 1-47.		0
2588	The Correlation between Frontal Assessment Battery and Unified Parkinsonâ€™s Disease Rating Scale in the Early Stages of Parkinson's Disease. The Neuroscience Journal of Shefaye Khatam, 2015, 3, 24-30.	0.4	0
2589	Biomimetic Materials: Polymeric Substrates for Axonal Regeneration. , 0, , 913-931.		0
2590	Motor Patterns Recognition in Parkinsonâ€™s Disease. , 2016, , 1-16.		0
2591	Iatrogeny of Alzheimerâ€²s disease: A view point. Journal of Craniovertebral Junction and Spine, 2016, 7, 4.	0.4	0
2592	Ion-Catalyzed Reactive Oxygen Species in Sporadic Models of Parkinsonâ€™s Disease. , 2016, , 75-113.		0
2593	Intuitive Navigation in Computer Applications for People with Parkinsonâ€™s. Journal of Biomusical Engineering, 2016, 04, .	0.0	0
2595	Investigation on the Removal of Entacapone From Contaminated Water Using Magnetic-Activated Carbon. Journal of Sabzevar University of Medical Sciences, 2016, 23, 458-467.	0.1	0
2596	Case Report of Physical Therapy using Proprioceptive Neuromuscular Facilitation for Activity Improvement in a Patient with Parkinson's Disease. PNF and Movement, 2016, 14, 219-229.	0.0	0
2598	Movement is the Song of the Body: Reflections on the Evolution of Rhythm and Music and its Possible Significance for the Treatment of Parkinson's Disease. Evolutionary Studies in Imaginative Culture, 2017, 1, 73.	0.1	1
2600	Sudden Unexpected Death in Parkinsonâ€™s Disease and the Pharmacological Modulation of the Ca2+/cAMP Signaling Interaction: A Shot of Good News. Brain Disorders & Therapy, 2017, 06, .	0.1	0
2602	Could Clinical Use of Stimulant Medications Increase Risk for Parkinson's Disease or Other Neurological Sequelae? A Review of the Evidence. Journal of Pharmacology & Clinical Research, 2017, 3, .	0.1	1

#	Article	IF	Citations
2603	Prevalence and Predisposing Factors of Parkinson Disease: A Community-Based Study In Barangay Mangilag Sur, Candelaria, Quezon: A Research Protocol. Journal of Medicine University of Santo Tomas, 2017, 1, 109-119.	0.0	1
2606	On Heredity Factors of Parkinsonâ€™s Disease: A Parametric and Bayesian Analysis. Advances in Parkinson S Disease, 2018, 07, 31-42.	0.2	0
2607	The effect of the accompanying parkinsonism on rehabilitation in stroke patients. Sisli Etfal Hastanesi Tip Bulteni, 2018, 52, 64-69.	0.1	1
2609	Motor Patterns Recognition in Parkinsonâ€™s Disease. , 2018, , 1237-1252.		0
2610	Central Pain in Parkinsonâ€™s Disease: A Case Report. Case Reports in Clinical Medicine, 2018, 07, 297-305.	0.1	0
2611	Mild Cognitive Impairment in Parkinson Disease: A Neuropsychological Study of 25 Patients. World Journal of Neuroscience, 2018, 08, 470-479.	0.1	0
2612	Care of Patients with Neurologic Disease. , 2018, , 375-386.		0
2614	ParkinsonÂ: la rÃ©Ã©ducation virtuelle et la physiothÃ©rapie classique ont un effet comparable. Kinesitherapie, 2018, 18, 19-20.	0.0	0
2615	GLP-1 receptor agonists for Parkinson's disease. The Cochrane Library, 0, , .	1.5	4
2617	Slurring of Speech and Lip Paresthesia: Symptoms of Levodopa End of Dose Wearing Off in Parkinson's Disease

. Cureus, 2018, 10, e2986. | 0.2 | 0 |
2619	Optimizing Parkinsonâ€™s disease Diagnosis: A Clinical Review Magnetic Resonance Imaging (MRI). Neuroscience and Neurological Surgery, 2018, 2, 01-02.	1.0	0
2623	Motor Symptoms of Parkinsonâ€™s Disease â€“ A Review Literature. Neurophysiology and Rehabilitation, 2018, , 38-41.	0.0	1
2624	Indications for Deep Brain Stimulation Therapy in Parkinsonâ€™s Disease. , 2019, , 3-19.		0
2625	Parkinsonian gait characterization from regional kinematic trajectories. , 2018, , .		3
2626	Parkinsonâ€™s Disease Diagnosis by fMRI Images Using MFCC Feature Extraction. Communications in Computer and Information Science, 2019, , 152-160.	0.4	0
2627	A Preliminary Study on Parkinsonâ€™s Disease with Regularized Logistic Regression Method. Open Journal of Social Sciences, 2019, 07, 126-132.	0.1	0
2628	Mitochondrial Dysfunction in Aging and Neurodegeneration. Advances in Medical Diagnosis, Treatment, and Care, 2019, , 76-101.	0.1	0
2629	Environmental Aspects of Alzheimer's and Parkinson's Diseases Neuropathologies. Advances in Environmental Engineering and Green Technologies Book Series, 2019, , 236-265.	0.3	1

#	Article	IF	Citations
2630	Derivation and Analysis of Dynamic Handwriting Features as Clinical Markers of Parkinsonâ€™s Disease. , 2019, , .		2
2631	Pain and Parkinson disease in the elderly. Revista Neurociencias, 2009, 17, 220-230.	0.0	1
2633	MODELING OF PARKINSONâ€™S DISEASE USING ENVIRONMENTAL NEUROTOXINS (REVIEW). Toxicological Review, 2019, , 9-15.	0.2	1
2637	Altered communication in Parkinsonâ€™s disease, its role in stigmatisation of the condition and effect on social relationships. Progress in Health Sciences, 2019, 1, 147-155.	0.1	1
2638	Parkinsonism and Related Disorders. , 0, , .		0
2639	Differences in male and female lower extremity joint kinematics during walking. Rehabilitacja Medyczna, 2019, 23, 39-46.	0.2	0
2640	Effects of aging on speech perception of individuals with and without Parkinson disease. Clinical Archives of Communication Disorders, 2019, 4, 72-82.	0.3	0
2642	The trend of incidence and burden of neurological disease in Iran between 1990 and 2017: Based on global burden of disease estimations. Current Journal of Neurology, 0, , .	0.0	0
2643	Influence of sensory integration training on postural instability in elderly with parkinsonian disease following stereotactic surgery. Bulletin of Faculty of Physical Therapy, 2019, 24, 90-98.	0.2	0
2644	Parkinson HastalarÄ±nda Halusinasyon ve Risk FaktÃ¶rleri. KÄ±rÄ±kkale Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , 388-394.	0.0	0
2645	Support Vector Machine Integrated with SASS-SM Approach for Parkinsonâ€™s Diseases Classification. Advances in Science, Technology and Engineering Systems, 2020, 5, 1125-1131.	0.4	0
2646	Sources of Intraspeaker Variation in Parkinsonian Speech Related to Speaking Style. Communications in Computer and Information Science, 2020, , 24-41.	0.4	0
2647	Dopaminergic Neuron-Related Stem Cells. Learning Materials in Biosciences, 2020, , 173-187.	0.2	0
2652	U-133, a Chaperone Inducer, Eliminates Sleep Disturbances in a Model of the Preclinical Stage of Parkinsonâ€™s Disease in Aged Rats. Advances in Gerontology, 2020, 10, 254-259.	0.1	4
2654	Trends in Mortality From Parkinson Disease in the United States, 1999â€“2019. Neurology, 2021, 97, e1986-e1993.	1.5	18
2655	An ensembleâ€based feature selection framework for early detection of Parkinson's disease based on feature correlation analysis. Mathematical Methods in the Applied Sciences, 0, , .	1.2	0
2657	Multimodal classification of Parkinsonâ€™s disease using delay differential analysis. , 2020, , .		2
2658	Neuroprotective Role of Diosmin on Rotenone Induced Neurotoxicity in SH-SY5Y Neuroblastoma Cells. Bioscience Biotechnology Research Communications, 2020, 13, 1782-1787.	0.1	1

#	Article	IF	Citations
2659	GC-MS Based Metabolic Profiling of Parkinsonâ€™s Disease with Glutathione S-transferase M1 and T1 Polymorphism in Tunisian Patients. Combinatorial Chemistry and High Throughput Screening, 2020, 23, 1041-1048.	0.6	5
2660	Ameliorative effects of flavonoids and polyketides on the rotenone induced Drosophila model of Parkinsonâ€™s disease. NeuroToxicology, 2020, 81, 209-215.	1.4	13
2661	Contribution of Application of Deep Learning Approaches on Biomedical Data in the Diagnosis of Neurological Disorders: A Review on Recent Findings. Communications in Computer and Information Science, 2020, , 87-97.	0.4	3
2662	Schlaf-wach-StÃ¶rungen bei Alzheimer- und Parkinson-Krankheit. , 2020, , 417-430.		0
2663	Serotonin in Parkinson's disease. Handbook of Behavioral Neuroscience, 2020, 31, 969-979.	0.7	2
2664	Intracerebroventricular administration of dopamine in Parkinson's disease: treatment of motor fluctuations and dyskinesia. , 2020, , 511-526.		0
2665	Identifying robust markers of Parkinsonâ€™s disease in typing behaviour using a CNN-LSTM network. , 2020, , .		6
2666	Progression of motor symptoms in Parkinson's disease. , 2020, , 267-281.		0
2667	Acoustic characteristics of Italian Parkinsonian speech: a study on early-stage patients. , 0, , .		1
2669	Environmental and genetic risk factors for Parkinson's disease. , 2020, , 57-71.		0
2670	A Glance into Regional Parkinsonâ€™s Disease Characteristics: What Differs from Northwest to Southeast of Turkey?. Neuroscience and Medicine, 2020, 11, 63-73.	0.2	0
2671	Predicting UPDRS Scores in Parkinsonâ€™s Disease Using Voice Signals: A Deep Learning/Transfer-Learning-Based Approach. Communications in Computer and Information Science, 2020, , 100-123.	0.4	1
2672	Cognitive and language deficits in persons with Parkinson's disease. Specijalna Edukacija I Rehabilitacija, 2021, 20, 203-218.	0.3	0
2673	Quantitative analysis of cerebrovascular characteristics of Parkinsonâ€™s disease treated with acupuncture based on magnetic resonance angiography. Brain Science Advances, 2021, 7, 141-154.	0.3	2
2674	Parkinson's Disease Classification using Quantile Transformation and RFE. , 2021, , .		2
2675	Diet Quality and Risk of Parkinsonâ€™s Disease: The Rotterdam Study. Nutrients, 2021, 13, 3970.	1.7	15
2676	Evaluation of Patients with Parkinsonâ€™s Disease in Intensive Care Units: A Cohort Study. Parkinson's Disease, 2021, 2021, 1-7.	0.6	4
2677	Does Caffeine Consumption Affect the Symptoms of Parkinsonâ€™s Disease? A Systematic Review of Clinical Trials. Archives of Neuroscience, 2021, 8, .	0.1	2

#	Article	IF	Citations
2678	Unraveling the Neuroprotective Effect of Tinospora cordifolia in a Parkinsonian Mouse Model through the Proteomics Approach. ACS Chemical Neuroscience, 2021, 12, 4319-4335.	1.7	18
2679	Mild repetitive head impacts alter perivascular flow in the midbrain dopaminergic system in awake rats. Brain Communications, 2021, 3, fcab265.	1.5	7
2681	Gender and Age Difference in Clinical Features and severity of Parkinsonâ€™s Disease: A Cross-Sectional Study in Southern Morocco. Archives of Neuroscience, 2020, 7, .	0.1	2
2682	Alpha-synucleinâ€™ in PreNAC(46-56) Fibril BÃ¶lÃ¼tÃ¼nÃ¼n MolekÃ¼ler Dinamik SimÃ¼lasyon YÃ¶ntemi ile Konformasyonel DeÄŸerlendirmesi. KahramanmaraÅŸ SÃ¼tÃ§Ã¼ Ä°mam Ãœniversitesi TarÄ±m Ve DoÄŸa Dergisi, 0, , .	0.2	1
2683	Dermatological Manifestations of Parkinson's Disease: Clues for Diagnosis. Cureus, 2020, 12, e10836.	0.2	1
2684	The Social Value of Improvement in Activities of Daily Living among the Advanced Parkinsonâ€™s Disease Population. Forum for Health Economics and Policy, 2021, 23, 1-23.	0.2	2
2685	Amyotrophic lateral sclerosis and frontotemporal lobar degeneration. , 2014, , 209-248.		3
2688	Molecular chaperones in Parkinson's disease--present and future. Journal of Parkinson's Disease, 2011, 1, 299-320.	1.5	29
2689	Aging, Angiotensin system and dopaminergic degeneration in the substantia nigra. , 2011, 2, 257-74.		23
2690	Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire. American Journal of Neurodegenerative Disease, 2012, 1, 160-7.	0.1	24
2691	The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. American Journal of Neurodegenerative Disease, 2013, 2, 29-34.	0.1	35
2692	Association between serum biochemical levels, related to bone metabolism and Parkinson's disease. Journal of Research in Medical Sciences, 2013, 18, S39-42.	0.4	10
2693	Demographic study of parkinson's disease in Iran: Data on 1656 cases. Iranian Journal of Neurology, 2011, 10, 19-21.	0.5	5
2694	Parkinsonism associated with multiple sclerosis: A report of eight new cases and a review on the literature. Iranian Journal of Neurology, 2014, 13, 88-93.	0.5	6
2695	Bone marrow-derived mesenchymal stem cells increase dopamine synthesis in the injured striatum. Neural Regeneration Research, 2012, 7, 2653-62.	1.6	2
2696	Treatment of neurological and psychiatric disorders with deep brain stimulation; raising hopes and future challenges. Basic and Clinical Neuroscience, 2013, 4, 266-70.	0.3	10
2697	Stem cell-based approach for the treatment of Parkinson's disease. Medical Journal of the Islamic Republic of Iran, 2015, 29, 168.	0.9	39
2698	Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. P and T, 2015, 40, 504-32.	1.0	153

#	Article	IF	Citations
2699	Vascular risk factors aggravate the progression of Parkinson's disease: a five-year follow-up study in Chinese patients. International Journal of Clinical and Experimental Medicine, 2015, 8, 9897-903.	1.3	5
2701	Genetic association of cyclooxygenase-2 gene polymorphisms with Parkinson's disease susceptibility in Chinese Han population. International Journal of Clinical and Experimental Pathology, 2015, 8, 13495-9.	0.5	2
2702	Combining Human Disease Genetics and Mouse Model Phenotypes towards Drug Repositioning for Parkinson's disease. AMIA ... Annual Symposium proceedings, 2015, 2015, 1851-60.	0.2	14
2704	Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology. Yale Journal of Biology and Medicine, 2016, 89, 37-47.	0.2	88
2705	MicroRNA-7 inhibits neuronal apoptosis in a cellular Parkinson's disease model by targeting Bax and Sirt2. American Journal of Translational Research (discontinued), 2016, 8, 993-1004.	0.0	46
2707	The association between fear of falling and quality of life for balance impairments based on hip and ankle strategies in the drug On- and Off-phase of patients with idiopathic Parkinson' disease. Medical Journal of the Islamic Republic of Iran, 2016, 30, 453.	0.9	5
2708	Demographic features and clinical characteristics of patients with Parkinson's disease in Isfahan, Iran. Iranian Journal of Neurology, 2018, 17, 6-10.	0.5	1
2710	The trend of incidence and burden of neurological disease in Iran between 1990 and 2017: Based on global burden of disease estimations. Iranian Journal of Neurology, 2019, 18, 134-142.	0.5	3
2711	Comparison of the calcium-related factors in Parkinson's disease patients with healthy individuals. Caspian Journal of Internal Medicine, 2020, 11, 28-33.	0.1	1
2712	attenuates microglia mediated neuroinflammation and MPTP-induced behavioral and oxidative changes in Parkinson's disease mouse model. EXCLI Journal, 2021, 20, 835-850.	0.5	4
2713	Awareness, Treatment, and Rehabilitation of Elderly with Parkinson's Disease - China, 2015-2017. China CDC Weekly, 2020, 2, 241-244.	1.0	0
2714	Monoamine oxidase A and B inhibitory activities of 3,5-diphenyl-1,2,4-triazole substituted [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives. Bioorganic Chemistry, 2022, 118, 105493.	2.0	8
2715	In-silicoPrediction of the Beta-carboline Alkaloids Harmine and Harmaline as Potent Drug Candidates for the Treatment of Parkinsonâ€™s disease. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2021, 20, 250-263.	1.1	6
2716	Clinical Association between Gout and Parkinsonâ€™s Disease: A Nationwide Population-Based Cohort Study in Korea. Medicina (Lithuania), 2021, 57, 1292.	0.8	8
2717	Respiratory disorders of Parkinsonâ€™s disease. Journal of Neurophysiology, 2022, 127, 1-15.	0.9	11
2718	Cost-Effectiveness of Apomorphine Sublingual Film as an "On-Demand" Treatment for "OFF" Episodes in Patients with Parkinson's Disease. Journal of Health Economics and Outcomes Research, 2021, 8, 82-92.	0.6	4
2719	Replacement of Chalcone-Ethers with Chalcone-Thioethers as Potent and Highly Selective Monoamine Oxidase-B Inhibitors and Their Protein-Ligand Interactions. Pharmaceuticals, 2021, 14, 1148.	1.7	7
2720	Cholinesterase inhibitors for gait, balance, and fall in Parkinson disease: a meta-analysis. Npj Parkinson's Disease, 2021, 7, 103.	2.5	11

#	Article	IF	Citations
2721	Review of Metabolomics-Based Biomarker Research for Parkinsonâ€™s Disease. Molecular Neurobiology, 2022, 59, 1041-1057.	1.9	13
2722	Impact of Î±â€synuclein spreading on the nigrostriatal dopaminergic pathway depends on the onset of the pathology. Brain Pathology, 2022, 32, e13036.	2.1	12
2723	Risk factors for the development of degenerative cervical myelopathy: a review of the literature. Neurosurgical Review, 2022, 45, 1675-1689.	1.2	18
2724	Association between plasminogen activator inhibitor-1 gene polymorphisms and susceptibility to Parkinsonâ€™s disease in Chinese patients. Acta Neurologica Belgica, 2021, , 1.	0.5	5
2725	Feature Selection Using Multiple Ranks with Majority Vote-Based Relative Aggregate Scoring Model for Parkinson Dataset. Lecture Notes in Networks and Systems, 2022, , 1-19.	0.5	2
2726	Deconstructing the molecular genetics behind the PINK1/Parkin axis in Parkinsonâ€™s disease using Drosophila melanogaster as a model organism. Egyptian Journal of Medical Human Genetics, 2021, 22, .	0.5	3
2727	FBXO7 triggers caspase 8-mediated proteolysis of the transcription factor FOXO4 and exacerbates neuronal cytotoxicity. Journal of Biological Chemistry, 2021, 297, 101426.	1.6	6
2728	Insights on Genetic and Environmental Factors in Parkinsonâ€™s Disease from a Regional Swedish Case-Control Cohort. Journal of Parkinson's Disease, 2022, 12, 153-171.	1.5	5
2729	Prevalence of Parkinsonâ€™s Disease in Adults Aged 65 Years and Older in China: A Multicenter Population-Based Survey. Neuroepidemiology, 2022, 56, 50-58.	1.1	9
2730	Cognition, motor symptoms, and glycolipid metabolism in Parkinsonâ€™s disease with depressive symptoms. Journal of Neural Transmission, 2022, 129, 563-573.	1.4	5
2731	Antioxidative role of Traditional Chinese Medicine in Parkinson's disease. Journal of Ethnopharmacology, 2022, 285, 114821.	2.0	16
2732	Can detection and prediction models for Alzheimerâ€™s Disease be applied to Prodromal Parkinsonâ€™s Disease using explainable artificial intelligence? A brief report on Digital Neuro Signatures.. Open Research Europe, 0, 1, 146.	2.0	0
2733	Pluripotent Stem Cell Derived Neurons as In Vitro Models for Studying Autosomal Recessive Parkinsonâ€™s Disease (ARPD): PLA2G6 and Other Gene Loci. Advances in Experimental Medicine and Biology, 2021, , 115-133.	0.8	3
2734	Validation and Reliability of the Japanese Version of the Modified Parkinson Activity Scale (M-PAS). Progress in Rehabilitation Medicine, 2021, 6, n/a.	0.3	2
2735	Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in <scp>GBA</scp> Mutation Carriers. Annals of Neurology, 2022, 91, 424-435.	2.8	46
2736	Dopaminergic neuronal death in the substantia nigra associates with change in serum levels of TNF-Î± and IL-1Î²; evidence from early experimental model of Parkinsonâ€™s disease. Neurological Research, 2022, 44, 544-553.	0.6	4
2737	WATSU therapy for individuals with Parkinson's disease to improve quality of sleep and quality of life: A randomized controlled study. Complementary Therapies in Clinical Practice, 2022, 46, 101523.	0.7	1
2738	Intracellular hydrogen peroxide produced by 6-hydroxydopamine is a trigger for nigral dopaminergic degeneration of rats via rapid influx of extracellular Zn2+. NeuroToxicology, 2022, 89, 1-8.	1.4	5

#	Article	IF	Citations
2739	Beta, gamma and High-Frequency Oscillation characterization for targeting in Deep Brain Stimulation procedures. Tecno LÃ³gicas, 2020, 23, 11-32.	0.1	0
2740	Gait Modelling of People with Parkinsonâ€™s Disease. , 2020, , .		1
2741	Estimation of Orofacial Kinematics in Parkinsonâ€™s Disease: Comparison of 2D and 3D Markerless Systems for Motion Tracking. , 2020, , .		4
2742	Parkinsonâ€™s Disease: Possible Mechanisms for Nutritional Approaches. Journal of Restorative Medicine, 2020, 10, .	0.7	0
2743	AdaBoost for Parkinson's Disease Detection using Robust Scaler and SFS from Acoustic Features. , 2021, , .		2
2744	Genome Editing Technology for the Study and Correction of Neurodegenerative Diseases. Neurochemical Journal, 2021, 15, 339-352.	0.2	1
2745	Pathogenic Mechanisms of Cytosolic and Membrane-Enriched Î±-Synuclein Converge on Fatty Acid Homeostasis. Journal of Neuroscience, 2022, 42, 2116-2130.	1.7	7
2746	Environmental Impact on the Epigenetic Mechanisms Underlying Parkinsonâ€™s Disease Pathogenesis: A Narrative Review. Brain Sciences, 2022, 12, 175.	1.1	31
2747	Compensation in Time and Space: Prominence Marking in Aging and Disease. Languages, 2022, 7, 21.	0.3	1
2748	New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders. International Journal of Molecular Sciences, 2022, 23, 975.	1.8	32
2749	Neural Stem/Progenitor Cell Transplantation in Parkinsonâ€™s Rodent Animals: A Meta-Analysis and Systematic Review. Stem Cells Translational Medicine, 2022, 11, 383-393.	1.6	3
2750	Analyzing the Effects of Parameters for Tremor Modulation via Phase-Locked Electrical Stimulation on a Peripheral Nerve. Journal of Personalized Medicine, 2022, 12, 76.	1.1	2
2751	High-Throughput Sequencing Haplotype Analysis Indicates in LRRK2 Gene a Potential Risk Factor for Endemic Parkinsonism in Southeastern Moravia, Czech Republic. Life, 2022, 12, 121.	1.1	1
2752	Effects of Computer-Based Cognitive Rehabilitation on Attention, Executive Functions, and Quality of Life in Patients with Parkinsonâ€™s Disease: A Randomized, Controlled, Single-Blinded Pilot Study. Dementia and Geriatric Cognitive Disorders, 2021, 50, 519-528.	0.7	1
2753	Association between Mediterranean diet and Parkinsonâ€™s disease in adults: A systematic review and meta-analysis of cohort studies. Mediterranean Journal of Nutrition and Metabolism, 2022, , 1-10.	0.2	1
2754	Novel approaches for quantifying beta synchrony in Parkinsonâ€™s disease. Experimental Brain Research, 2022, 240, 991-1004.	0.7	7
2755	Mitochondrial DNA homeostasis impairment and dopaminergic dysfunction: A trembling balance. Ageing Research Reviews, 2022, 76, 101578.	5.0	15
2756	Dopaminergic imaging in degenerative parkinsonisms, an established clinical diagnostic tool. Journal of Neurochemistry, 2023, 164, 346-363.	2.1	10

#	Article	IF	Citations
2757	Prevalence and Cost of Care for Parkinsonâ€™s Disease in Luxembourg: An Analysis of National Healthcare Insurance Data. PharmacoEconomics - Open, 2022, , .	0.9	0
2758	The Signaling and Pharmacology of the Dopamine D1 Receptor. Frontiers in Cellular Neuroscience, 2021, 15, 806618.	1.8	14
2759	A Transcriptome Analysis of mRNAs and Long Non-Coding RNAs in Patients with Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 1535.	1.8	13
2760	Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinsonâ€™s disease. Scientific Reports, 2022, 12, 526.	1.6	18
2761	Endoplasmic Reticulum Stress and miRNA Impairment in Aging and Age-Related Diseases. Frontiers in Aging, 2022, 2, .	1.2	3
2762	Target Selection for Magnetic Resonanceâ€Guided Focused Ultrasound in the Treatment of Parkinson's Disease. Journal of Magnetic Resonance Imaging, 2022, 56, 35-44.	1.9	4
2763	Can detection and prediction models for Alzheimerâ€™s Disease be applied to Prodromal Parkinsonâ€™s Disease using explainable artificial intelligence? A brief report on Digital Neuro Signatures.. Open Research Europe, 0, 1, 146.	2.0	2
2765	miR-126-5p Targets SP1 to Inhibit the Progression of Parkinsonâ€™s Disease. European Neurology, 2022, 85, 235-244.	0.6	6
2766	Direct neuronal reprogramming: Fast forward from new concepts toward therapeutic approaches. Neuron, 2022, 110, 366-393.	3.8	45
2767	Transcranial Direct Current Stimulation (tDCS) as a Useful Rehabilitation Strategy to Improve Cognition in Patients With Alzheimer's Disease and Parkinson's Disease: An Updated Systematic Review of Randomized Controlled Trials. Frontiers in Neurology, 2021, 12, 798191.	1.1	13
2768	Modulation of histone deacetylase, the ubiquitin proteasome system, and autophagy underlies the neuroprotective effects of venlafaxine in a rotenone-induced Parkinson's disease model in rats. Chemico-Biological Interactions, 2022, 354, 109841.	1.7	18
2769	Efficacy of electroconvulsive therapy in Parkinsonâ€™s disease: A clinical trial. Neuroscience Letters, 2022, 772, 136449.	1.0	1
2770	Voice characteristics from isolated rapid eye movement sleep behavior disorder to early Parkinson's disease. Parkinsonism and Related Disorders, 2022, 95, 86-91.	1.1	14
2771	Sleep alterations are related to cognitive symptoms in Parkinson's disease: A 24-hour ambulatory polygraphic EEG study. International Journal of Psychophysiology, 2022, 173, 93-103.	0.5	6
2772	Increased homocysteine levels correlate with cortical structural damage in Parkinson's disease. Journal of the Neurological Sciences, 2022, 434, 120148.	0.3	13
2773	Sudden unexpected death in Parkinson's disease: Insights from clinical practice. Clinics, 2022, 77, 100001.	0.6	5
2774	Alpha-Lipoic Acid Attenuates MPTP/MPP+-Induced Neurotoxicity: Roles of SIRT1-Dependent PGC-1Î± Signaling Pathways. Neurotoxicity Research, 2022, 40, 410-419.	1.3	5
2775	Parkinson's disease: The prevalence of the LRRK2-G2019S mutation among the population of the South-West of Morocco. Gene Reports, 2022, 27, 101547.	0.4	2

#	Article	IF	Citations
2776	Prussian Blue Nanozyme as a Pyroptosis Inhibitor Alleviates Neurodegeneration. Advanced Materials, 2022, 34, e2106723.	11.1	91
2777	Adenosine A1 receptor ligands bind to Î±-synuclein: implications for Î±-synuclein misfolding and Î±-synucleinopathy in Parkinsonâ€™s disease. Translational Neurodegeneration, 2022, 11, 9.	3.6	4
2778	A cross-sectional survey of genetic counselors providing carrier screening regardingÂGBAÂvariants and Parkinson disease susceptibility. Journal of Assisted Reproduction and Genetics, 2022, 39, 747.	1.2	0
2779	Akkermansia muciniphila induces mitochondrial calcium overload and Î± -synuclein aggregation in an enteroendocrine cell line. IScience, 2022, 25, 103908.	1.9	35
2780	Modeling the cellular fate of alpha-synuclein aggregates: A pathway to pathology. Current Opinion in Neurobiology, 2022, 72, 171-177.	2.0	5
2781	Thymol protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinsonâ€™s disease via inhibiting oxidative stress. BMC Complementary Medicine and Therapies, 2022, 22, 40.	1.2	7
2782	Spotting-based differentiation of functional dopaminergic progenitors from human pluripotent stem cells. Nature Protocols, 2022, , .	5.5	6
2783	Tremor-related feature engineering for machine learning based Parkinsonâ€™s disease diagnostics. Biomedical Signal Processing and Control, 2022, 75, 103551.	3.5	13
2784	Ocular features of patients with Parkinson's disease examined at a Neuro-Optometry Clinic in a tertiary eye care center. Indian Journal of Ophthalmology, 2022, 70, 958.	0.5	3
2787	Management of psychiatric disorders in patients with parkinson's diseases. Indian Journal of Psychiatry, 2022, 64, 330.	0.4	1
2788	Gutâ€“Brain Cross Talk: Microbiome and Micronutrients. , 2022, , 33-47.		0
2789	Longitudinal Assessment of Behaviour and Associated Bio-Markers Following Chronic Consumption of Î²-Sitosterol Î²-D-Glucoside in Rats: A Putative Model of Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2022, 16, 810148.	1.4	1
2790	Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease. Frontiers in Neurology, 2022, 13, 788427.	1.1	18
2791	LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease. Translational Neurodegeneration, 2022, 11, 10.	3.6	13
2792	Electromyographic measures of asymmetric muscle control of swallowing in Parkinsonâ€™s disease. PLoS ONE, 2022, 17, e0262424.	1.1	0
2793	Total shoulder arthroplasty for osteoarthritis in patients with Parkinson's disease: a matched comparison of 90-day adverse events and 5-year implant survival. Journal of Shoulder and Elbow Surgery, 2022, 31, 1436-1441.	1.2	11
2794	Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinsonâ€™s Disease. Medicinal Chemistry, 2022, 18, 757-771.	0.7	3
2795	Prodrug Therapies for Infectious and Neurodegenerative Diseases. Pharmaceutics, 2022, 14, 518.	2.0	3

#	Article	IF	Citations
2796	Peripheral Immune Cell Numbers and C-Reactive Protein in Parkinsonâ€™s Disease: Results from a Population-Based Study. Journal of Parkinson's Disease, 2022, 12, 667-678.	1.5	8
2797	Long-Term Motor Cortical Electrical Stimulation Ameliorates 6-Hydroxydopamine-Induced Motor Dysfunctions and Exerts Neuroprotective Effects in a Rat Model of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2022, 14, 848380.	1.7	2
2798	Review of the recruitment process for a large investigator-initiated trial in early Parkinsonâ€™s disease. Trials, 2022, 23, 141.	0.7	0
2799	Effects of Cannabis in Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 495-508.	1.5	17
2800	Global Characterization of Peripheral B Cells in Parkinsonâ€™s Disease by Single-Cell RNA and BCR Sequencing. Frontiers in Immunology, 2022, 13, 814239.	2.2	22
2801	Retinal Microvascular Density Was Associated With the Clinical Progression of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2022, 14, 818597.	1.7	10
2802	A Comprehensive Review on Preclinical Evidence-based Neuroprotective Potential of Bacopa monnieri against Parkinson's Disease. Current Drug Targets, 2022, 23, 889-901.	1.0	4
2803	Relationships of Nutritional Factors and Agrochemical Exposure with Parkinsonâ€™s Disease in the Province of Brescia, Italy. International Journal of Environmental Research and Public Health, 2022, 19, 3309.	1.2	4
2804	Association between Residential Greenness and Incidence of Parkinsonâ€™s Disease: A Population-Based Cohort Study in South Korea. International Journal of Environmental Research and Public Health, 2022, 19, 3491.	1.2	2
2805	Does the Expression and Epigenetics of Genes Involved in Monogenic Forms of Parkinsonâ€™s Disease Influence Sporadic Forms?. Genes, 2022, 13, 479.	1.0	6
2806	The Relationship between Parkinsonâ€™s Disease and Acute Myocardial Infarction in Korea : A Nationwide Longitudinal Cohort Study. Journal of Korean Neurosurgical Society, 2022, 65, 507-513.	0.5	7
2807	Anti-Apoptotic Effects Of Valproic Acid Treatment On Dopaminergic Neuronal Loss In A 6-Hydroxydopamine Model Of Parkinsonâ€™s Disease In Rats. Anadolu KliniÄŸi TÄ±p Bilimleri Dergisi, 0, , .	0.1	0
2808	The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinsonâ€™s Disease in England. Pharmacoeconomics, 2022, 40, 559-574.	1.7	5
2809	The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity. Journal of Cell Biology, 2022, 221, .	2.3	8
2810	The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the <scp>United States</scp> medicare database. Pharmacoepidemiology and Drug Safety, 2022, , .	0.9	4
2811	Editorial: Genetic and Epigenetic Mechanisms of Parkinson's Disease. Frontiers in Neuroscience, 2022, 16, 842709.	1.4	2
2812	Non-invasive electrical stimulation of peripheral nerves for the management of tremor. Journal of the Neurological Sciences, 2022, 435, 120195.	0.3	11
2813	Gastrointestinal Biopsy Obtained During Cancer Screening, a Biological Marker for Î±-Synucleinopathy?. Journal of Neuropathology and Experimental Neurology, 2022, 81, 356-362.	0.9	1

#	Article	IF	Citations
2814	Turning markers into targets â€“ scoping neural circuits for motor neurofeedback training in Parkinsonâ€™s disease. , 2022, 1, 1-27.		1
2815	Paraquat-induced intracellular Zn2+ dysregulation causes dopaminergic degeneration in the substantia nigra, but not in the striatum. NeuroToxicology, 2022, 90, 136-144.	1.4	2
2816	Mitochondria-associated membranes: A hub for neurodegenerative diseases. Biomedicine and Pharmacotherapy, 2022, 149, 112890.	2.5	21
2817	Development of early diagnosis of Parkinsonâ€™s disease on animal models based on the intranasal administration of Î±-methyl-p-tyrosine methyl ester in a gel system. Biomedicine and Pharmacotherapy, 2022, 150, 112944.	2.5	0
2818	Insertion force reduction of micro-texture on 316L electrode for Parkinsonâ€™s surgery by Laser processing. Materials Today Communications, 2022, 31, 103403.	0.9	0
2819	In vitro and in vivo NMR based metabolomics in Parkinson's disease. Journal of Magnetic Resonance Open, 2022, 10-11, 100050.	0.5	3
2820	Tailoring a luminescent metalÂâ˜Âorganic framework precise inclusion of Pt-Aptamer nanoparticle for noninvasive monitoring Parkinson's disease. Chemical Engineering Journal, 2022, 441, 136009.	6.6	17
2821	Long-term exposure to particulate air pollution and incidence of Parkinson's disease: A nationwide population-based cohort study in South Korea. Environmental Research, 2022, 212, 113165.	3.7	10
2822	Guidelines for the Diagnosis and Treatment of Parkinsonâ€™s Disease. , 2021, 9, .		1
2823	Evaluation of Recurrent Neural Network Models for Parkinson's Disease Classification Using Drawing Data. , 2021, 2021, 1702-1706.		2
2824	Iron status, immune system, and expression of brain divalent metal transporter 1 and dopamine receptors D1 interrelationship in Parkinsonâ€™s disease and the role of grape seed and green coffee bean extracts and quercetin in mitigating the disease in rats. Journal of HerbMed Pharmacology, 2021, 11, 63-74.	0.4	0
2825	Deep brain stimulation for movement disorder treatment: exploring frequency-dependent efficacy in a computational network model. Biological Cybernetics, 2022, 116, 93-116.	0.6	8
2826	Immunotherapeutic Approaches for the Treatment of Neurodegenerative Diseases: Challenges and Outcomes. CNS and Neurological Disorders - Drug Targets, 2021, 21, .	0.8	0
2827	Insights Into Amentoflavone: A Natural Multifunctional Biflavonoid. Frontiers in Pharmacology, 2021, 12, 768708.	1.6	32
2828	Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?. Nature Reviews Neuroscience, 2022, 23, 115-128.	4.9	92
2829	Well-Water Consumption and Risk of Parkinsonâ€™s Disease: A Meta-Analysis of 15 Observational Studies. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 3705-3714.	1.0	2
2830	Tai Chi Training as a Primary Daily Care Plan for Better Balance Ability in People With Parkinson's Disease: An Opinion and Positioning Article. Frontiers in Neurology, 2021, 12, 812342.	1.1	0
2831	Pharmabiotic Based on Lactobacillus fermentum Strain U-21 Modulates the Toxic Effect of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine as Parkinsonism Inducer in Mice. Human Physiology, 2021, 47, 891-900.	0.1	1

#	Article	IF	Citations
2832	Predicting Fall Counts Using Wearable Sensors: A Novel Digital Biomarker for Parkinsonâ€™s Disease. Sensors, 2022, 22, 54.	2.1	9
2833	An Implementation of FastAI Tabular Learner Model for Parkinsonâ€™s Disease Identification. , 2021, , .		1
2834	Early Repetitive Transcranial Magnetic Stimulation Exerts Neuroprotective Effects and Improves Motor Functions in Hemiparkinsonian Rats. Neural Plasticity, 2021, 2021, 1-14.	1.0	7
2835	Androgens and Parkinson's Disease: A Review of Human Studies and Animal Models. Androgens: Clinical Research and Therapeutics, 2021, 2, 294-303.	0.2	6
2836	Proof of Concept in Artificial-Intelligence-Based Wearable Gait Monitoring for Parkinsonâ€™s Disease Management Optimization. Biosensors, 2022, 12, 189.	2.3	14
2837	Dietary fat intake and risk of Parkinson disease: results from the Swedish National March Cohort. European Journal of Epidemiology, 2022, 37, 603-613.	2.5	10
2838	Lipid-Based Nanocarriers for Neurological Disorders: A Review of the State-of-the-Art and Therapeutic Success to Date. Pharmaceutics, 2022, 14, 836.	2.0	18
2839	Ca2+ Dyshomeostasis Links Risk Factors to Neurodegeneration in Parkinsonâ€™s Disease. Frontiers in Cellular Neuroscience, 2022, 16, 867385.	1.8	7
2840	REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinsonâ€™s disease: a cross-sectional and longitudinal study. Journal of Neurology, 2022, 269, 4836-4845.	1.8	4
2841	Plasma branched-chain and aromatic amino acids correlate with the gut microbiota and severity of Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, 48.	2.5	25
2842	An Exploratory Study Using Electronic Medical Records to Assess the Feasibility of Establishing Cohorts of Patients with Genetic Causes of Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, , 1-9.	1.5	0
2843	The association between LIN28A gene rare variants and Parkinsonâ€™s disease in Chinese population. Gene, 2022, 829, 146515.	1.0	2
2844	Structural and mechanistic insights into modulation of Î±-Synuclein fibril formation by aloin and emodin. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130151.	1.1	2
2875	CRISPR/Cas9-Mediated Disruption of ZNF543 Gene: An Approach Toward Discovering Its Relation to TRIM28 Gene in Parkinsonâ€™s Disease. Molecular Biotechnology, 2023, 65, 243-251.	1.3	1
2878	Effect of Theta Burst Stimulation-Patterned rTMS on Motor and Nonmotor Dysfunction of Parkinson's Disease: A Systematic Review and Metaanalysis. Frontiers in Neurology, 2021, 12, 762100.	1.1	8
2879	Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinsonâ€™s Disease Motor Progression. Frontiers in Neuroscience, 2021, 15, 765765.	1.4	6
2881	Bio-Inspired Algorithms. Advances in Medical Technologies and Clinical Practice Book Series, 2022, , 1-22.	0.3	0
2882	Mitochondrial Dysfunction in Aging and Neurodegeneration. , 2022, , 253-278.		0

#	Article	IF	Citations
2883	The diagnostic value of diffusion kurtosis imaging in Parkinsonâ€™s disease: a systematic review and meta-analysis. Annals of Translational Medicine, 2022, 10, 474-474.	0.7	2
2884	Second Sphere Interactions in Amyloidogenic Diseases. Chemical Reviews, 2022, 122, 12132-12206.	23.0	8
2885	Neurodegenerative Disorders and Sleep. Sleep Medicine Clinics, 2022, 17, 307-314.	1.2	11
2886	An investigation about the relationship between dysarthria level of speech and the neurological state of Parkinsonâ€™s patients. Biocybernetics and Biomedical Engineering, 2022, 42, 710-726.	3.3	7
2887	Neuropsychiatric Symptoms in Clinically Defined Parkinsonâ€™s Disease: An Updated Review of Literature. Behavioural Neurology, 2022, 2022, 1-16.	1.1	6
2888	CREB Inactivation by HDAC1/PP1Î³ Contributes to Dopaminergic Neurodegeneration in Parkinson's Disease. Journal of Neuroscience, 2022, 42, 4594-4604.	1.7	10
2889	The Common Marmosetâ€”Biomedical Research Animal Model Applications and Common Spontaneous Diseases. Toxicologic Pathology, 2022, 50, 628-637.	0.9	10
2890	Functional behavior of DHA and EPA in the formation of babies brain at different stages of age, and protect from different brain-related diseases. International Journal of Food Properties, 2022, 25, 1021-1044.	1.3	29
2891	Managing Bipolar Disease Complicated with Psychosis in Conjunction with Polypharmacy, Parkinsonâ€™s Disease, and Multiple Comorbidities. Case Reports in Psychiatry, 2022, 2022, 1-7.	0.2	0
2892	The Chinese Parkinson's Disease Registry (<scp>CPDR</scp>): Study Design and Baseline Patient Characteristics. Movement Disorders, 2022, 37, 1335-1345.	2.2	13
2893	The Emerging Role of Marine Natural Products for the Treatment of Parkinsonâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2023, 22, 801-816.	0.8	3
2894	Aging and Neuropsychiatric Disease: A General Overview of Prevalence and Trends. Physiology, 0, , .	4.0	0
2896	An Automatic Evaluation Method for Parkinson's Dyskinesia Using Finger Tapping Video for Small Samples. Journal of Medical and Biological Engineering, 2022, 42, 351-363.	1.0	3
2897	Evaluation of an individualized, tablet-based physiotherapy training programme for patients with Parkinsonâ€™s disease: the ParkProTrain study, a quasi-randomised controlled trial. BMC Neurology, 2022, 22, 176.	0.8	5
2898	Needs of patients with parkinsonism and their caregivers: a protocol for the PRIME-UK cross-sectional study. BMJ Open, 2022, 12, e057947.	0.8	1
2899	Early detection of Parkinson disease using stacking ensemble method. Computer Methods in Biomechanics and Biomedical Engineering, 2023, 26, 527-539.	0.9	8
2900	Modeling the blood-brain barrier for treatment of central nervous system (CNS) diseases. Journal of Tissue Engineering, 2022, 13, 204173142210959.	2.3	10
2901	Glutamate modulation for the treatment of levodopa induced dyskinesia: aÂbrief review of the drugs tested in the clinic. Neurodegenerative Disease Management, 2022, 12, 203-214.	1.2	5

#	Article	IF	Citations
2902	Digital healthcare platform ecosystem design: A case study of an ecosystem for Parkinson's disease patients. Technovation, 2023, 120, 102551.	4.2	5
2903	Explainable machine learning with pairwise interactions for the classification of Parkinsonâ€™s disease and SWEDD from clinical and imaging features. Brain Imaging and Behavior, 2022, 16, 2188-2198.	1.1	12
2904	Library-Derived Peptide Aggregation Modulators of Parkinsonâ€™s Disease Early-Onset Î±-Synuclein Variants. ACS Chemical Neuroscience, 2022, 13, 1790-1804.	1.7	3
2905	Novel insights into the role of circular <scp>RNAs</scp> in Parkinson disease: An emerging renaissance in the management of neurodegenerative diseases. Journal of Neuroscience Research, 2022, 100, 1775-1790.	1.3	10
2906	Penetrance of Parkinson's disease LRRK2 G2385Râ€associated variant in the Chinese population. European Journal of Neurology, 0, , .	1.7	3
2907	Machine Learning Classifiers to Evaluate Data From Gait Analysis With Depth Cameras in Patients With Parkinsonâ€™s Disease. Frontiers in Human Neuroscience, 2022, 16, .	1.0	3
2908	Induced pluripotent stem cells: a tool for modeling Parkinsonâ€™s disease. Trends in Neurosciences, 2022, 45, 608-620.	4.2	17
2909	Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies. Frontiers in Neurology, 0, 13, .	1.1	6
2910	Coping Styles in Patients with Parkinsonâ€™s Disease: Consideration in the Co-Designing of Integrated Care Concepts. Journal of Personalized Medicine, 2022, 12, 921.	1.1	2
2911	Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform. Ageing Research Reviews, 2022, 79, 101658.	5.0	22
2912	A Pitx3-deficient developmental mouse model for fine motor, olfactory, and gastrointestinal symptoms of Parkinson's disease. Neurobiology of Disease, 2022, 170, 105777.	2.1	3
2919	Offline Policy Evaluation for Learning-based Deep Brain Stimulation Controllers. , 2022, , .		0
2920	Platelets and the Role of P2X Receptors in Nociception, Pain, Neuronal Toxicity and Thromboinflammation. International Journal of Molecular Sciences, 2022, 23, 6585.	1.8	7
2921	Neurocognitive correlates of numerical abilities in Parkinsonâ€™s disease. Neurological Sciences, 2022, 43, 5313-5322.	0.9	1
2922	An Efficient Rotation Forest-Based Ensemble Approach for Predicting Severity of Parkinsonâ€™s Disease. Journal of Healthcare Engineering, 2022, 2022, 1-9.	1.1	6
2923	Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders. Frontiers in Psychiatry, 0, 13, .	1.3	14
2924	A Concise Review of Common Plant-derived Compounds as a Potential Therapy for Alzheimer's Disease and Parkinson's Disease: Insight into Structure-Activity-Relationship. CNS and Neurological Disorders - Drug Targets, 2023, 22, 1057-1069.	0.8	6
2926	Far infrared light irradiation enhances AÎ² clearance via increased exocytotic microglial ATP and ameliorates cognitive deficit in Alzheimerâ€™s disease-like mice. Journal of Neuroinflammation, 2022, 19, .	3.1	10

#	Article	IF	Citations
2927	Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions?. Neuroepidemiology, 2022, 56, 309-318.	1.1	13
2928	Molecular mechanisms highlighting the potential role of COVID-19 in the development of neurodegenerative diseases. Physiology International, 2022, 109, 135-162.	0.8	4
2929	Moving the Dial Toward Equity in Parkinsonâ€™s Disease Clinical Research: a Review of Current Literature and Future Directions in Diversifying PD Clinical Trial Participation. Current Neurology and Neuroscience Reports, 2022, 22, 475-483.	2.0	12
2930	Closing the loop for patients with Parkinson disease: where are we?. Nature Reviews Neurology, 2022, 18, 497-507.	4.9	19
2932	Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinsonâ€™s disease. Cell Reports Medicine, 2022, 3, 100661.	3.3	48
2933	Efficacy and safety of apomorphine pump infusion in Filipino patients insufficiently controlled on oral anti-Parkinson medications: an open-label, pilot study. International Journal of Neuroscience, 2024, 134, 131-136.	0.8	0
2934	Exploration of the Common Gene Characteristics and Molecular Mechanism of Parkinsonâ€™s Disease and Crohnâ€™s Disease from Transcriptome Data. Brain Sciences, 2022, 12, 774.	1.1	3
2935	Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinsonâ€™s disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial. Chinese Medicine, 2022, 17, .	1.6	0
2936	RIP kinases and necroptosis in aging and aging-related diseases. , 2022, 1, 2-20.		8
2937	Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T Î±-synuclein rat model of Parkinsonâ€™s disease. Behavioural Brain Research, 2022, 432, 113968.	1.2	5
2938	Development of bromo- and fluoro-based Î±, Î²-unsaturated ketones as highly potent MAO-B inhibitors for the treatment of Parkinson's disease. Journal of Molecular Structure, 2022, 1266, 133545.	1.8	24
2940	Neuropathy in Parkinson's disease: Risk determinants and impact on quality of life. Annals of Indian Academy of Neurology, 2022, 25, 428.	0.2	2
2941	Activated or Impaired: An Overview of DNA Repair in Neurodegenerative Diseases. , 2022, 13, 987.		8
2942	Therapeutic Potential of Astrocyte Transplantation. Cell Transplantation, 2022, 31, 096368972211054.	1.2	13
2943	Gender features of clinical manifestations, diagnosis and treatment of Đarkinsonâ€™s disease in North Ossetia-Alania Republic. Vestnik Nevrologii, Psihiatrii I Nejrohirurgii, 2022, , 353-356.	0.0	0
2944	Experimental Studies of Geroprotective and Anti-Aging Effects of Chemical Compounds of Portulaca oleracea L. (Review). Advances in Gerontology, 2022, 12, 122-127.	0.1	1
2945	Mutant VPS35-D620N induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway. Human Molecular Genetics, 2022, 31, 3886-3896.	1.4	1
2946	Phonemes based detection of parkinsonâ€™s disease for telehealth applications. Scientific Reports, 2022, 12, .	1.6	16

#	Article	IF	Citations
2947	Yerbamate Tea Consumption: A Protective Factor in Parkinson Disease. Clinical Neuropharmacology, 2022, 45, 79-83.	0.2	0
2948	An insight into reactivity and bioactivity properties of quorum sensing peptides against PDE10A: a computational peptidology approach. Journal of Molecular Modeling, 2022, 28, .	0.8	1
2949	Long noncoding RNA SNHG14 knockdown exerts a neuroprotective role in MPP+-induced Parkinsonâ€™s disease cell model through mediating miR-135b-5p/KPNA4 axis. Metabolic Brain Disease, 2022, 37, 2363-2373.	1.4	5
2950	Speech processing for early Parkinsonâ€™s disease diagnosis: machine learning and deep learning-based approach. Social Network Analysis and Mining, 2022, 12, .	1.9	6
2951	Diagnostic and therapeutic agents that target alpha-synuclein in Parkinsonâ€™s disease. Journal of Neurology, 2022, 269, 5762-5786.	1.8	11
2952	Handsâ€“feet wireless devices: Testâ€“retest reliability and discriminant validity of motor measures in Parkinson's disease telemonitoring. Acta Neurologica Scandinavica, 2022, 146, 304-317.	1.0	1
2953	Nicotine Has a Therapeutic Window of Effectiveness in a Drosophila melanogaster Model of Parkinsonâ€™s Disease. Parkinson's Disease, 2022, 2022, 1-11.	0.6	0
2954	Systematic Review on Saliva Biomarkers in Patients Diagnosed with Morbus Alzheimer and Morbus Parkinson. Biomedicines, 2022, 10, 1702.	1.4	10
2955	GCase Enhancers: A Potential Therapeutic Option for Gaucher Disease and Other Neurological Disorders. Pharmaceuticals, 2022, 15, 823.	1.7	12
2956	Nitric Oxide Involvement in Cardiovascular Dysfunctions of Parkinson Disease. Frontiers in Pharmacology, 0, 13, .	1.6	4
2957	Spectrofluorimetric and stability-indicating thin layer chromatographic methods for determination of cabergoline, a prolactin inhibitor in pharmaceuticals. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022, 281, 121639.	2.0	0
2958	Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinsonâ€™s disease: a systematic review and meta-analysis. Journal of Comparative Effectiveness Research, 2022, 11, 889-904.	0.6	3
2959	PD Disease State Assessment in Naturalistic Environments Using Deep Learning. Proceedings of the AAAI Conference on Artificial Intelligence, 2015, 29, .	3.6	71
2960	Association between trichlorophenols and neurodegenerative diseases: A cross-sectional study from NHANES 2003â€“2010. Chemosphere, 2022, 307, 135743.	4.2	7
2961	The role of microRNA-485 in neurodegenerative diseases. Reviews in the Neurosciences, 2023, 34, 49-62.	1.4	6
2962	The role of histone modifications: from neurodevelopment to neurodiseases. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	63
2963	The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the cognitive and motor functions in rodents: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2022, 140, 104792.	2.9	10
2964	The potential use of mesenchymal stem cells and their exosomes in Parkinsonâ€™s disease treatment. Stem Cell Research and Therapy, 2022, 13, .	2.4	31

#	Article	IF	Citations
2966	Biotechnology applications in neurodegenerative diseases. , 2022, , 89-103.		0
2967	Systematic review of Mendelian randomization studies on Parkinsonâ€™s disease. Medizinische Genetik, 2022, 34, 143-150.	0.1	0
2968	Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinsonâ€™s disease and other synucleinopathies. Npj Parkinson's Disease, 2022, 8, .	2.5	41
2969	Neuroprotective Properties of Bis-Sulfonamide Derivatives Against 6-OHDA-Induced Parkinson's Model via Sirtuin 1 Activity and in silico Pharmacokinetic Properties. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	4
2970	Rhythmic auditory stimulation promotes gait recovery in Parkinson's patients: A systematic review and meta-analysis. Frontiers in Neurology, 0, 13, .	1.1	5
2971	Gut microenvironmental changes as a potential trigger in Parkinsonâ€™s disease through the gutâ€“brain axis. Journal of Biomedical Science, 2022, 29, .	2.6	25
2972	Essential tremor-Parkinson's disease syndrome: clinical characteristics and subtypes using cluster analysis. Chinese Medical Journal, 0, Publish Ahead of Print, .	0.9	0
2973	Transcriptome Profiling Reveals Differential Expression of Circadian Behavior Genes in Peripheral Blood of Monozygotic Twins Discordant for Parkinsonâ€™s Disease. Cells, 2022, 11, 2599.	1.8	1
2974	Association of Diet and Physical Activity With All-Cause Mortality Among Adults With Parkinson Disease. JAMA Network Open, 2022, 5, e2227738.	2.8	7
2975	Risk of Parkinson Disease Among Adults With vs Without Posttraumatic Stress Disorder. JAMA Network Open, 2022, 5, e2225445.	2.8	4
2976	Role of Protein Damage Inflicted by Dopamine Metabolites in Parkinsonâ€™s Disease: Evidence, Tools, and Outlook. Chemical Research in Toxicology, 2022, 35, 1789-1804.	1.7	9
2977	Trial of Cinpanemab in Early Parkinsonâ€™s Disease. New England Journal of Medicine, 2022, 387, 408-420.	13.9	134
2978	Lewy Body Disease Primate Model with Î±â€Synuclein Propagation from the Olfactory Bulb. Movement Disorders, 2022, 37, 2033-2044.	2.2	6
2979	Cost-effectiveness of the add-on exenatide to conventional treatment in patients with Parkinsonâ€™s disease when considering the coexisting effects of diabetes mellitus. PLoS ONE, 2022, 17, e0269006.	1.1	0
2980	Neuroprotective Effects of Intermittent Theta Burst Stimulation in Parkinsonâ€™s Disease (NET-PD): A Study Protocol for a Delayed-Start Randomized Double-Blind Sham-Controlled Trial. Journal of Clinical Medicine, 2022, 11, 4972.	1.0	0
2981	Single-cell transcriptomics reveals the cell fate transitions of human dopaminergic progenitors derived from hESCs. Stem Cell Research and Therapy, 2022, 13, .	2.4	3
2982	Research Progress of Music Therapy on Gait Intervention in Patients with Parkinsonâ€™s Disease. International Journal of Environmental Research and Public Health, 2022, 19, 9568.	1.2	5
2983	A bibliometric analysis of neuroimaging biomarkers in Parkinson disease based on Web of Science. Medicine (United States), 2022, 101, e30079.	0.4	3

#	Article	IF	Citations
2984	The relationship of alpha-synuclein to mitochondrial dynamics and quality control. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	14
2985	A generic optimization and learning framework for Parkinson disease via speech and handwritten records. Journal of Ambient Intelligence and Humanized Computing, 2023, 14, 10673-10693.	3.3	11
2986	Petri net transition times as training features for multiclass models to support the detection of neurodegenerative diseases. Biomedical Physics and Engineering Express, 0, , .	0.6	2
2987	Clinical and Genetic Features of Multiplex Families with Multiple System Atrophy and Parkinsonâ€™s Disease. Cerebellum, 2024, 23, 22-30.	1.4	0
2988	Inhibition of Î±-synuclein aggregation by MT101-5 is neuroprotective in mouse models of Parkinsonâ€™s disease. Biomedicine and Pharmacotherapy, 2022, 154, 113637.	2.5	0
2989	Parkinsonâ€™s Disease Detection Using Smartphone Recorded Phonemes in Real World Conditions. IEEE Access, 2022, 10, 97600-97609.	2.6	5
2990	Artificial Intelligence for Diabetes-related Complications: The Eye as a Window to the Systemic Health. RSC Nanoscience and Nanotechnology, 2022, , 305-345.	0.2	0
2991	Transcranial magnetic stimulation in the treatment of depressive disorder in Parkinsonâ€™s disease. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 79.	0.1	0
2992	Decoding the Role of Familial Parkinsonâ€™s Disease-Related Genes in DNA Damage and Repair. , 2022, 13, 1405.		5
2993	Scent-delivery devices as a digital healthcare tool for olfactory training: A pilot focus group study in Parkinson's disease patients. Digital Health, 2022, 8, 205520762211290.	0.9	2
2994	Molecular Insights into the Role of ER Stress in Neurodegenerative Diseases. , 2022, , 219-249.		0
2995	The BE (2)-M17 Cell Line Has a Better Dopaminergic Phenotype than the Traditionally Used for Parkinson's Research SH-SY5Y, Which is Mostly Serotonergic. SSRN Electronic Journal, 0, , .	0.4	0
2996	Post-translational Modifications in Parkinsonâ€™s Disease. Advances in Experimental Medicine and Biology, 2022, , 85-94.	0.8	1
2997	Sleep disorders in patients with Parkinson's disease during COVID-19 pandemic: A caseâ€“Control study. Annals of Indian Academy of Neurology, 2022, 25, 394.	0.2	1
2998	Emerging roles of leptin in Parkinsonâ€™s disease: Chronic inflammation, neuroprotection and more?. Brain, Behavior, and Immunity, 2023, 107, 53-61.	2.0	5
2999	Design of a Parkinsonian Biomarkers Combination Optimization Method Using Rodent Model. , 2022, , .		0
3000	Inflammatory markers and depression in Parkinsonâ€™s disease: a systematic review. Neurological Sciences, 2022, 43, 6707-6717.	0.9	5
3001	Exploring brain changes of impulse control disorders in Parkinson's disease: An ALE study. Frontiers in Aging Neuroscience, 0, 14, .	1.7	6

#	Article	IF	Citations
3002	Correlation of Serum Uric Acid with Cognition, Severity, and Stage of Disease in Patients with Idiopathic Parkinsonâ€™s Disease and Vascular Parkinsonism: A Cross-Sectional Study. The Open Neurology Journal, 2022, 16, .	0.4	0
3003	Cortical atrophy is associated with cognitive impairment in Parkinsonâ€™s disease: a combined analysis of cortical thickness and functional connectivity. Brain Imaging and Behavior, 2022, 16, 2586-2600.	1.1	5
3004	Diet quality, sleep and quality of life in Parkinsonâ€™s disease: a cross-sectional study. Irish Journal of Medical Science, 0, , .	0.8	3
3005	Design and Implementation of Wearable Cap for Parkinsonâ€™s Population. Lecture Notes in Networks and Systems, 2023, , 83-91.	0.5	0
3006	Regulation of mitochondrial dysfunction induced cell apoptosis is a potential therapeutic strategy for herbal medicine to treat neurodegenerative diseases. Frontiers in Pharmacology, 0, 13, .	1.6	10
3007	Calabria as a Genetic Isolate: A Model for the Study of Neurodegenerative Diseases. Biomedicines, 2022, 10, 2288.	1.4	4
3008	Zonisamideâ€™s Efficacy and Safety on Parkinsonâ€™s Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review. BioMed Research International, 2022, 2022, 1-17.	0.9	5
3009	Tear Biomarkers in Alzheimerâ€™s and Parkinsonâ€™s Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review). International Journal of Molecular Sciences, 2022, 23, 10123.	1.8	14
3010	Putaminal Recombinant Glucocerebrosidase Delivery with Magnetic Resonance<scp>â€“</scp>Guided Focused Ultrasound in Parkinson's Disease: A Phase I Study. Movement Disorders, 2022, 37, 2134-2139.	2.2	19
3011	Gut-oriented disease modifying therapy for Parkinson's disease. Journal of the Formosan Medical Association, 2022, , .	0.8	1
3012	Modelling Parkinson's Disease in C. elegans: Strengths and Limitations. Current Pharmaceutical Design, 2022, 28, 3033-3048.	0.9	3
3013	The multiple functions of PrPC in physiological, cancer, and neurodegenerative contexts. Journal of Molecular Medicine, 2022, 100, 1405-1425.	1.7	5
3014	Beta amyloid deposition and cognitive decline in Parkinsonâ€™s disease: a study of the PPMI cohort. Molecular Brain, 2022, 15, .	1.3	9
3015	Effects of square-stepping exercise on executive function in individuals with Parkinson's disease: A randomized controlled pilot study. Geriatric Nursing, 2022, 47, 273-279.	0.9	0
3016	Does the Gut Microbial Metabolome Really Matter? The Connection between GUT Metabolome and Neurological Disorders. Nutrients, 2022, 14, 3967.	1.7	17
3017	Diffusion along perivascular spaces provides evidence interlinking compromised glymphatic function with aging in Parkinson's disease. CNS Neuroscience and Therapeutics, 2023, 29, 111-121.	1.9	14
3018	Anionic lipid vesicles have differential effects on the aggregation of early onset-associated Î±-synuclein missense mutants. Journal of Biological Chemistry, 2022, 298, 102565.	1.6	2
3020	Therapeutic Approaches to Non-Motor Symptoms of Parkinson's Disease: A Current Update on Preclinical Evidence. Current Neuropharmacology, 2023, 21, 560-577.	1.4	2

#	Article	IF	Citations
3021	A Community-based study on the prevalence and predisposing factors of Parkinsonâ€™s disease in Barangay Mangilag Sur, Quezon Province, Philippines. Clinical Parkinsonism & Related Disorders, 2022, 7, 100169.	0.5	0
3022	Quantifying Motor Skills in Early-Stage Parkinson's Disease Using Human Controller Modeling. IFAC-PapersOnLine, 2022, 55, 96-101.	0.5	0
3023	Generative Adversarial Networks as a Data Augmentation Tool for CNN-Based Parkinson's Disease Diagnostics. IFAC-PapersOnLine, 2022, 55, 108-113.	0.5	5
3024	The problem of pharmacoresistant tremor in Parkinsonâ€™s disease and essential tremor. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 24.	0.1	1
3025	The impact of Parkinsonâ€™s disease on results of primary total knee arthroplasty. EFORT Open Reviews, 2022, 7, 701-709.	1.8	1
3026	The efficient generation of knockout microglia cells using a dual-sgRNA strategy by CRISPR/Cas9. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	1
3027	Neuroprotective role of coconut oil for the prevention and treatment of Parkinsonâ€™s disease: potential mechanisms of action. Biotechnology and Genetic Engineering Reviews, 0, , 1-33.	2.4	3
3028	People with mild Parkinson's disease have impaired force production in upper limb muscles: A crossâ€sectional study. Physiotherapy Research International, 0, , .	0.7	2
3029	Plasma-derived phosphoglycerate mutase 5 as a biomarker for Parkinsonâ€™s disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	0
3030	Effects of nordic walking exercise on gait, motor/non-motor symptoms, and serum brain-derived neurotrophic factor in individuals with Parkinson's disease. Frontiers in Rehabilitation Sciences, 0, 3, .	0.5	3
3031	The association of comorbidity with Parkinson's disease-related hospitalizations. Parkinsonism and Related Disorders, 2022, 104, 123-128.	1.1	9
3032	Gray matter, white matter and cerebrospinal fluid abnormalities in Parkinsonâ€™s disease: A voxel-based morphometry study. Frontiers in Psychiatry, 0, 13, .	1.3	20
3033	Polyphenols-Based Nanosheets of Propolis Modulate Cytotoxic Amyloid Fibril Assembly of Î±-Synuclein. ACS Chemical Neuroscience, 2022, 13, 3168-3179.	1.7	4
3034	Common signatures of differential microRNA expression in Parkinsonâ€™s and Alzheimerâ€™s disease brains. Brain Communications, 2022, 4, .	1.5	6
3036	Therapeutic function of a novel rat induced pluripotent stem cell line in a 6â€˜OHDAâ€˜induced rat model of Parkinson's disease. International Journal of Molecular Medicine, 2022, 50, .	1.8	0
3037	Parkinson's disease and suicide among individuals seeking care within the United States Veterans Health Administration. Parkinsonism and Related Disorders, 2022, 105, 58-61.	1.1	2
3038	Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinsonâ€™s Disease: Preclinical and Clinical Studies. Cells, 2022, 11, 3468.	1.8	11
3039	Prevalence and characteristics of dry eye disease in Parkinsonâ€™s disease: a systematic review and meta-analysis. Scientific Reports, 2022, 12, .	1.6	9

#	Article	IF	Citations
3040	The ADORA1 mutation linked to early-onset Parkinsonâ€™s disease alters adenosine A1-A2A receptor heteromer formation and function. Biomedicine and Pharmacotherapy, 2022, 156, 113896.	2.5	8
3041	Probable role of the hyperpolarization-activated current in the dual effects of CB1R antagonism on behaviors in a Parkinsonism mouse model. Brain Research Bulletin, 2022, 191, 78-92.	1.4	1
3042	Targeting epigenetics as a promising therapeutic strategy for treatment of neurodegenerative diseases. Biochemical Pharmacology, 2022, 206, 115295.	2.0	9
3043	Neurogenic supine hypertension and cardiovascular autonomic dysfunction in patients with parkinson's disease. Annals of Indian Academy of Neurology, 2023, 26, 33.	0.2	0
3044	The Control Center of Anger. , 2022, , 51-77.		0
3045	Parkinson's disease and related disorders. , 2023, , 3-19.		0
3046	Risk of dementia or Parkinsonâ€™s disease in the presence of SjÃ¶grenâ€™s syndrome: A systematic review and meta-analysis. Frontiers in Integrative Neuroscience, 0, 16, .	1.0	3
3047	Effects of Non-Immersive Virtual Reality and Video Games on Walking Speed in Parkinson Disease: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 6610.	1.0	2
3048	Use of common spatial patterns for early detection of Parkinsonâ€™s disease. Scientific Reports, 2022, 12, .	1.6	2
3049	Neuroprotection and Non-Invasive Brain Stimulation: Facts or Fiction?. International Journal of Molecular Sciences, 2022, 23, 13775.	1.8	11
3050	Effects of Insole with Toe-Grip Bar on Barefoot Balance and Walking Function in Patients with Parkinsonâ€™s Disease: A Randomized Controlled Trial. Geriatrics (Switzerland), 2022, 7, 128.	0.6	2
3051	Analysis of handgrip strength, pulling force using the upper limbs, and ground reaction forces in the task of boarding a bus between healthy elderly individuals and those with Parkinsonâ€™s disease. Physiotherapy Theory and Practice, 0, , 1-10.	0.6	1
3052	Assessing the association between white matter lesions and Parkinsonâ€™s disease. Neurological Sciences, 2023, 44, 897-903.	0.9	2
3053	Analysis of slow and fast sleep spindle properties in Parkinson's disease â€“ A comparative EEG study. International Journal of Psychophysiology, 2022, 182, 220-230.	0.5	0
3054	Endothelial LRP1-ICD Accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 Activation in a Mouse Model of Parkinsonâ€™s Disease. Molecular Neurobiology, 2023, 60, 979-1003.	1.9	4
3055	The BE (2)-M17 cell line has a better dopaminergic phenotype than the traditionally used for ParkinsonÂ´s research SH-SY5Y, which is mostly serotonergic. IBRO Neuroscience Reports, 2022, 13, 543-551.	0.7	2
3056	A Deep Convolutional Autoencoder-Based Approach for Parkinsonâ€™s Disease Diagnosis Through Speech Signals. Lecture Notes in Computer Science, 2022, , 15-26.	1.0	0
3057	Empagliflozin enhances neuroplasticity in rotenone-induced parkinsonism: Role of BDNF, CREB and Npas4. Life Sciences, 2023, 312, 121258.	2.0	7

#	Article	IF	Citations
3058	Converging links between adult-onset neurodegenerative Alzheimerâ€™s disease and early life neurodegenerative neuronal ceroid lipofuscinosis?. Neural Regeneration Research, 2023, 18, 1463.	1.6	1
3059	Association between Parkinsonâ€™s Disease and Diabetes Mellitus: From Epidemiology, Pathophysiology and Prevention to Treatment. , 2022, 13, 1591.		10
3060	Parkinsonâ€™s disease: Pathology and treatment. AIP Conference Proceedings, 2022, , .	0.3	0
3061	Transformers for 1D signals in Parkinsonâ€™s disease detection from gait. , 2022, , .		6
3062	Transformer-based severity detection of Parkinson's symptoms from gait. , 2022, , .		0
3063	Mitochondria: how eminent in ageing and neurodegenerative disorders?. Human Cell, 2023, 36, 41-61.	1.2	5
3064	Neurotrophic Role of the Next-Generation Probiotic Strain L. lactis MG1363-pMG36e-GLP-1 on Parkinsonâ€™s Disease via Inhibiting Ferroptosis. Nutrients, 2022, 14, 4886.	1.7	13
3065	An Update on Peripheral Blood Extracellular Vesicles as Biomarkers for Parkinson's Disease Diagnosis. Neuroscience, 2023, 511, 131-146.	1.1	4
3066	Association between use of ÃŸ2-adrenergic receptor agonists and incidence of Parkinsonâ€™s disease: Retrospective cohort analysis. PLoS ONE, 2022, 17, e0276368.	1.1	2
3068	Whole-brain dynamical modelling for classification of Parkinsonâ€™s disease. Brain Communications, 2022, 5, .	1.5	5
3069	Effects of cannabinoids in Parkinsonâ€™s disease animal models: a systematic review and meta-analysis. BMJ Open Science, 2022, 6, .	0.8	1
3070	Plasma sphingolipid abnormalities in neurodegenerative diseases. PLoS ONE, 2022, 17, e0279315.	1.1	6
3071	Arthroscopic Rotator Cuff Repair In Patients With Parkinsonâ€™s Disease: A Propensity Score Matching Study With Minimum 2-Year Follow-up. BMC Musculoskeletal Disorders, 2022, 23, .	0.8	1
3072	Incidence of Parkinson disease in North America. Npj Parkinson's Disease, 2022, 8, .	2.5	47
3073	Aberrant corticospinal tract characteristics in prodromal PD: A diffusion tensor imaging study. Clinical Parkinsonism & Related Disorders, 2023, 8, 100182.	0.5	0
3074	Post-translational modification of lysine residues in erythrocyte Î±-synuclein. Journal of Biochemistry, 2023, 173, 177-184.	0.9	4
3075	The Critical Roleplay of Iron Neurochemistry in Progression of Parkinsonâ€™s Disease. , 2023, , 87-108.		0
3076	Iron and Neuro-Cognition. , 2023, , 3-22.		0

#	Article	IF	Citations
3077	A traditional East Asian herbal complex, Majainhwan for constipation in Parkinsonâ€™s disease: A retrospective study. Journal of Korean Medicine, 2022, 43, 8-19.	0.1	0
3078	RCSN Cell System for Identifying Dopaminergic Neurotoxicity. , 2022, , 239-254.		0
3079	Automatic SPECT Image Processing for Parkinsonâ€™s Disease Early Detection. Communications in Computer and Information Science, 2022, , 17-23.	0.4	1
3081	Differential contributions of depression, apathy, and anxiety to neuropsychological performance in Parkinsonâ€™s disease versus essential tremor. Journal of Clinical and Experimental Neuropsychology, 2022, 44, 651-664.	0.8	2
3082	Association between C-reactive protein-albumin ratio and overall survival in Parkinson's disease using publicly available data: A retrospective cohort study. Heliyon, 2023, 9, e12671.	1.4	2
3083	Community Choir Improves Vocal Production Measures in Individuals Living with Parkinson's Disease. Journal of Voice, 2023, , .	0.6	1
3084	Effects of Music-Based Interventions on Motor and Non-Motor Symptoms in Patients with Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 2023, 20, 1046.	1.2	7
3085	Physical exercise for people with Parkinsonâ€™s disease: a systematic review and network meta-analysis. The Cochrane Library, 2023, 2023, .	1.5	13
3087	The role of the endolysosomal pathway in Î±-synuclein pathogenesis in Parkinsonâ€™s disease. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	4
3088	Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinsonâ€™s Disease. Journal of Movement Disorders, 2023, 16, 22-41.	0.7	8
3089	Lipidomic and Metallomic Alteration of Caenorhabditis elegans after Acute and Chronic Manganese, Iron, and Zinc Exposure with a Link to Neurodegenerative Disorders. Journal of Proteome Research, 0, , .	1.8	1
3090	Potential Therapeutic Effects of Policosanol from Insect Wax on Caenorhabditis elegans Models of Parkinsonâ€™s Disease. Journal of NeuroImmune Pharmacology, 2023, 18, 127-144.	2.1	2
3091	Detecting Parkinsonâ€™s Disease from Electroencephalogram Signals: An Explainable Machine Learning Approach. , 2022, , .		5
3092	Parkin Knockdown Modulates Dopamine Release in the Central Complex, but Not the Mushroom Body Heel, of Aging Drosophila. ACS Chemical Neuroscience, 2023, 14, 198-208.	1.7	4
3093	Impairement of functional ability in patients with Parkinsonâ€™s disease, a qualitative study. , 2022, 22, 48-54.		0
3094	Antioxidative Effects of Parnassia palustris L. Extract on Ferrous Sulfate-Induced Cellular Injury of Cultured C6 Glioma Cells. Korean Journal of Clinical Laboratory Science, 2022, 54, 298-306.	0.1	0
3095	Neuroprotection in Parkinson's Disease. , 2011, , 162-176.		0
3096	Î±-Synuclein Promotes Neuronal Dysfunction and Death by Disrupting the Binding of Ankyrin to Î²-Spectrin. Journal of Neuroscience, 2023, 43, 1614-1626.	1.7	6

#	Article	IF	Citations
3097	Analysis of LIN28A variants in patients with Parkinsonâ€™s disease. Journal of Human Genetics, 0, , .	1.1	0
3098	First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells. Movement Disorders, 0, , .	2.2	1
3099	Enrollment of Participants From Marginalized Racial and Ethnic Groups. Neurology: Clinical Practice, 2023, 13, e200113.	0.8	3
3100	Renal function and neurodegenerative diseases : a two-sample Mendelian randomization study. Neurological Research, 2023, 45, 456-464.	0.6	2
3101	The Executive-Function-Related Cognitiveâ€“Motor Dual Task Walking Performance and Task Prioritizing Effect on People with Parkinsonâ€™s Disease. Healthcare (Switzerland), 2023, 11, 567.	1.0	2
3102	The deficiency of Maged1 attenuates Parkinson's disease progression in mice. Molecular Brain, 2023, 16, .	1.3	2
3103	Activation of Embryonic Gene Transcription in Neural Precursor Cells Derived from the Induced Pluripotent Stem Cells of the Patients with Parkinsonâ€™s Disease. Biochemistry (Moscow), 2023, 88, 515-525.	0.7	0
3104	Role of the iNOS isoform in the cardiovascular dysfunctions of male rats with 6-OHDA-induced Parkinsonism. Nitric Oxide - Biology and Chemistry, 2023, 134-135, 49-60.	1.2	0
3105	Epigenetic Mechanisms of Aging and Aging-Associated Diseases. Cells, 2023, 12, 1163.	1.8	5
3106	Loss of RAB39B does not alter MPTP-induced Parkinsonâ€™s disease-like phenotypes in mice. Frontiers in Aging Neuroscience, 0, 15, .	1.7	1
3107	Necroptosis in CNS diseases: Focus on astrocytes. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
3108	Efficacy of Tai Chi on lower limb function of Parkinsonâ€™s disease patients: A systematic review and meta-analysis. Frontiers in Aging Neuroscience, 0, 15, .	1.7	4
3109	Insights of Endocytosis Signaling in Health and Disease. International Journal of Molecular Sciences, 2023, 24, 2971.	1.8	8
3110	The ePark study protocol: A decentralized trial of individual video-assisted cognitive behavioural therapy for depressive disorder in Parkinson's disease. Contemporary Clinical Trials Communications, 2023, 32, 101080.	0.5	0
3111	Development of Isopropyl-Tailed Chalcones as a New Class of Selective MAO-B Inhibitors for the Treatment of Parkinsonâ€™s Disorder. ACS Omega, 2023, 8, 6908-6917.	1.6	15
3112	Intranasal Delivery of a Silymarin Loaded Microemulsion for the Effective Treatment of Parkinsonâ€™s Disease in Rats: Formulation, Optimization, Characterization, and In Vivo Evaluation. Pharmaceutics, 2023, 15, 618.	2.0	4
3113	Detection of ATXN2 Expansions in an Exome Dataset: An Underdiagnosed Cause of Parkinsonism. Movement Disorders Clinical Practice, 2023, 10, 664-669.	0.8	2
3114	The Fault in Our Astrocytes - cause or casualties of proteinopathies of ALS/FTD and other neurodegenerative diseases?. Frontiers in Molecular Medicine, 0, 3, .	0.6	0

#	Article	IF	Citations
3115	Sphingolipids in neurodegenerative diseases. Frontiers in Neuroscience, 0, 17, .	1.4	12
3116	Childhood Trauma and Parkinson Disease. Neurology: Clinical Practice, 2023, 13, .	0.8	3
3117	Considerations for developing a targeted amino acid supplement for people with Parkinsonâ€™s disease that promotes health while accounting for pathophysiology and medication interference. Nutrition Reviews, 0, , .	2.6	0
3118	Formal Verification of Deep Brain Stimulation Controllers for Parkinson's Disease Treatment. Neural Computation, 2023, 35, 671-698.	1.3	0
3119	Proactive and Integrated Management and Empowerment in Parkinsonâ€™s Disease protocol for a randomised controlled trial (PRIME-UK) to evaluate a new model of care. Trials, 2023, 24, .	0.7	6
3120	Reliability and validity of visual analysis of [18F]FE-PE2I PET/CT in early Parkinsonian disease. Nuclear Medicine Communications, 2023, 44, 397-406.	0.5	1
3121	Review on physical signs, biochemical and radiological bio-markers for detection of Prodromal Parkinson's disease. Critical Reviews in Physical and Rehabilitation Medicine, 2023, , .	0.1	0
3122	Ginkgolide A improves the pleiotropic function and reinforces the neuroprotective effects by mesenchymal stem cell-derived exosomes in 6-OHDA-induced cell model of Parkinsonâ€™s disease. Aging, 0, , .	1.4	4
3123	Inner retinal layersâ€™ alterations of the microvasculature in early stages of Parkinsonâ€™s disease: a cross sectional study. International Ophthalmology, 2023, 43, 2533-2543.	0.6	4
3124	Techniques for the detection and management of freezing of gait in Parkinson's disease â€“ A systematic review and future perspectives. MethodsX, 2023, 10, 102106.	0.7	3
3125	Facilitators and barriers to the delivery of palliative care to patients with Parkinsonâ€™s disease: a qualitative study of the perceptions and experiences of stakeholders using the socio-ecological model. BMC Health Services Research, 2023, 23, .	0.9	4
3126	ClinicalÂand genetic analysis of Vietnamese patients diagnosed with earlyâ€onset Parkinson's disease. Brain and Behavior, 2023, 13, .	1.0	6
3127	A Screening Model for the Prediction of Early Onset Parkinsonâ€™s Disease from Speech Features. Cognitive Science and Technology, 2023, , 839-846.	0.2	0
3128	Disassociation between fluctuation shift over frequency and glucose metabolism in motor cortex of Parkinsonâ€™s disease: a hybrid PET/fMRI study. Cerebral Cortex, 0, , .	1.6	0
3129	Cytokine profiles of plasma extracellular vesicles as progression biomarkers in Parkinsonâ€™s disease. Aging, 0, , .	1.4	2
3130	Synergistic associations of depressive symptoms and aging on cognitive decline in early Parkinsonâ€™s disease. Clinical Parkinsonism & Related Disorders, 2023, 8, 100192.	0.5	1
3131	Oral and intestinal dysbiosis in Parkinson's disease. Revue Neurologique, 2023, 179, 937-946.	0.6	4
3132	Neighborhood Social Determinants of Health in Patients Seen in Neurology Movement Disorders Clinics. Neurology: Clinical Practice, 2023, 13, .	0.8	0

#	Article	IF	Citations
3133	Challenges in Targeting Nasal Passage and Nose-to-Brain Delivery via Nanoemulsions. , 2023, , 59-82.		1
3134	Paradoxical kinesia may no longer be a paradox waiting for 100 years to be unraveled. Reviews in the Neurosciences, 2023, .	1.4	0
3135	Neurocognitive Psychiatric and Neuropsychological Alterations in Parkinsonâ€™s Disease: A Basic and Clinical Approach. Brain Sciences, 2023, 13, 508.	1.1	6
3136	C1q and central nervous system disorders. Frontiers in Immunology, 0, 14, .	2.2	3
3137	Effects of wearable visual cueing on gait pattern and stability in patients with Parkinsonâ€™s disease. Frontiers in Neurology, 0, 14, .	1.1	1
3138	Genetic Evidence for Endolysosomal Dysfunction in Parkinsonâ€™s Disease: A Critical Overview. International Journal of Molecular Sciences, 2023, 24, 6338.	1.8	2
3139	Estudo epidemiolÃ³gico das doenÃ§as neurodegenerativas na RegiÃ£o da Guarda - Portugal. Global Academic Nursing Journal, 2023, 4, .	0.0	0
3140	The Gut Dysmotility Questionnaire for Parkinson's disease: Insights into development and pretest studies. Frontiers in Neurology, 0, 14, .	1.1	2
3141	The assessment of executive functions to test the integrity of the nigrostriatal network: A pilot study. Frontiers in Psychology, 0, 14, .	1.1	2
3142	Comparative Study of Machine Learning Models for Early Detection of Parkinsonâ€™s. Lecture Notes in Electrical Engineering, 2023, , 51-69.	0.3	0
3143	Cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in tremor-dominant Parkinsonâ€™s disease. Acta Neurologica Belgica, 2023, 123, 1429-1437.	0.5	3
3144	Exploring the role of cerebrospinal fluid as analyte in neurologic disorders. Future Science OA, 2023, 9, .	0.9	0
3145	Deletion of Calhm2 alleviates MPTP-induced Parkinson's disease pathology by inhibiting EFHD2-STAT3 signaling in microglia. Theranostics, 2023, 13, 1809-1822.	4.6	4
3147	PARK7/DJ-1 in microglia: implications in Parkinsonâ€™s disease and relevance as a therapeutic target. Journal of Neuroinflammation, 2023, 20, .	3.1	5
3148	Deep Transfer Learning for Early Parkinson's Disease Detection. , 2023, , .		1
3150	Evaluating theÂPerformance ofÂDiadochokinetic Tests inÂCharacterizing Parkinsonâ€™s Disease Hypokinetic Dysarthria. Communications in Computer and Information Science, 2022, , 102-119.	0.4	0
3157	Offline Learning of Closed-Loop Deep Brain Stimulation Controllers for Parkinson Disease Treatment. , 2023, , .		0
3162	Targeting Sigma-1 Receptor: A Promising Strategy in the Treatment of Parkinsonâ€™s Disease. Neurochemical Research, 2023, 48, 2925-2935.	1.6	5

#	Article	IF	Citations
3163	The Digital Twin in Human Activities: The Personal Digital Twin. , 2023, , 1045-1079.		0
3167	Non-pharmacological Approaches Based on Mind-Body Medicine to Enhancement of Cognitive and Brain Reserve in Humans. Contemporary Clinical Neuroscience, 2023, , 151-175.	0.3	0
3175	Micronutrient levels in Parkinson's disease. , 2023, , 579-602.		0
3176	Blackberry (Morus nigra) usage in Parkinson's disease. , 2023, , 719-734.		0
3177	Role of dietary antioxidants and redox status in Parkinson's disease. , 2023, , 667-697.		0
3182	Clinical cases on functional neurosurgery and motor speech disorders. , 2023, , 357-418.		0
3208	Pretectum p1 (Prosomere 1). , 2023, , 499-535.		0
3220	Uncovering the neurophysiology of mood, motivation and behavioral symptoms in Parkinsonâ€™s disease through intracranial recordings. Npj Parkinson's Disease, 2023, 9, .	2.5	0
3237	Lateral flow assay for early diagnosis of neurodegenerative disorder. , 2024, , 81-98.		0
3241	Xanthan gum and its composite-based hydrogels. , 2024, , 89-108.		0
3269	Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinsonâ€™s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. CNS Drugs, 2023, 37, 941-956.	2.7	0
3279	Monitoring the Effect of Levodopa Using Sustained Phonemes in Parkinsonâ€™s Disease Patients. , 2023, , .		0
3281	Unraveling the role of glial cell lineâ€“derived neurotrophic factor in the treatment of Parkinsonâ€™s disease. Neurological Sciences, 0, , .	0.9	1
3282	Adaptive Spatio-Temporal Directed Graph Neural Network for Parkinson's Detection using Vertical Ground Reaction Force. , 2023, , .		0
3283	The risk of Parkinsonâ€™s disease in diabetic people: an updated systematic review and meta-analysis. Acta Neurologica Belgica, 0, , .	0.5	0
3287	The Change of Vocal Tract Length in People with Parkinsonâ€™s Disease. , 2023, , .		0
3288	Chitosan-Based Biomaterials for Tissue Engineering of Glial Cells. Advances in Bioinformatics and Biomedical Engineering Book Series, 2023, , 416-441.	0.2	0
3295	Endocrinology and metabolism. , 2024, , 179-295.		0

#	Article	IF	Citations
3297	Nutraceuticalâ€™s potentials in neurodegenerative disease. , 2024, , 199-213.		0
3299	A Deep Learning Approach for Grading of Motor Impairment Severity in Parkinsonâ€™s Disease. , 2023, , .		1
3300	The Neuroscience of Functional Neurosurgery. , 2024, , 369-381.		0
3305	Epigenetic modulations induced by natural products. , 2024, , 199-227.		0
3311	Evaluation of Handwriting Kinematics and Pressure for Differential Diagnosis of Parkinson's Disease Analysis. Advances in Medical Technologies and Clinical Practice Book Series, 2024, , 321-338.	0.3	0
3318	Introduction on Stem Cell Therapy and Regeneration. , 2024, , .		0